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Abstract 
 
 
In healthy individuals, the α7 and α4β2 nAChRs are concentrated in regions of the 
brain involved with learning, cognition and memory, which are relevant to diseases 
such as Alzheimer’s disease. Hence, these receptors have become significant from a 
pharmacological and drug discovery perspective. The tetrahydroquinoline compound 
4BP-TQS has been reported to act as a potent allosteric agonist on the α7 nAChR. 
The natural product desformylflustrabromine is able to act as a positive allosteric 
modulator (PAM) on the α4β2 nAChR. This thesis describes the development of 
synthetic routes directed towards 4BP-TQS and desformyflustrabromine analogues, 
and their pharmacological effects on α7 and α4β2 nAChRs. 
 
In the first half of the project a total of 51 analogues of 4BP-TQS were synthesized 
by performing a multicomponent reaction (MCR) between a substituted 
benzaldehyde, an  aniline and an activated alkene. The pharmacological properties of 
these compounds were then studied by our collaborators in UCL pharmacology. 
These compounds exhibited interesting and wide ranging pharmacological properties 
with individual compounds acting as either allosteric agonists, antagonists, type I or 
type II positive allosteric modulators or allosteric antagonists of 4BP-TQS.  
 
The second part of the project involved the development of new chemistry directed 
towards the synthesis of desformylflustrabromine analogues. Initial work focused on 
the investigation of a novel Pd-catalysed allylation procedure for introducing an allyl 
group at the C-2 position of indole. Although the desired transformation was not 
successfully achieved, a novel regioselective Pd-catalysed C-3 diallylation of 
substituted indoles was discovered. The diallylated products were shown to be 
versatile intermediates which could undergo a variety of different reactions. By 
subjecting the diallylated products to ring-closing metathesis, a series of spirocyclic 
alkaloid-like structures were obtained in excellent yields. It was also demonstrated 
that the diallylated products could be desymmetrized using a proline-catalysed 
Mannich reactions to give enantioenriched products. 
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Chapter 1 
 Introduction 
 
1.1 Nicotinic Acetylcholine Receptors 
 
The nervous system is an organ system, consisting of a network of specialized cells 
called neurons. It is through these neurons that messages are sent, received, and 
processed to coordinate the actions of animals and allow communication between 
cells.
1
 The transmission of messages occurs from the pre-synaptic neuron to the 
post-synaptic neuron at a synaptic cleft, located between the axon terminal of the 
pre-synaptic neuron and dendrites of the postsynaptic neuron (Figure 1).
1, 2
 Two 
types of synapses co-exist electrical and chemical. In electrical synapses the pre- and 
post- synaptic neurons are separated by 3.5 nm
3
 and so conduct nerve impulses faster 
than chemical synapses, where the pre- and post-synaptic neurons are separated by 
20-40 nm.
1
 Electrical impulses are found in the central nervous system (CNS) and 
the peripheral nervous system (PNS) to produce simple responses compared to the 
more complex chemical synapses. An important characteristic of electrical synapses 
is that they are bi-directional.
3
  
In contrast, in a chemical synapse the message is transmitted between neurons via a 
chemical messenger or neurotransmitter.
4
 The neurotransmitter, which is stored in 
synaptic vessels localised at the end of the pre-synaptic terminal, is released from the 
post-synaptic terminal into the synaptic cleft where it will bind onto specific 
receptors localised on the cell surface of the post-synaptic neuron. Neurotransmitters 
are often classified as either excitatory or inhibitory.  Excitatory neurotransmitters 
cause depolarisation and promote the generation of action potentials whereas 
inhibitory neurotransmitters cause hyperpolarisation and suppress the generation of 
action potentials. Communication across the chemical synapse can normally only 
occur in one direction,that is from the pre-synaptic to the post-synaptic membrane.  
When an action potential arrives at the synaptic knob it is depolarised which 
stimulates the release of the neurotransmitter from the synaptic vesicles.
2
 The 
depolarisation opens voltage gated calcium channels allowing calcium ions to 
rapidly enter the cell.
2
 This triggers exocytosis of the synaptic vesicles containing 
the neurotransmitter, and hence, its release into the synaptic cleft, which is 
12 
 
subsequently followed by binding onto the specific receptor on the post-synaptic 
neuron (Figure 1). This binding of the neurotransmitter at the post-synaptic neuron 
causes a conformational change of the receptor, which activates the receptor.   
 
Figure 1. Diagram showing how messages are transmitted between neurons.
5
 
On activation of ligand gated ion channels (LGIC), such as nAChRs, the opening of 
the ion channel which is part of the overall structure of these types of proteins, 
allows ions (Na
+
, K
+
 or Ca
2+
) to move into and out of the ion channel according to 
the electrochemical gradient, resulting in either depolarisation or hyperpolarisation 
of the postsynaptic neurone.
2
 In case of both excitatory and inhibitory 
neurotransmitters, the greater the amount of neurotransmitter in the membrane, the 
greater the depolarisation. However, a threshold potential exists in the membrane 
which regulates and propagates signalling in the CNS, an action potential is 
generated in the post-synaptic cell only when the membrane potential (-70 mV at 
resting state) is equal to or greater than the threshold potential (-40- -55 mV).
1
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Acetylcholine (ACh) was one of the first neurotransmitters to be discovered (Figure 
1a), playing a role in neurotransmission in the CNS and PNS. 
1
 
 
Figure 1a 
 
It is formed from one acetyl-coenzyme A and one choline unit in a reaction catalysed 
by choline O–acetyltransferase (ChAT). Upon formation of ACh, it is then released 
from the nerve terminals in the cholinergic synapse. ACh release into the nerve 
terminals in the presynaptic cleft occurs if a high concentration of Ca
2+
 ions is 
present inside the cell. Once diffused into the synaptic cleft acetylcholine binds to 
nAChRs present on the post-synaptic neuron, which becomes activated.
2 
NAChRs are found on both  pre- and  post- synaptic neurons.
6
 Pre-synaptic nAChRs 
are mainly found in the CNS whereas post-synaptic nAChRs are found mainly at the 
neuromuscular junction and autonomic ganglia.
6  
1.2 Structure and Function of nAChRs  
 
NAChRs are members of the ligand gated ion channel (LGIC) superfamily.
7
 They 
were the first neurotransmitter receptors and ion channels to be characterised in 
detail.
7
 They are present in many tissues of the body and have a modulatory 
role.They contribute to the control of the resting membrane potential, modulation of 
synaptic transmission and mediation of fast excitatory transmission.
7
  
There is a common structure amongst nAChRs, consisting of five polypeptide 
subunits assembled from a diverse collection of subunits which assemble together to 
form a pentameric transmembrane structure.
8, 9
 At the centre of this structure the ion 
channel is formed. 
The mechanism of nAChRs is similar for all receptors regardless of the different 
combinations of subtypes.
6, 9, 10
 NAChRs are excitatory and are activated by ACh. 
The muscular nicotinic receptor of the Torpedo californica is considered the 
prototype for all the nAChRs, as receptors in this species of fish are very similar to 
those present in humans.
11
  
14 
 
 
Figure 2: Schematic representation of nicotinic acetylcholine receptor. Bottom: Quaternary 
organization of the heteromeric (centre left) and homomeric (centre right) neuronal receptors.
10
 
1.2.1 Subunit Subtypes 
The four subunits are assigned the Greek letters α, β, γ and δ on the basis of their 
increasing apparent molecular weights.
11
  
To date, 17 nAChR subunits have been identified in vertebrates, which are divided 
into muscle-type and neuronal-type subunits.
6
 Of these, 12 subunits, α2-α10, and β2-
β4 have been identified in neuronal receptor subtypes, which exist in various 
homomeric or heteromeric combinations.
6, 8
An example of a neuronal subtype is the 
(α7)5 nAChR,
11
 a receptor subtype this project has focused on. 
In neuronal nAChRs the α subunits possess a pair of extracellular cysteines Cys 192 
and Cys 193 which are believed to be required for acetylcholine binding whereas the 
β subunits do not.6, 8 In general, each receptor subtype is defined by the combination 
of subunits it contains. This combination of subunits produces subtle changes in the 
ACh binding site and the ion channel, resulting in each receptor subtype exhibiting 
different levels of affinity for various drugs and cholinergic ligands.
11
 Another effect 
of  neuronal nAChR subtypes as a result of combination of subunits is the ability to 
selectively control  the type of ions which flow through the receptor, such as 
differences in cation permeability,
11
 typically much more calcium being allowed 
through the neuronal type than through the muscle type.
12
  
1.2.2 Subunit structure of nAChRs 
The nAChR subunits share the same transmembrane structure and similar amino 
acid sequences, which are 450-700 amino acids long. Each subunit is made up of a 
large extracellular amino-terminal (N-terminus) domain,
13
 which consists of about 
220 amino acids, four transmembrane domains and a small carboxy-terminal (C-
terminus) domain of about 15 amino acids in the extracellular space (Figure 3).
13
 
15 
 
The terminus contains two cysteine molecules bound by a disulphide bond, which 
forms the characteristic Cys-loop.
13
 The transmembrane domains of which there are 
four (M1, M2, M3 and M4) are about 20 amino acids long each, and are separated by 
loops.
13
 The loop between M3 and M4 is larger than the loop between M1 and M2 
by about 130 amino acids, being involved in the regulation of the channel activities 
and also containing phosphorylation sites.
13
  
 
Figure 3.Common structure of a nAChR.
13
  
The transmembrane domains are arranged anti-clockwise, with M2 facing into the 
ion channel pore and the amino acids in the M2 domain forming the main part of the 
ion channel.
14
 There is strong evidence to suggest that the ion channel has mainly an 
α-helical structure, which is mainly negatively charged, as ion channels are only 
permeable to cations.
14
  
The orthosteric binding domains are located at the interface of the subunits, and can 
range from two to five sites depending on the composition of the subunits. In 
addition, modulation of nAChRs can occur by binding to the allosteric domain that is 
distant from the primary active binding site.
12, 15
 
16, 17
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1.3  Heteromeric and Homomeric Receptors 
Neuronal nAChRs form either in heteromeric or homomeric structures.
6
 Heteromeric 
nAChRs are normally made up of α2-α6 and β2-β4 combinations, existing in many 
subunit arrangements to form functional channels, e.g. the α4β2 receptor.6 In 
contrast homomeric receptors  consist of five copies of a single type of subunit, α7, 
α8 and α9 have been shown to form functional homomeric pentamers, with an equal 
number of ACh binding sites, when expressed as recombinant receptors.
6
 The 
subunit composition and arrangement of the subunits in the neuronal nAChRs is 
what gives them their distinct pharmacological and biophysical properties.
11
  The  
most striking pharmacological characteristic of the α7 homomeric receptor is its 
marked permeability to calcium ions.
12  
A number of agonists bind to α7 nAChRs to activate the receptor’s ion-channel, 
these include: ACh, nicotine, epibatidine, and cytosine.
18
 In the brain, neuronal 
nAChRs are located in the hippocampus and cerebral cortex at the pre-synaptic 
membranes.
18
 There they regulate the release of ACh and other important 
neurotransmitters. These receptors are involved in cognitive processes such as 
learning, memory and attention.
19-21
   Changes in the functional activity of nAChRs 
have been implicated in a number of diseases, particularly Alzheimer’s. Moreover, 
amyloid β released in Alzheimer’s disease patients also extensively binds to α7 
nAChRs in the brain and prevents their natural function. As the acetylcholine level is 
limited in the brain of a patient suffering from Alzheimer’s disease, targeting the α7 
nAChR was considered a promising way to enhance cognitive functions.
22
  
An understanding of the functional and molecular properties of these receptors is 
important for understanding their functions in the brain, and to aid development of 
new drug therapies. The α7 nAChR subtype is currently of therapeutic interest, 
particularly, for Alzheimer’s and schizophrenia.23 
1.4 . Orthosteric and Allosteric binding site 
 
The site occupied by the natural ligand, ACh, which is typically located at the 
interface between subunits, is called the orthosteric site.
24
 Depending on the 
composition of the subunits, the number of orthosteric binding sites present can 
17 
 
range from two to five binding sites. An allosteric binding site is a location distinct 
from the orthosteric site where the ligand binds to stabilise the protein in a 
preferential conformation .
24
  
In α7 nAChRs there are 5 potential ACh binding sites. Not all binding sites need to 
be occupied to stabilize the open active state of the receptor, but the probability of 
the channel opening increases upon more orthosteric binding sites being occupied by 
the agonist. 
13, 25
 Different  nAChR ligands can stabilize the conformational state of a 
receptor to which they preferentially bind. Agonists such as acetylcholine (ACh) and 
(-)-nicotine respectively stabilize the active and desensitized states.
13, 26
  
 
Figure 4a: Schematic diagram showing allosteric and orthosteric site of a protein with two 
conformational states, resting (close) and active (open).
24
 
 
Figure 4b. A schematic diagram of the three state model in nAChRs.
24
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Binding of an agonist or a competitive antagonist to an orthosteric site of the nAChR 
stabilises its active and resting states, respectively, whereas binding of an effector at 
an allosteric site alters the overall properties by modifying the energy barriers 
between transitions resulting in a displacement of the equilibrium between states 
(Figure 4b).
13, 24
 Agonists are characterised by having higher affinity for the active 
state than for the resting state, and conversely antagonists have higher affinities for 
the resting/inactive receptor states. 
  
Binding of a ligand to an allosteric site located at some distance from the orthosteric 
site of the receptor complex can also modulate the nAChR signalling via an effect on 
the equilibrium between the resting and active receptor states or on the 
desensitisation kinetics. 
13, 25
 For the description of an allosteric transition state 
model of nAChRs a three state model initially proposed by Heidmann and Changeux 
was developed that involves a resting state, an activated state and a desensitized 
closed channel state, which is a process by which receptors become insensitive to the 
agonist. The changes between these states can be monitored using electrophysiology 
methods.
24
  
 
Structure functional studies carried out on nAChRs have revealed that the short 
amino acid segment between the second and third transmembrane domains is an 
important determinant in the gating process that takes place during receptor 
activation.
8
  
1.5 Alzheimer’s Disease (AD) 
 
Alzheimer’s disease (AD) is a progressive and fatal brain disorder that causes 
memory loss, deterioration of the cognitive centre of the brain, and dementia. Over 
30 million people worldwide are afflicted with the disease. It is estimated that by 
2050, there could be more than 100 million AD patients worldwide. AD dramatically 
affects the quality of life of the sufferers and their families, and despite massive 
investments, there are few, if any, effective treatments for AD. The AD pathogenesis 
involves a complex interplay of genetic and biochemical factors, including an 
increased production of β amyloid peptide and an increased phosphorylation of the 
micro-tubule-associated tau protein.  
19 
 
AD progression is associated with a significant disruption of several 
neurotransmitter systems, including the cholinergic, GABAergic, adrenergic, 
serotoninergic, and glutamatergic systems. Alterations of cholinergic and 
glutamatergic systems have been extensively studied, leading to many 
acetylcholineasterase (AChE) inhibitors.
13
  
1.5.1 Current drug treatments for Alzheimer’s Disease in USA (FDA) and UK 
 
Acetylcholinesterase (AChE) is an enzyme responsible for catalysing the breakdown 
of acetylcholine into acetyl-COA and choline. This enzyme is significant for 
regulating neurotransmission at synapses in the nervous system. The significance of 
AD progression has been reported to be a result of deficits in the cholinergic 
neurotransmission. Donepezil hydrochloride 1, rivastigamine tartrate 2, 
galanthamine hydrobromide 3, tacrine hydrochloride 4, and memantine 5 are 
currently used to treat cognitive symptoms of Alzheimer's disease by acting as 
inhibitors for AChE. They are prescribed to patients suffering with mild to moderate 
stages of AD. These inhibitors are proposed to work by increasing the efficiency of 
cholinergic neurotransmission by preventing the hydrolysis of released ACh, thus 
making more ACh available at the cholinergic synapse.  
 
Figure 5. Structures of cholinesterase inhibitors currently prescribed to patients in USA and UK.  
Despite alleviating effects of cholinesterase inhibitors for AD, inactivation of AChE 
on an excess level can lead to side effects that can be potentially life threatening to 
20 
 
any living organism with a nervous system. In fact, some irreversible 
organophosphate AChE inhibitors are used as insecticides and as chemical warfare 
agents. 
1.6 Non-selective compounds for nAChRs 
 
Many nicotinic ligands have come from a natural source, some having been obtained 
from sources such as nicotine from the plant Nicotiana tabacum, cytisine an alkaloid 
from Cytisus of the family Fabaceae and others from venoms or poisons obtained 
from reptiles or amphibians such as epibatidine, an alkaloid found on the skin of the 
endangered Ecuadorian frog, Epipedobates tricolor. 
1.6.1 Agonists 
               
                             
  
Figure 6. A few selected agonists 
 
Nicotine ditartarte 6 a nicotinic acetylcholine receptor (nAChR) agonist exhibits 
binding affinity (Ki) values of 1, > 1000, 4000 and 7130 nM at α4β2, α1β1δγ, rat α7 
and human α7 receptors, respectively (Figure 6).  
Although (-)-cytisine 7 is considered to be selective for α4β2 (2000-fold higher than 
α7 subtype), selectivity towards heteromeric subtypes is lower with affinity ratios 
between α4β2, α2β2, α2β4, α3β2, α3β4, and α4β4 being 0.4, 5, 14, 56 and 1, 
respectively. Epibatidine 8 is known to be a very potent nicotinic agonist exhibiting 
Ki values of  0.02 and 233 nM for α4β2 and α7 nicotinic receptors, respectively.13 
A number of analogues derived from natural products such as epibatidine and 
nicotine show high potency but fail to exhibit subtype selectivity on nAChRs. As a 
result these compounds are unfit for clinical use due to the risk of unwanted 
metabolic reactions. 
 
21 
 
1.6.2 Antagonists 
 
 
Figure 7. A few non-selective antagonists 
Tubocurare is a mono–quaternary alkaloid found from the plant Chondrodenron 
Tomentosum. Its salt (+)-tubocurarine chloride 9 shows affinity with a number of 
receptors. TMPH hydrochloride 10 is a potent non-competitive antagonist of 
nAChRs. It produces long-lasting inhibition of neuronal nAChRs formed by the 
combination of the most abundant α and β subunits (i.e. α3, α4 and β2, β4 
respectively). Little inhibition of muscle-type (α1β1γδ) or α7 receptors is displayed 
with 10. Strychnine hydrochloride 11 was the first alkaloid to be identified in plants 
of Strychnos, family Longaniaceaea. It is a nicotinic receptor antagonist and 
displays competitive antagonism at α7 receptors and non-competitive antagonism at 
α4β2 receptors. 
1.7 Ligands selective for α7 nAChRs 
 
Rather than targeting the acetylcholinesterase enzyme, extensive research by 
academic and industrial institutes are finding alternative ways to understand  how 
22 
 
agonists, antagonists, type I and type II PAMs can modulate the activity of α7 
nAChRs selectively, which are heavily localised in the brain and has been reported to 
be associated with AD. The compounds mentioned above are being used as leads for 
a new generation of nAChR ligands to minimize cross-activities at mAChRs or other 
receptors. 
1.7.1 Agonists  
 
In response to the challenges associated with the designs targeting specific neuronal 
α/β subtypes several α7 selective nAChR- selective agonists have been reported. 
Agonists are characterised by having higher affinity for the active state than for the 
resting state, and conversely antagonists have higher affinity for the resting/inactive 
receptor states. 
Choline, the endogenous precursor for ACh and metabolic product of ACh 
hydrolysis, has been shown to be a full agonist on native and recombinant α7 
nAChRs with EC50 values around 1 mM, with little or no activity on α4β2, α3β4, 
α3β2, and muscle-type nAChRs.13, 27, 28 However, due to the low potency of this 
compound, the synthesis and pharmacological characterisation has not sparked any 
interest in the development of analogues. 
AR-R 17779 12 a spirooxazolidinone, which is a conformationally restricted 
analogue of (CCh), is a full agonist at the α7 nAChR (Ki 90 nM) displaying 
pronounced selectivity against  numerous heteromeric α/β nAChR combinations.13, 
29, 30
 Due to the limitations of AR-R17779 12 in vivo, attributed to poor 
pharmacokinetic characteristics, AR-R17779 12 displays varying degrees of 
pharmacological effects in cognition models. 
13, 31-35
 
 
   
Figure 8. A few selected examples of selective α7 nAChRs. 
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Quinuclidine structures containing cation centres where the bicyclic ring system is 
coupled directly to an aryl amide, bisarylamide, or a heteroarylamide group (Figure 
8) have been a scaffold of choice for several α7 nAChRs ligands in the 
pharmaceutical industry.
29, 36
 Due to its basic nitrogen, the bridgehead position 
occupied within an azabicyclic system are able to create maximal electrostatic 
interaction combined with minimal steric demand. Owing to the strong basicity of 
quinuclidine derivatives (pKa 10-11), these α7 ligands exist under physiological 
conditions in the cationic form, with a well-defined orientation of the proton.  The p 
– chlorobenzamide analogue PNU-282987 13 has been shown to stimulate signalling 
through an α7/5-HT3 chimera and through native α7 nAChRs with EC50 values of 128 
nM and 3 nM, respectively and a of Ki  27 nM.
37, 38
 TC-1698 14 an analogue of 
nicotine by substitution of the pyrrolidine group for an azabicyclo[3.2.2]nonane ring 
is a full agonist at the α7 nAChR EC50 = 440 nM. TC-1698 has been shown to be 
neuroprotective.
13, 27, 39
 
 
1.7.2 Antagonists 
 
Analogous to nAChR agonists, most of the antagonists for the receptors have been 
obtained from natural sources. Methyllcaconitine 15 (MLA), isolated from 
Delphinium and Consolida species, is a highly selective competitive antagonist of the 
α7 nAChRs (Ki = 1.4 nM). The molecule has also been subjected to small 
modifications which has resulted in elatine and nudicauline, which are equipotent to 
and slightly more potent than MLA as α7 antagonists, respectively. 13, 40    
                                            
                                           Figure 9. Structure of MLA 15 
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Conas peptides obtained from the venom of predatory cone snails provides an array 
of pharmacologically active peptides.
13, 41
 These peptides containing 12-20 amino-
acid residues have the potential to be interesting templates in the design of new 
nAChR ligands.
42, 43
 α-Conotoxin is divided into subfamilies A, M, S, and O based 
on disulphide connectivity. α-Conotoxins possess four cysteine residues with 
disulphide bond formed between the first and third and between the second and 
fourth cysteine residues.The α4/3 –conotoxin ImI was the first α-conotoxin reported to 
inhibit neuronal nAChR signalling (IC50 = 100-200nM).
44
 Recently, α-conotoxin ImII 
has been shown to inhibit α7 nAChR activity with an IC50 = 441 nM. In contrast to 
ImI, ImII does not displace [
125 
I]-α-bungarotoxin binding from the receptor, 
indicating that the two toxins bind to different sites of the receptor.
43
 α-Bungarotoxin 
is another neurotoxin that blocks neuromuscular transmission via irreversible 
inhibition of nicotinic ACh receptors (nAChRs). It functions by preventing the 
opening of nicotinic receptor-associated ion channels and is selective for α7 receptors 
over α3β4 receptors (IC50 values are 1.6 nM and > 3 μM respectively).
10
 
 
1.7.3 Allosteric modulation on α7-nAChRs 
 
The initial functional characterization of the chick α7 nAChR revealed that this 
homomeric receptor displays a rather low sensitivity to ACh and an unusually fast 
desensitization.
24
 Subsequently, numerous studies have confirmed that native α7 
nAChRs of the mammalian central nervous system share similar functional 
properties. Another important feature is the high calcium permeability of the α7 
nAChR.
24
 
In addition to extensive studies aimed at characterizing nAChR subtype selective 
agonists and antagonists, considerable interest has been generated by the 
identification of a diverse group of allosteric modulators of nAChRs,
45-47
 which bind 
to an allosteric site. These include positive allosteric modulators (PAMs), which 
increase the agonist responses by lowering the energy barrier between the resting 
state and active states. In contrast, allosteric ligands that increase the energy barrier 
causing a reduction of the agonist response are termed as negative allosteric 
modulators (NAMs or non-competitive antagonists).
8, 24
 Several α7 selective PAMs 
have been identified and are divided into two types, type I and type II.
8, 24
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1.7.3.1 PAMs of α7 nAChRs 
Currently, positive nAChR modulators at present are useful for the treatment of 
psychotic disorders.
26
 The anthelminthic agent, ivermectin 16 (IVM) was identified 
as the first positive allosteric modulator of the α7 nAChR.24 Ivermectin was found to 
increase maximal ACh-induced current, reduce desensitization and reduce the EC50 
value of ACh.
24
  
 
Figure 10. Structure of ivermectin. 
It was also shown to increase the efficacy of partial agonists, such as 
dimethylphenylpiperazinium (DMPP) (a partial agonist at the α7 nAChR, which 
became almost a full agonist following exposure of the receptor to ivermectin).
24
 
Following this observation, several molecules have been reported to enhance the 
ACh-induced currents at the α7 nAChR. For example, 5-hydroxyindole (5-HI) 17k 
causes a significant increase of subsequent ACh-evoked current.
24
 However, high 
concentrations (1–20 mM) are required for potentiating the α7 nAChRs current, 
since 5-HI is a non-selective and weak ligand (5-HI also modulates the 5-HT3 
receptor).
24
 Genistein 18, a well-known tyrosine kinase inhibitor was found to act as 
an α7 PAM, which like 5-HI, predominantly affected apparent peak current.24  
26 
 
                             
Figure 11. Positive allosteric modulators 5-hydroxyindole (5-HT) 17 and Genistein 18 at α7 
nAChRs.
24
 
1.7.3.2 Type I and Type II PAMs  
 
In addition to compounds 17 and 18 above, a number of compounds have been 
recently reported as positive allosteric modulators with little effect on desensitisation 
kinetics. Ng et al. recently described compound 19 (Figure 12), derived from a 
chemical class previously exploited as GABAA modulators, to enhance α7 nAChR 
currents induced by ACh without affecting desensitization kinetics.
24
 NS-1738 20, 
an analog from a biarylurea series was reported to enhance the potency of ACh as 
well as the maximal efficacy. NS-1738 also improved recognition memory 
performance in rats.
24
  
 
 
 
Figure 12. Structures of type I PAMs.
24
 
 
Type I PAMs as mentioned above, behave by increasing the peak current amplitude 
response whereas type II PAMs, increase both the peak current response and the 
current decay profile. Hence, type II PAMs elicit a longer lasting action than type I 
PAMs towards receptor activation.  
27 
 
PNU-120596 21 one of the better characterized urea analogs, not only increased the 
maximal amplitude and potency of ACh-induced α7 nAChR current by several fold 
(EC50 = 216 nM), but also almost suppressed desensitisation (Figure 13). Another 
striking feature of 21 is its ability to restore responses in an otherwise desensitized 
receptor.
24
 In other words, while continuous exposure to agonist (nicotine) 
desensitizes the α7 nAChR and reduces the response to a non-detectable level, 
application of 21 during continued exposure to the agonist is able to restore a current 
even larger than the peak current evoked by the agonist alone.
24
 This phenomenon 
does not appear to be unique to 21, but may be a common feature of Type II PAMs 
as revealed by analysis of structurally diverse compounds.
24
   
                                  
 
Figure 13.
24
 
Studies have found that compounds with a type II agonist profile preferentially 
stabilizes a state of the receptor that differs from the state normally stabilized by 
agonists. Although both 21 and 20 (Figure 13) are urea derivatives, 20 exhibited 
only minimal effects on the desensitisation kinetics of α7 nAChRs, unlike 21, 
suggesting that these molecules may have different mechanisms or sites of action.
24
 
In vivo studies indicate that 21 improved performance in a rodent short-term 
recognition memory model and further increased the phosphorylation of camp 
response element-binding protein (CREB), a well-recognized biochemical process 
implicated in learning and memory. These observations collectively demonstrate that 
Type II PAMs also exhibit in vivo efficacy in models of cognition.  
Analogs belonging to the tetrahydroquinoline series have also been described as α7 
nAChR PAMs, useful for the treatment of conditions associated with reduced 
nAChR transmission.
24
 Like 21, a prototype 22 (TQS) (Figure 13), increased peak 
current and slowed desensitization of current responses.
24
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1.8 Advantages of α7 PAMs over α7 agonists 
 
A key advantage of allosteric modulation is enhanced receptor activity only in the 
presence of the endogenous agonist, thereby preserving the overall integrity of 
neurotransmission. 
48, 49
 
Positive allosteric modulators (PAMs) have a long and successful clinical track 
record exemplified by the benzodiazepine family of drugs (e.g., diazepam), which 
function as allosteric modulators of GABAA receptors.
48, 50
 The enhancement of α7 
nAChR activity via positive allosteric modulation would provide the advantages of 
employing an allosteric modulatory approach to treat patients afflicted by CNS 
disorders.
48
 It has been postulated that α7 nAChR PAMs might have advantages over 
orthosteric agonists in that they might modulate cholinergic responses and reduce 
receptor desensitisation more effectively. Because coordination of synaptic events is 
crucial in neuronal communication, an ideal therapeutic approach would be to 
enhance the strength of an existing synapse without disrupting overall control 
provided by the endogenous neurotransmitter. At the single ion channel level, this 
would require a drug that does not activate the channel by itself but instead modifies 
the agonist-induced responses.
51-53
  
A number of subtype selective ligands have been developed but none alone offers 
the characteristics of an ideal α7 nAChR PAM where a high selectivity, potency and 
modulation, accompanied by the maintenance of rapid receptor desensitisation 
kinetics are observed.  
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                                               Chapter 2 
2 Synthesis of 4BP-TQS Analogues and Pharmacological Study 
on α7 nAChRs 
2.1  Previous work 
 
Recently work conducted by Millar and co-workers found that  23 (Figure 14) acted 
as an allosteric agonist, which was able to activate the nAChR by binding at a 
transmembrane allosteric site in the absence  of  an endogenous agonist.
54
 Becker 
and co-workers reported that tetrahydroquinoline sulphonamide compounds such as  
22 and 24 (Figure 14), which are a closely related analogs of 23, exhibited positive 
allosteric modulator activity at the α7 nAChR.26 Becker  reports the synthesis of 22 
but not 23. However, indirectly the synthesis of the halogenated tetrahydroquinoline 
compound 24, is reported in the patent. The patent generally discusses the synthesis 
of halogenated TQS compounds where the halogen is either a chlorine, bromine or 
iodine, but no structure or experimental data are provided for these compounds.
26
 
The patent neither specifies nor separates the stereoisomers and  nor does it assign 
the stereochemistry for compounds 22 and  24.  Nevertheless, they have shown a 
more detailed report on compound  25, which is an analogue of  22, they showed that 
the major diastereoisomer from the Pavarov  reaction  to form 25 was the cis-cis 
isomer 25b (Figure 14a),  and in fact they even report separating enantiomers of 
25b, but do not indicate which stereoisomer(s) is/are biologically active.  
  
                                                                       Figure 14 
Thus, prior to the start of our work it had not been proven which isomer(s) of 22 or 
23 were biologically active, nor which was the biologically active enantiomer in 
each case. In the initial work carried out by our collaborators, samples of compound 
30 
 
23 were purchased commercially and the stereochemistry of the compound was not 
specified by the suppliers. Computational docking studies employed a 2D structure 
of 23 and the software arbitrarily modelled the cis-trans isomer. However, we 
believe that the stereochemistry of 23 originally used in Millar’s study was likely to 
be the cis-cis isomer 23b, on the basis of the observations reported by Becker and 
co-workers on the stereochemistry of 25 obtained from the Pavarov reaction. 
      
Figure 14a                                                                                                                                                              
As previously demonstrated by Couterier,
55
 Millar and co-workers showed agonist 
activation on the receptor by ACh causes rapid desensitisation (Figure 15 A, Left).
54
 
Similarly studies with 22 displayed no agonist activity on the  nAChRs (not 
shown),
8, 46, 54
 but 22 caused dramatic potentiation of agonist induced responses, 
together with a dramatic reduction in the rate of desensitisation when 22 was co-
applied with ACh (Figure 15 A (right).
54
 Despite the absence of agonist activity of 
22, a closely related compound 23 was found to act as a potent agonist of α7 
nAChRs.  
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Figure 15.
54
 Positive allosteric modulation of α7 nAChRs by TQS 22, examined by two- electrode 
voltage-clamp recording in Xenopus oocytes. (A) Representative recordings are shown illustrating 
responses to the application of acetylcholine (100 μM) (Left) and of acetylcholine (100 μM) co-
applied with TQS 22 (100 μM) (Right). The duration of agonist applications are indicated by a 
horizontal line. (Scale bars: vertical, 1 μA; horizontal, 5 s). (B) Dose-response data  are presented for 
a range of concentrations of TQS 22 (0.03-100 μM) on responses evoked by a sub-maximal (EC50) 
concentration of acetylcholine. Data were obtained with either wild type α7 nAChRs (filled circles) or 
α7 nAChRs containing the M253L mutation (open circles). Data are means ± SEM of at least three 
independent experiments, each from different oocytes.
54
  
The agonist response induced by 23 displayed little evidence of desensitisation 
(Figure  16 A (Right))
54
, unlike the response observed with ACh (Figure 16 A 
(Left).
54
 The response that was generated by maximal concentration of 23 was larger 
(46 ± 9-fold) than the maximal acetylcholine responses recorded from the same 
oocyte (egg). An increase in the response was observed after agonist application 
ceased, which suggested channel blocking by 23, in addition to its agonist action.  
Half maximal agonist activation required a lower concentration of 23 (EC50 = 10.1 ± 
12.7 µM) than acetylcholine (EC50 = 128 ± 11.8 µM).
54
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Figure 16.
54
 Agonist activation of α7 nAChRs by acetylcholine and 23, examined by two-electrode 
voltage-clamp recordings in Xenopus oocytes. (A) Representative recordings are shown illustrating 
responses to the application of acetylcholine (3 mM) (Left) and of 23 (60 μM) (Right) which were 
conducted 27 times. The duration of agonist applications are indicated by a horizontal line. (Scale 
bars: vertical, 1 μA; horizontal, 5 s). Dose- response data are presented for a range of concentrations 
of 23 (B) or acetylcholine (C) with wild type α7 nAChRs (filled circles) or with α7 nAChRs 
containing either the W148F mutation (open triangles) or the M253L mutation (open squares). Data 
are means ± SEM of at least three independent experiments, each from different oocytes.
54
  
The differences in kinetics and the extent of receptor desensitisation were also 
observed with ACh and 23.
54
 In addition, mutagenic studies of the M253L mutation 
involving replacement of methionine for a leucine in the nAChR’s transmembrane 
domain, led to complete loss of agonist induced response with 23 (Figure 16 B) 
33 
 
whereas ACh showed agonist actiity on the mutant (Figure 16 C). These studies, 
conducted by Millar and co-workers, supported the hypothesis that ACh and 23 
activate α7 nAChRs through different binding sites. In contrast, a mutation known to 
be located close to the conventional agonist-binding site (W148F) had significantly 
greater effect on the agonist potency of ACh than 23 (Figure 16 B and C).
54
  The 
site directed mutagenic studies support the hypothesis that 23 acts as an agonist by 
binding to the same allosteric site that is responsible for potentiation by PAMs such 
as 20 and 21. It was suggested from computer docking simulations conducted with 
an α7 nAChR homology model that it is likely 23 acts as an agonist by binding at a 
similar location to 20,
9
 which has been previously reported to bind to an intrasubunit 
transmembrane cavity.
9, 56
  
It has been reported that W148F is located close to the ACh binding site.
54
 Similarly 
the M253L residue is located close to the binding site for 23.
54
 Further evidence that 
ACh and 23 bind to distinct sites comes from α7-selective antagonist studies with 
MLA 15, which was found to be a competitive antagonist of ACh acting on α7 
nAChRs,
57, 58
 as demonstrated previously,
54 
however, 15 was found to act as a non-
competitive or reversible antagonist to responses induced by 22.
8, 54
 Taken together, 
these findings provided by Millar and co-workers suggested strong evidence that 
ACh and 23 cause agonistic activation of α7 nAChRs by binding to distinct 
orthosteric and allosteric sites, respectively.
8, 54
  
2.1.1 Pavarov reaction 
 
The Pavarov reaction is a variant of the hetero Diels-Alder reaction in which 
tetrahydroquinolines
59-61
 are formed in a multicomponent fashion by the coupling of 
an aniline 26, aldehyde 27, and an alkene 28 via an in situ imine formation (Scheme 
9).  
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Scheme 9. General scheme for the synthesis of tetrahydroquinoline compounds. 
 
This reaction is proposed to follow by a [4 + 2] cycloaddition in a concerted process, 
or a stepwise intramolecular electrophilic aromatic substitution sequence.
59
 
Literature surrounding the Pavarov reaction have involved the use of expensive 
metal triflates,
62
 triphenyl phosphonium perchlorate,
63
 trifluoroacetic acid,
64
 boron 
trifluoride diethyl ether,
59
 and chiral lanthanide Lewis acids to catalyse the 
reaction.
65
  
A wide variety of aniline and aldehydes are known to participate in the Pavarov 
reaction, however, the dienophile component is usually restricted to activated, 
electron rich alkenes, such as enol ethers and cyclic conjugated dienes.
59
  
The stereochemical outcome of these reactions for example with cyclopentadiene as 
the dienophile have commonly observed a mixture of cis: cis and cis: trans 
diastereoisomers with no other isomer being detected (Scheme 10).
66-68
 The 
diastereoselectivity of the product formed has been associated with a number of 
factors such as temperature, solvent and the type of Lewis acid used. For example, 
Powell and Batey employed a mildly Lewis acidic lanthanide DyOTf3 and 
maintained a low concentration of the imine upon addition of aldehyde (Scheme 10) 
to minimize competititve side reactions of these intermediates to maintain good yield 
and high diastereoselectivity.
69
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Scheme 10. Pavarov reaction catalysed by Dy(OTf)3 showing selectivity for the cis: cis 
diastereoisomer as the major product over the cis: trans diastereoisomer.
69 
                                                                                                                                                                                                                                                                                                             
2.2 Aim and Objectives 
 
Having mentioned that the stereochemistry of  23 was unknown in Millar’s study, it 
would therefore seem reasonable to prove which stereoisomers are formed in the 
Pavarov reaction, and thus to shed some light on which stereoisomer is biologically 
active. On establishing the stereochemistry of 23b, which has been reported to bind 
to the intrasubunit transmembrane binding site,
54
 analogues of compound 23b 
(Figure 16) were synthesised in this project by applying a structure activity 
relationship (SAR) approach.  This was to test for allosteric modulation and agonist 
activity at the α7 nAChR. The TQS analogues of 23b can be readily synthesised via 
a Lewis-acid catalysed  3-component reaction between an aniline 26, a substituted 
benzaldehyde 27 and a suitably activated alkene 28 (Scheme 9), most commonly 
known as the Pavarov reaction.
59
  
 
Biological studies of these compounds will provide us with information to 
investigate their mode of binding at the α7 nAChRs, with a view to developing a 
detailed understanding of how subtype selective ligands interact with the α7 nAChR. 
These studies will provide us with information about whether these compounds 
could be used with the purpose of modulating the response of endogenous nAChR 
agonists, such as ACh. Compounds exhibiting allosteric behaviour at the α7 nAChR 
are currently being developed as possible treatments for Alzheimer’s disease and 
36 
 
schizophrenia,
26
 so there is scope for these compounds to be of therapeutic utility in 
the future. 
 
2.3  Results and Discussion 
 
The literature surrounding the synthesis of cyclopentaquinoline compounds are 
limited.
26, 67
 In addition, the Lewis acids commonly used in the synthesis of other 
Pavarov reactions require long reaction times, some Lewis acids are expensive, too 
acidic or are moisture sensitive resulting in degradation, requiring excess amounts of 
Lewis acid to be employed. However, one of the major drawbacks with these Lewis 
acids is their limited substrate compatibility. A report by Perumal
67
 and a patent by 
Becker et al. reported use of InCl3 as the Lewis acid to be compatible with electron 
withdrawing groups, such as the sulphonamide functionality in sulphanilamide. 
Given that the stereochemistry of 23 was not known from Millar’s study, using  
InCl3, 23 was synthesised which was isolated as the cis: cis major isomer 23b in 
82% yield. The pharmacological response of 23 was found to be similar to the 
response initially reported for 23b exhibiting 38 and 45 fold, respectively.
54, 71
 This 
suggests that the stereochemistry of 23 might be the cis: cis isomer. Based on this 
study, this Lewis acid proved successful for the synthesis of 23b from the preformed 
imine 29 (Figure 17) and cyclopentaquinoline analogues of 23b in the presence of 
cyclopentadiene as the dienophile and a substituted benzaldehyde in acetonitrile at 
room temperature.
26
  
 
Figure 17 
Our initial studies involved modifying the aldehyde component. The rationale 
behind synthesising these initial analogues was to compare the pharmacological 
response of 23b with compounds when the position of the bromine atom is varied 
(Table 2, Entry 3 and 13) and when more than one bromine atom is present on the 
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phenyl ring (Table 2, Entry 11). The synthesis of analogues with increasing halogen 
atomic radii was also considered to be another approach to acquire interesting 
pharmacological data (Table 2, Entry 2, 4 and 7). Modifications by incorporating a 
hydrogen (Table 2, Entry 1), methyl group (Table 2, Entry 12) and a hydroxyl 
group (Table 2, Entry 5) at the para position on the phenyl group, and a bioisostere 
of bromine such as a triflouromethyl group at the para position on the phenyl were 
also considered (Table 2, Entry 10). In addition, it seemed sensible to synthesise an 
analogue 2-Napthyl-TQS 25b (Table 2, Entry 9) of the well documented 1-Napthyl-
TQS 22b (Table 2, Entry 14) given that it acts as a potent type II PAM as reported 
by Gill. It is worth mentioning that the diastereoisomer of the previously 
documented compound 22 was not known.
54
  
In all cases the reaction proceeded smoothly to give the corresponding 
cyclopentaquinolines (Table 2, Entry 1-14) as the cis: cis diastereoisomer from the 
four possible conformations in Scheme 11.  
 
Entry No. R
1 
dr
 
(22-25b to 30b-
39b: unknown
(b)
)
 
Yield (%) 
1 30b 4-H 95: 5
 
51 
2 23b 4-Br 95: 5
 
82 
(a) 
3 31b 3-Br 95: 5
 
49 
4 32b 4-Cl 95: 5
 
63 
5 33b 4-OH 81 : 19
 
32 
6 24b 4-F 89 : 11 
 
2 
7 34b 4-I 92 : 8
 
15 
8 35b
(c) 3-I (c) 8 
9 25b 2-Napth 92 : 8 
 
9 
10 36b 4-CF3 95 :5 72 
11 37b 3,4-DiBr 95 :5 37 
38 
 
12 38b 4-Me 95 :5 44 
13 39b 2-Br 95 :5 60 
14 22b 1-Napth 83: 17 22 
Table 2 (a) Product made via the preformed imine 29 (b) Configuration of minor isomer not determined 
for 22b-25b to 30b-39b; (c) Ratio of isomers could not be determined from crude nmr as broad peaks 
were observed, however, after purification the isomer 35b was observed. 
The structural assignment of cis- and trans-isomers was made on the basis of 
comparing the measured coupling constant values between protons –C12H and –C11H 
and protons –C12H and –C7H (Scheme 11) by 
1
H NMR and the calculated coupling 
csonstant values of the protons determined using PC model system v8.5 software, 
under the guidance of Dr. Abil Aliev.  
For example in (Table 2, Entry 1), 
1
H NMR analysis of the reaction between 
benzaldehyde 27, sulphanilamide 26 and cyclopentadiene 28 showed stereoselectivity 
for the cis-cis diastereoisomer 30b entirely, out of the four possible stereoisomers.    
                
Scheme 11. Structure of four possible diastereoisomers of 30 formed during the reaction with their 
calculated coupling constant values (Hz), determined by PC Model system v8.5 software. 
The structural assignment of 27b was made on the basis of the measured coupling 
constant values by 
1
H NMR (J12-11 = 8.7 Hz and J12-7 = 3.2 Hz). The computer model 
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system showed that the coupling constant values were consistent with the cis-cis 
configuration  30b (Figure 19) with calculated coupling constant values J12-11= 7.2 Hz 
and J12-7 = 4.5 Hz, respectively (Table 3). This stereochemistry measured is further 
supported by Perumal and co-workers, reporting coupling constant values of J12-11 = 
8.6 and J12-7 = 2.9 Hz, respectively for the structure shown below 40b  (Figure 18).
67
  
 
  40b 
Figure 18.   
On using the computer model system to determine the torsion angle between protons 
(H-12-C-12-C-11-H-11) for the model structure for Entry 1 was calculated to be -
34.1˚, which is consistent with the measured coupling constant of J12-11 = 8.7 Hz by 
1
H NMR as mentioned before for 30b. Similarly, torsion angle (H-12-C-C-7-H-7) 
for the model structure was calculated to be 53.8˚ which is consistent with the 
observed coupling constant J12-7 = 3.1 Hz, with a syn relationship for these protons 
(Figure 19). In contrast, coupling constant values calculated by the model system for 
isomers 30a (J12-11 = 11.9 Hz and J12-7 = 11.2 Hz), 30c (J12-11 = 12.0 Hz and J12-7 = 
4.3 Hz and 30d (J12-11 = 6.7 Hz and J12-7 = 11.1 Hz) did not correspond with the 
measured coupling constant values for 30b determined by 
1
H NMR. 
40 
 
 
Figure 19. Calculated structure of compound 30b determined by PC Model system v8.5 software. 
Similar coupling constants were measured for other cyclopentaquinoline compounds 
synthesised, further supporting the synthesis of all cis: cis diastereoisomer in each 
case. Calculated and measured coupling constants for compounds 22b-25b and 30b-
39b are tabulated below (Table 3). 
R-1 Compound 
No. 
J12-11  
measured 
(Hz) for 
22b-25b to 
30b-39b 
J12-11  
calculated 
(Hz) for 
22b-25to 
30b-39b. 
J12-7 
measured 
(Hz) for 
22b-25b to 
30b-39b. 
J12-7 calculated 
(Hz) for 22b-
25b to 30b-
39b 
4-Br 23b 8.7 7.2 3.1 3.2 
3-Br 31b 8.5 7.1 3.1 3.2 
4-Cl 32b 9.0 7.1 3.1 3.2 
4-OH 33b 8.1 7.1 3.1 3.2 
4-F 24b 8.8 7.1 3.4 3.2 
4-I 34b 8.7 7.1 3.3 3.2 
3-I 35b 8.5 7.1 2.6 3.2 
2-
Napth 
25b 8.4 7.1 2.7 3.2 
4CF3 36b 8.5 7.0 2.7 3.1 
J12-11 = 7.2 Hz 
J 12-7 = 4.5 Hz 
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3,4-
DiBr 
37b 8.7 7.1 3.2 3.2 
4-Me 38b 8.4 7.1 3.4 3.3 
2-Br 39b 7.0 6.7 2.9 3.0 
1Napth 22b 8.8 6.8 1.6 3.0 
Table 3. Measured coupling constants (Hz) determined by 
1
H NMR and measured coupling constants 
(Hz) determined by PC Model system v8.5 software. 
The mechanism for this multicomponent reaction is still under debate but has been 
proposed to occur via a stepwise mechanism as suggested by Whiting (Scheme 12).
70
 
The postulated mechanism is thought to occur by nucleophilic attack of the 
cyclopentadiene on the top face of the activated imine, since the imine is not 
electrophilic enough for a nucleophlilic attack, a suitable Lewis acid is used such as 
InCl3. The new carbon-carbon bond formed rotates to enable nucleophilic attack by 
the aromatic ring on the carbocation. Re-aromatisation then drives the reaction to 
favour the observed cis: cis diastereoisomer. 
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Scheme 12. Proposed mechanism towards the cis: cis isomer, (below) 3D structure of 23b.
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2.4 Biological testing results (work conducted by JasKiran Gill and 
Neil Millar, at UCL Pharmacology)  
 
It was of interest to initially study the allosteric agonist response of the para-
halogenated TQS compounds and to compare it with the agonist response of 23b. As 
observed previously for 23b, compounds containing either a chlorine or an iodine 
atom at the para position (32b and 34b, respectively) were found to have potent 
agonist activity on α7 nAChRs (Figure 18 and 19).  
 
 
Figure 18. Compounds exhibiting allosteric agonist activity at the α7 nAChRs together with their 
potency values Imax (fold > 3mM ACh). 
 
However, replacement of the bromine atom at the para position for a fluorine atom 
(24b) led to a complete loss of agonist activity (Figure 19). The half maximal 
agonist response (EC50) values determined for 23b, 32b, and 34b were not 
significantly different from one another. Interestingly, the agonist concentrations of 
these compounds causing half-maximal activation were significantly lower than that 
of acetylcholine (EC50 128 ± 12 µM). 
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                                  Figure 19. Dose response curve
71
 and structure of 24b. 
 
Activation of α7 nAChRs by acetylcholine results in rapidly desensitising responses 
when ACh is applied for a long duration as previously reported by Couturier.
55
 
When α7 nAChR activation with p-halogenated TQS compounds was studied (Table 
4).
72
 A significant slowing in the rate of desensitisation was observed as the atomic 
radii of the halogen increased, with 23b and 34b showing largely non-desensitizing 
responses
54
 when examined over a long timescale (Figure 20). 
 
Substituent Van der Waals radii (Ǻ) 
H 1.20 
F 1.47 
Cl 1.77 
Br 1.92 
I 2.06 
Me 2.0
(b) 
O of OH 1.52 
 
Table 4. Showing the effective van der waals radii value of bound substituent on phenyl from liquid 
state calulations rw, Ǻ.
(b) 
Van der Waals radii value of a free methyl group (Ǻ). 73 
Interestingly, when a halogen at the para position was replaced with a methyl group, 
long applications resulted in a similar non-desensitizing response as observed with 
24b
32b
23b
34b
38b 
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23b and 34b. This might be due to the similar atomic radii of the methyl group 
compared to bromo and iodo group (Table 4). 
 
Figure 20. Graph illustrating the activation and desensitisaton rates upon continued exposure of 
maximum concentration of agonist on the α7 nAChR. 71 
 
In addition, the rate at which receptors return to their resting state after agonist 
activation differs between the three halogen-containing agonists (Figure 20). Rates of 
desensitisation, rates of activation, and also rates of recovery after removal of agonist 
were found to increase as the size of the halogen atom decreased (Figure 20). 
However, introduction of the fluorine atom at this position (24b) resulted in a 
complete loss of agonist activity. A further difference in activation by acetylcholine 
and by 23b, 32b or 34b is the slower activation rate that is observed with the latter 
compounds (Figure 20). However, in all cases, levels of desensitization caused by 
these compounds were much slower than the very rapid desensitization that is 
characteristic of α7 nAChRs when activated by acetylcholine.55 
The differences in activation rates of para-halogenated TQS compounds prompted our 
collaborators to examine the consequence of coapplication of acetylcholine with 
allosteric agonist 34b (Figure 21). This was to see if allosteric agonists can 
potentiate/increase the ACh response at the α7 nAChRs when co-applied. Although 
this was not observed, interestingly, the response of receptor activation obtained can 
be explained by dividing the response into two components (Figure 21). The initial 
response is the rapid activation and desensitisation, characteristic of ACh activation. 
This is followed by a secondary response, which is a slow but increased rate of 
activation and very slow desensitisation, characteristic of the 34b response when 
applied on its own (Figure 21). These two components of the agonist response are, 
32b 
23b 
38b 
34b 
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presumably, a consequence of the ability of acetylcholine to access its extracellular 
orthosteric binding site more rapidly than the allosteric agonists are able to access 
their binding sites.  
 
 
 
Figure 21. Profile showing activation of α7 nAChR by acetylcholine (3mM) (left), (right) profile  
showing activation upon coapplication of acetylcholine (3 mM) with 4IP-TQS 34b (100 μM). 71 
 
This observation is further evidence for a difference in the mechanism of action of 
these two classes of agonist. In previous studies Millar and co-workers have 
demonstrated that the response to a submaximal concentration of 23b is greatly 
potentiated by the subsequent coapplication of acetylcholine, indicating that 23b 
may be more potent as a positive allosteric modulator than as an allosteric agonist.
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Similar experiments conducted with other allosteric agonists described in the present 
study suggest that this is a common phenomenon for this series of compounds. 
Interestingly, 35b and 36b also exhibited allosteric agonist responses at the α7 
nAChR. However, their responses were much lower in comparison to the para-
halogenated compound and 38b with Imax values of 2.0 ± 0.4 and 0.94 ± 0.14, 
respectively (Figure 22).
71
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Figure 22. Bar graph of TQS compounds with allosteric agonist responses at the α7 nAChR.71 
 
Of particular note, a much faster activation rate was observed with ACh than with 
any of the allosteric agonists examined. 
 
2.4.1 PAM activity at the α7 nAChR 
 
The pharmacological effect of the relative influence of the size and position of other 
groups attached to the phenyl ring were examined. Inclusion of a hydrogen atom or 
hydroxyl group at the para-position (30b and 33b) resulted in complete loss of 
agonist activity (Figure 22), with atomic radii values of 1.20 and 1.54 Ǻ (Table 4) 
respectively, which are significantly smaller in comparison to the atomic radii values 
of the halogens (Table 4). These findings support the conclusion that a relatively 
large group attached to the 4-position of the phenyl ring is required for agonist 
activity. In addition, 25b, in which the naphthyl group is attached in an orientation 
different from that in TQS 22b (Figure 22) displayed agonist activity in contrast to 
22b.
54
 Taken together, these findings provide strong evidence that a relatively large 
group is required at the 4-position of the phenyl ring to confer agonist activity.  
        39b  33b  37b   32b  35b  24b  27b 22b  32b  23b   34b  38b  25b  36b 
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Despite the lack of agonist activity observed with 22b, in all cases, PAM activity 
was retained (Figure 23 and 24). It seems, therefore, that relatively minor changes 
to the structure of these compounds can have a profound influence on their 
pharmacological properties. It is possible that these differences can be explained 
entirely by steric effects. For example, the slower activation rate observed with 34b 
than with either 23b or 32b may be a consequence of reduced accessibility to its 
binding site. 
 
Figure 23 Bar graph of TQS compounds with type II PAM responses at the α7 nAChR 71 
 
Although it is possible that the differences in size between fluorine and the other 
three halogens could explain the differences in agonist activity observed, differences 
in chemical properties may also be significant. For example, halogens differ in their 
electrostatic surface potential and eletronegativities. Indeed, such differences have 
been suggested to be responsible for the ability of organic compounds containing 
chlorine, bromine, or iodine (but not those containing fluorine) to form halogen 
bonds.
74, 75
 However, the fact that agonist activity was seen when the halogen atom 
was replaced by a methyl group 38b or a trifluoromethyl group 36b but not when it 
was replaced with a hydrogen atom 30b or a hydroxyl group 33b suggests that the 
sterics and not electronics of the group attached to the 4-position of the phenyl ring 
         39b         31b        37b        32b         35b        33b        30b      22b 
49 
 
may be more important than its electrostatic properties in determining allosteric 
agonist activity.  
 
It is clear that alterations at the para-position of the phenyl ring have a dramatic 
effect on the agonist effects of this series of compounds. It is also of interest that the 
compounds lacking agonist activity (39b, 31b, 35b, 37b, 24b, 33b, and 30b), all 
increased acetylcholine-induced responses (Figure 24) when tested for PAM 
activity.
46, 54
  
 
 
Figure 24. Compounds exhibiting positive allosteric agonist activity together with their potency 
values fold Potentiation values refers to sub maximal (EC50) concentration of ACh (100 µM). Imax 
Potency (fold > 100µM ACh). 
 
Such effects are typical of a range of compounds that have been described as nAChR 
PAMs. Relatively small changes in chemical structure result in clear 
pharmacological differences. For example, as has been reported previously,
46, 54
 
minimal desensitization  is observed with TQS 22b (Figure 25 A), which acts as a 
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classic “type II” PAM, causing potentiation of acetylcholine evoked responses and a 
dramatic loss of receptor desensitization. In contrast, progressively faster rates of 
desensitization were observed with the other PAMs examined (Figure 25 B). The 
terms “type I” and “type II” have been used extensively to describe PAMs acting on 
α7 nAChRs that either have no effect on receptor desensitization  (type I) or cause a 
loss of desensitization (type II). Just as differences were observed in the rates of 
desensitization of α7 nAChRs after activation by 23b, 32b, and 33b, our 
collaborators JasKiran Gill and Neil Millar observed a marked difference in the rate 
of desensitization after potentiation of acetylcholine-evoked responses with different 
PAMs (Figure 25).
71
  
 
Figure 25A. Graph illustrating the differences in activation and desensitization rates for various 
PAMs. The PAM (100 μM) was preapplied for 5 s and then coapplied with a submaximal (EC50) 
concentration of acetylcholine (100 μM).71 
 
 
 
Figure 25B. Graph illustrating the differences in activation and desensitization rates for various 
PAMs. The PAM (100 μM) was preapplied for 5 s and then coapplied with a submaximal (EC50) 
concentration of acetylcholine (100 μM) 71 
5 s 
31b 
37b 
39b 
22b 
33b 
24b 
35b 
30b 
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This study suggests that in addition to the size of the halogen atom being important 
in determining pharmacological properties, the position of the halogen is also 
critical. This was illustrated by the finding that changing the location of the bromine 
from the para position to either the ortho or meta position  and changing the position 
of iodine from the para position to meta position resulted in loss of agonist activity 
(39b, 31b and 35b), respectively (Figure  25A). Likewise, no agonist activity was 
observed for 37b, indicating that the allosteric agonist properties of 23b can also be 
lost by the addition of a second halogen atom to the phenyl ring at the 3 position. 
Taken together, these results clearly show that the position, as well as the size, of 
groups attached to the phenyl ring is critical in determining agonist activity. 
 
2.4.2 Antagonism by 4FP-TQS 24b of 4BP-TQS 28b Evoked Responses 
 
As has been described above, the replacement of a single bromine atom with a 
fluorine atom converts the allosteric agonist 23b into a PAM that lacks agonist 
activity 24b. On the basis of previous studies with α7- selective allosteric 
modulators,
54
 
76
 it seems reasonable to hypothesize that 23b (an allosteric agonist) 
and 24b (a type II PAM) might bind competitively at a common allosteric site. 
Hence, would be reasonable to predict that 24b would act as an antagonist if 
coapplied with 23b, if the hypothesis is correct. The hypothesis was tested by 
applying 23b (10 µM) and then coapplying 23b with a range of concentrations of 
24b (Figure 26). As predicted, the coapplication of 24b resulted in a dose dependent 
inhibition of responses evoked by 23b, with an IC50 concentration of 4.4 ±1.3 μM 
(Figure 26).  
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Figure 26. Antagonism by 4FP-TQS 24b of 4BP-TQS 23b-evoked responses on α7 nAChRs.Graph 
showing activation of wild-type α7 nAChRs by 4BP-TQS 23b (10 μM) followed by the coapplication 
of 4FP-TQS 24b (100 μM). 71 
 
In contrast, coapplication of 4FP-TQS 24b with acetylcholine results in a dose-
dependent potentiation of responses evoked by acetylcholine, with an EC50 
concentration of 23 ± 8.1 μM (Figure 27) at the native α7 receptor. However, no 
potentiation of ACh by 24b was observed at the mutant α7 receptor. 
 
 
Figure 27. Dose-response data presented for a range of concentrations of 4FP-TQS on responses 
evoked by a submaximal (EC50) concentration of ACh with either wild-type α7 nAChRs or α7 
nAChRs containing the M253L mutation
71 
 
These findings suggest that 23b and 24b bind to a common site, which is distinct 
from that of acetylcholine. It was also demonstrated that α7 nAChR PAMs such as 
24b can act as antagonists of responses evoked by allosteric agonists such as 23b. 
The simplest explanation for this observation is that these two chemically similar 
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allosteric modulators interact at a common site. The binding of a PAM such as 24b 
to its allosteric site can have two different effects: allosteric potentiation of responses 
to orthosteric agonists such as acetylcholine and antagonism of responses to 
allosteric agonists such as 24b. The former is presumably a consequence of 24b and 
acetylcholine binding to different sites, and the latter is a consequence of 24b and 
23b binding competitively to a common site.  
 
2.4.3 Influence of the Transmembrane M253L Mutation 
 
 
It is well established that acetylcholine activates nAChRs by binding to an 
extracellular site. In contrast, recent studies have proposed that α7-selective PAMs 
such as 22b and allosteric agonists such as 23b act via a transmembrane binding site. 
54, 76, 77
 Evidence supporting this proposal is that potentiation by 22b and agonist 
activation by 23b are completely suppressed on α7 receptors containing the 
transmembrane mutation M253L.
54
 In contrast, M253L has been shown to have no 
significant effect on activation by the conventional orthosteric agonist 
acetylcholine.
54
 The effect of M253L on agonist activation by 32b, 34b, and 38b 
were examined, and it was found to cause complete loss of agonist activation. In 
addition, the effect of M253L on allosteric potentiation by 30b, 31b, 33b, 24b, 35b, 
37b, and 39b were examined, a complete loss of PAM activity of these compounds 
were observed. These findings support the conclusion that all of the TQS-related 
compounds examined in this study act by a similar mechanism of action. The 
simplest explanation  is that they all act via a common allosteric binding site, as has 
been proposed previously for 22b and 23b.
54
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2.4.4  Conclusion 
 
1) Allosteric agonists and PAMs of α7 nAChRs bind to a common transmembrane 
site.
54, 76, 77
 This is supported by evidence that the effects of both allosteric 
agonists and PAMs can be blocked completely by a single point mutation 
(M253L) located in the transmembrane region: a mutation that has no 
significant effect on agonist activation by acetylcholine.
76
  
2) As atomic radius of the halogen increases the rate of desensitisation is slowed 
significantly. 
3) 38b elicits allosteric agonist activity at the α7 nAChRs suggesting that sterics 
not electronics governs allosteric agonist activity (Figure 28). 
 
 Figure 28. Structure of 38b.  
 
4) Both allosteric agonists and PAMs are presumably able to stabilise the open 
state of the receptor.  
5) The difference between the two classes of allosteric modulator is that those 
compounds that lack agonist activity are able to stabilise the open conformation 
of the receptor efficiently only in the presence an orthosteric agonist, such as 
acetylcholine. 
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2.5 Synthesis of methylated TQS compounds 
 
Having previously reported that 38b elicits allosteric agonist activity at the α7 
nAChR,
71
 it was proposed that subtle changes to the TQS structure were made by 
varying the position of the methyl group, as well as the number of methyl groups 
attached to the phenyl group. This might result in differences in the chemical and 
pharmacological properties as was observed with the halogenated TQS compounds.  
There are 19 different benzaldehydes incorporating only methyl substituents on the 
aromatic ring, of which 13 of these methyl benzaldehydes are commercially 
available. The other 6 methyl benzaldehydes are not commercially available and were 
synthesised (Figure 29).  
                                        
                                               
Figure 29. Structures of substituted methyl benzaldehydes that are not commercially available. 
Literature surrounding the synthesis of the 6 non-commercial methyl benzaldehydes 
are limited, with use of reagents such as sulphuric acid,
78
 potassium permanganate,
79
 
titanium tetrachloride,
80
 carbon disulphide
81
 and NaOH (16 M) in the Reimer 
Teimann reaction.
82
 However, neither seemed promising as some conditions either 
require use of starting materials and reagents which are expensive, the reaction results 
in a mixture of products, requires harsh conditions or is laborious. Although a mild 
procedure using trimethyl- or triethyl- orthoformate seemed a promising approach to 
synthesise the corresponding benzaldehyde in one step,
83
 no reaction occurred, 
affording just the starting material (Scheme 13). 
 
56 
 
 
 Scheme 13. Reaction of 2, 4-dimethyl phenol with trimethyl orthoformate and aluminium trichloride. 
Some years ago Langer and co-workers demonstrated that salicylates can be formed 
by TiCl4-mediated [3+3] cyclization of 1,3-bis (silyl enol ethers) 41 with 4-
(silyloxy)pent3-en-2-ones 42 in moderate to good yields (Scheme 14).
84
 However, 
overall this method is laborious as the starting materials need to be synthesised, in 
addition triflation of the hydroxyl group and reduction to the corresponding aldehyde 
adds additional steps. An alternative approach was to synthesise these compounds 
from more readily available aryl precursors. 
 
Scheme 14. General scheme for the synthesis of  salicylates under Lindel’s reaction conditions.84 
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2.6.1 Synthetic route towards methyl substituted benzaldehydes. 
 
Given that many poly-methylated phenols are cheap and commercially available, we 
envisaged that the desired methyl benzaldehydes could potentially be synthesised by 
formylation of the corresponding phenol in an electrophilic aromatic substitution 
reaction with dichloromethyl methyl ether in the presence of a Lewis acid,
85
 followed 
by cross-coupling of the phenol-derived triflate
85
 with methylboronic acid.
86
   
 
 
 
 
                    
58 
 
 
 
Scheme 14 (a) Product 44a-g: AlCl3 (1.2 eq), Cl2HCOMe (1.2 eq), -10°C in CH2Cl2, -10°C, 2 hrs.
85
 b) 
Product 45a-g : NEt3 (3eq), Tf2O (1.1 eq), CH2Cl2, -78°C, 2.5 hrs.
85
 
The phenols 43a-e underwent formylation with dichloromethyl methyl ether and AlCl3 
in moderate to good yields to give aldehydes 44a-g, which was converted into the 
corresponding trifluoromethanesulfonates 45a-f (Scheme 14). The formylation of 
phenols 43c and 43d gave a mixture of isomeric aldehydes where 43d gave the major 
product as the undesired para-substitution product 44e. The desired ortho-substitution 
product 44f was therefore obtained selectively by column chromatography isolated in 
15%. This was subsequently converted into aryl trifluoromethanesulfonate 45e (Scheme 
14). The formylation of phenol 43c, gave a mixture of isomeric aldehydes 44c and 44d, 
which were converted to a mixture of the two corresponding triflates 45c and 45d. This 
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mixture of isomers is not problematic as both triflates 45c and 45d will be converted 
into aldehyde 46d upon Suzuki coupling with methyl boronic acid.  
With the desired trifluoromethansulfonates in hand, we then turned our attention to the 
proposed Suzuki cross-coupling with methyl boronic acid (Scheme 15 and 16(b)). A 
procedure reported by Molander
86
 involving use of (dppf)PdCl2  as the catalyst for the 
cross-coupling of methyl boronic acid with aryl triflates proved successful, giving 
excellent conversion of the aryl trifluoromethanesulfonates 45a-f to give the desired 
product 46a-f. 
 
Scheme 14 
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Scheme 15: (a) PdCl2dppf.CH2Cl2 (10 mol%), K2CO3 (2 eq), MeB(OH)2 (3 eq), THF : H2O (20: 1), 
reflux, 24 hrs.
(b) 
PdCl2dppf.CH2Cl2 (15 mol%), K2CO3 (3eq), MeB(OH)2 (5eq).
86
 
The remaining aldehyde 46f could be easily synthesized from commercially available 
diphenol 43f (Scheme 16) via trifluoromethanesulfonate formation and cross-coupling 
followed by a reduction/oxidation sequence to convert the ester to the aldehyde 46f. 
 
Scheme 16. Conditions: (a) Tf2O, Et3N, CH2Cl2, 99%;
85
 (b) MeB(OH)2, K2CO3, PdCl2.dppf, THF:H2O, 
reflux, 87 %;
86
 (c) DIBAL (1.5 eq), diethyl ether, -78°C, 4hrs, 63 %.
87
 (d) Oxalyl chloride (1.1 eq), 
anhyd. DMSO (2 eq), CH2Cl2 (3 ml), methylbenzyl alcohol (1 eq) and NEt3 (3 eq) at -78°C, 3 hrs, 
18%. 
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All possible combinations of mono-, di-, tri-, tetra-, and penta-methylated TQS 
compounds were synthesised. Under previous conditions reported by Becker,
26
 the 
corresponding methylated TQS compounds were synthesised and isolated with yields 
ranging from 12 %-99 %, as shown (Table 5) below.  
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Entry No. Benz-
aldehyde 
dr 47b-64b: 
unknown
(a) 
dr 
unknown
(a)
 
:47a-64a 
Yield (%) 
1 47b 2-Me 93 :7 - 99 
2 48b 3-Me 92 : 8 - 81 
3 49b 2,4-DiMe 91 : 9 - 99 
4 50b 3, 4-
DiMeTQS 
85 :15 - 17 
5 51a 2, 3, 4, 5, 6-
PentaMe 
- 5: >95 10 
6 52b 2, 4, 5-TriMe >95: 5 - 32 
7 53b 3, 5-DiMe >95: 5   - 12 
8 54b 2, 5-DiMe 92 : 8 - 56 
9 55a 2, 6-DiMe - 5:  > 95 21 
10 56b 2, 3-DiMe 87 : 13 - 33 
11 57a 2, 3, 5, 6-
TetraMe 
- 5: >95 46 
12 58a 2, 4, 6-TriMe - 5: >95 35 
13 59b 2,3,4-TriMe 89 : 11 - 66 
14 60b 2,3,5-TriMe 86 : 14 - 36 
15 61a 2,3,6-TriMe - 5 : >95 35 
16 62b 3,4,5-TriMe 76 : 24 - 59 
17 63b 2,3,4,5- 89 : 11 - 56 
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TetraMe 
18 64a 2,3,4,6-
TetraMe 
- 5 : >95 28 
Table 5 
(a)
 Configuration of the minor diastereoisomer not determined. 
 
From the 18 methylated TQS compounds synthesised, compounds 51a, 55a, 57a, 58a, 
61a and 64a were isolated as the single trans: cis isomer (Table 5). Compounds 52b 
and 53b were isolated as the single cis: cis isomer (Table 5). The other 10 methylated 
TQS compounds were isolated as a mixture of isomers, with the major isomer being 
the cis: cis isomer (Table 5) and the minor isomer not determined. The configuration 
of these compounds was further supported by PC model system software (data shown 
in experimental section). This stereochemistry measured is further supported by 
Perumal and co-workers, reporting coupling constant values of J12-11 = 8.6 and J12-7 = 
2.9 Hz, respectively for the structure shown below 40b (Figure 18).
67
  
 
Figure 18.  Stucture of 40b 
 
 
 
 
 
 
 
 
 
63 
 
2.6.2 Biological test results of methylated TQS compounds (work conducted 
by JasKiran Gill and Neil Millar, UCL Pharmacology) 
  
Given the interesting pharmacological response observed with 38b, which behaved 
as a potent allosteric agonist at the α7 nAChRs,71 it seemed reasonable to explore 
similar compounds by varying the position of the methyl group, and the number of 
methyl groups introduced on the phenyl ring. These modifications resulted in an 
array of pharmacological responses to be observed at the α7 nAChRs.  
From the 19 compounds synthesised, compounds 38b, 49b, 50b, 56b, 59b, 62b and 
63b (shown below) exhibited allosteric agonist activity at the α7 nAChR (Figure 
30). 
 
Figure 30. Allosteric agonists (a) Imax at (fold > 3 mM ACh); 
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These compounds gave responses ranging from 2.6 to 16.3 fold, with 49b exhibiting 
the greatest allosteric agonist response of 16.3 fold (Figure 30).  
Compounds 47b, 48b, 52b, 53b and 54b (shown below) exhibited type II positive 
allosteric agonist activity (Figure 30). 
     
Figure 31. Type II PAMs Imax (fold > 100 µM ACh). 
 
The biological activity of these type II PAMs showed potentiation responses of ACh 
at the α7 receptor, ranging from 2.1 to 40 fold, with 47b exhibiting the greatest 
potentiation of ACh with 40 fold (Figure 31).  
Compounds 51a, 64a and 60b showed type I PAM activity (Figure 32 below), with 
potentiation responses of ACh ranging from 2.4 to 5.3 fold. Compound 60b showed 
the greatest potentiation of ACh response (Figure 32).  
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                                      Figure 32.Type I PAM Imax (fold > 100 µM ACh) 
It is worth mentioning that 60b exists as the cis: cis isomer whereas 51a and 64a are 
trans: cis isomers (Figure 31). 
For compounds 57a and 58a, neither potentiated nor inhibited ACh-evoked 
responses were measured (Figure 33). This might be because the aromatic ring with 
the methyl groups are symmetrical, cancelling the overall response. 
 
Figure 33. No effect on ACh response 
Compounds 55a and 61a behaved as antagonists for ACh with moderate inhibitory 
effects at the α7 receptor (Table 6, Figure 34).  
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Figure 34. Antagonists for ACh 
Compound % inhibition of ACh of 
100 mM 
IC50 μM 
55a 73.6 ± 4.2 43 ± 14 
61a 68.2 ± 2.8 23 ± 2.8 
Table 6. 
Compound 61a is more potent than 55a, with IC50 values of 23 and 43 µM, 
respectively. However, 55a showed greater % inhibition of ACh than 61a with a 
inhibition value of 74 %. 
It is worth mentioning that most of the methylated TQS compounds tested were 
isolated as a mixture of diastereoisomers, so there might be a major influence of the 
minor isomer on the overall pharmacological response of each methylated TQS 
compound. However, with methylated TQS compounds 51a, 64a, 57a, 58a, 55a and 
61a, which were isolated as the single isomer in the trans: cis configuration with 
>95: 5 diastereoselectivity, we can be confident in concluding that trans: cis isomers 
exhibit either a type I PAM, antagonist of ACh or show no pharmacological effect. 
None of theses compounds were allosteric agonists or a type II PAM. Similarly, 
compounds  52b and 53b which have been isolated as the single isomer in the cis: 
cis configuration with >95: 5 diastereoselectivity, we can be confident in concluding 
that the pharmacological response observed is of a type II PAM and not of any other 
pharmacological effect that might be influenced by the minor diastereoisomer.  
Given that most of the methylated TQS compounds were isolated as a mixture of 
diastereoisomers, these isomers could be separated by HPLC. If the minor isomer 
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isolated is determined to be the trans: cis isomer, the pharmacological trend between 
trans: cis isomers and with cis: cis isomers can be investigated.  
Since methylated TQS compounds isolated as the cis: cis isomer showed either type 
II PAM or allosteric activity, differences in the pharmacological behaviour between 
cis: cis isomers were discussed. For example, a 3D structure for compound 38b 
which is an allosteric agonist shows that the methyl group is pointing outwards 
whilst compound 47b a type II PAM, the methyl group is pointing towards the 
heterocycle (Figure 35). Both 38b and 47b exist as the cis: cis isomer, so it might be 
that the orientation of the methyl group is what brings out the differences in the 
pharmacological responses observed. It could also be that rotation about the C-aryl 
bond axis shows no change in the position of the methyl group in 38b whilst in 47b 
the position of the methyl group relative to the axis of C-aryl bond significantly 
varies. However in 47b, restricted rotation about the axial C-aryl bond could lock the 
phenyl ring into the conformation shown below (Figure 35) 47b, with the ortho 
methyl group pointing away from the cyclopentene ring. 
 
Figure 35. 3D models of cis: cis isomer of 38b (above) and 47b (below). 
To explain the pharmacological differences observed between cis: cis and trans: cis 
isomers, a 3D structure of compound 49b (which exists as the cis: cis isomer) and 
compound 58a (a trans: cis isomer) were compared. Significant differences between 
the two 3D structures where observed (Figure 36 and 37). An energy minimized 
structure of 58a shows that the phenyl group is slightly pointing in a pseudo-axial 
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position from the main structure 58a (Figure 37 far right). As previously discussed, 
restricted rotation about the axial C-aryl bond could lock the phenyl ring into the 
conformation shown below (Figure 36 and 37). If a trans: cis isomer of 49b or a 
cis: cis isomer of 58a was also subjected for pharmacological tests, key information 
would be obtained to explain the differences in pharmacological activity observed. 
This is due to be investigated.  
 
Figure. 36. 3D Structure and Model of 49b 
   
 
Figure 37. 3D structure of 58a (far right) ball and stick 3D Model of 58a (middle). Energy minimized 
3D model of 58a (far left).  
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2.6.3 Conclusion 
 
1. Varying the position of the methyl group on the phenyl ring induces different 
pharmacological responses. For example, replacing a methyl group at the 4- 
position (in 38b) with one at the 2- position (in 47b) on the phenyl ring, changes 
the pharmacological response from an allosteric agonist to a type II PAM.  
 
2. The cis: cis substituted methylated TQS compounds show either an allosteric 
agonist or type II PAM response whereas trans: cis substituted methylated TQS 
compounds show either no effect on ACh, act as antagonists for ACh or give 
type I PAM responses. 
3. Different levels in the potentiation of ACh responses for type II PAMs are 
observed, ranging from 2.1 to 40 fold. 
4. Differences in agonist responses are observed for allosteric agonists, ranging 
from 2.6 to 16.3 fold. 
5. Similarly, amongst the trans: cis substituted methylated compounds, differences 
in the potentiation of ACh and antagonist activity varies. 
6. Interestingly, only 60b of all the cis: cis isomers produced exhibits type I PAM 
activity.  
7. The pharmacological response is likely to be a result of a combination of: 
a) The configuration of the compound,  
70 
 
b) The position of methyl group and/or  
c) The number of methyl groups present.  
 
2.6.4 Future Work 
 
Given that many of the methylated TQS compounds were obtained as a mixture of 
diastereoisomers, a possibility could be to isolate each isomer by HPLC. If the minor 
isomer of 50b isolated is a trans: cis isomer we could determine if there is a 
pharmacological trend observed. For example a trans: cis isomer of 50b might result 
in either an antagonist or type I PAM pharmacological response (Figure 38). 
 
Figure 38 
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2.7  Additional examples of p-substituted TQS compounds 
 
Additional examples by modification of the aldehyde component were made. It was 
of interest to study whether if replacing the methyl group, with other substituents e.g. 
a methoxy group at the para position 65b would still maintain allosteric agonist 
activity. Another approach was to introduce a methyl sulphone group. Increasing the 
steric bulk at the para position by incorporating a t-butyl and an i-propyl group 68b  
and 69b would be an interesting pharmacological study to compare with 38b and 
23b, since allosteric responses seem to be largely influenced by steric and not 
electronic effects influenced as previously reported.
71
  
The effect of changing the hybridisation of the carbon substituted was then studied, 
with a p-vinyl group 70b, which was introduced in 23b via a Suzuki cross coupling 
reaction using a vinyl-BF3K salt. In addition the effect of the presence of a cyano- 
group at the para position 66b was also examined.  
Introduction of an azide group was achieved by a copper catalysed reaction of 
bromobenzaldehyde. Evidence of azide attachment to the phenyl ring was 
determined by analysing the IR spectroscopy peak at 2100 cm
-1 
being present, which 
is characteristic for an azide group (Scheme 17).  
 
             Scheme 17. Synthesis of p-azido benzaldehyde89 and p-azido TQS 71b. 
Under previous conditions reported by Becker,
26
 the corresponding TQS compounds 
were synthesised and  isolated with yields ranging from 3%-24% as shown in Table 
7. InCl3 proved to be ineffective to catalyse the reaction with para-azide 
benzaldehyde, however on employing Sc(OTf)3 as the Lewis acid 71b was isolated in 
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24% yield. All the compounds were isolated as cis: cis diastereoisomer as the major 
isomer. 
 
Entry No.  R
1
 dr 65b-73b: 
unknown
(a) 
Yield (%) 
1 65b 4-OMe 80 : 20 16 
2 66b 4-CN 77 : 23 6 
3 67b 4-SO2Me 91 : 9 3 
4 68b 4-t-butyl 95 :5 16 
5 69b 4-i-propyl 83 : 17 19 
6 70b 4-vinyl 91 : 9 14 
7 71b 4-N3 71 : 29 24
b 
8 72b 4-NO2 95 : 5 21 
9 73b 2,3,4-triOMe 91 : 9 10 
Table 7 (a) Minor diastereoisomer not determined. (b) Sc(OTf)3 used as the Lewis acid to catalyse the 
MCR.  
 
2.7.1 Biological test results (conducted by JasKiran Gill and Neil 
Millar, UCL Pharmacology) 
 
In comparison with 38b (para-Me) and 59b (2, 3, 4-TriMe), which exhibited 
allosteric agonist activity, 65b (para-OMe) and 73b (2, 3, 4-TriOMe) gratifyingly 
retained allosteric agonist activity at the α7 nAChR (Figure 39). However, 
compounds 65b and 73b showed potency values of 4.4 and 1.3 fold, respectively, 
73 
 
which were not as efficacious as their methylated equivalents with potency values 
of 8.7 and 12.1 fold, respectively (Figure 39).  
 
 
 
                       Figure 39. Allosteric agonists Imax potency (fold > 3mM ACh). 
Compounds 72b and 71b exhibited allosteric agonist activity with potency values of 
1.4 and 11.8 fold, respectively (Figure 39). It seems that a relatively large group at 
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the para position on the phenyl ring is required to maintain allosteric agonist 
activity,
71
 as incorporation of an isopropyl group as in 69b gave a similar agonist 
response of 7.1 fold with respect to 38b. Incorporation of a vinyl- group 70b 
behaved as a potent allosteric agonist with an Imax value of 144.7 ± 42.8 (Figure 
39).  
Compound 66b behaved as a type II PAM with a potency value of 4.1 ± 0.5 fold 
(Figure 40). In addition, the tert-butyl group in 68b seemed to be too large and 
bulky to retain allosteric agonist activity, behaving as a type II PAM with a 3.9 ± 
0.5 efficacy (Figure 40). It seems that there is an atomic radius range for a 
substituent at the para position to elicit allosteric agonist activity. 
                              Type II PAM                          Antagonist 
           
Figure 40. (a) Fold > 100µM ACh, (b) % inhibition of 100μM of ACh 72 ± 27. 
Interestingly, when a methyl sulphone 67b was present at the para position it acted 
as an inhibitor for ACh with a % inhibition of 72 (Figure 40). 
 
2.7.2 Irradiation study  
 
The rationale behind synthesising p-azide-TQS 71b was to explore photochemical 
ligation of the compound to the receptor tested. This was to study where the 
compound binds to the α7 receptor. It has been known that aryl azides can rearrange 
and lose nitrogen to form nitrene derivatives when irradiated or thermally activated  
(Scheme 18).
90
 As a result photochemistry of aryl azides has received considerable 
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attention due to the utility of these compounds in photo imaging and photo affinity 
labelling.
91-94
  
 
                                                                             Scheme 18.
91
 
Irradiation of p–N3TQS 71b for 1 hr using a photochemical UV lamp turned the 
sample from a translucent orange solution to form an orange precipitate. Although 
the IR of the sample only showed a peak at 2100 cm
-1
 corresponding to an azide 
attachment, no peak at 1800 cm
-1 
corresponding to the azepine was observed. The 
1 
H NMR of the sample showed only the p-N3TQS. On several attempts, 71b did not 
show any photoactivity even after irradiation for several hours. As a result, this work 
was not progressed further. 
All compounds synthesised were isolated as the cis-cis diastereoisomer which was 
further supported through the PC model software data in experimental section. 
 
2.8  Heteroaromatic Benzaldehyde Analogues 
 
The rationale behind  the synthesis of TQS compounds using heteroaromatic 
benzaldehydes was to increase solubility, and to reduce complications experienced 
by the Millar group on constructing dose–response curves due to the compounds 
sticking to the tubing.
71
 From a medicinal chemist’s point of view it was of interest 
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to introduce nitrogen containing heteroaromatic benzaldehydes such as 2-pyridine 
and 2-pyrrole benzaldehyde, however, incorporation of such groups in the MCR 
reaction gave a complicated  mixture which made it difficult to determine by 
1
H 
NMR whether the product was formed. This led us to move to bioisosteres of the 
phenyl group, such as furan and to incorporate groups such as a bromine and methyl 
group which from our previous study were found to behave as allosteric agonists 
when present in 4BP- TQS and 4MP-TQS.
71
 All four products were isolated in 
yields ranging from 8-32%, in a >95: 5 ratio with the cis: cis isomer (Figure 41) as 
the major isomer. The minor isomer was not determined.  
 
           
                                   Figure 41. Structures of heteroaromatic TQS compounds. 
Biological tests of the heteroaromatic TQS compounds are currently under 
investigation by our collaborators JasKiran Gill and Neil Millar. 
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2.8.1 Conclusion 
 
For the additional TQS compounds synthesised by modification of the benzaldehyde 
component, all compounds were isolated as the cis: cis isomer. This is supported with 
the use of PC Model V8 software – a table showing the comparison of measured 
coupling constant values with the calculated coupling constant values is shown in the 
experimental chapter. 
Although biological tests for the heteroaromatic TQS compounds are currently in the 
pipeline, the additional para substituted TQS compound 67b behaved as an antagonist 
for ACh while compounds 66b and 68b acted as type II PAM (Figure 42a). 
                                   Type II PAMs                              Antagonists 
           
Figure 42a 
Allosteric agonist activity was retained with 65b and 73b, although, the activity was 
significantly lower than 38b
71
 and 59b (Figure 42b).  
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Figure 42b 
Since the photochemical activation of the azide group proved unsuccessful in our 
study, other photoactive groups other than azide could be considered for 
photochemical ligation, such as, aryl ketones 78 or diazirines 79, which form reactive 
diradicals 80 and carbenes 81, respectively (Scheme 19 and 20).
95-97
 
 
 
Scheme 19. 
  
Scheme 20. 
Introduction of an aryl ketone 78 could be achieved with commercially available 3-
benzoylbenzoic acid 82, which can be converted to a primary alcohol source upon 
reduction followed by oxidation to give the aldehyde substrate 83 for MCR (Scheme 
21). 
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Scheme 21 
Introduction of a diaziridine group could be achieved from a protected bromo phenyl 
methanol 85 which reacts with N-(trifluoroacetyl)piperidine 86 to give 87.The 
ketone could then be converted to the oxime 88, followed by tosylation to give 89. 
Reaction with liquid ammonia incorporates the diaziridine group 90. Subsequent 
oxidation with iodine gives the diaziridine 91 (Scheme 22). This could then be 
converted to the aldehyde for the MCR with TEMPO. 
 
                                                                 Scheme 22 
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2.9  Modification of Sulphanilamide Component for the Synthesis of 
4BP-TQS Analogues 
 
On having synthesised several analogues of 23b by varying the benzaldehyde 
component (in blue) figure, variation of the sulphanilamide component to study the 
pharmacological responses at the α7 nAChRs was then explored. 
                                                                        
                                                                               23b 
It was of interest to study the pharmacological response by varying the position of the 
sulphonamide moiety from the para- position to the ortho- or meta- position, as well 
as examining compounds without the sulphonamide group. Since all the required 
sulphanilamide reagents were commercially available, subjecting them to the same 
protocol used earlier led to the synthesis of the corresponding compounds which were 
isolated as the cis: cis isomer as the major diastereoisomer (Scheme 23), with the 
minor diastereoisomer not determined. Diastereoisomeric ratio of 92b and 93b were 
>95: 5 ratio of cis: cis:  unknown isomer whilst 94b in 91:9 cis: cis: unknown isomer 
ratio (Figure 43). 
 
Scheme 23 
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                            Figure 43. Structures of substituted sulphanilamide TQS compounds 
Biological results for 92b and 93b are currently being investigated by Neil Millar and 
JasKiran Gill. However, 94b was found to act as an antagonist of ACh, which 
suggests the sulphonamide group, is critical to maintain allosteric agonist activity and 
PAM activity at the α7 nAChR (Table 8).   
Compound % Inhibition of 100μM of ACh 
94 70 ± 10 
                                                          Table 8 
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2.10  Modification of the cyclopenta- ring component of 4BP-TQS  
 
                                                                         
                                                                                 23b 
Having synthesised a number of analogues of 4BP-TQS 23b by varying the 
benzaldehyde (in blue) and aniline component (in red), variation of the 
cyclopentene- ring structure (in green) was also then considered.  
2.10.1 Synthesis of furano- and pyrano- quinolines 
 
Since the pioneering work by Pavarov,
98
 the synthesis of furano- and pyrano-
quinolines has been extensively studied with a number of Lewis acids  ZrCl4,
99
 
Bi(III)Cl4,
100
 Mg(OCl)4,
68
 TMSCl,
101
 and lanthanide trichloride catalysts
102
 with 
various substituted anilines and aldehydes.  
We considered altering the cyclopentene ring structure in 23b by using five and six 
membered cyclic enol ethers 95 for the synthesis of  pyrano- and furanoquinoline 
analogues 96 (Table 9, Scheme 24).
102, 103
    
 
 
83 
 
 
Scheme 24 
Entry R
2 
R
1 
Cyclic enol Solvent Lewis 
acid 
Yield 
96a: 96b 
1 SO2NH2 Br DHP MeCN GdCl3 0.02% : 
0.2%  
2 SO2NH2 Br DHF MeCN GdCl3 (a) 
Table 9. One pot synthesis of pyrano- and furano-quinolines; (a)  Difficult to isolate, although peaks 
correspond to the product. 
Despite the success with InCl3 in the synthesis of 4BP-TQS analogues, no reaction with 
dihydropyran (DHP) or dihydrofuran (DHF) in the presence of InCl3 occurred. 
However, GdCl3 proved to be a useful Lewis acid to catalyse the MCR between 4-
bromo benzaldehyde, DHP and sulphanilamide. 
1
H NMR of the crude material showed 
desired peaks around 1.2-2 ppm, and the compounds were each successfully isolated 
despite the low yield (Entry 1, Table 9).  
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Figure 44 
Similarly, reaction with DHF seemed to be successful from the 
1
H NMR of the crude 
mixture. However, isolation of the furano-TQS compound proved unsuccessful (Table 
9).The structural assignment of 96a and 96b was made on the basis of the coupling 
constants measured by 
1
H NMR (J12-11 = 5.4 Hz and J12-7 = 2.5 Hz for 96a and J12-11 = 
2.5 Hz and J12-7 = 10.5 Hz) for 96b. Further confirmation using the computer model 
system showed the coupling constant values were consistent with the cis configuration 
for 96a with calculated values of J12-11 = 6.5 Hz and J12-7 = 3.1 Hz, respectively. 
Similarly, the stereochemistry was deduced through this method for 96b. This suggests 
that GdCl3 is a suitable Lewis acid to catalyse the three-component Diels-Alder 
reaction between sulphanilamide, 4-bromobenzaldehyde with cyclic enols 3,4-
dihydropyran and 2,3-dihydrofuran (Table 9), however, a low yield was obtained.  
Optimisation of the pyrano-quinoline synthesis with various Lewis acids was explored 
with CAN, FeCl3, GdCl3, ScOTf3, BF3.OEt2. However, none of the Lewis acids gave 
promising results. Given that the optimisation of the pyrano-quinoline synthesis was 
unsuccessful, this work was not further studied and the amount of pyrano-quinoline 
which was isolated was sufficient for biological studies. 
A report by Lavilla and co-workers demonstrated that unsaturated lactams 97 can be 
employed in Pavarov–type multicomponent reactions, catalysed by ScOTf3 to give the 
corresponding compound as the cis: cis isomer selectively (Scheme 25).
104
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                                                                           Scheme 25.
104
 
Based on their study we decided to introduce a benzyl lactam in place of a small 
cyclopentene-ring. This was achieved by synthesising the enamine 101 from 
glutarimide 98, which was benzylated 99,
105, 106
 reduced with NaBH4 to give the 
amide alcohol 100,
107
 followed by mesylate formation
107
 and to give the 
corresponding unsaturated benzylated lactam 101 (Scheme 26). This was subjected to 
the MCR with 4-bromobenzaldehyde and sulphanilamide to give 102 in 27% yield as 
the cis: cis isomer (Scheme 26). 
 
 
                                                                     Scheme 26
106, 107
  
Additional modifications of the cyclopenta-ring involved introducing an epoxide with 
mCPBA, which gave the corresponding product 103 (Scheme 27).   
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                                                                            Scheme 27.
108
 
Subjecting  28b to allylic oxidation conditions,
109
 afforded 104 (Scheme 28). The 
stereochemistry was determined by NOE suggesting that H-11, H-12 and H-13 were 
all at the same face. 
 
Scheme 28
109
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2.10.2 Biological test results (conducted by JasKiran Gill and Neil Millar, UCL 
Pharmacology). 
 
Compounds 102, 104 and 96a behaved as antagonists for both ACh and 23b whilst 
96b behaved as an antagonist for ACh only (Figure 45 and Table 10).  
 
Figure 45. Antagonist response as a % inhibition of ACh 100 μM. 
Compound 102 showed the greatest % inhibition of 23b with 94% with respect to 
104 and 96a (Table 10). This might be because of the relatively large benzyl group. 
102 is a more potent inhibitor of ACh and 23b than 96a with % inhibition of ACh 
and 23b value of 72% and 94%, 63% and 88%, respectively (Table 10). 
Compound % Inhibition of   100 μM 
ACh 28b (4BP-
TQS) 
96a 63 ± 14 88 ± 2.1 
96b 22 ± 4.3 - 
102 72  ± 4.5 94 ± 0.4 
104 25 ± 3.0 42 
Table 10 
Interestingly, a significant difference in the % inhibition of ACh and 23b between 
96a and 96b were observed (Table 10), with 96a showing 63 and 88% inhibition for 
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ACh and 28b, while 96b with 22% for ACh only, respectively. This difference 
between 96a and 96b might be a result of the configuration of both compounds.  
Compound 103 exhibited allosteric agonist activity with an Imax value of 6.4 fold 
(Figure 46).   
 
Figure 46. Agonist response 103 Imax/potency (fold when >3 mM ACh). 
 
2.11 Conclusions/Future Work 
 
Various substituted benzaldehydes were used in the synthesis of cyclopentaquinoline 
analogues of 23b under Becker’s protocol.26 On varying the benzaldehyde 
component a total of 45 TQS compounds were isolated in poor to excellent yields.  
On varying the position of the sulphonamide group and with no sulphonamide group 
present, a total of three TQS compounds were synthesised in yields ranging from 26-
65% yield.  
Modifications of the cyclo-penta ring component gave 5 TQS compounds ranging 
from very poor to moderate yields. 
The use of InCl3 led to selectivity towards for the cis-cis diastereoisomer as the 
major product using sterically unhindered benzaldehydes whereas the trans: cis 
isomer was favoured with sterically hindered benzaldehydes. 
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Gadolinium trichloride was an effective Lewis acid catalyst for the synthesis of 
pyrano-quinoline, though in low yield. Another method that could possibly be used 
for synthesising pyrano- and furano-quinolines is shown below (Scheme 29).
110-112
 
 
Scheme 29 
On having varied the aniline, benzaldehyde and dienophile component, another area 
to introduce modification is at the secondary nitrogen, such as, by introducing an 
oxygen atom via a hetero Diels-Alder approach as demonstrated by Batey and co-
workers in the synthesis of Chromans (3,4-Dihydrobenzopyrans) (Scheme 30).
113
 
 
Scheme 30 
113
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3 Ligands for α4β2 nAChRs  
 
For α4β2 nAChRs there are two potential binding sites where agonists and 
antagonists bind.  The ACh binding site resides at the interface of the α subunit and 
the neighbouring subunit. Nature has produced an array of potent and selective 
ligands such as epibatidine, cysteine and nicotine, which have provided a basis for 
drug design for nAChRs due to their therapeutic potential. A common feature of 
these ligands and their analogues is their low affinity for α7 relative to α4β2 
nAChRs. 
 
3.1  Agonists 
 
Modifications of the linker between the pyridine and pyrrolidine rings in nicotine has 
resulted in several high-affinity and potent nAChRs.
36
 The A-85380 compound 105 
binds to the native α4β2 nAChRs with affinities comparable to that of (-)- 
epibatidine Ki  0.015 nM and 0.009 nM, respectively.
114-116
 Its analog 5-Iodo-
A85380 109 showed extremely high affinity for the same receptor with Ki = 0.010 
nM (Figure 46). 
117
  
Cysteine is a potentially interesting lead for the development of subtype selective 
nAChR ligands due to its inherent preference for neuronal nAChRs over the muscle-
type nAChRs in comparison to other ligands ACh, nicotine, or epibatidine. 
Bromination at the 3-position of the pyridone ring of cysteine resulted in a 10-fold 
increase in agonist potency 106 and efficacy on the α4β2 nAChR compared to that 
of (-)-cysteine (Ki =  0.16 nM) (Figure 46).
10
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                                                                                Figure 46 
 
The replacement of oxygen for sulphur led to thiocysteine 107, which was shown to 
bind with subnanomolar affinity at the α4β2 subtype, with improved selectivity to 
cysteine itself.
10, 118
 Epibatidine analogues in which the basic nitrogen on the 
bicyclo[2.2.1]heptane nucleus has been moved from position 7 into position 2 have 
been shown to retain the high affinity of epibatidine 108 on the α4β2 subtype  with 
Ki 0.056 nM (Figure 46).
119
  
 
3.1.1 Antagonists 
 
Analogues of naturally existing antagonists have also shown selectivity for the α4β2 
receptor. 
    
Figure 47 
The introduction of n –alkyl groups ranging from methyl to dodecyl at the pyridine 
nitrogen of (S)-nicotine has produced compounds 111 displaying binding affinities 
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ranging from high-nano molar to mid-micromolar concentrations at the native α4β2 
nAChRs. There is a clear correlation between the n –alkyl chain lengths of the 
compounds and binding affinities at α4β2, except for NONI 111, which displayed 
weak binding to the receptor, but was a potent dopamine inhibitor.
120
 The pyridyl 
ether A-186253 110 displays high selectivity for α4β2 over the α3β4 and α7 
receptors in binding assays.
121
 The most potent competitive nAChR antagonists have 
come from epibatidine,
122-124
 with a Ki value of 1 pM in the epibatidine binding assay 
on rat brain α4β2 nAChRs 112, has the highest binding affinity reported to date.123 A 
purely competitive nicotinic acetylcholine receptor antagonist is dihydro-beta-
erythroidine (DhβE) 113, an alkaloid originating from Erythrina seeds. Sub-
micromolar concentrations of DhβE have been found to block both human and rat 
α4β2 nAChRs with moderate selectivity for the neuronal α4 receptor subunit (IC50 
value 0.37 μM for α4β2 receptor) (Figure 47).125 
 
3.1.2 PAMs 
 
Desformylflustrabromine 114 is a metabolite of the marine bryozoans Flustra 
foliacea.
126, 127
 It is a derivative of tryptamine.
127, 128
 When co-applied with ACh, 
dFBr was shown to selectively potentiate ACh-induced responses on α4β2 nAChRs 
in the nano- molar range (EC50 = 120 nM), with potent type II positive allosteric 
modulator selectivity for α4β2 nAChRs.127, 129 When co-applied with ACh it causes 
an increase in the affinity and efficacy.
127, 129
 This pharmacological response is 
similar to that observed with PNU-120596 which is a PAM on α7 nAChRs (Figure 
48).
127, 130, 131
 
                                           
        Figure 48 
LY-2087101 115 displays 14.7-fold selectivity for α4β2 over homomeric (α7) 
receptors.
132
  The amplitudes of submaximal ACh-induced responses (100%) at α4β2 
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nAChRs were potentiated to 742 ± 63 fold, in the presence of 3 µM 115.
132
 
Submaximal ACh-induced responses at α4β2 nAChRs were potentiated in a 
concentration-dependent manner by LY 2087101 115 (between 30 nM and 30 µM), 
yielding EC50 values for potentiation of 0.99 and 1.1 µM at α4β2  nAChRs, 
respectively.
132
 At concentrations required for potentiation LY-2087101 115 did not 
displace [
3
H]-epibatidine from the agonist binding site and potentiation was 
observed at all agonist concentrations, suggesting a competitive allosteric 
mechanism of action (Figure 48). 
127
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3.2 Synthesis of Desformylflustrabromine (DfBr) analogues for 
α4β2 nAChRs 
 
Indoles and indole derived heterocycles are common structural precursors in alkaloid 
natural products, pharmaceuticals, medicinal products and organic materials,
133-139
 
such as, desformylflustrabromine 114 (Figure 49), a natural product which has been 
synthesised via a non-catalytic method as reported by Lindel et al.
126, 129
  Compound 
114 is reported to act as a selective PAM on the  α4β2 receptor of nAChRs.140, 141 
Given the importance of indoles, much effort has been focused on the development 
of selective functionalisation of indoles at the N1, C2 and C3 sites. Standard 
alkylation protocols necessitate the use of strong nucleophilic bases such as Grignard 
reagents which lead to a complicated mixture of C1- and C3-alkylated products.
142
 
Many groups have contributed towards solving the challenges associated with 
selective functionalization of substituted  indoles through palladium catalysis.
143-153
 
 
                                                                
Figure 49. Structure of desformylflustrabromine 114.
140
 
 
3.2.1  Aim 
 
The prenyl functionality at the C-2 position present on the indole unit in 
desformylflustrabromine 114 was of interest. At present this prenyl moiety in 114 
has been introduced via a classical boron-mediated prenylation method, which 
requires (Scheme 31) a large volume of 9-BBN to synthesise the starting material 
prenyl-9-BBN.
140, 141
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Scheme 31
129
 
We were interested in exploring a catalytic approach to introduce an allyl 
functionality on indoles, by developing a direct Pd-catalysed allylation of indole 
(Scheme 32).  
 
Scheme 32 
This approach could potentially eliminate the use of moderately expensive (100 ml = 
£82) pyrogenic chemicals such as 9-BBN, which is used in stoichiometric 
amounts.
126
 An extension of this methodology with introduction of substituted allylic 
electrophiles would be especially valuable, given the wide range of biologically 
active molecules containing prenylated indoles of this type. In addition, a catalytic 
version of the C-H activation would be highly desirable from an atom-economic and 
environmental perspective. 
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3.3  Results and Discussion 
 
3.3.1 Directing group approach for regioselective C-2 allylation  
 
A few groups have demonstrated regioselective alkylation of indoles with the use of 
directing groups such as N –pyrimidyl,154-156 N-acetate,157-159 N-pivalic acid.158-160 
Recently a paper by Garcia-Rubia and coworkers reported that C-2 alkenylation of 
indoles 117 could be regioselectively achieved over C-3 alkenylation 118 in a ratio 
of >98: <2, respectively in 75% isolated yield.
161 
This was achieved using a 1-(2-
pyridyl)sulfonyl moiety on the indole 116 as the directing and activating group as 
well as a readily removable protecting group on the indole nitrogen using the 
protocol shown (Scheme 33).
139, 161-165  
                                                                              Scheme 33.  
In addition, the reaction conditions were found to be compatible with a variety of 
substituted electron rich and electron poor alkenes as well as simple non-conjugated 
alkene such as 1-octene when using N-pyridylsulfonyl (Scheme 33) as the directing 
group. The reaction is suggested to proceed via a Heck mechanism to afford the 
product (Scheme 34). Removal of the directing group under mild conditions in the 
presence of zinc or magnesium can also be achieved leading to direct formation of 
C2-alkenyl 119 or C2-alkyl 120 indoles
166
 unlike the N-pyrimidyl directing group 
which requires harsh conditions to be removed (Scheme 35). 
154
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                                                             Scheme 34. Proposed mechanism 
 
                                                                 Scheme 35 
Although no precedent for regioselective C-2 allylation of indoles using a directing 
group has been reported to our knowledge, it was decided to explore the use of a 1-
(2-pyridyl)sulfonyl moiety for the selective incorporation of an allyl moiety at the C-
2 position of indole. It was proposed that using allyl acetate as the allyl precursor 
would result in acetate elimination and give Pd(II)(OAc)2, which would be reused 
into the catalytic cycle without need of re-oxidation with Cu(II)(OAc)2.  
N–pyridylsulfonylindole 116 was synthesised by a two step procedure involving 
chlorination of 2-mercaptopyridine to give pyridine-2-sulfonyl chloride 126.
167
 
Compund 126 was then subjected to nucleophilic attack by the indole nitrogen to 
afford 116 in 58% yield (Scheme 36).
161
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Scheme 36 
The reaction was conducted in the absence of the Cu(OAc)2.H2O oxidant under 
Garcia-Rubia’s conditions, however, only the starting material 116 was observed 
with trace amounts of 123 in the crude mixture. This suggests that the oxidant is 
crucial for palladium coupling at the C-2 position of 116 and to reactivate the 
catalyst. Based on this result it was decided to repeat the reaction under Garcia-
Rubia’s protocol for C-2 coupling and to see if acetate elimination will be favoured 
over β-hydride elimination to give the C-2 allylated product 125 (Scheme 37). The 
reaction was conducted at a slightly lower temperature at 60 °C than reported by 
Garcia-Rubia to prevent any unwanted side reactions. 
 
Scheme 37 
Only the β-hydride elimination product 123 was observed in the reaction mixture, 
this compound was isolated in 53% yield (Scheme 37). The structure was assigned 
as 123 not 124 using HMBC spectroscopic data. The HMBC analysis showed a 
3
J 
coupling between the carbonyl carbon signal at 170.9 ppm and –CH2 at 4.77 ppm. 
99 
 
No acetate elimination product 125 was observed suggesting that β-hydride 
elimination is dominant under these conditions. The regioselectivity might be due to 
the greater acidity of the CH2 protons near to the indole ring than the acidity of CH2 
protons near the acetate group, hence, elimination of the Pd-complex and the acidic 
proton near the indole ring is favoured.  
The reaction between 116 and 128 was then explored, since it was considered that 
the benzoate group is a slightly better leaving group than the acetate group in allyl 
acetate, which might facilitate benzoate elimination over β-hydride elimination. The 
reaction was screened in a range of solvents as the nature of the solvent can control 
the regioselectivity of the reaction
168
 and also might facilitate β-benzoate 
elimination. THF, DMA, toluene, DMF and DMSO were screened as the solvents, 
with 20 mol% of Pd(MeCN)2Cl2 as the catalyst and Cu(OAc)2.H2O as the oxidant at 
60 °C,  with the reaction being monitored over a period of 52 hrs by TLC (Table 
11). The reaction after 17 hrs showed no reaction in THF, DMA and toluene whereas 
an additional spot was observed which corresponded to 125 when the reaction was 
conducted in DMF or DMSO. On leaving the reaction for a further 35 hrs, a second 
spot was observed which corresponded to 129 in DMF and DMSO. Similarly, 129 
was also observed in THF, DMA and toluene after 35 hrs. In addition, DMA showed 
a faint spot corresponding to compound 125 after 35 hrs.  
Major products observed from crude 
1
H NMR from these reactions are shown in 
(Scheme 38, Table 11). 
 
Scheme 38 
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Solvent Time (hrs) Major products  
DMF 52 125 and 129 (0.4 : 1)
a 
DMSO 52 125 and 129 (1.8 : 1)
a 
THF 52 129  
Toluene 52 129 
DMA 52 125 and 129 (0.5 : 1)
a 
                   Table 11. (a) Ratio of major isomers determined by 
1
H NMR. 
On repeating the reaction in THF on large scale, 129 was isolated in 35% yield 
(Scheme 39) 
 
Scheme 39. 
Analysis by 
1
H NMR and HMBC showed that compound 129 was formed only, no 
presence of 125 was observed. This is supported by the HMBC spectrum, which 
shows the carbonyl carbon signal at 166.4 ppm (denoted as C-21 in Figure 49) 
having a 
3
J coupling with the CH2 at 5.03 ppm (denoted as H-19 in Figure 49). 
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Figure 49 
When the reaction was performed in DMSO on a large scale (Scheme 40) 125 was 
isolated in 10% yield. Analysis by 
1
H NMR and HMBC showed that C-9 at 109.1 
ppm has 
4
J coupling with H-17 at 3.97ppm (Figure 50), which supports the formation 
of 125. 
 
  Scheme 40 
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Figure 50. 
The presence of 125 suggests that in polar aprotic solvents with large dielectric 
constants such as DMSO, DMF and DMA, elimination of the benzoate group can be 
favoured over β-hydride elimination. A possible explanation might be that polar, 
aprotic solvents such as DMSO, does not solvate the oxygen through hydrogen 
bonding.  Hence, the lone pair on the carbonyl oxygen is less solvated, making it 
available to coordinate with the palladium intermediate complex in a syn 
conformation, enabling elimination of the benzoate leaving group (Figure 51 (a)). On 
the other hand non-polar and weakly polar aprotic solvents with small dielectric 
constants favour β-hydride elimination to give 129 (Figure 51 (b)) only.  
 
                                                                    Figure 40 (a) and (b). 
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Although the directing group approach for regioselective C-2 allylation of indole 
afforded 125 in 10% yield, this synthetic approach was not promising enough to be 
investigated further. 
 
3.3.2 Non-directing group approach for regioselective allylation 
 
Given the lack of success with the directing group approach for regioselective C-2 
allylation, an alternative strategy was to focus on using indoles without directing 
groups, via the Tsuji-Trost allylation reaction. Tsuji and co-workers in 1965 were the 
first to report this reaction using a pre-formed π-allyl palladium complex with 
acetoacetate or ethyl malonate, which worked stoichiometrically (Scheme 41).
169
  
      
                                                                   Scheme 41169 
However, although organometallic reagents such as Grignard,
170, 171
 act as 
nucleophiles, further independent studies by Trost and Tsuji building on previous 
work by Tsuji reported that π-allyl palladium complexes on the other hand were able 
to act as an electrophile towards C-nucleophiles such as malonates, acetoacetates, 
and enamines.
170-172
 In addition, the Pd(0) regenerated after the reaction offered a 
catalytic process, which is now widely used in organic synthesis for the formation of 
C-C bonds (Scheme 42).
170
  
 
Scheme 42. General catalytic cycle of the Tsuji-Trost allylation. 
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As for allyl sources in the Tsuji-Trost reaction, a number of allylic precursors have 
been reported to be used for catalytic allylation reactions, with carbonate, acetates, 
and phosphonates being most widely used.
148, 152, 153, 170, 173, 174
  
Regioselectivity for N1 or C3 alkylation has been achieved via Palladium catalysed 
allylation reaction using indole as the substrate by controlling the reaction conditions 
such as solvent, temperature, ligand and base. 
134, 175
 Recent reports such as by 
Rawal have explored a number of non-asymmetric approaches for C-3 allylation of  
indoles using allyl carbonate as the allyl source (Scheme 43a). 
176
 
152, 173
 However, 
the use of allyl acetate proved to be an ineffective allyl precursor under the 
conditions resulting in lower yield of the desired product 133 in 20% and the N-
allylated product 134 was also obtained in 19% yield (Scheme 43b).
152
  
 
Scheme 43a
152
 
 
Scheme 43b
136 
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Chan,
177
 Liao
178
 and You
179
 however have demonstrated a catalytic and 
enantioselective approach for intra- or intermolecular versions using highly activated 
allylic acetates as the electrophiles with various Pd- and Ir- chiral complexes. For 
example, Chan  has demonstrated that an asymmetric C-3 mono allylation of simple 
indoles 127a, with 1,3-diphenyl allyl acetate 135 in the presence of a chiral ferrocene 
type ligand 136, which gave the desired C-3 mono allylated product 137 in 74% 
yield and 95% ee (Scheme 44).
177
 
 
Scheme 44. Indole (0.3 mmol), [Pd(C3H5)Cl]2 (2.5 mol %), ligand (5 mol %), 1,3-diphenyl-2-
propenyl acetate (1.2 equiv), K2CO3 (2 equiv) in CH3CN (2 mL).
177
 
The aim of the project is to explore a regioselective C-2 direct Pd-catalysed 
allylation of indole using allyl acetate, in the absence of a directing group. The initial 
study was to determine the outcome of this reaction under the similar conditions 
reported by Chan, replacing the chiral ligand by a commercially available achiral 
diphosphine dppf ligand and allyl acetate. If the reaction works, it would be the first 
example to our knowledge of a regioselective C-2 allylation of indole using 
commerically available reagents in the absence of a directing group.To our surprise a 
mixture of 139 and 138a in 2: 1 ratio was observed in the crude mixture. No β-H 
elimination product 140 or C-2 allyl indole 141 were observed.
180
 The diallyl 
indolenine was isolated in 15% yield (Scheme 45). 
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Scheme 45. 
The earliest record of diallyl indolenine 138a was by Pini in 1980 via a non-catalytic 
reaction between indole and allyl bromide in the presence of a Grignard reagent. In 
addition to diallylindolenine 138a, byproducts 139, 142 and 143 were identified 
(Scheme 46).
181
 
 
                                                                     Scheme 46
181
 
However, recently, Rawal reported a Pd catalysed approach towards diallyl 
indolenine 138a which was isolated in 26% yield. In addition, 2-methyl indolenine 
145 was also isolated in 22% yield. The compounds 138a and 145 were formed 
using N-alloc indoles 146 and 147 where the allyl source is the more reactive 
carboxylate on the indole nitrogen (Scheme 47).
182, 183
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Scheme 47 
 
3.3.2.1 Optimisation of diallylindolenine formation 
 
Although no C-2 allylation was observed, this reaction was interesting due to the use 
of allyl acetate and indole, both of which are cheap and commercially available. In 
addition, the isolation of compound 138a could be potentially useful to create more 
complex structures with potential therapeutic properties. As a result of this 
interesting finding, a series of optimisation studies to favour 138a commenced. 
Variation of the temperature, the type of bidentate ligand used, and the number of 
equivalents of potassium carbonate and allyl acetate were considered. The results are 
summarized in the (Table 12). 
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Entry K2CO3 
(eq) 
Allyl 
acetate 
(eq)  
Ligand T°C  Conversion
% 
Ratio of  
139 :138a 
1 2 1.5 Dppf 40 53 (15%)
a 
2 : 1
(a) 
 
2 2 2.2 Dppf 40 62 1 : 1
(b)
  
3 2 7 Dppf 40 29 1: 0.2
(c)
 
4 0 5 Dppf 40 - No reaction 
5 1  5 Dppf 23-80
(d) 
52 1: 0.4 
(c) 
 
6 3 5 Dppf 23-80
(d) 
91 0.8: 1.3 
(c)
 
7 4 5 Dppf 23-80
(d) 
95     1 : 1 
(c) 
8 3 5 Dppf r.t 97 1 : 2 
9 3 5 Dppe r.t 13 1 : 0 
10 3 5 Rac-
BINAP 
r.t 63 (45%)
(e)
 1 : 1 
11 3 5  DPEPHO
S 
r.t >95% (82%)
(f)
 Trace: 1
 
12 3 5 Xantphos r.t 76 (47%)
(g)
 0.6 : 1
 
Table12.
(a) 
Diallylindolenine isolated in 15% yield. 
(b)
 Diallylindolenine isolated in 30% yield. 
(c)
 
Reaction mixture observed by 
1
H NMR resulted in unwanted side reactions making integration of 
products difficult, values are an estimate.
(d) 
Temperature of reaction was conducted at 23°C for 4 hours 
then increased to 80°C overnight. 
(e)
 Diallylindolenine isolated in 45% yield. 
(f)
Diallylindolenine 
isolated in 82% yield.
(g)
 Diallylindolenine isolated in 47% yield. 
Initially the effect of increasing the number of equivalents of allyl acetate in the 
reaction was studied. On increasing from 1.5 equivalents to 2.2 equivalents of allyl 
acetate the ratio of 139 to 138a improved from 2: 1 to 1: 1 (Entries 1 and 2). 
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However, on addition of 7 equivalents of allyl acetate, a complex mixture made it 
difficult to examine the 
1
H NMR to integrate the ratio of 139 and 138a accurately. It 
was deduced however from this reaction more 139 were formed upon increasing the 
equivalents of allyl acetate.Given that a complex mixture is formed with 7 
equivalents of allyl acetate all further optimisation reactions were conducted using 5 
eq of allyl acetate to prevent unwanted side reactions (as observed with 7 equivalents 
of allyl acetate, (Entry 3). 
The effect of the base was then explored, when no base was present no reaction 
occurred (Entry 4) suggesting that the anion on nitrogen needs to be generated in 
order for the reaction to occur. On increasing the number of equivalents of base added 
to the reaction, formation of 138a at room temperature was observed within a few 
hours when monitored by TLC (Entries 6 and 7) with 3 and 4 equivalents of K2CO3, 
but with 1 eq of K2CO3 only formation of 139 was observed (Entry 5). Furthermore, 
increasing the temperature of the same reaction (Entry 5, 6 and 7) from room 
temperature to 80
°
C resulted in a complicated mixture, despite complete consumption 
of the starting material (Entries 5, 6 and 7). Based on the approximated ratio of 139: 
138a (Entries 5, 6, and 7) the reaction with 3 equivalents of K2CO3 gave the best 
result of 139: 138a with 0.8: 1.3 ratio, respectively. This reaction was repeated with 5 
equivalents of allyl acetate and 3 equivalents of K2CO3 at room temperature, 
favouring the formation of 138a over 139 in a ratio of 2: 1 (Entry 8). No reaction was 
observed with the use of a weak base such as KOAc.  
Further, optimisation was achieved by screening various bidentate phosphine 
ligands.
145
 We examined a panel of well-established commercially available 
phosphine ligands to see the effect of lower bite angle phosphine ligands such as 
BINAP and dppe (Figure 41). The yield of 138a was increased from 30% with dppf 
to 45% with BINAP. However, decreasing the bite angle of the phosphine ligand 
further to 86
o
 caused the reaction to become significantly slower even upon heating 
for several days, showing selectivity for 139 only. Recently, Rawal reported 
benzylation of indoles using DPEPhos as the ligand, with 15% of the dibenzylated 
indolenine as the side product.
173
 Intrigued by his work we considered ligands with a 
larger bite angle such as DPEPhos (104
o
). A substantial increase in the yield of 138a 
from 30% with dppf to 82% with DPEPhos was observed (Entries 10 and 11). 
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Increasing the bite angle further to 108
o
 with Xantphos resulted in the yield of 138a 
being reduced to 47% (Entry 12).  
 
                
                       Figure 41. A few selected phosphine bidentate ligands and their bite angles.
184
 
It can be concluded from this study that the bite angle is not of much importance in 
comparison to the backbone of the ligand. The presence of aflexible ether 
functionality between the phenyl groups as in DPEPhos seems to be preferable to the 
rigid ether functionality present in Xantphos. Furthermore, the oxygen in DPEPhos 
might also be assisting with coordination to the metal centre, further stabilizing the 
metal complex. The short functionalized saturated alkane backbone in dppe makes 
the reaction significantly slower.  
Below is a summary of the optimised conditions for the synthesis of 138a (Scheme 
48). 
 
Scheme 48. Optimised conditions for the synthesis of 138a. 
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3.4  Mechanism 
 
 
Scheme 49. Showing ligand exchange and formation of the active species. 
We propose that the reaction proceeds via the Tsuji-Trost allylation mechanism.The 
indole 127a (pKa 16.7 (H2O)) reacts via the nitrogen anion generated in the presence 
of the base, since the anion is more nucleophilic than the parent indole 127a.
185
 This 
is supported with our optimization result that when no base is present no reaction 
occurs (Table 12, Entry 4).   
Equation 1: Illustrates the coordination of the active Pd(0)Ln species to allyl acetate 
anti to the leaving group, followed by oxidative addition to generate the π-allyl 
complex (Scheme 50a). 
Equation 2: Illustrates depending on the strength of the nucleophile two pathways 
are possible:  
a) Soft nucleophiles – direct addition to the allyl Pd complex. 
b) Hard nucleophiles – attack at the Pd followed by reductive elimination. 
However, given the pKa of indole is 16.7 (H2O), which is less than pKa of <25 it is 
classified as a soft nucleophile.
134
 Hence the reaction is followed by nucleophilic 
attack at the terminal η3-allyl Pd (II) ionic complex anti to Pd(II)Ln  (equation 2) this 
is known to occur via an outer sphere mechanism.
186-188
  
Equation 3: Monoallylindole as the substrate to furnish a new allylation via equation 
2 mechanism (Scheme 50a). 
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Scheme 50a. Proposed reaction mechanism via Tsuji–Trost allylation mechanism  
Another possible mechanism could be that upon formation of monoallyl indole via 
the Tsuji-Trost allylation mechanism, nucleophilic attack on allyl acetate by the 
nitrogen anion gives intermediate II, which upon [3+3] allyl shift rearrangement 
might give the corresponding diallylindolenine (Scheme 50 b). 
 
Scheme 50b. Another proposed mechanism towards diallylindolenine via [3+3] allyl shift of 1, 3–
diallyl indole. 
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3.5  Substrate scope of diallylation (and monoallylation) of 
substituted indoles 
 
With optimised conditions in hand, the scope of this double dearomatizing allylation 
reaction was explored. Pleasingly, a wide range of substituted indoles could undergo 
this reaction in good to excellent yields. The reaction was tolerant of a variety of 
substituents on the benzene ring and also at the C-2 position of the pyrrole unit. 
Gratifyingly, indoles bearing an electron-donating group (Table 13, Entries 2-5) 
gave the corresponding products 138b-138e in excellent yields ranging from 88-76% 
(Table 13).  
 
Entry Substrate Product Yield (%) 
1 
  
82 
2 
  
76 
3 
  
76 
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4 
  
88 
5 
  
80 
6 
  
58
(a)
 
7 
  
56 
(a) 
8 
  
41
(b)
 
9 
  
32
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10 
  
98 
11 
  
74
 
12 
  
66 
13 
  
57 
14 
 
N.R N.R
( c )
 
15 
  
30 
116 
 
16 
  
66 
17 
  
50 
Table 13. All reactions were conducted at r.t. unless stated otherwise for 24 hrs. (a) Heated for 8 hrs 
at 50
o
C. (b) Heated for 3 hrs at 50 
o
C then left to stir for 21 hrs at r.t. (c) Left to stir for 48 hrs. 
 
The halogenated indoles gave moderate yields of the desired product ranging from 
32-58% (Entries 6-9) under standard conditions. No reaction occurred with 127f 
and 127g at room temperature, however, when heated at 50 
°
C the reaction 
proceeded to give the diallyl indolenines 138f and 138g in moderate yields in 58% 
and 56%, respectively. This is behaviour observed with substituted bromo indoles 
might be due to poor overlap of the 4p orbital of bromine with the phenyl group, 
hence resulting in poor electron donating ability.
189
  In the presence of an external 
energy in form of heat this might overcome the activation energy. This mismatch in 
orbital overlap decreases as you go from bromine to fluorine and hence, reaction 
proceeds to give the diallylated products without need of thermal energy. However, 
as electronegativity increases from bromine to fluorine the electron withdrawing 
ability by induction increases resulting in lower yield.
189
  
The presence of a substituent at C-2 in 127j and 127k did not impair the reaction at 
all, despite the potential steric crowding around the reaction site, with 138j affording 
the corresponding product in 98% yield (Entry 10). Based on this result, the effect 
of varying the position of the methyl group on the reaction was then explored. Both 
127l and 127m gave the corresponding diallylated products in moderate yields in 
66% and 57%, respectively (Entry 12 and 13), much lower than when the methyl 
group was at the 2-position (Entry 10).  
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It is worth nothing that when the methyl group is present on the nitrogen in 127n no 
reaction occurred. This suggests that the reaction is affected by the electronic nature 
of the indole as well as the position of the functional group on the indole. In addition 
the proton on the nitrogen is necessary for the reaction to occur. 
A reaction with a 5-hydroxyl indole resulted in a complex mixture which was 
difficult to examine by 
1
H NMR. No diallylated product was present despite the 
electron donating ability of the hydroxy group. This observation was avoided by 
increasing the distance of the hydroxyl group from indole by an extra CH2 group, to 
prevent direct influence of the OH group on the indole substrate. As expected the 
reaction worked giving the tri-allylated indolenine 148 in 30% yield (Entry 15). It 
was interesting to see that under the reaction conditions, allylation on the oxygen 
was observed. It is possibsle that the yield of 148 could have been improved had the 
number of equivalents of allyl acetate added to the reaction been increased. After 
silyl protection of the hydroxyl group 138n was obtained in good yield of 66% 
(Entry 16). Furthermore the presence of a fused cyclopentane ring at the 6 and 7 
position on the indole 127q gave the corresponding 138o product in modest yield of 
50% (Entry 17).  
A previous report by Trost had described the formation of a tricyclic alkaloid 150 by 
conducting a palladium catalysed  allylation on Boc-protected tryptamine 149, using 
trialkylborane and allyl alcohol (Scheme 51).
190
 Application of our condition 
resulted in allylation of 149, which gave 150 in excellent yield (Scheme 44). 
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Scheme 51. Showing Trost reaction condition for the synthesis of 150 (above); our optimised 
condition for the synthesis of 150 (below).  
 
The presence of strongly electron-withdrawing groups on the indole 127r and 127s 
led to lower reactivity at room temperature. However, on heating at 50 
°
C only the 
N-allylated products were formed, which were isolated in excellent yields (Table 14, 
Entries 18-19).  
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Entry Substrate Product Yield (%) 
18 
  
86 
19 
  
79 
Table 14. 
The reaction scope with various substituted allyl acetates was also studied but this 
resulted in no reaction, giving just the starting materials under the protocol 
conditions. However when crotyl acetate 152 was employed as the allyl precursor 
the branched mono allyl indole 153a product was observed and was isolated in 43% 
yield (Table 15). This was interesting as it is known that reactions involving 
unsymmetrically substituted allyl substrates often give a substrate-dependent product 
distribution.
33-36
 For example with allylation using (E)-substrates with Pd-complexes 
having bidentate phosphine ligands usually results in formation of the linear (E)-
product.
28 
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Entry Substrate Product Yield% 
1 
  
43%
(a) 
2 
 
  
Trace
(b) 
Table 15. 
(a)
 Reaction conducted at 40°C. 
(b)
 Trace amounts of cyclopenta-indolenine 
not isolated. 
 
With (Z)-but-2-ene-1,4-diyl diacetate as the allyl precursor, trace amounts of the 
cyclopenta indolenine 153b was observed in the 
1
H NMR, but this was not isolated. 
 
3.6  Reactions of substituted diallyl indolenine  
 
Having explored the substrate scope of the protocol with various substituted indoles 
127a-127q, the reactivity of the substituted diallyl products was then studied to 
create simple and complex molecules that could be interesting from a synthetic and 
pharmaceutical perspective. 
On reduction of 127a using NaBH4 and allylation under Luche allylation 
conditions
191, 192
 the corresponding products 154 and 155 were obtained in moderate 
yields of 50% and 60%, respectively (Scheme 52).   
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Scheme 52 
We thought it would be of interest to explore the reactivity of substituted diallyl 
indolenines under Ugi conditions as it would lead to an efficient route to complex 
molecules with potential drug like characteristics in two synthetic steps.
193
 
Gratifyingly, the reaction worked efficiently when using heteroaromatic and 
aliphatic carboxylic acids with sterically hindered isocyanides giving the 
corresponding Ugi products in excellent yields (Scheme 53).  
 
Scheme 53 
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These Ugi products isolated could undergo further modification, particularly 
compound 156f, which would be a suitable substrate to afford a cyclic product with 
potentially interesting biological activity. For example, compound 157 has been 
reported to undergo cyclisation to give the piperizinedione structure 158  (Scheme 
54).
194
  
                                         
Scheme 54 
Several attempts were made to conduct ring closing metathesis of the diallyl 
functionality present in the indolenine compounds 138a and 138k, however, all 
proved unsuccessful with Grubbs 1
st
 generation, 2
nd
 generation and Grubbs-Hoveyda 
catalysts. This might be due to the imine nitrogen’s ability to coordinate to the metal 
catalyst as a good ligand, hence, leading to the deactivation of the catalyst. However, 
on subjecting the products isolated from the Ugi reaction to the Grubbs 1
st
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generation catalyst, the reaction provided the desired spirocyclic indoline 
compounds in excellent yields (Table 16).  
 
Entry Substrate Product Yield % 
1 
  
98 
2 
  
89 
3 
  
96 
124 
 
4 
  
77 
Table 16 
3.6.1 Reaction with Methyl Chloroformate 
 
An alternative strategy for functionalization of the imine was devised via reaction 
with methyl chloroformate, which gave diallyl 2-chloroindolines 160a and 160b 
rather than the 1, 2-allyl shift 161 or cyclisation 162 of the allyl functionality 
(Scheme 55) proposed.  
 
 
Scheme 55. Above: Structure of product 160 observed from the reaction; Below: Showing the  
possible products formed from the reaction between 5-methoxy diallyl indolenine and methyl 
chloroformate.  
Nevertheless, these substrates readily underwent ring-closing metathesis to generate 
the corresponding spirocycles 163a-b (Table 17). With room for further 
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functionalization at the chloride atom such as in situ metallation via Grignard 
formation in the presence of an aldehyde for example, butrylaldehyde.
195
  
 
Product Yield% Product Yield% 
 
88 
 
78 
 
83 
 
66 
Table 17 
 
Interestingly, when 2-Me diallylindolenine 138j was subjected under the same 
reaction conditions, 164 was obtained in 86% yield (Scheme 56). 
 
126 
 
  
Scheme 56. Structure of product 156 formed upon subjecting 138j to methyl choroformate. 
 
3.6.2 Asymmetric Proline Catalysed Mannich Reaction 
 
A strategy for conducting an enantioselective catalytic addition of a carbon 
nucleophile to the imine group present in diallylindoline was envisaged. List has 
demonstrated that amino ketones 167 can be formed in moderate yield and excellent 
ee using an asymmetric L-proline catalysed Mannich reaction between aldehydes or 
ketones with amines. One such example is a proline catalysed Mannich reaction with 
acetone, p–nitro benzaldehyde 165 and p-methoxy aniline 166 (Scheme 57).196  
 
Scheme 57. 
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On subjecting our pre-formed imine 138b under the procedure reported by List as 
previously mentioned above (Scheme 57), the reaction worked to give the Mannich 
product 168 (Scheme 58), however the reaction did not go to completion. In 
addition, extracting the Mannich product from DMSO proved to be very difficult. 
Nevertheless, the Mannich product was isolated in 18% yield with a moderate 60% 
ee (Scheme 58).  
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Scheme 58 
 
Based on this interesting result the reaction was optimised by screening a range of 
solvents using an excess of acetone in a minimum amount of solvent. A ratio of 1: 4 
solvent: acetone ratio at 0 °C to r.t. over a period of 2 days was decided. 
 
3.6.2.1 Optimisation 
 
 
Solvent       Conversion of  S.M %
(a)
 e.r. 
DMSO 95 99 : 1 
CHCl3 95 99 : 1 
MeCN 69 >99: 1 
MeOH 95 55: 45 
DMF 63 99 : 1 
Table 18. (a) Conversion of starting material 138b (%) from crude mixture determined by 
1
H NMR 
(not isolated). 
Excluding the reaction in methanol, which resulted in the racemisation of the 
Mannich product, the reactions conducted in other solvents gave excellent 
enantiomeric ratios of the Mannich product formed (Table 18). Considering factors 
128 
 
such as complete conversion of the reaction, ease of extraction of product from the 
solvent and excellent e.r, the reaction condition involving use of chloroform as the 
solvent was selected to study the reaction scope with a few substituted 
diallylindolenines.  
 
3.6.2.2 Proline catalysed asymmetric Mannich reaction  
 
The solvent ratio of chloroform: acetone was increased to 1: 4.5 to ensure there was 
sufficient excess of acetone for the reaction to go to completion. Gratifyingly, L-
proline was able to catalyse the Mannich reaction of acetone with substituted diallyl 
indolenines 138a, 138b, 138h to give the corresponding 3-aminoketones 168a-c in 
good yield and with very high enantioselectivity (Table 19).  
 
Substrate e.r. (Major : Minor) Yield% 
  138a 99: 1  168a 81 
138b 99 : 1 168b 96 
138h 99: 1  168c 64
(a) 
Table 19. 
(a) 
30 mol% L-proline in DMSO: Acetone (1: 4) 2 days 0 °C→ r.t. 
The diallyl indolenine 138a and 5-methoxy diallylindolenine 138b underwent the 
Mannich reaction in good-excellent yields to give 168a and 168b, respectively. 
Despite the reaction with 5-chloro diallylindolenine 138h not going to completion in 
CHCl3: acetone, the reaction worked very well in DMSO: acetone (1: 4), and the 
product 168c was isolated in moderate yield. These highly enantioenriched 
compounds could then be converted into the spirocyclic indolines in good yield by 
Boc protection of the amine followed by RCM. 
Below showing HPLC traces of racemic and enantioenriched product 168a.   
168a : racemic. 
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168a : enantioenriched. 
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3.6.2.3 Reaction mechanism  
 
The reaction occurs via the asymmetric proline catalysed Mannich reaction, with 
nucleophilic attack on the imine occurring via the enamine.
197
 The major isomer of 
the Mannich product is yet to be determined, however, it is proposed that the 
reaction proceeds via a 6-membered transition state. The (R)-isomer is proposed to 
form when the imine proton is facing downwards in the axial position in the chair-
like transition state, this transition state has also been suggested by Tian and co-
workers
198
 further supporting our study whereas the (S)-isomer is thought to form 
when the imine proton faces upwards in the axial position in the boat-like transition 
state. It is likely that the (R)-isomer is favored over the (S)-isomer. 
 
 
Scheme 59 
Although we have demonstrated an efficient route for the asymmetric L-proline 
catalysed Mannich reaction with a few substituted diallyl indolenines, which 
furnished the Mannich products isolated in excellent yields and enantiomeric ratio, 
towards the end of this work similar chemistry was recently published by Tian and 
co-workers.
198
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3.7  Conclusion/Future Work 
 
Although the directing group approach did not prove successful enough for further 
study, we were able to carry out C-2 allylation using polar aprotic solvents with 
larger dielectric constants to give 125 in 10% yield (Scheme 60).  
 
Scheme 60 
By varying the type of solvent such as using weakly polar aprotic solvents/non polar 
solvents with smaller dielectric constants the conditions favoured 129 with E- 
configuration of the alkene, which was isolated in 35% yield (Scheme 61).  
 
Scheme 61 
Although in both cases complete conversion was not observed, optimisation of 
reaction conditions towards the synthesis of 125 by varying the temperature or 
screening with a range of palladium catalysts could be investigated.  
To favour elimination of the leaving group over beta-hydride elimination, use of a 
sterically hindered allyl precursor such as methyl or dimethyl allyl acetate could be 
investigated (Figure 42) to enable formation of 125 with additional methyl groups.  
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   Figure 42. Structures of substituted allyl acetates which might favour acetate elimination over β-
hydride elimination when subjected under the reaction condition.  
In order for the reaction to be an efficient catalytic process, various Pd(II) catalysts 
such as Pd(OAc)2 and Pd2(dba)3 could be examined. 
A novel mild and efficient method has been developed for regioselective C-3 
diallylation which can be performed with substituted indoles using allyl acetate 
(Scheme 62). 
 
Scheme 62. Protocol for the synthesis of substituted diallyl indolenines 
 
It has been demonstrated that these diallylated products are versatile substrates when 
subjected to further elaboration to give the corresponding spirocyclic products in 
excellent yields in two steps. We have also demonstrated that asymmetric Mannich 
reactions can be performed easily giving enantioenriched products (Figure 43).   
                               
Figure 43. Regions of further elaboration introduced on substituted diallylindolenines. 
Given the success with the synthesis of spiro-indolines, it would be reasonable to 
explore the synthetic scope of the spiro-indoline carbamates by functionalisation at 
the chloride atom, such as formation of a Grignard and reaction with an aldehyde 
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(Scheme 63). This would give rise to additional interesting examples of biological 
interest.  
 
                                           
                                                                          Scheme 63 
Biological tests of these alkaloid compounds synthesised on the α4β2 nAChR would 
give us information about any compounds with interesting pharmacological 
properties.  
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4 Experimental 
 
4.1 General Methods and Experimentation 
 
General Information 
Chemicals: 
All chemicals were purchased from Sigma-Aldrich, Acros, Alfa Aesar, Santa Cruz 
Biotechnology and used without further purification unless otherwise stated.  
 
Solvents:  
Anhydrous tetrahydrofuran, dichloromethane and toluene were collected under argon 
from an LC Technologies solvent purification system, having passed through two 
columns packed with molecular sieves. Acetonitrile (MeCN) were dried over 3 Å 
molecular sieves. 3Å Molecular sieves were freshly dried at 240
°
C and allowed to 
cool to room temperature under positive argon pressure before use. All other 
solvents used as received unless otherwise stated. Petrol refers to petroleum ether 
(b.p. 40-60°C).  
 
Method: 
All reactions were conducted with continuous magnetic stirring using either a round 
bottom flask or a carousel tube screw cap lid, under ambient conditions unless 
otherwise stated. 
 
Chromatography/Purification: 
All reactions were monitored by thin-layer chromatography (TLC) on pre-coated 
silica gel 60 F254 on aluminium plates (Merck KGaA). Silica gel plates were 
examined under UV light at 254 nm. 
Flash column chromatography was carried out using normal phase silica gel (33-70 
μm) supplied by VWR and sand (VWR).  
Chiral High Performance Liquid Chromatography (HPLC) was measured using a 
Varian prostar and prepstar, with a UV detector system at 254 nm. The enantiomeric 
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excess was determined using a CHIRALPAK-AD column (Daicel; Chemical 
Industries, LTD) 25 × 0.46 cm.  
 
Characterization: 
Mass spectra were obtained at UCL on either a VG70-SE (FAB), Thermo Finnigan 
MAT900Xp (EI and CI) or Waters LCT Premier XE (ES) mass spectrometer. 
1
H 
NMR spectra were recorded at 400 or 600 MHz on a Bruker AMX400 and AMX600 
spectrometer using the residual protic solvent CDCl3 (δ = 7.26 ppm, s), DMSO-d6 (δ 
= 2.50, qn) or MeOD-d4 (δ = 3.31, qn) as the internal standard. Chemical shifts are 
quoted in ppm using the following abbreviations: s, singlet; d, doublet; t, triplet; q, 
quartet; qn, quintet; sext, sextet; dd (doublet of doublets), dt (doublet of triplets), m, 
multiplet defined as all multipeak signals where overlap or complex coupling of 
signals makes definitive descriptions of peaks difficult. The coupling constants (J) 
are measured in Hertz. 
13
C NMR spectra were recorded at 100 or 150 MHz on a 
Bruker AMX400 and AMX600 at 25°C in CDCl3 as described below. All chemical 
shifts were referenced with CDCl3 solvent (δ = 77.0 ppm, t), DMSO-d6 (δ = 39.5, 
septet) or MeOD-d4 (δ = 49.2, septet) as the internal standard. Chemical shifts are 
reported to the nearest 0.1 ppm. Coupling constants are defined as J and quoted in 
Hz to one decimal place. In the case of a mixture of diastereoisomers, only the major 
diastereoisomer was assigned, the minor disatereoisomer was not determined. 
Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FT-IR Spectrometer 
operating in ATR mode. Melting points were measured with a Gallenkamp apparatus 
and are uncorrected. Room temperature is defined as between 19-22ºC. Optical 
rotation[α]D values are given in 10−1deg cm2 g−1 at 20.0 oC, concentration (c) in g per 
100 mL measured on a Perkin-Elmer 343 polarimeter (sodium D-line, 589 nm).  
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Experimental 
General procedure for the synthesis of cyclopentaquinolines 
General method A: Indium trichloride (0.2 mmol) was added to a solution of 
aldehyde (1 mmol), sulphanilamide (1 mmol), and cyclopentadiene (3 mmol) in 
acetonitrile (0.1 M). The reaction mixture was stirred for 24 hrs at room temperature. 
To the reaction mixture EtOAc (3 ml) was added and washed with aqueous (0.08 M) 
Na2CO3 (3 ml), brine (10 mL) and water (10 ml), dried over MgSO4, and 
concentrated under reduced pressure.  
General method B: Indium trichloride (0.2 mmol) was added to a solution of the 
corresponding imine (1 mmol), and cyclopentadiene (3 mmol) in acetonitrile (0.08 
M). The reaction mixture was stirred for 24 hrs at room temperature. To the reaction 
mixture EtOAc (3 ml) was added and washed with aqueous (0.08 M) Na2CO3 (3 ml), 
brine (10 mL) and water (10 ml), dried over MgSO4, and concentrated under reduced 
pressure. 
4-Phenyl-3a, 4, 5, 9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
sulfonamide (30b)
 71
  
Method A: Purified by recrystallisation from isopropanol: petrol to give afforded 
the title compound as a pale orange solid (169 mg, 51%). 
 
 
                                                                      27b 
 
m.p. 142-144 °C; Rf = 0.45 (3 : 2 EtOAc : petrol); IRυmax 3343 (C-H), 3062 (C-H), 
2967 (N-H), 1598 (aromatic), 1313 (SO2-N), 1301 (S=O), 1147-1124 (S=O) cm
-1
; 
1
H 
NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 1.9 Hz, H-4), 7.52 (dd, 1H, J = 8.5, 1.9 
Hz, H-5), 7.41 (br s, 2H, H-3), 7.38 (d, 2H, J = 7.4 Hz, H-1), 7.32 (m, 1H, H-2), 
6.66 (d, 1H, J = 8.5 Hz, H-6), 5.90-5.88 (m, 1H, H-13), 5.70-5.67 (m, 1H, H-14), 
4.72 (br d, 1H, J = 3.1 Hz, H-7), 4.64 (s, 2H, NH2), 4.24 (br s, 1H, NH), 4.12 (br d, 
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1H, J = 8.7 Hz, H-11), 3.03 (dtd, 1H, J = 9.2, 8.7, 3.1 Hz, H-12), 2.56 (ddd, 1H, J = 
16.4, 9.2, 3.1 Hz, H-10), 1.83 (br dd, 1H, J = 16.4, 8.7 Hz, H-10); δ 13C NMR (150 
MHz, CDCl3) 149.8 (Cq), 141.7 (Cq), 133.4 (CH), 131.2 (CH), 130.8 (Cq), 128.8 (2 × 
CH), 128.2 (CH), 127.8 (CH), 126.4 (2 × CH), 125.9 (Cq), 125.5 (CH), 115.6 (CH), 
57.5 (CH), 45.9 (CH), 45.8 (CH), 31.6 (CH2). HRMS (EI) calcd. for C18H18O2N2S 
326.10889, found 326.10929.  
 
4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (23b).
71 
Method B: Purified by recrystallisation from isopropanol: petrol to give the title 
compound as cream coloured solid (151 mg, 37%). 
 
                                                                            23b 
m.p. 192-194 ˚C; Rf = 0.4 (3 : 2 EtOAc : petrol); IRυmax  3326 (C-H), 3261 (C-H), 
1598 (aromatic), 1316 (SO2-N), 1184 (S=O), 1149-1125 (SO2-N), 1086 (S=O), 722 
(C-Br) cm
-1
; 
1
H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 2.0 Hz, H-3), 7.53 (d, 1H, 
J = 2.0  Hz, H-4), 7.52 (d, 2H, J = 8.1 Hz, H-2), 7.29 (d, 2H, J = 8.1 Hz, H-1), 6.67 
(d, 1H, J = 8.4 Hz, H-5), 5.90-5.88 (m, 1H, H-13), 5.69-5.68 (m, 1H, H-10), 4.68 (d, 
1H, J = 3.1 Hz, H-7), 4.62 (s, 2H, NH2), 4.17 (br s, 1H, NH), 4.06 (d, 1H, J = 8.5 Hz, 
H-11), 2.98 (dtd, 1H, J = 9.7, 8.5, 3.1 Hz, H-12), 2.51 (ddd, 1H, J = 16.5, 9.7, 2.4 
Hz, H-9), 1.82 (br dd, 1H, J = 16.5, 8.5 Hz, H-9); δ 13C NMR (150 MHz, CDCl3) 
149.4 (Cq), 140.8 (Cq), 133.4 (CH), 132.0 (2 × CH), 131.9 (CH), 131.1 (Cq), 131.0 
(CH), 128.2 (2 × CH), 125.8 (Cq), 125.5 (CH), 121.6 (Cq), 115.8 (CH), 57.0 (CH), 
45.73 (CH), 45.70 (CH), 31.5 (CH2); HRMS (EI) calcd. for C18H18O2N2SBr 
405.02724, found 405.02674. 
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(E)-4-(4-Bromobenzylideneamino)benzenesulfonamide (29)
199, 200
 
To refluxed ethanol (absolute ethanol, 31 ml), sulphanilamide (3.45g, 20 mmol) was 
added and left to stir to form a white suspension. Addition of 4-bromobenzaldehyde 
(3.75 g, 20 mmol) was followed and refluxed for approximate 3 hrs. Reaction 
mixture was cooled to r.t. On evaporated of a small volume of ethanol the reaction 
mixture was cooled further to 0°C, filtered under gravity and dried to give the title 
compound as a white powder (5.72 g, 84%). 
 
40 
m.p. 195-196 ˚C; IRυmax 3284 (N-H), 2977.5 (=C-H),1619.9(C=N), 1580 (aromatic), 
1562 (N-H bend), 1498 (aromatic), 1333 (SO2-N), 1152 (O=S=O), 732 (CH=CH 
bend) cm
-1
; δ
 1
H NMR (600 MHz, DMSO) 8.66 (s, 1H, H-9), 7.90(d,  2H, J = 8.3 
Hz, H-4, 6), 7. 86 (d, 2 H, J = 8.4 Hz, H-11,15), 7.76 (d, 2H, J = 8.3 Hz, H-1,3), 
7.41 (d, 2H, J = 8.4 Hz,  H-12,14), 7.38 (s, 2H, NH2); 
13
C NMR (150 MHz, DMSO)  
161.8 (CH ), 154.1 (Cq), 141.4 (Cq), 134.8 (Cq), 132.1 (2 × CH), 130.8 (2 × CH), 
127.4 (2 × CH), 125.7 (Cq), 121.4 (2 × CH). 
4-(3-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (31b).
71 
A: Purified by recrystallisation from isopropanol: petrol to give title compound as a 
dark greenish gold coloured solid (178 mg, 49%). 
 
29b 
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mp 139-142 °C; Rf  = 0.44 (3 : 2 EtOAc : petrol); IRυmax 3260-3252 (C-H), 2921-
2900 (C-H), 1597 (aromatic), 1307 (SO2-N), 1187 (S=O), 1151-1128 (SO2-N), 1090 
(S=O) cm
-1
;  δ 
1
H NMR (600 MHz, CDCl3) 7.60 (d, 1H, J = 2.0 Hz, H-5), 7.57 (t, 
1H, J =1.6 Hz, H-1), 7.53 (dd, 1H, J = 8.5, 2.0 Hz, H-6), 7.45 (br d, 1H, J = 7.7 Hz, 
H-2), 7.34 (br d, 1H, J = 7.7 Hz, H-4), 7.26 (t, 1H, J = 7.7 Hz, H-3), 6.67 (d, 1H, J = 
8.5 Hz, H-8), 5.90-5.88 (m, 1H, H-13), 5.69-5.68 (m, 1H, H-14), 4.70 (s, 2H, NH2), 
4.68 (d, 1H, J = 3.1 Hz, H-7), 4.19 (br s, 1H, -NH), 4.10 (d, 1H, J = 8.1 Hz, H-11), 
3.01 (dtd, 1H, J = 9.4, 8.1, 3.1 Hz, H-12), 2.52 (ddd, 1H, J = 16.3, 9.4, 2.3 Hz, H-
15), 1.83 (br dd, 1H, J = 16.3, 8.1 Hz, H-15);  δ 
13
C NMR (150 MHz, CDCl3) 149.3 
(Cq), 144.1 (Cq), 133.4 (CH), 131.1 (Cq), 131.0 (CH), 130.9 (CH), 130.4 (CH), 129.5 
(CH), 128.2 (CH), 125.8 (Cq), 125.5 (CH), 125.2 (CH), 123.0 (Cq), 115.8 (CH), 57.0 
(CH), 45.72 (CH), 45.71 (CH), 31.5 (CH2); HRMS (EI) calcd. for C18H18O2N2SBr 
405.02724, found 405.02674. 
4-(4-Chlorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (32b).
71 
A: Purified by flash column chromatography using gradient method 10-30% EtOAc: 
petrol to give the title compound as a light pink foam (230 mg, 63%).    
 
30b 
Rf = 0.43 (3 : 2 EtOAc : Petrol); IRυ max 3342 (C-H), 3271 (C-H), 2923 (N-H), 1597 
(aromatic), 1313 (SO2-N), 1088 (S=O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.60 (d, 
1 H, J = 1.8 Hz, H-3), 7.52 (dd, 1 H, J = 8.4, 1.8 Hz, H-4), 7.37 (d, 2 H, J = 8.6 Hz, 
H-1), 7.35 (d, 2 H, J = 8.6 Hz, H-2), 6.67 (d, 1H, J = 8.4 Hz, H-5), 5.90-5.88 (m, 
1H, H-13), 5.70-5.67 (m, 1H, H-10), 4.70 (d, 1H, J = 3.4 Hz, H-7), 4.63 (s, 2H, 
NH2), 4.17 (br s, 1H, NH), 4.11 (br d, 1H, J = 8.7 Hz, H-11), 2.99 (dtd, 1H, J = 9.5, 
8.7, 3.4 Hz, H-12), 2.52 (ddd, 1H, J = 16.1, 9.5, 2.2 Hz, H-9), 1.82 (br dd, 1H, J = 
16.1, 8.7 Hz, H-9); δ 13C NMR (150 MHz, CDCl3) 149.3 (Cq), 140.1 (Cq), 133.4 
(Cq), 133.3 (CH), 131.0 (Cq), 130.9 (CH) 128.9 (2 × CH), 128.1 (CH), 127.7 (2 × 
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CH), 125.7 (Cq), 125.4 (CH), 115.6 (CH), 56.9 (CH), 45.7 (CH), 45.6 (CH), 31.3 
(CH2). HRMS (EI) calcd. for C18H17O2N2SCl [M]
+ 
359.0612, found 359.0627. 
4-(4-Hydroxyphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (33b).
 71 
A: Purified by flash column chromatography using a gradient elution of 40-60% 
EtOAc: petrol to give the title compound as an pink foam (110 mg, 32%). 
 
31b 
m.p. 213-215˚C; Rf = 0.31 (3 : 2 EtOAc: petrol); IRmax 3389 (C-H), 2923 (C-H), 
1501 (aromatic), 1307 (SO2-N, S=O), 1287 (O-H), 1149 (SO2-N) cm
-1; δ1H NMR 
(600 MHz, MeOD) 7.52 (d, 1H, J = 1.8 Hz, H-3), 7.42 (dd, 1H, J = 8.5, 1.8 Hz, H-
4), 7.26 (d, 2H, J = 8.5 Hz, H-1), 6.79 (d, 2H, J = 8.5 Hz, H-2), 6.75 (d, 1H, 8.5 Hz, 
H-5),  5.90-5.89 (m, 1H, H-13), 5.64-5.63 (m, 1H, H-14), 4.57 (d, 1H, J = 3.4 Hz, H-
7), 4.06 (d, 1H, J = 8.8 Hz, H-11), 2.95 (dtd, 1H, J = 9.6, 8.8, 3.4 Hz, H-12), 2.51 
(ddd, 1H, J = 16.2, 9.6, 2 Hz, H-10) 1.77 (br dd, 1H, J = 15.7, 8.8, H-10); δ 13C 
NMR (150 MHz, MeOD) 157.7 (Cq), 151.7 (Cq), 135.0 (CH), 134.4 (Cq), 132.6 (Cq), 
131.4 (CH), 130.6 (CH), 128.7 (2 × CH), 128.5 (CH), 126.4 (Cq), 125.6 (CH), 116.2 
(2 × CH), 57.8 (CH), 47.9 (CH), 47.7 (CH), 32.6 (CH2). HRMS (ES-) calcd. for 
C18H17N2O3 [M -H]
- 341.0952, found 341.0960. 
 
 
4-(4-Fluorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (24b).
26, 71 
A: Purified by flash chromatography (0-30% EtOAc: petrol) and recrystallisation 
from isopropanol: toluene: petrol to give title compound as a dark green amorphous 
solid (6 mg, 2%). 
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32b 
m.p. 52-54 ˚C; Rf  = 0.34 (3 : 2 EtOAc : petrol); IR υmax  3352 (C-H), 3226 (C-H), 
2921 (N-H), 2851 (N-H), 1600 (aromatic), 1221.7 (C-F), 1309 (SO2-N), 1188 (S=O), 
1150-1128 (SO2-N) cm
-1
;  δ 
1
H NMR (600 MHz, CDCl3) 7.60 (br d, 1H, J = 2.0 Hz, 
H-3), 7.55 (dd, 1H, J = 8.4, 2.0 Hz, H-4), 7.38 (m, 2H, H-2), 7.08 (m, 2H, H-1), 6.66 
(d, 1H, J = 8.4 Hz, H-5), 5.91-5.88 (m, 1H, H-13), 5.70-5.66 (m, 1H, H-10), 4.70 (d, 
1H, J = 3.2 Hz, H-7), 4.63 (s, 2H, NH2), 4.18 (br s, 1H, NH), 4.11 (d, 1H, J = 8.7 Hz, 
H-11), 2.98 (dtd, 1H, J = 10.1, 8.7, 3.2 Hz, H-12), 2.54 (ddd, 1H,  J = 15.8, 10.1, 2.3 
Hz, H-9), 1.82 (br dd, 1H, J = 15.8, 8.7 Hz, H-9); δ 13C NMR (150 MHz, CDCl3) 
162.3 (d, J = 246.5 Hz, Cq), 149.6 (Cq), 137.5 (Cq), 133.5 (CH), 131.1 (CH), 131.0 
(Cq), 128.2 (CH), 128.0 (d, J = 7.7 Hz, 2 × CH), 125.8 (Cq), 125.5 (CH), 115.7 (d, 
11.0 Hz, 2 × CH), 115.6 (CH), 56.9 (CH), 45.9 (CH), 45.7 (CH), 31.5 (CH2). HRMS 
(EI) calcd. for C18H17O2N2SF [M]
+ 
344.0989, found 344.0996.  
 
4-(4-Iodophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
sulfonamide (34b).
 71 
 
A: Purified by recrystallisation from isopropanol: toluene: petrol to give title 
compound as a brownish grey powder (68 mg, 15%). 
 
 
 
 
                                                                                      33b 
m.p. 220-222 ˚C; Rf = 0.34 (3: 2 EtOAc : petrol); IRυ max  3327 (C-H), 2936 (N-H), 
1598 (aromatic), 1149 (SO2-N) cm
-1; δ 
1
H NMR (600 MHz, CDCl3) 7.72 (d, 2H, J = 
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8.5 Hz, H-1), 7.59 (br s, 1H, H-3), 7.52 (dd, 1H, J = 8.4, 1.8 Hz, H-4), 7.16 (d, 2H, J 
= 8.5 Hz, H-2), 6.65 (d, 1H, J = 8.4 Hz, H-5), 5.90-5.87 (m, 1H, H-13), 5.70-5.67 
(m, 1H, H-10), 4.66 (m, 3H, NH2, H-7), 4.16 (br s, NH), 4.10  (d, 1H, J = 8.1 Hz, H-
11), 2.98 (dtd, 1H, J = 9.1, 8.1, 2.9 Hz, H-12), 2.51 (ddd, 1H, J = 15.7, 9.1, 1.5 Hz, 
H-9), 1.82 (br dd, 1H, J = 15.7, 8.1 Hz, H-9);  δ 13C NMR (150 MHz, CDCl3) 149.4 
(Cq), 141.5 (Cq), 137.9 (2 × CH), 133.4 (CH), 131.1 (Cq), 131.0 (CH), 128.4 (2 × 
CH), 128.2 (CH), 125.8 (Cq), 125.5 (CH), 115.8 (CH), 93.1 (Cq), 57.1 (CH), 45.72 
(CH), 45.71 (CH), 31.5 (CH2). HRMS (EI), cald. for C18H17O2N2SI [M]
+ 
452.00499, 
found 452.00563. 
 
4-(3-Iodophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
sulfonamide (35b).
 71 
A: Purified by recrystallisation from isopropanol: petrol to give title compound as 
pale brown powder (34 mg, 8%). 
 
34b 
Rf    0.34 (3 : 2 EtOAc: petrol); mp 177-179 °C; IR υmax 3338 (C-H), 3258 (C-H), 
2911 (N-H), 2901 (N-H), 1600 (aromatic), 1308 (SO2-N), 1191 (S=O), 1170 (SO2-
N), 1092 (S=O) cm
-1
;  δ 
1 
H NMR (600 MHz, CDCl3) 7.77 (br t, 1H,  J = 1.4 Hz, H-
1), 7.66 (br dt, 1H,  J = 7.9, 1.7 Hz, H-2), 7.60 (br d, 1H,  J = 1.7 Hz, H-5), 7.53 (dd, 
1H, J = 8.5, 1.7 Hz, H-6), 7.37 (br d, 1H, J = 7.8 Hz, H-4), 7.13 (t, 1H, J = 7.8 Hz, 
H-3), 6.67 (d, 1H, J = 8.5 Hz, H-9), 5.90-5.88 (m, 1H, H-13), 5.70-5.67 (m, 1H, H-
14), 4.65 (d, 1H, J = 3.2, H-7), 4.63 (s, 2H, NH2), 4.17 (br s, 1H, -NH), 4.10 (d, 1H, 
J = 8.3 Hz, H-11), 3.00 (dtd, 1H, J = 9.4, 8.3, 3.2 Hz, H-12), 2.52 (ddd, 1H, J = 
16.3, 9.4, 2.3 Hz, H-15), 1.84 (br dd, 1H, J = 16.3, 8.3, Hz, H-15);  δ 
13
C NMR (150 
MHz, CDCl3) 149.4 (Cq), 144.2 (Cq), 136.9 (CH), 135.4 (CH), 133.4 (CH), 131.1 
(Cq), 131.0 (CH), 130.6 (CH), 128.2 (CH), 125.8 (CH), 125.7 (Cq), 125.5 (CH), 
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115.8 (CH), 94.9 (Cq), 56.9 (CH), 45.7 (2 × CH), 31.5 (CH2); HRMS (EI) calcd. for 
C18H17O2N2SI [M]
+ 
452.00499, found 452.00563. 
4-(Naphthalen-2-yl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (25b).
26, 71 
A: Purified by recrystallisation from isopropanol: petrol to give title compound as a 
pale orange powder (35 mg, 9%). 
 
35b 
m.p. 180-182 ˚C; Rf  = 0.34 (3 : 2 EtOAc : petrol); IRυ max  3347 (C-H), 2727 (N-H), 
1598 (aromatic), 1314 (SO2-N), 1154 (S=O) cm
-1; δ 
1
H NMR (600 MHz, CDCl3) 
7.88-7.85 (m, 4H, H-10, 7, 6, 3), 7.63 (d, 1H, J = 1.6 Hz, H-20), 7.56-7.48 (m, 4H, 
H-18,1,2,8), 6.72 (d, 1H, J = 8.5 Hz, H-17), 5.91-5.89 (m, 1H, H-21), 5.69-5.67 (m, 
1H, H-22), 4.88 (d, 1H, J = 3.1 Hz, H-11), 4.66 (s, 2H, NH2), 4.37 (br s, 1H, NH), 
4.17 (d, 1H, J = 8.5, H-15), 3.14 (dtd, 1H, J = 9.4, 8.5, 3.1 Hz, H-16), 2.62 (ddd, 1H, 
J = 16.4, 9.4, 2.4 Hz, H-23), 1.80 (ddd, 1H, J = 16.4, 8.5, 1.4 Hz, H-23); δ 13C NMR 
(150 MHz, CDCl3) 149.8 (Cq), 139.2 (Cq), 133.5 (Cq), 133.4 (CH), 133.0 (Cq), 131.2 
(CH), 130.9 (Cq), 128.6 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 126.5 (CH), 
126.2 (CH), 126.0 (Cq), 125.5 (CH), 124.8 (CH), 124.7 (CH), 115.7 (CH), 57.6 
(CH), 45.9 (CH), 45.7 (CH), 31.7 (CH2). 
 
(3aS,4R,9bR)-4-(4-(Trifluoromethyl)phenyl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-sulfonamide (36b)
71
  
A: Under the same protocol conditions above with exception to sulphanilamide (2 
eq) and InCl3 (10 mol %) were considered. No purification required (941 mg, 72%). 
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36b 
m.p. 112-115 ˚C; Rf = 0.42 (1: 1 EtOAc : petrol); IRυ max 3359 (C-H), 2569 (N-H), 
1499 (aromatic), 1300 (-CF3), 1313 (SO2-N), 1153 (O=S=O) cm
-1
;  δ 
1
H NMR (600 
MHz, CDCl3) 7.70 (d, 2H, J = 8.0 Hz, H-1), 7.6 (d, 1H, J = 1.5 Hz, H-3), 7.54 (br d, 
3H, J = 8.0 Hz, H-4, 2), 6.69 (d, 1H, J = 8.6 Hz, H-5), 5.91-5.89 (m, 1H, H-13), 5.68 
(br d, 1H, J = 4.6 Hz, H-14), 4.78 (d, 1H, J = 2.7 Hz, H-7), 4.76 (s, 2H, NH2),  4.13 
(d, 1H, J = 8.5 Hz, H-11), 3.03 (dtd, 1H,  J = 9.4, 8.5, 2.7 Hz,  H-12), 2.53 (dtd, 1H, 
16.1, 9.4, 2.7 Hz, H-10), 1.79 (br dd, 1H, J = 16.1, 8.5 Hz, H-10); δ 13C NMR (150 
MHz, CDCl3) 149.3 (Cq), 145.8 (Cq), 133.4 (CH), 131.3 (Cq), 130.9 (CH), 130.1 (q, 
J = 32.8 Hz, Cq), 128.2 (CH), 126.8 (3 × CH), 125.8 (q, J = 3.7 Hz, 2 × CH), 125.7 
(Cq), 124.1 (q, J = 271.7 Hz, Cq), 115.9 (CH), 57.3 (CH), 45.7 (CH), 45.4 (CH), 31.5 
(CH2); HRMS (EI) calcd. for C19H17F3N2O2S [M]
+ 
394.0963, found 394.0963. 
 
4-(3,4-Dibromophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (37b)
71
  
A: Purified from hot isopropanol: petrol to give title compound as a light brown 
powder (180 mg, 37%). 
 
37b 
m. p. 143-145 ˚C;  Rf = 0.45 (1 : 1 EtOAc : petrol); IRυmax 3361 (C-H), 3255 (C-H), 
2929 (N-H), 1598 (aromatic), 1495 (aromatic), 1313 (SO2-N), 1307-1289 (O=S=O), 
1151-1127 (O=S=O), 1019.8 (S=O) cm
-1
; δ 
1
H NMR (600 MHz, CDCl3) 7.69 (d, 1H, 
J = 1.7 Hz, H-1), 7.63 (d, 1H, J =  8.2 Hz, H-3), 7.60 (d, 1H, J = 1.6 Hz, H-4), 7.53 
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(dd, 1H, J = 8.5, 1.6 Hz, H-5), 7.22 (dd, 1H, J =  8.2, 1.7 Hz, H-2), 6.68 (d, 1H, J = 
8.5 Hz, H-6), 5.90-5.88 (m, 1H, H-14), 5.69 (br d, 1H, J = 4.8 Hz, H-13), 4.67 (d, 
1H, J = 5.4 Hz, H-7), 4.66 (s, 2H, NH2), 4.14 (br s, 1H, NH), 4.10 (br d, 1H, J = 8.7 
Hz, H-11), 2.98 (m, 1H, H-12), 2.50 (m, 1H, H-10), 1.83 (m, 1H, H-10); 
13
C NMR 
(150 MHz, CDCl3) 149.1 (Cq), 142.9 (Cq), 134.1 (CH), 133.4 (CH), 131.6 (CH), 
131.5 (Cq), 131.0 (CH), 128.2 (CH), 126.7 (CH), 125.7 (Cq), 125.5 (CH), 125.3 (Cq), 
123.9 (Cq), 115.9 (CH), 56.6 (CH), 45.6 (CH), 45.5 (CH), 31.5 (CH2); HRMS (EI) 
calcd. for C18H16O2N2SBr2 [M]
+ 
481.9299, found 481.9300.  
4-p-Tolyl-3a,4,5,9b-tetrahydro-1H-cyclopenta[c]quinoline-8-
sulfonamide (38b)
26, 71
  
A: Under the same protocol conditions as above with sulfanilamide (1.5 eq) and 
InCl3 (0.2 mmol).Purification by flash chromatography dry load gradient method 
using 20-30% EtOAc: petrol gave the title compound as yellow crystals (374 mg, 
44%). 
           
38b 
m.p. 88-90 ˚C; Rf = 0.63 (1:1 EtOAc : petrol); IRυmax 3320 (C-H), 2924 (C-H), 2862 
(N-H), 1500 (aromatic), 1324.8 (SO2-N), 1163.7 (S=O) cm
-1
;  δ 
1
H NMR (600 MHz, 
CDCl3) 7.59 (d, 1H, J = 1.8 Hz, H-3), 7.51 (dd, 1H, J = 8.5, 1.8 Hz, H-4), 7.28 (d, 
2H, J = 8.0 Hz, H-2), 7.19 (d, 2H, J = 8.0 Hz, H-1), 6.64 (d, 1H, J = 8.5 Hz, H-5), 
5.89-5.87 (m, 1H, H-14), 5.69-5.67 (m, 1H, H-13), 4.67 (d, 1H, J = 2.9 Hz, H-7), 
4.66 (s, 2H, NH2), 4.21 (br s, 1H, NH), 4.10 (d, 1H, J = 8.6 Hz, H-11), 3.00 (dtd, 1H, 
J =  12.1, 9.1, 2.9 Hz, H-12), 2.55 (dtd, 1H, J = 16.4, 9.1, 2.9 Hz, H-10), 2.36 (s, 3H, 
H-8), 1.84 (dd, 1H, J = 16.4, 8.6 Hz, H-10); δ 13C NMR (150 MHz, CDCl3) 149.9 
(Cq), 139.3 (Cq), 137.5 (Cq), 133.4 (CH), 131.2 (CH), 130.7 (Cq), 129.5 (2 × CH), 
128.2 (CH), 126.4 (2 × CH), 125.9 (Cq), 125.4 (CH), 115.6 (CH), 57.3 (CH), 46.0 
(CH), 45.9 (CH), 31.6 (CH2), 21.2 (CH3); HRMS (EI) calcd. for C19H20O2N2S [M]
+ 
340.1246, found 340.1244. 
146 
 
 
4-(-2-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopena[c]quinoline-
8-sulfonamide (39b)
71
  
A: Purified by recrystallisation from hot isopropanol: petrol gave the title compound 
as pale yellow powder (523 mg, 60%). 
       
39b 
m.p. 204-206 °C; Rf = 0.41 (1 : 1 EtOAc : petrol), IR υmax 3396 (C-H), 3354 (C-H), 
3259 (N-H), 2927 (N-H), 1588 (aromatic), 1316 (SO2-N), 1157 (S=O), 1090, 665 
cm
-1
;  δ 
1
H NMR (600 MHz, CDCl3) 7.62 (d, 1H, J = 1.3 Hz, H-5), 7.59 (dd, 1H, J = 
8.0, 1.3 Hz, H-1), 7.57 (dd, 1H, J = 8.0, 1.1 Hz, H-4), 7.53 (dd, 1H, J = 8.0, 1.3 Hz, 
H-6), 7.37 (td, 1H, J = 8.0, 1.1 Hz, H-2), 7.18 (td, 1H, J = 8.0, 1.3 Hz, H-3), 6.67 (d, 
1H, J = 8.0 Hz, H-9), 5.91-5.89 (m, 1H, H-15), 5.69-5.67 (m, 1H, H-14), 5.06 (d, 
1H, J = 2.9 Hz, H-7), 4.76 (s, 2H, NH2), 4.14 (d, 1H, J = 7.0 Hz, H-11), 4.10 (s, 1H, 
NH), 3.29 (dtd, 1H, J =  9.9, 7.0, 2.9 Hz, H-12), 2.53 (dtd, 1H, J = 16.1, 9.9, 2.9 Hz, 
H-13), 1.75 (br dd, 1H, J = 16.1, 7.0 Hz, H-13);  δ 
13
C NMR (150 MHz, CDCl3) 
149.7 (Cq), 140.2 (Cq), 133.5 (CH), 133.3 (CH), 131.2 (Cq), 131.0 (CH), 129.2 (CH), 
128.2(CH), 127.9 (CH), 127.8 (CH), 126.1 (Cq), 125.4 (CH), 123.1 (Cq), 115.9 (CH), 
56.5 (CH), 45.6 (CH), 41.9 (CH), 31.5 (CH2); HRMS (EI) calcd. for C18H18O2N2SBr 
405.02724, found 405.02674. 
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TQS-4-(naphthalen-1-yl)-3a, 4, 5, 9b-tetrahydro-1H-
cyclopenta[c]quinoline-8-sulfonamide (22b)
71
 
 
A: Purified by recrystallisation from isopropanol: petrol gave the title compound as a 
pale yellow solid (216 mg, 22%). 
 
22b 
mp 203-205 °C; Rf = 0.35 (3 : 2 EtOAc : petrol), IRυmax 3344 (C-H), 3268 (C-H), 
2930 (N-H), 1496 (aromatic), 1321 (SO2-N), 1197 (S=O), 1127 (SO2–N), 1091 cm
-1
;  
δ 
1
H NMR (600 MHz, CDCl3) 8.09 (d, 1H, J = 8.2 Hz, H-20), 7.92 (d, 1H, J = 8.2 
Hz, H-23), 7.84 (d, 1H, J = 7.5 Hz, H-17), 7.73 (d, 1H, J = 7.5 Hz, H-19), 7.66 (d, 
1H, J = 1.9 Hz, H-10), 7.58-7.51 (m, 4H, H-22, 21, 18, 8), 6.73 (d, 1H, J = 8.1 Hz, 
H-7), 5.90-5.88 (m, 1H, H-11), 5.67-5.64 (m, 1H, H-12), 5.52 (d, 1H, J = 1.56 Hz, 
H-2), 4.66 (s, 2H, NH2), 4.25 (d, 1H, J = 8.83 Hz, H-6), 4.22 (s, 1H, NH), 3.34 (dtd, 
1H, J = 9.4, 7.3, 3.3  Hz, H-12),  2.58 (ddd, 1H, J = 16.7, 9.6, 2.4 Hz, H-15), 1.65 
(br dd, 1H, J = 16.2, 5.1 Hz, H-15);  δ 13C NMR (150 MHz, CDCl3) 150.3 (Cq), 
137.2 (Cq), 133.9 (Cq), 133.4 (CH), 131.2 (CH), 130.9 (Cq), 130.4 (Cq), 129.3 (CH), 
128.2 (d, 5.4 Hz, CH), 126.5 (CH), 126.3 (Cq), 122.7 (CH), 122.3 (CH), 115.9 (CH), 
53.3 (CH), 45.9 (CH), 43.7 (CH), 32.0 (CH2). 
 
Formylation of phenols 
General procedure C: 
To a solution of phenol (4 ml, 33 mmol) in CH2Cl2 (anhydrous) (50 ml) stirred at -
10°C under dry argon conditions was added AlCl3 (4.82 g, 36 mmol, 1.2 eq) and 
stirred for an additional 10 minutes. Dichloromethyl methyl ether (3.3 ml, 36 mmol, 
1.2 eq) was added dropwise via a syringe pump for 18 minutes at 7.7 ml/hr. The 
reaction was left to stir for a further 10 minutes before cold water (200 ml) was 
added slowly. The reaction was left to stir for 10 minutes. Extracted organic layer 
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with CH2Cl2 and washed with brine (100 ml) and water (150 ml), dried with MgSO4, 
filtered and evaporated. 
2-Hydroxy-3,5-dimethylbenzaldehyde (44a) 
 
    44a 
Purification by column chromatography with 100% petrol; brown viscous oil (3.2 g, 
65%); Rf = 0.97 (1 : 1  EtOAc : petrol); IRυmax 3201 (O-H), 2921 (C-H), 1646 
(C=O), 1467 (aromatic), 1260 (C-O)  cm
-1;  δ 1H NMR (600 MHz, CDCl3) 11.09 (s, 
1H, -OH), 9.81 (s, 1H, CHO), 7.20 (br s, 1H, 4-H), 7.15 (s, 1H, 6-H), 2.29 (s, 3H, 5-
Me), 2.23 (s, 3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 196.8 (CHO), 158.0 (Cq), 
139.1 (CH), 131.0 (CH), 128.6 (Cq), 126.6 (Cq), 119.9 (Cq), 20.3 (CH3), 15.1 (CH3); 
HRMS (EI) calcd. for C9H10O2 [M]
+ 
150.0680, found 150.0681. 
 4-Hydroxy-3,5-dimethylbenzaldehyde (44b)
201
 
 
    44b 
Compound used directly without purification; purple-pink powder (3.5 g, 71%). 
M.p. 92-95˚C [lit. 111-113°C]; Rf = 0.73 (1 : 1 EtOAc : petrol); IRυ max  3248 (O-H), 
2915 (C-H), 1664 (C=O), 1591 (aromatic), 1488 (aromatic), 1200 (C-O) cm
-1
; δ 1H 
NMR (600 MHz, CDCl3)  9.81 (s, 1H, CHO), 7.54 (s, 2H, 2-H), 5.38 (s, 1H, OH), 
2.31 (s, 6H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 191.6 (CHO), 158.1 (Cq), 131.1 
(2 × CH), 129.5 (Cq), 123.8 (2 × Cq), 15.9 (2 × CH3); HRMS (EI) calcd. for C9H10O2 
[M]
+
150.0680, found 150.0673. 
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4-Hydroxy-2, 3-dimethylbenzaldehyde (44c)
202
 
A mixture of 1: 0.4 ratio of 44c: 44d was observed in the crude material, each of 
which were isolated by purification by dry load flash column under gradient method 
0-30% EtOAc: petrol to isolate first 44c first then 44d. 
     
44c 
Isolated as white crystals (1.36g, 28%); m.p 155-157 °C [lit. 160-171 °C]; Rf = 0.51 
(1: 1 EtOAc: petrol); IRυ max 3251 (O-H), 2953 (C-H), 1651 (C=O), 1580 (aromatic), 
1251 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 10.2 (s, 1H, CHO), 7.54 (d, 1H, J = 
8.5 Hz, 6-H), 6.76 (d, 1H, J = 8.5 Hz, 5-H), 5.62 (s, 1H, OH), 2.61 (s, 3H, 2-Me), 
2.22 (s, 3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 192.0 (CHO), 158.5 (Cq), 142.3 
(Cq), 131.1 (CH), 128.3 (Cq), 124.1 (Cq), 113.1 (CH), 14.9 (CH3), 11.4 (CH3); 
HRMS (CI) calcd. for C9H11O2 [M+H]
+ 
151.0680, found 151.0753. 
2-Hydroxy-3,4-dimethylbenzaldehyde (44d)
203
 
 
    44d 
Isolated as a yellow powder (750 mg, 16%); m.p. 43-45 °C; Rf = 0.91 (1: 1 EtOAc : 
petrol); IRυ max 3200 (O-H), 2839 (C-H), 1645 (C=O), 1620 (aromatic), 1499 
(aromatic), 1230 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 11.37 (s, 1H, OH), 9.81 
(s, 1H, CHO), 7.29 (d, 1H,  J = 7.9 Hz, 6-H), 6.83 (d, 1H, J = 7.9 Hz, 5-H), 2.33 (s, 
3H, 4-Me), 2.17 (s,  3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 196.1 (CHO), 159.9 
(Cq), 147.3 (Cq), 130.9 (CH), 125.0 (Cq), 121.6 (CH), 118.6 (Cq), 21.1 (CH3), 10.8 
(CH3); HRMS (CI) calcd. for C9H11O2 [M+H]
+ 
151.0680, found 151.0752. 
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4-Hydroxy-2,5-dimethylbenzaldehyde (44e)
85
 
General procedure C: Using dichloromethyl methyl ether (1.1 eq) and AlCl3 (1.1 
eq) with respect to the phenol. A crude mixture of 44e and 44f were present in a ratio 
of 1: 0.4. Purification by dry load flash column gradient method 0-40% EtOAc: 
petrol enabled separation of isomers which gave: 
a)  Orange yellow solid (3.5 g, 55%). 
 
44e 
 m.p. 107-111˚C [lit. 130°C]; Rf = 0.63 (1 : 1 EtOAc : petrol); IRυmax 3236 (O-H), 
2927 (C-H), 1662 (C=O), 1579 (aromatic), 1269 (C-O) cm
-1; δ 1H NMR (600 MHz, 
CDCl3)  para dimethylphenolbenzaldehyde: 10.1 (s, 1H, CHO), 7.60 (s, 1H, H-6), 
6.65 (s, 1H, H-3), 5.77 (s, 1H, OH), 2.59 (s, 3H, 5-Me), 2.27 (s, 3H, 2-Me); δ 13C 
NMR (150 MHz, CDCl3) 191.6 (CHO), 158.1 (Cq), 141.5 (Cq), 135.7 (CH), 127.8 
(Cq), 122.1 (Cq), 118.0 (CH), 19.3 (CH3), 15.3 (CH3); HRMS (CI) calcd. for 
C9H11O2 [M + H]
+ 
151.0680, found 151.0743. 
2-Hydroxy-3,6-dimethylbenzaldehyde (44f)
85
 
 
    44f 
Purification by dry load flash column gradient method 0-40% EtOAc: petrol isolated 
minor isomer as a pale green oil (720 mg, 15%); Rf = 0.87 (1 : 1 EtOAc : petrol); 
IRυmax 2926 (C-H), 1633 (C=O), 1458 (aromatic), 1424 (aromatic), 1232 (C-O) cm
-
1; δ 1H NMR (600 MHz, CDCl3) 12.1 (s, 1H, OH), 10.3 (s, 1H, CHO), 7.24 (d, 1H,  
J = 7.4 Hz, 4-H), 6.62 (d, 1H, J = 7.4 Hz, 5-H), 2.57 (s, 3H, 6-Me), 2.21 (s, 3H, 3-
Me); δ 13C NMR (150 MHz, CDCl3) 195.8 (CHO), 161.7 (Cq), 139.5 (Cq), 138.4 
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(CH), 125.1 (Cq), 121.3 (CH), 118.1 (Cq), 18.1 (CH3), 15.1 (CH3); HRMS (EI) calcd. 
for C9H10O2 [M]
+ 
150.0680, found 150.0669. 
4-Hydroxy-2,3,5-trimethylbenzaldehyde (44g)
204
 
Using dichloromethyl methyl ether (1.1 eq) and AlCl3 (1.1 eq) with respect to 
phenol.  
 
44g 
Isolated as a yellow viscous oil (2.9 g, 60%); m.p. 123-125 °C; Rf = 0.91 (1 : 1 
EtOAc : petrol); IRυmax 3356 (O-H), 2926 (C-H), 1657 (C=O), 1570 (aromatic), 
1290 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 10.1 (s, 1H, CHO), 7.49 (s, 2H, 6-
H), 5.31 (d, 1H, J = 6.1 Hz, OH), 2.57 (s, 3H, 2-Me), 2.28 (s, 3H, 5-Me), 2.21 (s, 
3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 192.1 (CHO), 157.1 (Cq), 139.7 (Cq), 
132.6  (CH), 127.8 (Cq), 123.2 (Cq), 120.5 (Cq), 15.7 (CH3), 14.7 (CH3), 11.7 (CH3); 
HRMS (CI) calcd. for C10H13O2 [M + H]
+ 
165.0837, found 165.0906. 
Preparation of trifluoromethanesulfonate from phenols (44a-44g)  
General Procedure D: 
To a solution of phenol (2 g, 13 mmol) in CH2Cl2 (anhydrous) (13 ml) at -78°C 
under dry argon conditions was added triethylamine (4.04 g, 40 mmol, 3 eq) and 
stirred for 30 minutes. Trifluoromethylsulfonate anhydride (2.5 ml, 15 mmol, 1.1 eq) 
was added dropwise via a syringe pump for 18 minutes at 7.7 ml/hr. Reaction was 
left to stir for a further 2 hrs. Diluted in CH2Cl2 (15 ml), and washed with saturated 
solution of NaHCO3 (20 ml), brine (20 ml) and water (20 ml). Dried with MgSO4, 
filtered and concentrated to give the corresponding aryl triflates. 
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2-Formyl-4,6-dimethylphenyl trifluoromethanesulfonate (45a) 
 
45a 
Purified by column chromatography (0-40% EtOAc in petrol); Yellow viscous oil 
(2.4 g, 64%). Rf = 0.91 (1: 1 EtOAc : petrol); IRυmax 2883 (C-H), 1701 (C=O), 1598 
(aromatic), 1407 (O=S=O), 1207 (C-O), 1136 (C-F) cm
-1; δ 1H NMR (600 MHz, 
CDCl3) 10.19 (s, 1H, CHO), 7.62 (d, 1H, J = 2.0 Hz, 3-H), 7.38 (d, 1H, J = 2.0 Hz 5-
H), 2.42 (s, 3H, 6-Me), 2.40 (s, 3H, 4-Me); δ 13C NMR (150 MHz, CDCl3) 187.4 
(CHO), 145.9 (Cq), 139.1 (Cq), 138.8 (CH), 132.5 (Cq), 129.2 (Cq), 128.5 (CH), 
118.4 (q, J = 321 Hz, Cq), 20.9 (CH3), 16.5 (CH3); HRMS (EI) calcd. for 
C10H9F3O4S [M]
+ 
282.0174, found 282.0174. 
4-Formyl-2, 6-dimethylphenyl trifluoromethanesulfonate (45b)  
Method D:  Using 44b (94 mg, 0.63 mmol), trifluoromethylsulfonate anhydride 
(0.20 ml, 1.1 mmol, 1.9 eq) and NEt3 (0.28 ml, 0.2 mmol, 3.2 eq). 
 
45b 
Purified by column chromatography (0-20% EtOAc  in petrol); yellow oil (88 mg, 
53%); Rf = 0.89 (1:1  EtOAc: petrol); IRυmax 2922-2864 (ald C-H), 1701 (ald C=O), 
1604 (aromatic), 1290 (O=S=O), 1212 (C-O), 1132 (C-F) cm
-1; δ 1H NMR (600 
MHz, CDCl3) 9.96 (s, 1H, CHO), 7.66 (br s, 2H, H-3, 5), 2.47 (s, 6H, 6-Me and 2-
Me); δ 13C NMR (150 MHz, CDCl3) 191.1 (CHO), 150.8 (Cq), 135.4 (Cq) , 133.1 (2 
× Cq), 131.2 (2 × CH), 118.7 (q, J = 321 Hz, Cq), 17.5 (2 × CH3); HRMS (CI) calcd. 
for C10H10F3O4S [M + H]
+  
283.0174, found 283.0237. 
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4-Formyl-2,3-dimethylphenyl trifluoromethanesulfonate (45c)
202
 and 
6-formyl-2,3-dimethylphenyl trifluoromethanesulfonate (45d)
203
 
Method D: Using methyl phenol benzaldehyde (1 g) and trifluoromethylsulfonate 
anhydride (1.2 eq).  
Purification by dry load flash column chromatography gradient method in 0-20% 
EtOAc: petrol to give title compound as a mixture of isomers as a yellow oil (1.8 g, 
95%). 
                                                                    
                                                                         45c 
45c: Rf = 0.92 (1 : 1 EtOAc : petrol); IRυmax 2881 (C-H ald), 1695 (C=O ald), 1423 
(aromatic), 1390 (O=S=O), 1213 (C-O), 1137 (C-F) cm
-1; δ 1H NMR (600 MHz, 
CDCl3) 10.2 (s, 1H, CHO), 7.75 (d, 1H, J = 7.8 Hz, 5-H), 7.34 (d, 1H, J = 7.8 Hz 6-
H), 2.41 (s, 3H, 2-Me), 2.34 (s, 3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 187.1 
(CHO), 147.7 (Cq), 147.4 (Cq), 131.5 (Cq), 130.2 (CH), 127.8 (CH), 127.5 (Cq), 
118.7 (q, J = 320 Hz, Cq), 21.1 (CH3), 13.4 (CH3).  
                                                                   
                                                                           45d 
45d: 10.23 (s, 1H, CHO), 7.76 (d, 1H, J = 9.0 Hz, 5-H), 7.28 (d, 1H, J = 9.0 Hz 4-
H), 2.66 (s, 3H, 3-Me), 2.35 (s, 3H, 2-Me); δ 13C NMR (150 MHz, CDCl3) 191.5 
(CHO), 151.4 (Cq), 142.9 (Cq), 134.0 (Cq), 131.6 (Cq), 130.8 (CH), 119.4 (CH), 118. 
154 
 
7 (q, J = 290 Hz, Cq), 15.3 (CH3), 13.1 (CH3); HRMS (CI) calcd. for C10H10F3O4S 
[M + H]
+ 
283.0174, found 283.024837.  
2-Formyl-3,6-dimethylphenyl trifluoromethanesulfonate (45f)  
Method D: Prepared according to the general procedure using 2.2 eq. of 
trifluoromethanesulfonic anhydride and 3.2 eq triethylamine. 
 
45f 
Purified column chromatography (0-20% EtOAc in petrol); red-brown oil (925 mg, 
34%). Rf = 0.72 (1 : 1  EtOAc : petrol); IRυmax 2981 (C-H ald), 1612 (C=O ald), 
1455 (aromatic), 1350 (O=S=O), 1207 (C-O), 1132 (C-F)cm
-1; δ 1H NMR (600 
MHz, CDCl3) 10.4 (s, 1H, H-CHO), 7.41 (d, 1H,  J = 8.0 Hz, 4-H), 7.21 (d, 1H, J  = 
8.0 Hz, 5-H), 2.60 (s, 3H, 6-Me), 2.42 (s, 3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 
189.9 (CHO), 148.9 (Cq), 140.8 (Cq), 136.7 (CH), 132.0 (CH), 130.2 (Cq), 128.0 
(Cq), 121.4 (q, J = 299.3 Hz, Cq), 20.8 (CH3), 16.5 (CH3); HRMS (CI) calcd. for 
C10H9F3O4S [M]
+  
282.0174, found 282.0110. 
4-Formyl-2, 3, 6-trimethylphenyl trifluoromethanesulfonate (45g) 
Method D: Using 44g (300 mg, 1.8 mmol), trifluoromethylsulfonate anhydride (0.5 
ml, 1.7 eq) and NEt3 (0.80 ml, 5.8 mmol, 3.2 eq). 
 
45g 
Purified by column chromatography (0-10% EtOAc in petrol); yellow oil (250 mg, 
46%). Rf = 0.93 (1:1 EtOAc: petrol); IRυmax 2956 (ald C-H), 1699 (ald C=O), 1407 
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(aromatic), 1209 (O=S=O), 1136 (C-O), 1040 (C-F) cm
-1; δ 1H NMR (600 MHz, 
CDCl3)  10.30 (s, 1H, H-CHO), 7.61 (s, 1H, 5-H), 2.60 (s, 3H, 2-Me), 2.43 (s, 3H, 6-
Me), 2.34 (s, 3H, 3-Me); δ 13C NMR (150 MHz, CDCl3) 191.9 (CHO), 150.2 (Cq), 
139.9 (Cq), 133.6 (Cq), 132.6 (CH), 132.3 (Cq), 129.6 (Cq), 118.6 (q, J = 319.4 Hz, 
Cq), 17.2 (CH3), 14.7 (CH3), 14.0 (CH3); HRMS (EI) calcd. for C11H11F3O4S [M]
+ 
296.0330, found 296.0324. 
Methyl-2,4-dimethyl-3,6-bis(trifluoromethyl)sulfonyl)oxy)benzoate 
(45h) 
Under the same conditions mentioned above with methyl phenol benzaldehyde (1.35 
g) and trifluoromethylsulfonate anhydride (2.2 eq). 
 
    45h 
Purification by dry load flash column chromatography gradient method in 20% 
EtOAc: petrol to give the title compound as a yellow viscous oil (3.0 g, 98%). Rf = 
0.68 (1 : 1 EtOAc : petrol); IRυ max 1740 (C=O), 1420 (aromatic), 1399 (O=S=O), 
1206 (C-O), 1130 (C-F) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.22 (s, 1H, H-5), 3.94 
(s, 3H, H-1), 2.45 (s, 3H, H-4), 2.37 (s, 3H, H-2); δ 13C NMR (150 MHz, CDCl3) 
164.6 (Cq), 148.9 (Cq), 145.2 (Cq), 138.6 (Cq), 127.9 (Cq), 124.3 (Cq), 123.6 (CH), 
118.6 (q, J = 320.6 Hz, Cq), 118.4 (q, J = 320.6 Hz, Cq), 53.1 (CH3), 20.5 (CH3), 
11.1 (CH3); HRMS (CI)  calcd. for C12H11 F6O8S2 [M + H]
+ 
460.9721, found 
460.9785. 
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Suzuki cross coupling reaction between aryl triflate and 
methylboronic acid 
General procedure E: Under flame dry argon conditions, to a solution of aryl 
triflate (400 mg, 1mmol, 1eq) in THF (0.04 M), was added PdCl2(dppf).dcm (116 
mg, 10 mol%) and K2CO3 (397 mg, 3 mmol, 2 eq) which was left to stir for 5 
minutes. Water (0.8 M) (HPLC grade) was added followed by addition of methyl 
boronic acid (255 mg, 4 mmol, 3 eq). Ratio of THF: H2O (20: 1). Reaction was left 
to reflux overnight. After adding EtOAc (7 ml) to the reaction mixture, the organic 
layer was washed with water (2 × 10 ml), dried with MgSO4, filtered and 
concentrated. 
 2,3,5-Trimethylbenzaldehyde (46a)  
 
46a 
Dry load flash column 30% EtOAc: petrol to give the title compound as a brown oil 
(208 mg, 99%); Rf = 0.82 (1 : 1  EtOAc: petrol); IRυ max 2923 (C-H ald), 1692 (C=O 
ald), 1478 (aromatic) cm
-1; δ 1H NMR (600 MHz, CDCl3) 10.28 (s, 1H, CHO), 7.46 
(s, 1H, H-6), 7.20 (s, 1H, H-4), 2.52 (s, 3H, H-2), 2.33 (s, 3H, H-5), 2.30 (s, 3H, H-
3); δ 13C NMR (150 MHz, CDCl3) 193.5 (CHO), 138.3 (Cq), 136.4 (CH), 136.3 (Cq), 
135.4 (Cq), 134.3 (Cq), 130.1 (CH), 21.2 (CH3), 20.2 (CH3), 14.3 (CH3); HRMS (EI) 
calcd. for C10H12O [M]
+ 
148.0888, found 148.0876. 
 
3,4,5-Trimethylbenzaldehyde (46b)  
Under the same conditions as above using aryl triflate (500 mg), methyl boronic acid 
(5 eq), K2CO3 (3 eq) and PdCl2(dppf).dcm (15 mol%). 
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46b 
Purification by dry load flash column in 0-10% EtOAc: petrol to give the title 
compound as a yellow oil (159 mg, 61%). Rf = 0.93 (1 : 1 EtOAc : petrol); IRυ max  
2929 (C-H ald), 1694 (C=O ald), 1406 (aromatic) cm
-1; δ 1H NMR (600 MHz, 
CDCl3) 9.90 (s, 1H, H-1), 7.51 (s, 2H, H-2, 6), 2.36 (s, 6H, H-3, 5), 2.25 (s, 3H, H-
4); δ 13C NMR (150 MHz, CDCl3) 192.7 (CHO), 143.2 (Cq), 137.5 (2 × Cq), 133.9 
(Cq), 129.0 (2 × CH), 20.7 (2 × CH3), 16.2 (CH3); HRMS (EI) calcd. for C10H12O 
[M]
+ 
148.0888, found 148.0878. 
2, 3, 4-Trimethylbenzaldehyde (46c)  
Under the same conditions as above using aryl triflate (500 mg), methyl boronic acid 
(3 eq), K2CO3 (2 eq) and PdCl2(dppf).dcm (10 mol%). 
                                                                    
                                                                            46c 
Purification by dry load flash column in 0-40% EtOAc: petrol to give the title 
compound as a yellow oil (255 mg, 97%). Rf = 0.89 (1: 1  EtOAc : petrol); IRυ max   
2935 (C-H ald), 1693 (C=O ald), 1680 (aromatic), 1593 (aromatic) cm
-1;
 δ 1H NMR 
(600 MHz, CDCl3) 10.3 (s, 1H, CHO), 7.56 (d, 1H, J = 7.7 Hz, H-6), 7.16 (d, 1H, J 
= 7.7 Hz, H-5), 2.60 (s, 3H, H-3), 2.36 (s, 3H, H-4), 2.24 (s, 3H, H-2); δ 13C NMR 
(150 MHz, CDCl3) 193.2 (CHO), 143.5 (Cq),  139.2 (Cq), 137.0 (Cq), 132.8 (Cq), 
129.7 (CH), 127.8 (CH), 21.7 (CH3), 15.4 (CH3), 14.9 (CH3); HRMS (CI) calcd. for 
C10H13O [M + H]
+ 
149.0888, found 149.0959. 
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2,3,6-Trimethylbenzaldehyde (46e)  
Under the same conditions as above using aryl triflate (400 mg), methyl boronic acid 
(3 eq), K2CO3 (2 eq) and PdCl2(dppf).dcm (10 mol%). 
 
46e 
Purification by dry load flash column in 0-10% EtOAc: petrol to give the title 
compound as an orange yellow oil (209 mg, 99%). Rf = 0.91 (1:1  EtOAc : petrol); 
IRυ max 2930 (C-H ald), 1687 (C=O ald), 1461 (aromatic) cm
-1; δ 1H NMR (600 
MHz, CDCl3) 10.6 (s, 1H, CHO), 7.22 (d, 1H, J= 7.7 Hz, H-4), 6.98 (d, 1H, J = 7.7 
H-5),  2.52 (s, 3H, H-6), 2.48 (s, 3H, H-2), 2.29 (s, 3H, H-3); δ 13C NMR (150 MHz, 
CDCl3) 194.9 (CHO), 139.1 (Cq), 138.2 (Cq), 135.7 (Cq), 134.5 (CH), 133.3 (Cq), 
129.1 (CH), 20.5 (CH 3), 20.2 (CH3), 15.6 (CH3); HRMS (EI) calcd. for C10H12O 
[M]
+ 
148.0888, found 148.0873. 
2,3,4,5-Tetramethylbenzaldehyde (45g)  
Under the same conditions as above using 45g (800 mg), methyl boronic acid (5 eq), 
K2CO3 (3 eq) and PdCl2(dppf).dcm (15 mol%). 
 
46g 
Purification by dry load flash column in 0-10% EtOAc: petrol to give the title 
compound as a yellow oil (438 mg, 80%). Rf = 0.93 (1 : 1  EtOAc : petrol); IRυ max  
2931 (C-H ald), 1688 (C=O), 1600 (aromatic) cm
-1; δ 1H NMR (600 MHz, CDCl3) 
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10.25 (s, 1H, H-CHO), 7.46 (s, 1H, H-6), 2.58 (s, 3H, H-4), 2.33 (s, 3H, H-5), 2.27 
(s, 3H, H-2), 2.25(s, 3H, H-3); δ 13C NMR (150 MHz, CDCl3) 193.5 (CHO), 142.2 
(Cq), 136.8 (CH), 136.7 (Cq), 134.3 (Cq), 132.3 (Cq), 130.8 (CH), 21.8 (CH3), 17.0 
(CH3), 15.9 (CH3), 14.8 (CH3); HRMS (EI) calcd. for C11H14O [M]
+ 
162.1045, found 
162.1035. 
Methyl-2, 3, 4, 6-tetramethylbenzoate (45h)  
Under the same conditions as above using 45h (1 g), boronic acid (10 eq), K2CO3 (3 
eq) and PdCl2(dppf).dcm (15 mol%). 
 
   45i 
Purification by dry load flash column in 0-10% EtOAc: petrol to give the title 
compound as an orange yellow oil (447 mg, 87%). Rf = 0.68 (1:4  EtOAc : petrol); 
IRυ max 2949 (C-H), 1730 (C=O), 1435 (aromatic), 1268 (C-O) cm
-1; δ 1H NMR (600 
MHz, CDCl3) 6.86 (s, 1H, H-5), 3.90 (s, 3H, H-1), 2.25 (s, 3H, H-6), 2.22 (s, 3H, H-
4), 2.20(s, 3H, H-3), 2.15 (s, 3H, H-2); δ 13C NMR (150 MHz, CDCl3) 171.5 (Cq), 
137.7 (Cq), 132.9 (Cq), 132.8 (Cq), 132.5 (Cq), 131.3 (Cq), 129.3 (CH), 52.0 (CH3), 
20.9 (CH3), 19.3 (CH3), 17.6 (CH3), 15.3 (CH3); HRMS (EI) calcd. for C12H16O2 
[M]
+ 
192.1150, found 192.1153. 
2, 3, 4, 6-Tetramethylphenyl)methanol (45j)  
To a flame dried flask under an atmosphere of argon containing a solution of 
tetramethylbenzoate (50 mg, 0.26 mmol, 1 eq) in toluene (3 ml), were added DIBAL 
(39 μl, 5 mmol, 1.5 eq) in a solution of diethyl ether dropwise at -78°C. The reaction 
was stirred for 4 hrs at the same -78°C. Added CH2Cl2 (5 ml) to the reaction mixture 
and washed with brine (5 ml) and water (2 × 10 ml), dried with MgSO4, filtered and 
evaporated. Purification by dry load flash column in 20% EtOAc: petrol to give the 
title compound as a white oil (27 mg, 63%). 
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                                                                                     45j 
Rf = 0.81 (1 : 1  EtOAc : petrol); IRυ max  3383 (O-H), 2921 (C-H), 1443 (aromatic), 
1265 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 6.88 (s, 1H, H-5), 4.74 (s, 2H, H-1), 
2.37 (s, 3H, H-6), 2.35 (s, 3H, H-2), 2.26 (s, 3H, H-4), 2.18 (s, 3H, H-3); δ 13C NMR 
(150 MHz, CDCl3) 136.5 (Cq), 136.2 (Cq), 134.4 (Cq), 134.1 (Cq), 133.5 (Cq), 129.8 
(CH), 59.9 (CH2), 20.9 (CH3), 19.5 (CH3), 15.91 (CH3), 15.88 (CH3); HRMS (EI) 
calcd. for C11H16O [M]
+ 
164.1201, found 164.1195. 
2, 3, 4, 6-Tetramethylbenzaldehyde (46f)  
To a flame dried flask under an atmosphere of argon were added oxalyl chloride (0.3 
ml, 0.6 mmol, 2M, 1.1 eq) and anhydrous DMSO (78 μl, 1 mmol, 2 eq) to DCM (3 
ml) at -78°C. After stirring for 15 minutes methylbenzyl alcohol (90 mg, 0.55 mmol, 
1 eq) and NEt3 (2.29 ml, 2 mmol, 3 eq) was added and the reaction was left to stir for 
3 hrs. Added CH2Cl2 (5 ml) to the reaction mixture and washed with aqueous 
saturated sodium carbonate (15 ml), followed by brine (15 ml) and water (15 ml). 
Dried with MgSO4, filtered and evaporated. Purification by dry load flash column in 
20% EtOAc: petrol to give the title compound as a yellow oil (17 mg, 18%). 
 
46f 
Rf = 0.89 (1 : 1  EtOAc: petrol); IRυ max 2924 (C-H), 1690 (C=O), 1596 (aromatic) 
cm
-1; δ 1H NMR (600 MHz, CDCl3) 10.6 (s, 1H, H-CHO), 6.90 (s, 1H, H-5), 2.52 (s, 
3H, H-5), 2.51 (s, 3H, H-6), 2.30 (s, 3H, H-3), 2.19 (s, 3H, H-2); δ 13C NMR (150 
MHz, CDCl3) 194.5 (CHO), 142.2 (Cq), 139.2 (Cq), 137.9 (Cq), 134.3 (Cq), 131.5 
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(Cq), 131.2 (CH), 21.5 (CH3), 20.5 (CH3), 15.9 (CH3), 15.3 (CH3); HRMS (EI) calcd. 
for C11H14O [M]
+ 
162.1045, found 162.1031. 
(3aS,4R,9bR)-4-o-Tolyl-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (47b)  
A: Under the same protocol conditions as above with exception to sulphanilamide (2 
eq) added to the reaction. Purification by flash chromatography dry load method 
using 50% EtOAc: petrol gave the title compound as an off-white amorphous solid 
(850 mg, 99%). Isolated as a mixture of two diastereoisomers in 93: 7 ratio. 
                                                         
47b 
M.p. 75-78 ˚C; Rf = 0.35 (1 : 1 EtOAc : petrol); IRυ max 3360 (C-H), 3263 (C-H), 
2931 (N-H), 1494 (aromatic), 1461 (SO2-N), 1308 (SO2-N), 1290 (O=S=O), 1153 
(O=S=O) cm
-1
; Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.62 (d, 1H, J 
= 1.6 Hz, H-5), 7.53 (m, 2H, H-6, 4), 7.26 (td, 1H, J = 7.1, 1.5 Hz, H-1), 7.22 (td, 
1H, J = 7.1, 1.0 Hz, H-2), 7.20 (d, 1H, J = 7.1 Hz, H-3), 6.64 (d, 1H, J = 8.5 Hz, H-
9), 5.89-5.87 (m, 1H, H-16), 5.69-5.68 (m, 1H, H-15), 4.91 (d, 1H, J = 2.8 Hz, H-7), 
4.84 (s, 2H, NH2), 4.13 (d, 1H, J = 8.7 Hz, H-11), 3.09 (dtd, 1H, J = 10.8, 8.7, 2.8 
Hz, H-12), 2.61 (dtd, 1H, J = 16.4, 10.8, 2.8 Hz, H-13), 2.39 (s, 3H, H-14), 1.79 (br 
dd, 1H,  J = 16.4, 8.7 Hz, H-13); δ 13C NMR (150 MHz, CDCl3) 150.3 (Cq), 139.6 
(Cq), 135.1 (Cq), 133.5 (CH), 131.2 (CH), 130.79 (CH), 130.75  (Cq), 128.2 (CH), 
127.4 (CH), 126.5 (CH), 125.9 (Cq), 125.7 (CH), 125.4 (CH), 114.2 (CH), 53.7 
(CH), 46.0 (CH), 42.8 (CH), 31.7 (CH2), 19.3 (CH3); HRMS (EI) calcd. for 
C19H21O2N2S [M + H]
+ 
341.1312, found 341.1342. 
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(3aS,4R,9bR)-4-m-Tolyl-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (48b)  
A: Under the same protocol conditions above with exception to sulphanilamide (2 
eq) added to the reaction. Purification by flash chromatography dry load method 
using 50% EtOAc: petrol to afford the title compound as a pale amorphous crystals 
(685 mg, 81%). Isolated as a mixture of two diastereoisomers in 92: 8 ratio. 
 
48b 
m.p. 78 ˚C; Rf = 0.55 (1 : 1 EtOAc : petrol); IRυ max 3300 (C-H), 3252 (C-H), 2279 
(N-H), 1494 (aromatic), 1314 (SO2-N), 1152 (O=S=O) cm
-1
; Major diastereoisomer: 
δ 1H NMR (600 MHz, CDCl3) 7.60 (d, 1H, J = 1.8 Hz, H-5), 7.51 (dd, 1H, J = 8.2, 
1.8 Hz, H-6), 7.27 (t, 1H, J = 7.7 Hz, H-1), 7.19 (m, 2H, H-4, 3), 7.12 (d, 1H, J = 7.7 
Hz, H-2), 6.64 (d, 1H, J = 8.2 Hz, H-9), 5.89-5.87 (m, 1H, H-16), 5.67-5.66 (m, 1H, 
H-15), 4.83 (s, 2H, NH2), 4.66 (d, 1H, J = 2.9 Hz, H-7), 4.24 (s, 1H, NH), 4.10 (d, 
1H, J = 8.7 Hz, H-11), 3.01 (dtd, 1H, J = 10.8, 8.7, 2.9 Hz, H-12,  2.56 (dtd, 1H, J = 
16.3, 10.8 , 2.9 Hz, H-13), 2.38 (s, 3H, H-14), 1.83 (br dd, 1H, J = 16.3, 8.7 Hz,  H-
13); δ 13C NMR (150 MHz, CDCl3) 149.9 (Cq), 141.7 (Cq), 138.5 (Cq),  133.5 (CH), 
131.2 (CH), 130.8 (Cq), 128.7 (CH), 128.5 (CH), 128.2 (CH), 127.2 (CH), 125.9 
(Cq), 125.4 (CH), 123.5 (CH), 115.6 (CH), 57.5 (CH), 45.91 (CH), 45.90 (CH), 31.6 
(CH2), 21.7 (CH3); HRMS (EI) calcd. for C19H21O2N2S [M+H]
+ 
341.1324, found 
341.1324. 
(3aS,4R,9bR)-4-(2,4-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (49b)  
A: Purification by flash chromatography dry load gradient method 30-40% EtOAc: 
petrol gave the title compound as a pale orange crystals (835 mg, 99%). Isolated as a 
mixture of two diastereoisomers in 91: 9 ratio. 
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49b 
m.p. 125-128 ˚C; Rf = 0.42 (1:1 EtOAc : petrol); IRυ max 3359 (C-H), 3264 (C-H), 
2923 (N-H), 1498 (aromatic), 1310 (SO2-N), 1290 (O=S=O), 1152 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.61 (d, 1H, J = 1.7, Hz, H-4), 
7.51 (dd, 1H, J = 8.4, 1.7 Hz, H-5), 7.40 (d, 1H, J = 8.4 Hz, H-2), 7.06 (br d, 1H, J = 
8.4 Hz, H-1), 7.02 (br s, 1H, H-3), 6.64 (d, 1H, J = 8.4 Hz, H-6), 5.89-5.86 (m, 1H, 
H-14), 5.70-5.68 (m, 1H, H-13), 4.87 (d, 1H, J = 3.2 Hz, H-7), 4.76 (s, 2H, NH2), 
4.11 (d, 1H, J = 8.3 Hz, H-11), 3.06 (dtd, 1H,  J = 9.4, 8.3, 3.2 Hz, H-12), 2.61 (dtd, 
1H, J = 16.3, 9.4, 3.2 Hz, H-1), 2.35 (s, 3H, H-15), 2.33 (s, 3H, H-16), 1.80 (ddd, 
1H, J = 16.3, 8.3, 3.2 Hz, H-10); 
13
C NMR (150 MHz, CDCl3)  150.4 (Cq), 137.0 
(Cq), 136.6 (Cq), 135.0 (Cq), 133.5 (CH), 131.6 (CH), 131.3 (CH), 130.6 (Cq), 128.2 
(CH), 127.1 (CH), 125.9 (Cq), 125.6 (CH), 125.4 (CH), 115.6 (CH), 53.5 (CH), 46.0 
(CH), 43.0 (CH), 31.6 (CH2), 21.1 (CH3), 19.2 (CH3); HRMS (EI) calcd. for 
C20H23O2N2S [M+H]
+ 
355.1402, found 355.14769.  
 (3aS,4R,9bR)-4-(3,4-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (50b)  
A: Purification by flash chromatography dry load gradient method in 30-60% 
EtOAc: petrol gave the title compound as red yellow crystals (179 mg, 17%). 
Isolated as a mixture of two diastereoisomers in 85: 15 ratio. 
             
50b 
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m.p. 110-111 ˚C; Rf = 0.42 (1 : 1 EtOAc : petrol); IRυmax 3362 (C-H), 3269 (C-H), 
2921 (N-H), 1499 (aromatic), 1328 (SO2-N), 1158-1130 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.59 (dd, 1H, J = 2.0, 0.7 Hz, H-3), 
7.50 (dd, 1H, J = 8.4, 2.0 Hz, H-5), 7.15 (br s, 1H, H-4), 7.14 (brs, 1H, H-1), 7.12 
(dd, 1H, J = 7.7, 1.6 Hz, H-2), 6.65 (d, 1H, J = 8.4 Hz, H-6), 5.89-5.86 (m, 1H, H-
14), 5.69-5.67 (m, 1H, H-13), 4.64 (d, 1H, J = 3.3 Hz, H-7), 4.62 (s, 2H, NH2), 4.20 
(s, 1H, NH), 4.10 (d, 1H, J = 8.8 Hz, H-11), 3.00 (dtd, 1H,  J = 9.3, 8.8, 3.3 Hz, H-
12), 2.56 (dtd, 1H, J = 16.5, 8.8, 3.3 Hz, H-10), 2.29 (s, 3H, H-15), 2.27 (s, 3H, H-
16), 1.86 (ddd, 1H, J = 16.5, 9.3, 3.3 Hz, H-10); 
13
C NMR (150 MHz, CDCl3) 150.4 
(Cq), 139.2 (Cq), 137.1 (Cq), 136.1 (Cq), 133.5 (CH), 131.3 (CH), 130.5 (Cq), 130.0 
(CH), 128.2 (CH), 127.7 (CH), 125.9 (Cq), 125.4 (CH), 123.7 (CH), 115.6 (CH), 
57.3 (CH), 46.0 (CH), 45.9 (CH), 31.7 (CH2), 20.1 (CH3), 19.6 (CH3); HRMS (EI) 
calcd. for C20H23O2N2S [M+H]
+ 
355.1402, found 355.14770.  
4-(2,3,4,5,6-Pentamethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (51a)  
Method B: Hydrolysis of imine: 0.1M of HCl (20 ml) in water and EtOAc (1.5 ml). 
The reaction mixture was stirred for 1 hr. Purification by dry load flash column 
chromatography in 40% EtOAc: petrol gave the title compound as a white film (50 
mg, 34%). Isolated as a mixture of two diastereoisomers in  >95: 5 ratio. 
                      
51a 
m.p. 132-135˚C; Rf = 0.42 (1 : 1 EtOAc : petrol); IRυ max 3365 (C-H), 3260 (C-H), 
2926 (N-H), 1505 (aromatic), 1321 (SO2-N), 1153 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.81 (d, 1H, J = 2.2 Hz, H-6), 7.53 
(dd, 1H, J = 8.5, 2.2 Hz, H-8), 6.52 (d, 1H, J = 8.5 Hz, H-10), 5.95-5.93 (m, 1H, H-
13), 5.75-5.73 (m, 1H, H-14), 4.51 (s, 2H, NH2), 4.51 (d, 1H, J = 10.9 Hz, H-7), NH 
missing, 4.02 (br s, 1H, H-11), 3.09 (dt, 1H, J = 10.7, 6.8 Hz, H-13), 2.45 (m, 4H, H-
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15 and 5, 4, 3, 2 or 1), 2.28 (s, 3H, H-5, 4, 3, 2 or 1), 2.26 (br s, 3H, H – 5, 4, 3, 2 or 
1), 1.90 (br d, 1H, J = 16.8 Hz, H-15); δ 13C NMR (150 MHz, CDCl3) 149.4 (Cq), 
140.2 (Cq), 138.6 (Cq), 136.8 (CH), 135.1 (Cq), 134.9 (Cq), 133.7 (Cq), 133.6 (Cq), 
132.4 (Cq), 128.9 (CH), 128.7 (CH), 125.7 (CH), 122.6 (Cq), 113.9 (CH), 52.4 (CH), 
47.4 (CH), 38.9 (CH), 36.2 (CH2), 18.2 (CH3), 17.6 (CH3), 17.5 (CH3), 17.4 (2 × 
CH3); HRMS (ES) calcd. for C23H27O2N2S [M-H]
-
 395.1871, found  395.1793.  
(E)-4-((2,3,4,5,6-
Pentamethylbenzylidene)amino)benzenesulfonamide (51)
200
 
 
To a flame dried flask under an atmosphere of argon was added aniline (1.95 g, 11 
mmol, 1 eq) and refluxed for 20 mins in ethanol. This was followed by addition of 
aldehyde (2 g, 11 mmol). The reaction was left to stir for a further 2.5 hrs. Reaction 
was cooled and ethanol was evaported to give the title compound as a pale yellow 
powder (3.3 g, 88%) 
 
 
51 
M.p. 207-210 ˚C; IRυ max 3342 (C-H), 3253 (C-H), 1634 (C=N), 1589 (aromatic), 
1327 (SO2-N), 1157 (O=S=O) cm
-1 
;.
 δ 1H NMR (600 MHz, CDCl3) 8.96 (s, 1H, H-
6), 7.86 (d, 2H, J = 8.5 Hz, H-7, 8), 7.38 (s, 2H, NH2), 7.34 (d, 2H, J = 8.5 Hz, H-9, 
10), 2.28 (s , 6H, H-CH3), 2.23 (s, 3H, H-CH3), 2.19 (s, 6H, H-CH3); 
13
C NMR (150 
MHz, CDCl3)  166.2 (CH), 155.1 (Cq), 141.0 (Cq), 136.3 (Cq), 132.5 (2 × Cq), 132.3 
(Cq), 131.1 (2 × Cq), 26.9 (2 × CH), 121.0 (2 × CH), 16.9 (3 × CH3), 16.1 (2 × CH3); 
HRMS (CI) calcd. for C18H22O2N2S [M + H]
+ 
331.1402, found 331.1484.  
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(3aS,4R,9bR)-4-(2,4,5-Trimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (52b)  
A: Purification by flash chromatography dry load method in 40% EtOAc: petrol 
gave the title compound (below) as a yellow green powder (320 mg, 32%). Isolated a 
mixture of two diastereoisomers in >95: 5 ratio. 
          
 52b 
m.p. 210 ˚C; Rf = 0.42 (1: 1 EtOAc: petrol); IRυ max 3360 (C-H), 3266 (C-H), 2922 
(N-H), 1500 (aromatic), 1326 (SO2-N), 1290 (O=S=O), 1155 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.60 (d, 1H, J = 1.6 Hz, H-3), 7.52 
(dd, 1H, J = 8.7, 1.6 Hz, H-4), 7.25 (s, 1H, H-1), 6.96 (s, 1H, H-2), 6.65 (d, 1H, J = 
8.7 Hz, H-5), 5.89-5.86 (m, 1H, H-14), 5.70-5.69 (m, 1H, H-13), 4.84 (d, 1H, J = 2.6 
Hz, H-7), 4.62 (s, 2H, NH2), 4.11 (d, 1H, J = 9.0 Hz, H-11), 3.04 (dtd, 1H,  J = 9.2, 
9.0, 2.6 Hz,  H-12), 2.62 (dtd, 1H,  J = 16.7, 9.2, 2.6 Hz, H-10), 2.30 (s, 3H, H-17), 
2.26 (s, 3H, H-15), 2.23 (s, 3H, H-16), 1.82 (ddd, 1H, J = 16.7, 9.0, 2.6 Hz, H-10); δ 
13
C NMR (150 MHz, CDCl3) 150.5 (Cq), 136.7 (Cq), 135.5 (Cq), 134.4 (Cq), 133.5 
(CH), 132.2 (Cq), 132.1 (CH), 131.5 (CH), 130.5 (Cq), 128.2 (CH), 126.9 (CH), 
126.0 (Cq), 125.5 (CH), 115.5 (CH), 53.6 (CH), 46.1 (CH), 42.9 (CH), 31.7 (CH2), 
19.7 (CH3), 19.4 (CH3), 18.6 (CH3); HRMS (EI) calcd. for C21H25O2N2S [M+H]
+ 
369.1559, found 363.1629. 
 (3aS,4R,9bR)-4-(3,5-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (53b)  
A: Purified compound by flash chromatography dry load gradient method 30-40% 
EtOAc: petrol gave the titled compound as a yellow powder (126 mg, 12%). Isolated 
a mixture of two diastereoisomers in >95: 5. 
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      53b 
m.p. 194-196 ˚C; Rf = 0.42 (1 : 1 EtOAc : petrol); IRυ max 3363 (C-H), 3268 (C-H), 
2921 (N-H), 1494 (aromatic), 1327 (SO2-N), 1152-1129 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.59 (dd, 1H, J = 2.2, 0.6 Hz, H-4), 
7.51 (dd, 1H, J = 8.5, 2.2 Hz, H-5), 7.00 (s, 2H, H-1, 3), 6.95 (brs, 1H, H-2), 6.65 (d, 
1H, J = 8.5 Hz, H-6), 5.88-5.86 (m, 1H, H-14), 5.69-5.67 (m, 1H, H-13), 4.63 (d, 
1H, J = 3.0 Hz, H-7), 4.61 (s, 2H, NH2), 4.12 (d, 1H, J = 8.6 Hz, H-11), 3.01 (dtd, 
1H,  J = 9.6, 8.6, 3.0 Hz,  H-12), 2.55 (dtd, 1H, J = 16.6, 9.6, 3.0 Hz, H-10), 2.34 (s, 
6H, H-16, 15), 1.86 (ddd, 1H, J = 16.6, 8.6, 3.0 Hz, H-10); δ 13C NMR (150 MHz, 
CDCl3) 150.0 (Cq), 141.7 (Cq), 138.4 (2 × Cq), 133.4 (CH), 131.2 (CH), 130.6 (Cq), 
129.3 (CH), 128.2 (CH), 125.9 (Cq), 125.4 (CH), 124.2 (2 × CH), 115.5 (CH), 57.5 
(CH), 45.9 (CH), 45.9 (CH), 31.4 (CH2), 21.6 (2 × CH3); HRMS (EI) calcd. for 
C20H23O2N2S [M+H]
+ 
355.1402, found 355.14839. 
(3aS,4R,9bR)-4-(2,5-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (54b)  
A: Purification by flash chromatography dry load method in 50% EtOAc: petrol 
gave the title compound as a pale yellow powder (591 mg, 56%). Isolated a mixture 
of two diastereoisomers in 92: 8 ratio. 
 
                
54b 
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m.p. 193-195 ˚C; Rf = 0.42 (1 : 1 EtOAc : petrol); IRυ max 3360 (C-H), 3265 (C-H), 
2256 (N-H), 1598 (aromatic), 1307 (SO2-N), 1288 (O=S=O), 1153 (O=S=O), 1124 
(O=S=O) cm
-1; Major diastereoisomer : δ 
1
H NMR (600 MHz, CDCl3) 7.62 (dd, 1H, 
J = 2.2, 0.8 Hz, H-4), 7.53 (dd, 1H, J = 8.6, 2.2 Hz, H-5), 7.33 (d, 1H, J = 0.9 Hz, H-
1), 7.08 (d, 1H, J = 7.8 Hz, H-3), 7.03 (dd, 1H, J = 7.8, 0.9 Hz, H-2), 6.66 (d, 1H, J 
= 8.6 Hz, H-6), 5.89-5.87 (m, 1H, H-13), 5.70-5.68 (m, 1H, H-14), 4.87 (d, 1H, J = 
3.2 Hz, H-7), 4.84 (s, 2H, NH2), 4.13 (br s, 1H, NH), 4.11 (d, 1H, J = 8.6 Hz, H-11), 
3.06 (dtd, 1H,  J = 9.5, 8.6, 3.2 Hz,  H-12), 2.61 (dtd, 1H, J = 16.5, 9.5, 3.2 Hz, H-
10), 2.36 (s, 3H, H-15), 2.33 (s, 3H, H-16), 1.81 (ddd, 1H, J = 16.5, 8.6, 3.2 Hz, H-
10); δ 13C NMR (150 MHz, CDCl3) 150.4 (Cq), 139.4 (Cq), 135.9 (Cq), 133.5 (CH), 
131.9 (Cq), 131.2 (CH), 130.7 (CH, Cq), 128.2 (CH), 128.0 (CH), 126.3 (CH), 126.0 
(Cq), 125.4 (CH), 115.6 (CH), 53.8 (CH), 46.1 (CH), 42.8 (CH), 31.8 (CH2), 21.4 
(CH3), 18.8 (CH3); HRMS (EI) calcd. for C20H23O2N2S [M+H]
+ 
355.1402, found 
355.14794.  
4-(2,6-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (55a)  
A: Purification by flash chromatography dry load gradient method using 0-40% 
EtOAc: petrol gave title compound as a dark green solid (111 mg, 21%). Isolated a 
mixture of two diastereoisomers in >95: 5 ratio. 
            
55a 
m.p. 142-144 ˚C; Rf = 0.45 (3 : 2 EtOAc : petrol); IRυ max 3343 (C-H), 3062 (C-H), 
2967 (N-H), 1494 (aromatic), 1313 (SO2-N), 1301 (O=S=O), 1147-1124 (O=S=O) 
cm
-1
; Major diastereoisomer : δ 
1
H NMR (600 MHz, CDCl3) 7.82 (d, 1H, J = 1.9 Hz, 
H-4), 7.55 (dd, 1H, J = 8.4, 1.9 Hz, H-5), 7.13 (t, 1H, J = 7.6 Hz, H-2), 7.08-7.02 (br 
s, 2H, H-1,3), 6.58 (d, 1H, J = 8.5 Hz, H-6), 5.96-5.94 (m, 1H, H-13), 5.77-5.75 (m, 
1H, H-14), 4.81 (s, 2H, NH2), 4.36 (d, 2H, J = 10.8, H-7 and NH), 4.02 (br s, 1H, H-
11), 3.09 (dt, 1H, J = 10.8, 5.4 Hz, H-12),  2.56 (br s, 3H, H-16 or 15), 2.46 (m, 1H, 
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H-10), 2.28 (br s, 1H, H-16 or 15), 1.92 (br d, 1H, J = 16.8 Hz, H-10); δ 13C NMR 
(150 MHz, CDCl3) 149.6 (Cq), 138.5 (Cq), 136.7 (CH), 137.9 (Cq), 136.3 (Cq), 131.1 
(CH), 129.2 (Cq), 128.9 (CH), 128.6 (2 × CH), 127.9 (CH), 125.7 (CH), 122.9 (Cq), 
114.2 (CH), 52.1 (CH), 47.3 (CH), 38.3 (CH), 35.9 (CH2), 21.8 (CH3), 20.9 (CH3); 
HRMS (EI) calcd. for C20H22O2N2S [M]
+ 
354.1402, found 354.1403.  
 (3aS,4R,9bR)-4-(2,3-Dimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (56b)  
 
56b 
A: Purification by dry load flash column chromatography 30-40% EtOAc: petrol 
gave the title compound as a pale yellow white powder (528 mg, 33%). Isolated as a 
mixture of two diastereoisomers in 87: 13 ratio. 
mp. 202-205˚C; Rf = 0.35 (1 : 1  EtOAc : petrol); IRυ max 3350 (C-H), 3263 (C-H), 
2925 (N-H), 2848 (N-H), 1495 (aromatic), 1455 (SO2-N), 1337 (SO2-N), 1155 
(O=S=O) cm
-1
; Major diastereoisomer : δ 
1
H NMR (600 MHz, CDCl3) 7.61 (d, 1H, J 
= 1.7 Hz, H-6), 7.52 (dd, 1H, J = 8.4, 1.7 Hz, H-9), 7.39 (d, 1H, J = 7.7 Hz, H-5), 
7.15 (br dt, 2H, J = 17.8, 7.2 Hz, H-1, 2), 6.65 (d, 1H, J = 8.4 Hz, H-8), 5.89-5.87 
(m, 1H, H-17), 5.70-5.67 (m, 1H, H-16), 4.97 (d, 1H, J = 3.0 Hz, H-7), 4.69 (s, 2H, 
NH2), 4.13 (d, 1H, 6.3 Hz, H-11), 3.07 (dtd, 1H,  J = 9.5, 6.3, 3.0 Hz, H-12), 2.59 
(dtd, 1H, J = 16.4, 9.5, 3.0 Hz, H-15), 2.32 (s, 3H, H-4), 2.27 (s, 3H, H-3), 1.77 (dr 
dd, 1H, J = 16.4, 6.3 Hz, H-15); δ 13C NMR (150 MHz, CDCl3)  150.4 (Cq), 139.3 
(Cq), 137.4 (Cq), 133.6 (Cq), 133.4 (CH), 131.3 (CH), 130.6 (Cq), 129.2 (CH), 128.2 
(CH), 126.0 (CH), 125.4 (CH), 123.4 (CH) , 115.7 (CH), 54.1 (CH), 46.0 (CH), 43.1 
(CH), 31.7 (CH2), 21.0 (CH3), 14.7 (CH3); HRMS (CI) calcd. for C20H23O2N2S  
[M+H]
+ 
355.1402, found 355.1477. 
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(3aS,4R,9bR)-4-(2,3,5,6-Tetramethylphenyl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-sulfonamide (57b)  
B: Purification by dry load flash column gradient method 0-10% EtOAc: petrol gave 
the title compound as a pale orange powder (221 mg, 46%). Isolated as a mixture of 
two diastereoisomers in  >95: 5 ratio. 
 
57a 
m.p. 212-215 ˚C; Rf = 0.97 (1: 1  EtOAc: petrol); IRυ max 3320 (C-H), 2927 (N-H), 
1498 (aromatic), 1470 (SO2-N), 1285  (SO2-N), 1140 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 
1
H NMR (600 MHz, DMSO-d6) 7.61 (d, 1H, J = 2.1 Hz, H-6), 
7.33 (dd, 1H, J = 8.0, 2.1 Hz, H-9), 6.97 (br s, 1H, H-2), 6.93 (s, 2H, NH2), 6.67 (d, 
1H, J = 8.0 Hz, H-8), 6.65 (s, 1H, NH), 5.92-5.90 (m, 1H, H-10), 5.77-5.75 (m, 1H, 
H-13), 4.26 (d, 1H, J = 10.7 Hz, H-7), 3.95 (br s, 1H, H-11), 3.36 (s, 1H, NH), 2.94 
(dt, 1H,  J = 10.8, 6.9 Hz, H-12), 2.35 (s, 3H, H-5 or 4), 2.36 (m, 1H, H-14), 2.22 (s, 
3H, H-1 or 3), 2.17 (s, 3H, H-1 or 3), 2.11 (s, 3H, H-5 or 4), 1.74 (br d, 1H, J = 15.6 
Hz, H-14); δ 13C NMR (150 MHz, DMSO–d6) 149.0 (Cq), 137.0 (CH), 136.6 (Cq), 
135.0 (Cq), 133.6 (Cq), 133.4 (Cq), 133.0 (Cq), 132.8 (CH), 130.9 (CH), 130.4 (Cq), 
127.6 (CH), 124.4 (CH), 120.7 (Cq), 113.4 (CH), 51.3 (CH),  46.7 (CH), 38.0 (CH), 
35.6 (CH2), 21.0 (CH3), 20.2 (CH3), 16.7 (CH3), 16.2 (CH3); HRMS (EI) calcd. for 
C22H26O2N2S [M]
+ 
382.1715, found 382.1712. 
 
(E)-4-((2, 3, 5, 6-
Tetramethylbenzylidene)amino)benzenesulfonamide (57)  
To a flame dried flask under an atmosphere of argon was added aniline (531 mg, 3 
mmol, 1 eq) and refluxed for 20 mins in ethanol (15 ml). This was followed by 
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addition of aldehyde (0.486 ml, 3 mmol) and stir for a further 1 hr. The reaction 
mixture was cooled and ethanol was evaporated to give the title compound as a 
white powder (966 mg, 99%) 
 
57 
M.p. 203-206 ˚C; IRυ max 3330 (C-H)), 3072 (C-H), 2926 (N-H), 1624 (C=N), 1586 
(aromatic), 1336 (SO2-N), 1154 (O=S=O) cm
-1;  δ 
1
H NMR (600 MHz, CDCl3) 8.85 
(s, 1H, H-6), 7.86 (d, 2H, J = 8.4 Hz, H-7, 8), 7.38 (s, 2H, NH2), 7.35 (d, 2H, J = 8.4 
Hz, H-9, 10), 7.10 (s, 1H, H-2),  2.27 (s, 6H, H-4,5), 2.22 (s, 6H, H-1,3); 
13
C NMR 
(150 MHz, CDCl3)  165.5 (CH), 155.0 (Cq), 141.1 (Cq), 134.3 (Cq), 133.7 (3 × Cq), 
133.0 (CH), 132.4 (Cq), 127.1 (2 × CH), 121.0 (2 × CH), 19.7 (2 × CH3), 15.9 (2 × 
CH3); HRMS (CI) calcd. for C17H21O2N2S [M+H]
+ 
317.12455, found  317.13264. 
 
(3aS,4R,9bR)-4-Mesityl-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (58a)  
Method A: Purification by flash chromatography dry load gradient method using 
10-30% EtOAc: petrol gave the title compound as a pale orange oil (130 mg, 35%). 
Isolated as a mixture of two diastereoisomers in  >95: 5 ratio. 
 
                                                                58a 
Rf = 0.45 (1: 1 EtOAc : petrol); IRυ max 3364 (C-H), 3264 (C-H), 2918 (N-H) 2851 
(N-H), 1600 (aromatic), 1502 (aromatic), 1328 (SO2-N), 1154 (O=S=O) cm
-1
; Major 
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diastereoisomer: : δ 1H NMR (600 MHz, CDCl3) 7.81 (d, 1H, J = 2.1 Hz, H-3), 7.54 
(dd, 1H, J = 8.6, 2.1 Hz, H-4), 6.88 (m, 2H, H-1, 2), 6.55 (d, 1H, J = 8.6 Hz, H-5), 
5.95-5.92 (m, 1H, H-13), 5.76-5.74 (m, 1H, H-14), 4.70 (s, 2H, NH2), 4.31 (d, 1H, J 
=  11.0 Hz, H-7), 4.01 (br s, 1H, H-11), 3.10 (dt, 1H, J = 10.9, 6.8  Hz, H-12), 2.52 
(br s, 3 H, H-17or 16), 2.50 (br d, 1H, J = 17.7 Hz, H-10), 2.24 (br s, 3H, H-17 or 
16), 1.92 (br d, 1H, J = 17.7, H-10), 1.59 (br s, 3H, H-25); δ 13C NMR (150 MHz, 
CDCl3) 149.7 (Cq), 138.3 (Cq), 137.7 (Cq), 137.5 (Cq), 136.7 (CH), 133.3 (Cq), 131.8 
(CH), 129.4 (CH), 129.1 (Cq), 128.9 (CH), 128.6 (CH), 125.7 (CH), 122.9 (Cq), 
114.4 (CH), 52.0 (CH), 47.3 (CH), 38.5 (CH), 36.0 (CH2), 20.9 (2 × CH3), 21.4 
(CH3); HRMS (ES) calcd. for C21H23O2N2S [M-H]
- 
367.1559, found 367.1480. 
(3aS,4R,9bR)-4-(2,3,4-Trimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (59b)  
 
Purification by dry load flash column chromatography gradient method 0-50% 
EtOAc: petrol gave the title compound as a yellow white powder (622 mg, 66%). 
Isolated as a mixture of two diastereoisomers in 89: 11 ratio. 
                                    
 
59b 
m.p. 210-213 ˚C; Rf = 0.53 (1 : 1  EtOAc : petrol); IRυ max 3360 (C-H), 3267 (C-H), 
2931 (N-H), 2843 (N-H), 1598 (aromatic), 1307 (SO2-N), 1152 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.61 (d, 1H, J = 1.4 Hz, H-
11), 7.51 (dd, 1H, J = 8.5, 1.4 Hz, H-9), 7.28 (d, 1H, J = 7.9 Hz, H-5), 7.07 (d, 1H, J 
= 7.9 Hz, H-4), 6.64 (d, 1H, J = 8.5 Hz, H-8), 5.88-5.86 (m, 1H, H-14), 5.68 (br d, 
1H, J = 5.4 Hz, H-13), 4.94 (d, 1H, J = 2.8 Hz, H-6), 4.70 (s, 2H, NH2), 4.11 (d, 1H, 
J = 9.4 Hz, H-12), 4.08 (br s, 1H, NH), 3.06 (dtd, 1H,  J = 9.4, 8.9, 2.8 Hz, H-16), 
2.58 (ddd, 1H, J = 16.5, 9.4, 2.8 Hz, H-15), 2.31 (s, 3H, H-3), 2.28 (s, 3H, H-2), 
2.22 (s, 3H, H-1), 1.78 (br dd, 1H, J = 16.5, 8.9 Hz, H-15); δ 13C NMR (150 MHz, 
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CDCl3)  150.5 (Cq), 137.0 (Cq), 135.8 (Cq), 135.7 (Cq), 133.44 (Cq), 133.43 (CH), 
131.4 (CH), 130.5 (Cq), 128.2 (CH), 127.6 (CH), 126.0 (Cq), 125.4 (CH),122.8 (CH), 
115.6 (CH), 54.2 (CH), 46.0 (CH), 43.2 (CH), 31.7 (CH2), 21.0 (CH3), 16.2 (CH3), 
15.1 (CH3); HRMS (ES) calcd. for C21H25O2N2S [M + H]
+ 
369.1559, found 
369.1637. 
 
(3aS,4R,9bR)-4-(2,3,5-Trimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (60b)  
 
 Purfication by dry load flash column chromatography gradient method 0-50% 
EtOAc: petrol gave the title compound as a pale yellow powder (181 mg, 36%). 
Isolated as a mixture of two diastereoisomers in 86: 14 ratio. 
 
60b 
m.p. 235-238 ˚C; Rf = 0.55 (1 : 1  EtOAc : petrol); IRυ max 3360 (C-H), 3267 (C-H), 
2931 (N-H), 2843 (N-H), 1598 (aromatic), 1307 (SO2-N), 1152 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.61 (d, 1H, J = 1.8 Hz, H-
11), 7.52 (dd, 1H, J = 8.5, 1.8 Hz, H-9), 7.19 (br s, 1H, H-5), 6.96 (br s, 1H, H-3), 
6.66 (d, 1H, J = 8.5 Hz, H-8), 5.88-5.86 (m, 1H, H-14), 5.69 (br d, 1H, J = 5.2 Hz, 
H-13), 4.93 (d, 1H, J = 2.8 Hz, H-6), 4.62 (s, 2H, NH2), 4.12 (d, 1H, J = 8.5 Hz, H-
12), 3.06 (dtd, 1H, J  = 9.5, 8.5, 2.8 Hz, H-16), 2.58 (ddd, 1H, J = 16.4, 9.5, 2.8 Hz, 
H-15), 2.32 (s, 3H, H-4), 2.28 (s, 3H, H-2), 2.22 (s, 3H, H-1), 1.79 (br dd, 1H, J = 
16.4, 8.5 Hz, H-15); δ 13C NMR (150 MHz, CDCl3) 150.6 (Cq), 139.2 (Cq), 135.2 
(Cq), 133.4 (CH), 131.3 (CH), 130.5 (Cq), 130.4 (Cq), 130.0 (CH), 128.2 (CH), 125.7 
(Cq), 125.4 (CH), 123.9 (CH), 115.6 (CH), 54.0 (CH), 46.1 (CH), 43.1 (CH), 31.7 
(CH2), 21.4 (CH3), 20.9 (CH3), 14.3 (CH3); quaternary carbon overlapping with 
another peak; HRMS (ES) calcd. for C21H25O2N2S [M + H]
+ 
369.1635, found 
369.1637. 
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(3aS,4R,9bR)-4-(2,3,6-Trimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (61a)  
Purification by dry load flash column chromatography gradient method 20-45% 
EtOAc: petrol gave the title compound as an orange yellow solid (373 mg, 82%). 
Isolated as a mixture of two diastereoisomers in  >95: 5 ratio. 
                   
                                                                       61a 
m.p. 125-128˚C; Rf = 0.51 (1:1  EtOAc : petrol); IRυ max 3365 (C-H), 3266 (C-H), 
2925 (C-H), 2811 (N-H), 1503 (aromatic), 1327 (SO2-N), 1175 (O=S=O) cm
-1
; 
Major diastereisomer δ 1H NMR (600 MHz, CDCl3) 7.82 (d, 1H, J = 1.7 Hz, H-11), 
7.55 (dd, 1H, J = 8.8, 1.7 Hz, H-9), 7.34 (d, 2H, J = 7.8 Hz, H-2), 7.05 (d, 1H, J = 
7.8 Hz, H-3), 6.95 (d, 1H, J = 8.8 Hz, H-8), 5.94 (br s, 1H, H-14), 5.77-5.75 (m, 1H, 
H-13), 4.73 (s, 2H, NH2), 4.39 (s, 1H, NH), 4.36 (d, 1H, J = 8.8 Hz, H-6), 4.02 (br s, 
1H, H-12), 3.09 (dtd, 1H, J = 10.8, 8.8, 2.8 Hz, H-16), 2.46-2.44 (m, 4H, H-15, 5), 
2.25 (s, 6H, H-1, 4), 1.90 (br dd, 1H, J = 15.7, 8.8 Hz, H-15);  δ 13C NMR (150 
MHz, CDCl3) 149.4 (Cq), 137.1 (Cq), 136.7 (CH), 136.6 (Cq), 136.1 (Cq), 136.0 (Cq), 
129.6 (CH), 129.0 (Cq), 128.9 (CH), 128.6 (CH), 128.1 (CH), 122.8 (Cq), 114.1 
(CH), 52.4 (CH), 47.4 (CH), 47.0 (CH), 36.0 (CH2), 21.8 (CH3), 20.8 (CH3), 17.3 
(CH3); HRMS (ES) calcd. for C21H25O2N2S [M + H]
+
 369.1621, found 369.1637. 
(3aS,4R,9bR)-4-(3,4,5-trimethylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (62b)  
Purification by dry load flash column 0-50% EtOAc: petrol gave the title compound 
as a yellow oil (308 mg, 59%). Isolated as a mixture of two diastereoisomers in 76: 
24 ratio. 
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62b 
Rf = 0.51 (1: 1  EtOAc : petrol); IRυ max 3358 (C-H), 3264 (C-H), 2930 (N-H), 1496 
(aromatic), 1329 (SO2-N), 1158 (O=S=O) cm
-1; Major diastereoisomer: δ 1H NMR 
(600 MHz, CDCl3) 7.59 (d, 1H, J = 2.0 Hz, H-7), 7.51 (dd, 1H, J = 8.5, 2.0 Hz, H-
9), 7.02 (s, 2H, H-1), 6.63 (d, 1H, J = 8.5 Hz, H-8), 5.88-5.86 (m, 1H, H-13), 5.69-
5.68 (m, 1H, H-12), 4.71 (s, 2H, NH2), 4.60 (d, 1H, J = 2.9 Hz, H-4), 4.19 (s, 1H, 
NH), 4.08 (d, 1H, J = 8.6 Hz, H-11), 3.00 (dtd, 1H,  J = 9.5, 8.6, 2.9 Hz, H-10), 2.57 
(ddd, 1H, J = 16.4, 9.5, 2.9 Hz, H-14), 2.31 (s, 6H, H-2), 2.18 (s, 3H, H-3), 1.88 
(ddd, 1H, J = 16.4, 8.6, 2.9 Hz, H-14); δ 13C NMR (150 MHz, CDCl3) 150.1 (Cq), 
138.5 (Cq), 136.9 (2 × Cq), 134.5 (Cq), 133.6 (CH), 131.3 (CH), 130.5 (Cq), 128.2 
(CH), 125. 9 (Cq), 125.6 (2 × CH), 125.4 (CH), 115.5 (CH) 57.2 (CH), 46.0 (CH), 
45.9 (CH), 31.8 (CH2), 20.9 (2 × CH3), 15.4 (CH3); HRMS (ES) calcd. for 
C21H25O2N2S [M-H]
- 
367.1470, found 367.1480. 
(3aS,4R,9bR)-4-(2,3,4,5-Tetramethylphenyl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-sulfonamide (63b)  
 
Purification by dry load flash column chromatography gradient method 0-50% 
EtOAc: petrol gave the title compound as a pale yellow powder (181 mg, 56%). 
Isolated as a mixture of two diastereoisomers in 89: 11 ratio. 
 
63b 
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Rf = 0.49 (1: 1  EtOAc : petrol); IRυ max 3354-3261 (C-H), 2927 (N-H), 1487 
(aromatic), 1309 (SO2-N), 1151 (O=S=O) cm
-1; Major diastereoisomer: δ 1H NMR 
(600 MHz, CDCl3) 7.52 (dd, 1H, J = 8.6, 1.6 Hz, H-9), 7.50 (d, 1H, J = 1.6 Hz, H-
11), 7.18 (s, 1H, H-5), 6.65 (d, 1H, J = 8.6 Hz, H-8), 5.88-5.86 (m, 1H, H-14), 5.69 
(br d, 1H, J = 4.8Hz, H-13), 4.92 (d, 1H, J = 2.8 Hz, H-6), 4.76 (s, 2H, NH2), 4.11 
(d, 1H, J = 8.7 Hz, H-12), 4.10 (s, 1H, NH), 3.05 (dtd, 1H,  J = 10.7, 8.7, 2.8 Hz, H-
16), 2.59 (ddd, 1H, J = 16.2, 10.7, 2.8 Hz, H-15), 2.32 (s, 3H, H-4), 2.26 (s, 3H, H-
2), 2.24 (s, 3H, H-1), 2.23 (s, 3H, H-3), 1.81 (br dd, 1H, J = 16.2, 8.7 Hz, H-15); δ 
13
C NMR (150 MHz, CDCl3) 150.6 (Cq), 136.2 (Cq), 135.8 (Cq), 134.2 (Cq), 134.0 
(Cq), 133.5 (CH), 131.3 (CH), 130.9 (Cq), 130.5 (Cq), 128.2 (CH), 126.1 (Cq), 125.4 
(CH), 124.6 (CH), 115.6 (CH), 54.1 (CH), 46.1 (CH), 43.2 (CH), 31.7 (CH2), 21.2 
(CH3), 16.6 (CH3), 16.2 (CH3), 15.2 (CH3); HRMS (ES) calcd. for C22H25O2N2S [M-
H]
- 
381.1715, found 381.1637. 
(3aS, 4R, 9bR)-4-(2,3,4,6-Tetramethylphenyl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-sulfonamide (64a)  
Purification by dry load flash column chromatography gradient method 0-40% 
EtOAc: petrol to give the title compound as a colourless oil (20 mg, 28%). Isolated 
as a mixture of two diastereoisomers in >95: 5 ratio. 
 
64a 
Rf = 0.59 (1 : 1  EtOAc : petrol); IRυ max 3356 (C-H), 3259 (C-H), 2923 (N-H), 1503 
(aromatic), 1327 (SO2-N), 1145 (O=S), 1139 (O=S=O) cm
-1
; Major diastereoisomer: 
δ 1H NMR (600 MHz, CDCl3) 7.81 (d, 1H, J = 1.5 Hz, H-11), 7.54 (dd, 1H, J = 8.5, 
1.5 Hz, H-9), 6.88 (s, 1H, H-3), 6.54 (d, 1H, J = 8.5 Hz, H-8), 5.95-5.93 (br s, 1H, 
H-14), 5.76-5.74 (br s, 1H, H-13), 4.72 (s, 2H, NH2), 4.37 (s, 1H, NH), 4.33 (d, 1H, 
J = 7.9 Hz, H-6), 4.02 (br d, 1H, J = 10.0 Hz, H-12), 3.08 (dtd, 1H,  J = 10.0, 7.9, 
2.9 Hz, H-16), 2.45 (m, 4H, H-15, 5), 2.28 (s, 3H, H-2), 2.17 (s, 3H, H-4), 2.15 (s, 
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3H, H-1), 1.90 (d, 1H, J = 16.3 Hz, H-15); δ 13C NMR (150 MHz, CDCl3)  149.5 
(Cq), 136.7 (CH), 136.5 (Cq), 136.2 (2 × Cq), 135.5 (Cq), 135.3 (Cq), 133.8 (Cq), 
130.1 (CH), 128.9 (CH), 128.6 (CH), 125.7 (CH), 122.7 (Cq), 114.1 (CH), 52.2 
(CH), 47.4 (CH), 47.0 (CH), 36.1 (CH2),  21.6 (CH3), 20.8 (CH3),17.7 (CH3), 15.8 
(CH3); HRMS (ES) calcd. for C22H25O2N2S [M–H]
-
 381.1637, found 381.1637. 
4-(4-Methoxyphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (65b).
  
Method A: Purified by flash column chromatography using a gradient elution of 10-
50 % EtOAc: petrol gave the title compound as an orange foam (228 mg, 16%). 
Isolated as a mixture of two diastereoisomers in 80: 20 ratio. 
 
65b 
Rf = 0.33 (1:1 EtOAc : petrol); IR υ max 3358 (C-H), 3054 (C-H), 2932- 2839 (N-H), 
1512 (aromatic), 1304 (SO2-N), 1244 (S=O), 1128 (SO2-N), 1090 (S=O) cm
-1
; Major 
diastereoisomer:  δ 
1
H NMR (600 MHz, CDCl3) 7.54 (d, 1H, J = 2.0 Hz, H-19), 7.42 
(dd, 1H, J = 8.5, 2.0 Hz, H-17), 7.31 (d, 2H, J = 8.6,  H-1,3), 6.89 (d, 2H, J = 8.6 Hz, 
H-4,6), 6.75 (d, 1H, J = 8.5 Hz, H-16), 5.87-5.85 (m, 1H, H-13), 5.60-5.57 (m, 1H, 
H-14), 4.56 (d, 1H, J = 3.3 Hz, H-7), 4.03 (br d, 1H, J = 8.7 Hz, H-11), 3.75 (s, 3H, 
H-21), 2.91 (dtd, 1H, J = 9.5, 8.7, 3.3 Hz, H-12), 2.48 (ddd, 1H, J = 16.3, 9.5, 2.3 
Hz, H-15), 1.70 (br dd, 1H, J = 16.3, 8.7 Hz, H-15);  δ 13C NMR (600 MHz, CDCl3) 
160.3 (Cq), 151.6 (Cq), 135.6 (Cq), 135.1 (CH), 132.6 (Cq), 131.4 (CH), 128.7 (2 × 
CH), 128.4 (CH), 126.5 (Cq), 125.7 (CH), 116.5 (CH), 114.9 (2 × CH), 57.8 (CH), 
55.8 (CH3), 47.6 (CH), 47.1 (CH), 32.7 (CH2); HRMS (ES-) calcd. for C18H17N2O3 
[M - CH3]
- 341.0952, found 341.0960.  
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(3aS,4R,9bR)-4-(4-Cyanophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (66b)  
Method A: Purification by dry load flash chromatography gradient method 70-50% 
EtOAc: petrol gave title compound as brown solid (69 mg, 6%). Isolated as a 
mixture of two diastereoisomers in 77: 23 ratio. 
 
66b 
m.p. 210-212˚C; Rf = 0.14 (1 :1 EtOAc : petrol); IRυ max 3354 (C-H), 3269 (C-H), 
2930 (N-H), 2229 (nitrile), 1501 (aromatic), 1328 (SO2-N), 1158 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.70 (br d, 2H, J = 8.0 Hz, H-
1, 3), 7.61 (d, 1H, J = 1.5 Hz, H-16), 7.54 (m, 3H, H-14, 6, 4), 6.69 (d, 1H, J = 8.3 
Hz, H-13), 5.91-5.89 (m, 1H, H-17), 5.68-5.67 (m, 1H, H-18), 4.78 (d, 1H, J = 2.6 
Hz, H-7), 4.66 (s, 2H, NH2), 4.19 (s, 1H, NH), 4.13 (d, 1H, J = 8.5 Hz, H-11), 3.00 
(dtd, 1H,  J = 9.5, 8.5, 2.6 Hz, H-12), 2.50 (dtd, 1H, J = 16.1, 9.5, 2.6 Hz, H-19), 
1.77 (ddd, 1H, J = 16.1, 8.5, 2.6 Hz, H-19); δ 13C NMR (150 MHz, CDCl3) 148.9 
(Cq), 147.2 (Cq), 133.4 (CH), 132.7 (2 × CH), 131.6 (Cq), 130.9 (CH), 129.2 (Cq), 
128.2 (CH), 127.3 (2 × CH), 125.7 (Cq), 125.6 (CH), 115.9 (CH), 111.7 (-CN), 57.3 
(CH), 45.7 (CH), 45.5 (CH), 31.4 (CH2); HRMS (EI) calcd. for C19H18O2N3S [M+ 
H]
+ 
352.1042, found 352.1118.  
(3aS,4R,9bR)-4-(4-(Methylsulfonyl)phenyl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-sulfonamide (67b)  
Method A: Using sulphanilamide (2 eq) and InCl3 (9 mol %). Purification by dry 
load flash chromatography method 10% MeOH: DCM gave the title compound as a 
brown powder (51 mg, 3%). Isolated as a mixture of two diastereoisomers in 91: 9 
ratio. 
179 
 
         
67b 
m.p. 182-185˚C; Rf = 0.7 (1 : 9  MeOH : DCM); IRυ max 3353 (C-H), 3264 (C-H), 
2925 (N-H), 2853 (N-H), 1598 (aromatic C=C), 1303 (SO2-N), 1147 (O=S=O) cm
-1
;  
Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.98 (d, 2H, J = 8.3 Hz, H-1, 
3), 7.64 (d, 2H, J = 8.3 Hz, H-4, 6), 7.62 (d, 1H, J = 1.9 Hz, H-16), 7.55 (dd, 1H, J = 
8.5, 1.9 Hz, H-14), 6.71 (d, 1H, J = 8.5 Hz, H-13), 5.92-5.90 (m, 1H, H-17), 5.69-
5.67 (m, 1H, H-18), 4.82 (d, 1H, J = 3.6 Hz, H-7), 4.67 (s, 2H, NH2), 4.22 (1H, s, 
NH), 4.12 (d, 1H, J = 8.5 Hz, H-11), 3.09 (s, 3H, H-22), 3.04 (dtd, 1H,  J = 9.4, 8.5, 
3.6 Hz, H-12), 2.52 (dtd, 1H, J = 16.3, 9.4, 3.6 Hz, H-19), 1.78 (ddd, 1H, J = 16.3, 
8.5, 3.6 Hz, H-19); 
13
C NMR (150 MHz, CDCl3) 148.9 (Cq), 148.2 (Cq), 139.9 (Cq), 
133.4 (CH), 131.6 (Cq), 130.9 (CH), 128.2 (CH), 128.0 (2 × CH), 127.5 (2 × CH), 
125.8 (Cq), 125.6 (CH), 116.0 (CH), 57.3 (CH), 45.7 (CH), 45.6 (CH), 44.6 (CH3), 
31.4 (CH2); HRMS (EI) calcd. for C19H20O4N2S2 [M]
+ 
404.0869, found 404.0868. 
 (3aS,4R,9bR)-4-(4-Tert-butylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (68b)  
Method A: Using sulphanilamide (2 eq) and InCl3 (11 mol %). Purification by dry 
load flash chromatography method 50% EtOAc: petrol to afford the title compound 
as a orange yellow solid (112 mg, 16%). Isolated as a mixture of two 
diastereoisomers in 95: 5 ratio. 
        
68b 
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m.p. 215˚C; Rf = 0.66 (1: 1 EtOAc : petrol); IRυ max 3362 (C-H), 3062 (C-H), 2962 
(N-H), 1498 (aromatic), 1328 (SO2-N), 1297 (O=S=O), 1147-1124 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 2.2 Hz, H-
16), 7.51 (dd, 1H, J = 8.6, 2.2 Hz, H-14), 7.41 (d, 2H, J = 8.6 Hz, H-4,6), 7.33 (d, 
2H, J = 8.6 Hz, H-1,3), 6.63 (d, 1H, J = 8.6 Hz, H-13), 5.89-5.87 (m, 1H, H-17), 
5.70-5.68 (m, 1H, H-18), 4.68 (d, 1H, J = 2.8 Hz, H-7), 4.65 (s, 2H, NH2), 4.22 (brs, 
1H, NH), 4.10 (d, 1H, J = 8.6  Hz, H-11),  3.00(1H,  dtd,  J = 9.2, 8.6, 2.8 Hz, H-12),  
2.58 (dtd, 1H, J = 16.6, 9.2, 2.8 Hz, H-19), 1.87 (br dd, 1H, J = 16.6, 8.6 Hz, H-19), 
1.33 (s,  9H, H-22, 23, 24); 
13
C NMR (150 MHz, CDCl3) 150.8 (Cq), 150.0 (Cq), 
138.7 (Cq), 133.4 (CH), 131.2 (CH), 130.6 (Cq), 128.2 (CH), 126.2 (2 × CH), 125.9 
(Cq), 125.72 (Cq), 125.7 (2 × CH), 125.4 (CH), 115.5 (CH), 57.3 (CH), 45.9 (CH), 
45.90 (CH), 34.2 (Cq), 31.6 (CH2), 31.4 (-C(CH3)3); HRMS (EI) calcd. for 
C22H26O2N2S [M]
+ 
382.17150, found 382.17123.  
(3aS,4R,9bR)-4-(4-Isopropylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (69b)  
Method A: Under the same protocol conditions above with exception to 
sulphanilamide (2 eq) and InCl3 (9 mol%) were considered. Purification by dry load 
flash chromatography method 50% EtOAc: petrol gave the title compound as a dark 
green amorphous solid (957 mg, 19%). Isolated as a mixture of two diastereoisomers 
in 83: 17 ratio. 
 
69b 
m.p. 203 ˚C; Rf =  0.64 (1 :1 EtOAc : petrol); IRυ max 3363 (C-H), 3257 (C-H), 2960 
(N-H), 2955 (N-H), 1498 (aromatic), 1332 (SO2-N), 1155-1129 (S=O) cm
-1
; Major 
diastereoisomer: δ 1H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 1.9 Hz, H-16), 7.51 
(dd, 1H, J = 8.5, 1.9 Hz, H-14), 7.33 (d, 2H, J = 7.9 Hz, H-4, 6), 7.25 (d, 2H,  J = 7.9 
Hz, H-1, 3), 6.63 (d, 1H, J = 8.5 Hz, H-13), 5.89-5.87 (m, 1H, H-17), 5.69-5.67 (m, 
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1H, H-18), 4.68 (d, 1H, J = 2.9 Hz, H-7), 4.65 (br s, 2H, NH2 ), 4.22 (brs, 1H, NH), 
4.10 (d, 1H, J = 9.8 Hz, H-11),  3.00 (1H,  dtd,  J = 11.4, 9.8, 2.9 Hz, H-12),  2.92 
(septet, 1H, J = 7.1 Hz, H-24), 2.57 (dtd, 1H, J = 16.3, 11.4, 2.9 Hz, H-19), 1.87 (br 
dd, 1H, J = 16.3, 9.8 Hz, H-19), 1.26 (d, 6 H, J = 7.1 Hz, H-22, 23); 
13
C NMR (150 
MHz, CDCl3) 150.0 (Cq), 148.6 (Cq), 139.1 (Cq), 133.5 (CH), 131.2 (CH), 130.6 
(Cq), 128.2 (CH), 126.8 (2 × CH), 126.5 (2 × CH), 125.9 (Cq), 125.4 (CH), 115.6 
(CH), 57.4 (CH), 46.0 (CH), 45.9 (CH), 34.0 (CH(CH3)2, 31.6 (CH2), 24.1 (2 × 
CH3); HRMS (EI) calcd. for C21H25O2N2S [M+H]
+ 
369.15585, found 369.1637. 
 (3aS,4R,9bR)-4-(4-Vinylphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (70b)  
Potassium carbonate (409 mg, 2.96 mmol, 3 eq), potassium tetraflourovinylborate 
(334 mg, 2.49 mmol, 2.5 eq), Pd(PPh3)2 (5 mol%, 57 mg), 28b (400 mg, 0.99 mmol, 
1 eq) was refluxed in toluene/EtOH/H2O (5.8: 1.6: 0.8) for 48 hrs at 80°C. To the 
reaction mixture EtOAc (6 ml) was added and washed with water (12 ml), dried with 
MgSO4 and concentrated. Purification by flash chromatography dry load method 
using 30% EtOAc: petrol gave the title compound as brown amorphous solid (49 
mg, 14%).   
 
70b 
m.p. 88-90 ˚C; Rf = 0.42 (1 : 1 EtOAc : Petrol) IRυ max 3360 (C-H), 2263 (N-H), 
1494 (aromatic), 1320 (SO2-N), 1154-1129 (O=S=O) cm
-1
; Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.59 (s, 1H, H-16), 7.52 (dd, 1H, J = 8.8, 2.6 Hz, H-
14), 7.43 (d, 2H,  J = 7.9 Hz, H-1,3),  7.36 (d, 2H, J = 7.9 Hz, H-6,4), 6.73 (dd, 1H, J 
= 11.0, 17.6 Hz, H-17), 6.66 (d, 1H, J = 8.8 Hz, H-13), 5.88 (br s, 1H, H-19), 5.77 
(d, 1H, J = 17.6 Hz, H-18), 5.67 (br d, 1H, J = 4.4 Hz, H-20), 5.27 (d, 1H,  J = 11.0 
Hz, H-18), 4.71 (s, 3H, NH2, H-7), 4.23 (s, 1H, NH), 4.10 (d, 1H, J = 7.0 Hz, H-11), 
3.01 (dtd, 1H,  J = 9.5, 7.0, 2.5 Hz,  H-12), 2.52 (dtd, 1H, 16.3, 9.5, 2.5 Hz, H-21), 
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1.84 (ddd, 1H, J = 16.3, 7.0, 1.4 Hz, H-21); δ 13C NMR (150 MHz, CDCl3)  150.0 
(Cq), 141.3 (Cq),  137.2 (Cq), 136.4 (CH), 133.5 (CH), 132.0 (CH), 131.3 (CH), 
130.8 (Cq), 128.2 (CH), 128.2 (Cq), 126.6 (4 × CH), 115.6 (CH), 114.3 (CH2), 57.3 
(CH), 45.9 (CH), 45.8 (CH), 31.7 (CH2); HRMS (EI) for C20H20O2N2S [M]
+ 
352.1245, found 352.1261. 
4-Azidobenzaldehyde (70)
205
 
To a flame dried flask under an atmosphere of argon was added 4-
bromobenzaldehyde (2.7 mmol, 1 eq, 500 mg), sodium ascorbate (27 mg, 0.27 
mmol), Cu(I)I (5 mg, 0.54 mmol), and sodium azide (350 mg, 10.8 mmol) was 
refluxed in EtOH/H2O (3.5 ml/1.5 ml). N, N dimethylethylenediamine (0.5 ml) was 
then added and left to reflux for 2 hrs. On having cooled the reaction mixture CH2Cl2 
(10 ml) was added and was washed with water (15 ml), dried with MgSO4, filtered 
and evaporated. Purification by dry load flash chromatography 10% EtOAc: petrol to 
give product as yellow viscous oil (80 mg, 20%).  
                                                      
                                                                              70 
Rf = 0.73 (1: 1 EtOAc : petrol); IRυmax 2837 (C-H of CHO), 2773 (C-H), 2095.0 
(N3), 1694 (C=O), 1506 (aromatic), 1284.9 (C-N) cm
-1; δ 
1
H NMR (600 MHz, 
CDCl3) 9.94 (s, 1H, H-1), 7.88 (d, 2H, J = 9.1 Hz, H-2), 7.16 (d, 2H, J = 9.1 Hz, H-
3); δ 13C NMR (150 MHz) 190.5 (CHO), 146.7 (Cq), 133.4 (2 × CH), 132.1 (2 × CH), 
120.0 (Cq). 
4-(4-Azidophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (71b)  
Dissolved 4-azidobenzaldehyde (0.55 mmol, 80 mg), sulphanilamide (120 mg), and 
Sc(OTf)3 (20 mol%) in MeCN. Cyclopentadiene (3 eq, 0.14 ml) was added to the 
reaction mixture and left to stir overnight. Extracted from EtOAc and washed with 
(0.1M) NaHCO3 solution (10 ml), brine (10 ml) and water (10 ml). The organic layer 
was dried with MgSO4, filtered and concentrated. Purification by flash 
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chromatography dry load gradient method 0-35% EtOAc: petrol gave the title 
compound as an orange-pink viscous oil (12 mg, 24%). Isolated as a mixture of two 
diastereoisomers in 71: 29 ratio. 
 
71b 
Rf = 0.45 (1: 1 EtOAc : petrol); IRυ max 3233 (C-H), 2995 (C-H), 2790 (N-H) 2254 
(N3), 1599 (aromatic), 1471 (SO2-N), 1382 (O=S=O), 1160 (O=S=O) cm
-1; δ 
1
H 
NMR (600 MHz, CDCl3) 7.60 (d, 1H, J = 1.5 Hz, H-17), 7.52 (m, 3H, H-1,3, and 
15), 7.29 (d, 2H, J = 8.5 Hz, H-4,6), 6.69 (d, 1H, J = 8.6 Hz, H-14), 5.90-5.87 (m, 
1H, H-18), 5.70-5.66 (m, 1H, H-19), 4.78 (s, 2H, NH2), 4.67 (d, 1H, J = 2.9 Hz, H-
7), 4.19 (s, 1H, NH), 4.10 (d, 1H, J = 8.5 Hz, H-12), 2.98 (dtd, 1H, J =  9.8, 8.5, 2.9 
Hz, H-13), 2.51 (dtd, 1H, J =  16.3, 9.8, 2.9 Hz, H-20), 1.81 (dd, 1H, J = 16.3, 8.5 
Hz, H-20); 
13
C NMR (150 MHz, CDCl3) 149.9 (Cq), 140.8 (Cq), 133.5 (CH), 132.0 
(2 × CH), 131.2 (Cq), 131.0 (CH), 128.2 (3 × CH), 125.8 (Cq), 125.4 (CH), 121.5 
(Cq), 115.8 (CH), 57.0 (CH), 45.73 (CH), 45.71 (CH), 31.2 (CH2); HRMS (EI) calcd. 
for C18H17O2N5S [M]
+ 
367.4270, found 367.4267. 
 
 (3aS,4R,9bR)-4-(4-Nitrophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (72b)
26
 
Method A: Under the same protocol conditions above with exception to 
sulphanilamide (2 eq) and InCl3 (10 mol%) were considered. Purification by 
recrystallisation in DCM: EtOAc gave the title compound as a yellow powder (157 
mg, 21%). Isolated as a mixture of two diastereoisomers in 95: 5 ratio. 
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72b 
m.p. 125˚C; Rf = 0.37 (1: 1 EtOAc : petrol); IRυ max 3360 (C-H), 3258 (C-H), 1599 
(aromatic), 1504 (N-O), 1346 (N-O), 1313 (SO2-N), 1166 (O=S=O) cm
-1
; Major 
diastereoisomer: δ 
1
H NMR (600 MHz, DMSO-d6) 8.27 (d, 2H, 8.7 Hz, H-1, 3), 7.74 
(d, 2H, J = 8.6 Hz, H-4, 6), 7.46 (d, 1H, J = 1.7 Hz, H-16), 7.36 (dd, 1H, J = 8.3, 1.7 
Hz, H-14), 7.00 (s, 2H, NH2), 6.82 (d, 1H, J = 8.4 Hz, H-13), 6.54 (s, 1H, NH), 
5.92-5.89 (m, 1H, H-17), 5.69-5.67 (br d, 1H, J = 4.4 Hz, H-18), 4.80 (d, 1H, J = 2.6 
Hz, H-7), 4.10 (d, 1H, J = 8.5 Hz, H-11), 3.00 (dtd, 1H,  J = 9.3, 8.5, 2.6 Hz,  H-12), 
2.32 (dtd, 1H,  J = 16.0, 9.3, 2.6 Hz, H-19), 1.60 (ddd, 1H, J = 16.0, 8.5, 2.6 Hz, H-
19); 
13
C NMR (150 MHz, DMSO-d6)  150.1 (Cq), 148.9 (Cq), 146.5 (Cq), 134.2 
(CH), 132.7 (Cq),  129.9 (CH), 127.9  (2 × CH), 126.8 (CH), 124.1 (CH), 124.0 (Cq), 
123.5 (2 × CH), 115.2 (CH), 55.6 (CH), 45.0 (CH), 44.7 (CH), 31.7 (CH2).  
4-(2,3,4-Trimethoxyphenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (73b)  
Method A: Purified by flash chromatography dry load gradient method 40-50% 
EtOAc: petrol gave the title compound as an orange viscous oil (42 mg, 10%). 
Isolated as a mixture of two diastereoisomers in 91: 9 ratio. 
 
 
         
 
73b 
Rf = 0.26 (1 :1 EtOAc : Petrol); IRυ max 3354 (C-H), 3257 (C-H), 2936 (N-H), 2848 
(N-H), 1494 (aromatic), 1464 (C-O), 1330 (SO2-N), 1296 (O=S=O), 1153 (O=S=O), 
1090 (C-O) cm
-1; Major diastereoiomser: δ 
1
H NMR (600 MHz, CDCl3) 7.60 (d, 1H, 
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J = 1.8 Hz, H-16), 7.50 (dd, 1H, J = 8.4, 1.8 Hz, H-14), 7.14 (d, 1H, J = 8.7 Hz, H-
4), 6.69 (d, 1H, J = 8.6 Hz, H-3), 6.63 (d, 1H, J = 8.4, H-13), 5.87-5.85 (m, 1H, H-
18), 5.69-5.66 (m, 1H, H-19), 4.94 (br d, 1H, J = 2.7 Hz, H-7), 4.86 (s, 2H, NH2), 
4.11 (br d, 1H, J = 8.8 Hz, H-11), 4.05 (br s, 1H, NH), 3.92 (br s, 3H, H-22), 3.88 (br 
s, 6H, H-17, 23), 3.09 (dtd, 1H, J = 10.5, 8.8, 2.7 Hz, H-12), 2.50 (ddd, 1H, J = 16.3, 
8.8, 2.7 Hz, H-15), 1.84 (ddd, 1H, J = 16.3, 10.5 Hz, H-15); δ 13C NMR (150 MHz, 
CDCl3) 153.2 (Cq), 151.2 (Cq), 150.4 (Cq), 142.1 (Cq), 133.7 (CH), 131.1 (CH), 
130.6 (Cq), 128.2 (CH), 127.5 (Cq), 126.1 (Cq), 125.3 (CH), 120.7 (CH), 115.6 (CH), 
107.1 (CH), 61.3 (CH3), 60.9 (CH3), 56.2 (CH3), 51.2 (CH), 45.9 (CH), 43.7 (CH), 
31.9 (CH2); HRMS (EI) calcd. for C21H24O5N2S [M]
+ 
416.14004, found 416.14087. 
4-(5-Bromofuran-2-yl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (74b)  
Method A: Purification by dry load flash chromatography gradient method 50-40% 
EtOAc: petrol gave the title compound as a dark green powder (172 mg, 25%). 
Isolated as a mixture of two diastereoisomers in >95: 5 ratio. 
                                                
                                                                              74b 
m.p. 168-169˚C; Rf = 0.53 (1 :1  EtOAc : petrol); IRυ max 3362 (C-H), 3263 (C-H), 
2936 (N-H), 1499 (aromatic), 1315 (SO2-N), 1153 (O=S=O), 1127 (C-O-C), 1090 
(C-O) cm
-1; Major diastereoiomser: δ 1H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 
1.9 Hz, H-11), 7.52 (dd, 2H, J = 8.6, 1.9 Hz, H-9), 6.67 (d, 1H, J = 8.6 Hz, H-8), 
6.29 (d, 1H, J = 3.4 Hz, H-17), 6.25 (d, 1H, 3.4 Hz, H-16), 5.85-5.82 (m, 1H, H-13), 
5.72-5.69 (m, 1H, H-14), 4.62 (s, 3H, H-2, NH2), 4.27 (1H, s, NH), 4.09 (d, 1H, J = 
8.9 Hz, H-6), 3.18 (dtd, 1H, J = 9.1, 8.9, 2.8, H-7), 2.58 (dtd, 1H, J = 16.5, 9.1, 2.8 
Hz, H-15), 2.24 (br dd, 1H, J = 16.5, 8.9 Hz, H- 15); 
13
C NMR (150 MHz, CDCl3)  
156.5 (Cq), 148.7 (Cq), 133.4 (CH), 131.4 (Cq), 131.0 (CH), 128.1 (CH), 126.0 (Cq), 
125.5 (CH), 121.2 (Cq), 115.7 (CH), 112.1 (CH), 108.9 (CH), 52.0 (CH), 45.5 (CH), 
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42.3 (CH), 32.6 (CH2); HRMS (CI) calcd. for C16H15O3N2SBr [M]
+
 395.2710, found 
395.0069. 
4-(5-Methylfuran-2-yl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (75b)  
Method A: Purification by dry load flash chromatography gradient method 30-50% 
EtOAc: petrol gave the title compound as a pale yellow orange viscous oil (69 mg, 
8%). Isolated as a mixture of two diastereoisomers in >95: 5 ratio. 
 
75b 
 Rf = 0.27 (1: 1  EtOAc : petrol); IRυ max 3361 (C-H), 3268 (C-H), 2923 (N-H), 1499 
(aromatic), 1319 (SO2-N), 1292 (C-O), 1154 (O=S=O), 1130.2 (C-O-C) cm
-1
; Major 
diastereoiomser: δ 1H NMR (600 MHz, CDCl3) 7.58 (d, 1H, J = 1.9 Hz, H-11), 7.51 
(dd, 1H, J = 8.6, 1.9 Hz, H-9), 6.64 (d, 1H, J = 8.6 Hz, H-8), 6.12 (d, 1H, J = 3.0 Hz, 
H-16), 5.94 (d, 1H, 3.0, 1.1 Hz, H-17), 5.84-5.81 (m, 1H, H-13), 5.72-5.69 (m, 1H, 
H-14), 4.70 (s, 2H, NH2), 4.64 (d, 1H, J = 3.0 Hz, H-2), 4.31 (s, 1H, NH), 4.08 (d, 
1H, J = 8.9 Hz, H-6), 3.18 (dtd, 1H,  J = 9.1, 8.9, 3.0 Hz, H-7), 2.60 (dddd, 1H, J = 
16.6, 9.1, 3.0 Hz, H-15), 2.30 (s, 3H, CH3), 2.23 (br dd, 1H, J = 16.6, 8.9 Hz, H-15); 
13
C NMR (150 MHz, CDCl3)  152.6 (Cq), 151.7 (Cq), 149.3 (Cq), 133.5 (CH), 131.2 
(CH), 131.0 (Cq), 128.1 (CH), 126.1 (Cq), 125.4 (CH), 115.7 (CH), 106.7 (CH), 
106.2 (CH), 52.0 (CH), 45.8 (CH), 42.5 (CH), 32.7 (CH2), 13.8 (CH3); HRMS (CI) 
calcd. for C17H19O3N2S 331.4020 [M + H]
+
 found 331.1119. 
4-(Furan-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
sulfonamide (76b)  
Method A: Purification by dry load flash chromatography gradient method 30-40% 
EtOAc: petrol gave the title compound as a pale yellow powder (319 mg, 32%). 
Isolated as a mixture of two diastereoisomers in >95: 5 ratio. 
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76b 
m.p. 182-184 ˚C; Rf = 5.57 (1: 1  EtOAc : petrol); IRυ max 3361 (C-H), 3200 (C-H), 
2940 (N-H), 1497 (aromatic), 1322 (SO2-N), 1147 (O=S=O), 1127 (C-O-C), 912 (C-
O) cm
-1
; Major diastereoiomser: δ 
1
H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 1.9 
Hz, H-11), 7.52 (dd, 1H, J = 8.6, 1.9 Hz, H-9), 7.40 (dd, 1H, J = 3.1, 0.8 Hz, H-18), 
6.66 (d, 1H, J = 8.6 Hz, H-8), 6.38 (dd, 1H, 3.1, 2.0 Hz, H-17), 6.26 (dt, 1H, J = 3.1, 
0.8 Hz, H-16), 5.85-5.82 (m, 1H, H-13), 5.72-5.69 (m, 1H, H-14), 4.71 (d, 1H, J = 
2.8 Hz, H-2), 4.63 (s, 2H, NH2), 4.33 (s, 1H, NH), 4.10 (d, 1H, J = 8.7 Hz, H-6), 
3.04 (dtd, 1H,  J = 9.0, 8.7, 2.8 Hz, H-7), 2.59 (dtd, 1H, J = 16.7, 9.0, 2.8 Hz, H-15), 
2.21 (ddd, 1H, J = 16.7, 8.7, 2.8 Hz, H-15); δ 13C NMR (150 MHz, CDCl3)  154.4 
(Cq), 149.1 (Cq), 142.0 (CH), 133.4 (CH), 131.1 (CH), 131.1 (Cq), 128.1 (CH), 126.1 
(Cq), 125.4 (CH), 115.7 (CH), 110.5 (CH), 106.0 (CH), 52.0 (CH), 45.7 (CH), 42.5 
(CH), 32.7 (CH2); HRMS (CI) calcd. for C16H17O3N2S [M + H]
+
 317.0882 found, 
317.0965. 
4-(Thiophen-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
8-sulfonamide (77b)  
Method A: Purification by dry load flash chromatography gradient method 30-40% 
EtOAc: petrol gave the title compound as a pale yellow powder (185 mg, 20%). 
Isolated a mixture of two diastereoisomers in >95: 5 ratio. 
 
77b 
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m.p. 174-177 ˚C; Rf = 0.57 (1 :1  EtOAc : petrol); IRυ max 3355 (C-H), 3261 (C-H), 
2911 (N-H), 1494 (aromatic), 1329 (SO2-N), 1155 (O=S=O) cm
-1
; Major 
diastereoiomser: δ 
1
H NMR (600 MHz, CDCl3) 7.59 (d, 1H, J = 2.1 Hz, H-11), 7.52 
(dd, 1H, J = 8.5, 2.1 Hz, H-9), 7.27 (dd, 1H, J = 5.1, 0.8 Hz, H-18), 7.10 (br d, 1H, J 
= 3.5 Hz, H-16), 7.02 (dd, 1H, 5.1, 3.5 Hz, H-17), 6.64 (d, 1H, J = 8.5 Hz, H-8), 
5.89-5.86 (m, 1H, H-13), 5.73-5.70 (m, 1H, H-14), 4.99 (d, 1H, J = 2.8 Hz, H-2), 
4.71 (s, 2H, NH2), 4.30 (1H, s, NH), 4.11 (d, 1H, J = 8.4 Hz, H-6), 3.06 (dtd, 1H, J = 
9.6, 8.4, 2.8 Hz, H-7), 2.67 (ddd, 1H, J = 16.4, 9.6, 2.8 Hz, H-15), 2.10 (dddd, 1H, J 
= 16.4, 8.4, 2.8 Hz, H- 15); 
13
C NMR (150 MHz, CDCl3)  149.1 (Cq), 144.9 (Cq), 
133.4 (CH), 131.3 (Cq), 131.2 (CH), 128.2 (CH), 126.9 (CH), 126.0 (Cq), 125.4 
(CH), 124.6 (CH), 124.3 (CH), 115.7 (CH), 54.1 (CH), 46.1 (CH), 45.8 (CH), 32.4 
(CH2); HRMS (CI) calcd. for C16H17O2N2S2 [M + H]
+
 333.0653 found, 333.0729. 
4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
6-sulfonamide (92b)  
Method A: Purification by dry load flash chromatography dry load gradient method 
0-50% EtOAc: petrol to afford title compound as a white foam (339 mg, 51%). 
Isolated as a mixture of two diastereoisomers in >95:5 ratio. 
                                                   
92b 
m.p. 95-97 ˚C; Rf = 0.58 (1: 1  EtOAc : petrol); IRυ max 3359 (C-H), 3274 (C-H), 
2927 (N-H), 2848 (N-H), 1487 (aromatic), 1450 (SO2-N), 1327 (SO2-N), 1163 
(O=S=O) cm
-1
; Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.65 (d, 1H, J 
= 7.8 Hz, H-14), 7.51 (d, 2H, J = 8.5 Hz, H-1, 3), 7.29 (d, 2H, J = 8.5 Hz, H-4, 6), 
7.25 (br d, 1H, J = 7.8 Hz, H-16), 6.81 (t, 1H, J = 7.8 Hz, H-15), 6.02(s, 1H, NH), 
5.84-5.82 (m, 1H, H-17), 5.68-5.66 (m, 1H, H-18), 4.83 (s, 2H, NH2), 4.63 (d, 1H, J 
= 2.9 Hz, H-7), 4.16 (d, 1H, J = 8.5 Hz, H-11), 3.02 (dtd, 1H,  J = 9.5, 8.5, 2.9 Hz, 
H-12), 2.51 (dtd, 1H, J = 16.4, 9.5, 2.9 Hz, H-19), 1.86 (ddd, 1H, J = 16.4, 8.5, 2.9 
Hz, H-19); 
13
C NMR (150 MHz, CDCl3)  143.3 (Cq), 140.7 (Cq), 134.4 (CH), 133.8 
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(CH), 132.0 (2 × CH), 131.1 (CH), 128.05 (2 × CH), 128.10 (Cq), 126.5 (CH), 124.9 
(Cq), 121.5 (Cq), 118.3 (CH), 56.6 (CH), 46.0 (CH), 44.9 (CH), 31.5 (CH2); HRMS 
(ES) calcd. for C18H17O2N2SBr [M-H]
- 
403.0194, found 403.0116. 
4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
7-sulfonamide (93b)  
Purification by flash chromatography dry load method 1: 1 EtOAc: petrol to afford 
title compound as a green crystalline foam (173 mg, 26%). Isolated as a mixture of 
two diastereoisomers in >95: 5 ratio as a percentage. 
                                                       
93b 
m.p. 112-115˚C; Rf = 0.28 (1:1  EtOAc : petrol); IRυ max 3361 (C-H), 3267 (C-H), 
2926 (N-H), 2849 (N-H), 1474 (aromatic), 1320 (SO2-N), 1159 (O=S=O) cm
-1
; 
Major diastereoisomer: δ 
1
H NMR (600 MHz, CDCl3) 7.51 (m, 3H, H-13, 1, 3), 7.28 
(d, 2H, J = 8.4 Hz, H-4, 6), 7.25  (dd, 1H, J = 7.2, 1.6 Hz, H-15), 7.17 (d, 1H, J = 1.6 
Hz, H-13), 7.15 (d, 1H, J = 7.2 Hz, H-16), 5.82-5.80 (m, 1H, H-17), 5.69-5.67 (m, 
1H, H-18), 4.77 (s, 2H, NH2), 4.62 (d, 1H, J = 3.0 Hz, H-7),  4.11 (d, 1H, J = 8.1 Hz, 
H-11), 2.99 (dtd, 1H, J = 9.1, 8.1, 3.0 Hz, H-12), 2.53 (dtd, 1H, J = 16.4, 9.1, 3.0  
Hz, H-19), 1.81 (br dd, 1H, J = 16.4, 8.1 Hz, H-19); 
13
C NMR (150 MHz, CDCl3)  
146.0 (Cq), 141.0 (Cq), 139.8  (Cq), 133.1 (CH), 131.9 (2 × CH), 131.3 (CH), 131.0 
(Cq), 130.0 (CH), 128.2 (2 × CH), 121.4 (Cq), 116.7 (CH), 113.7 (CH), 57.3 (CH), 
46.2 (CH), 45.7 (CH), 31.8 (CH2); HRMS (ES) calcd. for C18H17O2N2SBr [M-H]
- 
403.0195, found 403.0116. 
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4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolone 
(94b)
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Purification by dry load flash chromatography gradient method using 0-50% EtOAc: 
petrol gave the title compound as an orange white solid (213 mg, 65%). Isolated as a 
mixture of two diastereoisomers in 91: 9 ratio. 
 
94b 
mp 148-149 °C; Rf = 0.76 (1:1 EtOAc: petrol), IRυmax 2928 (C-H), 2846 (N-H), 
1472 (aromatic) cm
-1
; Major diastereoisomer: δ 
1
 H NMR (600 MHz, CDCl3) 7.49 (d, 
2H, J = 8.4 Hz, H-1, 3), 7.32 (d, 2H, J = 8.4 Hz, H-4, 6), 7.06 (br d, 1H, J = 7.7 Hz, 
H-16), 6.99 (td, 1H, J = 7.7, 1.5 Hz, H-14), 6.77 (td, 1H, J = 7.7, 1.2 Hz, H-15), 6.63 
(dd, 1H, J = 7.7, 1.2 Hz, H-13), 5.85-5.83 (m, 1H, H-17), 5.65-5.63 (m, 1H, H-18), 
4.60 (d, 1H, J = 2.9 Hz, H-7), 4.11 (d, 1H, J = 8.6 Hz, H-11), 3.70 (br s, 1H, NH), 
2.97 (dtd, 1H, J =  9.3, 8.6, 2.9 Hz, H-12), 2.58 (ddd, 1H, J = 16.4, 9.3, 2.9 Hz, H-
19), 1.79 (ddd, 1H, J = 16.4, 8.6, 2.9 Hz, H-19);  δ 13C NMR (150 MHz, CDCl3) 
145.3 (Cq), 142.1 (Cq), 134.1 (CH), 131.7 (2 × CH), 130.4 (CH), 129.1 (CH), 128.3 
(2 × CH), 126.5 (CH), 126.1 (Cq), 121.1 (Cq), 119.5 (CH), 116.1 (CH), 57.7 (CH), 
46.4 (CH), 46.0 (CH), 31.5 (CH2).  
5-(4-bromophenyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-
c]quinoline-9-sulfonamide (96a)  
 
To a dry flask under an atmosphere of argon were added 28b (5.00 mmol, 925 mg), 
sulphanilamide (5.49 mmol, 945 mg, 1.4 eq), 3, 4-dihydropyran (7 mmol, 0.6 ml, 1.4 
eq) and MeCN (5 ml). This was followed by addition of GdCl3 (20 mol%, 265 mg) 
and reaction was stirred overnight at r.t. Purification by dry load flash column 
chromatography 0-50%. Isolated two spots which were each further purified by 
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recrystallisation from isopropanol: petrol: toluene, which gave the title compound as 
a white powder (0.4 mg, 0.02%). 
 
 
96a 
 
Rf  = 0.32 (3 : 2 EtOAc/petrol); mp 192-194 °C; IRυ max 3344 (N-H), 2933 (N-H), 
1489 (aromatic), 1332 (SO2-N), 1191 (S=O), 1170 (N-SO2) ,1132 (N-SO2), 1092 
(S=O) cm
-1; δ 1 H NMR (600 MHz, CDCl3) 7.98 (br s, 1H, H-16), 7.62 (d, 1H, J = 
8.5 Hz, H-14), 7.52 (d, 2H, J = 8.4 Hz, H-1, 3), 7.25 (d, 2H, J = 8.4 Hz, H-4, 6), 6.63 
(d, 1H, J = 8.5 Hz, H-13), 5.27 (d, 1H, J = 5.4 Hz, H-11), 4.73 (d, 1H, J = 2.5 Hz, 
H-7), 4.70 (s, 2H, NH2), 4.32 (br s, 1H, -NH), 3.64 (dd, 1H, J = 11.8, 4.5 Hz, H-20), 
3.40 (td, 1H, J = 11.8, 2.5 Hz, H-20), 2.19-2.14 (m, 1H, H-12), 1.56-1.50 (m, 1H, H-
21), 1.49-1.45 (m, 1H, H-21), 1.42-1.35 (m, 1H, H-22), 1.32-1.27 (m, 1H, H-22); δ 
13
C NMR (150 MHz, CDCl3) 148.7 (Cq), 138.9 (Cq), 131.9 (2 × CH), 130.7 (Cq), 
128.5 (2 × CH), 127.3 (CH), 127.0 (CH), 121.8 (Cq), 119.8 (Cq), 114.1 (CH), 72.0 
(CH), 61.0 (CH2), 58.8 (CH), 38.2 (CH), 25.3 (CH2), 18.3 (CH2); HRMS (EI) 
C18H19BrO3N2S [M]
+ 
422.0311, found 422.0294. 
 
Trans:cis isomer isolated from above reaction (96b):  
Purified by recrystallisation from isopropanol: petrol: toluene gave title compound as 
a brown viscous oil (4.0 mg, 0.2%). 
 
 
96b 
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Rf 0.23 (3 : 2 EtOAc/petrol); IRυmax 3370 (C-H), 3321(C-H), 2936 (N-H), 2871 (N-
H), 1474 (aromatic), 1332 (-SO2-N), 1195 (-SO2-N), 1150 (-SO2-) cm
-1
;  (600 MHz, 
CDCl3)  δ 7.80 (d, 1H, J = 2.2 Hz, H-20), 7.61 (dd, 1H, J = 8.7, 2.2 Hz, H-18), 7.53 
(d, 2H, J = 8.4 Hz, H-1,3), 7.27 (d, 2H, J = 8.4 Hz, H-4,6), 6.56 (d, 1H, J = 8.7 Hz, 
H-17), 4.72 (d, 1H, J = 10.3 Hz, H-7), 4.65 (s, 2H, NH2), 4.52 (br s, 1H, -NH), 4.40 
(d, 1H, J = 2.5 Hz, H-11), 4.09 (br d, 1H, J = 11.4 Hz, H-14), 3.72 (td, 1H, 11.4, 2.5 
Hz, H-14), 2.02 (m, 1H, H-12), 1.81 (qt, 1H, J  = 12.8, 4.4 Hz, H-15), 1.70 (tt, 1H, J 
= 14.7, 4.4 Hz, H-16), 1.47 (m, 1H, H-16), 1.40 (m, 1H, H-15); δ 
13
C NMR (600 
MHz, CDCl3) 148.1 (Cq), 140.3 (Cq), 132.2 (2 × CH), 130.4 (CH), 129.5 (2 × CH), 
129.2 (Cq), 128.4 (CH), 122.3 (Cq), 120.0 (Cq), 114.0 (CH), 73.8 (CH), 68.5 (CH2), 
54.3 (CH), 38.4 (CH), 23.8 (CH2), 21.9 (CH2); (EI) C18H19BrO3N2S [M]
+ 
422.0311, 
found 422.0294. 
 
1-benzylpiperidine-2,6-dione (99)
105
 
 
Purification by dry load flash column chromatography gradient method 10-20-60% 
EtOAc: petrol gave title compound as a colourless oil (1.5 g, 86%). 
 
99 
Rf = 0.45 (3 : 2 EtOAc : petrol); IRυmax 3032 (C-H), 1722 (C=O), 1663 (aromatic), 
1344 (CH2), 1167 (C-N), 1136 (OC-N), 1013 (C-N) cm
-1; δ 
1
H NMR (600 MHz, 
CDCl3) 7.36 (t, 2H, J = 7.4 Hz, H-14, 12), 7.28 (t, 2H, J =  7.4 Hz, H-15, 11), 7.23 
(t, 1H,  J = 7.4 Hz, H-13), 4.94 (s, 2H, H-9), 2.67 (t, 4H, J = 6.6 Hz, H-4, 2), 1.93 
(qn, 2H, J =  6.6 Hz, H-3); δ 13C NMR (150 MHz, CDCl3) 172.6 (2 × Cq), 137.4 
(Cq), 128.9 (2 × CH), 128.5 (2 × CH), 127.5 (CH), 43.0 (CH2), 32.9 (2 × CH2), 17.4 
(CH2).  
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1-benzyl-6-hydroxypiperidin-2-one (100)
206
 
In a flame dried flask under an atmosphere of argon was added 99 (1.00 g, 4.93 
mmol) dissolved in MeOH (10 ml). Sodium borohydride (946 mg, 24.0 mmol, 5 eq) 
was added portionwise to the reaction mixture at 0°C and was stirred for 2 hrs. The 
reaction mixture was dissolved in CH2Cl2 (10 ml) then washed with water (2 × 60 
ml), dried with MgSO4, filtered and concentrated to give the title compound as a 
white oil (666 mg, 66%).  
 
100 
Rf = 0.12 (1 : 1 EtOAc : petrol); IRυ max 3347 (O-H), 1737 (C=O), 1624 (aromatic), 
1373 (OC-N), 1230 (C-O), 1045 (C-O) cm
-1
; δ 
1
H NMR (600 MHz, CDCl3) 7.29 (m, 
5H, H-11, 12, 13, 14, 15), 5.06 (d, 1H, J =  15.0 Hz, H-9), 4.93 (m, 1H, H-5), 4.38 
(d, 1H, J = 15.0 Hz, H-9), 2.55 (m,1H, H-3), 2.42 (m, 1H, H-3), 2.09 (m, 1H, H-4), 
1.82 (m, 2H, H-2), 1.77-1.71 (m, 1H, H-4); 
13
C NMR (150 MHz, CDCl3)  170.5 
(Cq), 137.7 (Cq), 128.9 (2 × CH), 128.2 (2 × CH), 127.6 (CH), 78.9 (CH), 47.2 
(CH2), 32.6 (CH2), 31.0 (CH2), 15.9 (CH2); HRMS (EI) cald. for C12H15NO2 [M]
+ 
205.1102, required 205.1104. 
1-benzyl-3,4-dihydropyridin-2(1H)-one (101)
105
 
Under argon conditions 100 (300mg, 1.46 mmol, 1eq) was dissolved in CH2Cl2 at 
0°C. Triethylamine (0.6 ml) was added dropwise followed by MsCl (0.2 ml) 
dropwise. The reaction mixture was stirred for 3 hrs at r.t. The reaction mixture was 
washed with aq. sat. NaHCO3 (2 × 25 ml), brine (50 ml) and water (50 ml). The 
organic layer was dried with MgSO4, filtered and evaporated to give the crude 
product. Purification by dry load flash chromatography 30% EtOAc: petrol gave the 
title compound as a pale yellow oil (101 mg, 37%).  
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101 
Rf = 0.48 (1 : 1 EtOAc : petrol); IRυ max 2990 (=C-H), 2845 (C-H),1655 (C=O, C=C 
alkene), 1590 (aromatic), 1403 (OC-N), 1391 (C-N) cm
-1
; 
1
H NMR (600 MHz, 
CDCl3) δ 7.32 (t, 2H, J = 7.5 Hz, H-13,11), 7.26 (t, 1H, J =  7.5 Hz, H-12), 7.23 (d, 
2H, J = 7.5 Hz, H-14, 10), 6.01 (dt, 1H, J = 7.8, 1.6 Hz, H-5), 5.13 (dt, 1H, J =  7.8,  
4.4 Hz, H-4), 4.69 (s, 2H, H-8), 2.59 (t, 2H, J = 9.9 Hz, H-2), 2.34 (tdd, 1H, J = 9.9, 
4.4, 1.6 Hz, H-3); 
13
C NMR (150 MHz, CDCl3)  169.6 (Cq), 137.1 (Cq), 129.6 (CH), 
128.9 (2 × CH), 127.7 (2 × CH), 127.6 (CH), 106.7 (CH), 49.1 (CH2), 31.4 (CH2), 
20.7 (CH2); HRMS (EI) calcd. for C12H13ON [M]
+ 
187.0997, found 187.0993. 
1-benzyl-5-(4-bromophenyl)-2-oxo-1,2,3,4,4a,5,6,10b-
octahydrobenzo[h][1,6]naphthyridine-9-sulfonamide (102)  
Under dry argon conditions, sulphanilamide (78 mg, 045 mmol, 1 eq), 4-
bromobenzaldehyde (80 mg, 0.43 mmol, 1 eq) and Sc(OTf)3 (20 mol%, 4 mg) were 
dissolved in dry MeCN (3 ml). After stirring for 5 minutes, N-benzyl lactam (80 mg, 
0.43 mmol, 1eq) was added to reaction mixture and left to stir for 24 hrs at room 
temperature under argon. The reaction mixture was diluted with EtOAc (5 ml) and 
washed with aq. sat. NaHCO3 (10 ml). The organic extract was washed with brine 
(10 ml) and water (10 ml), dried with MgSO4, filtered and concentrated. Purification 
by dry load flash chromatography gradient method 50-100% EtOAc: petrol gave the 
product as an off white amorphous solid (62 mg, 27%).  
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102 
m.p. 143-145 °C, Rf = 0.23 (3 : 2 EtOAc : petrol); IRυ max 3343 (C-H), 3062 (C-H), 
2967 (N-H), 1598 (C=O), 1494 (aromatic), 1391 (C-N), 1319 (SO2-N), 1301 
(O=S=O), 1147 (O=S=O) cm
-1
; δ
 1
H NMR (600 MHz, CDCl3)7.65 (d, 1H, J = 8.4 
Hz, H-14), 7.51 (s, 1H, H-16), 7.38 (d, 2H, J = 7.8 Hz, H-3,1), 7.18 (t, 1H, J = 7.4 
Hz, H-25), 7.15 (t, 2H, J = 7.4 Hz, H-26, 24), 6.99 (d, 2H, J = 7.4 Hz, H-27, 23), 
6.97 (d, 2H, J = 7.8 Hz, H-6, 4), 6.59 (d, 1H, J = 8.4 Hz, H-13), 5.41 (d, 1H, J = 14.5 
Hz, H-21), 4.73 (s,1H, NH), 4.64 (s, 2H, NH2), 4.34 (d, 1H, J = 4.2 Hz, H-7), 4.21 
(d, 1H, J = 3.4 Hz, H-11), 4.06 (d, 1H, J = 14.5 Hz, H-21), 2.58-2.44 (m, 2H, H-19), 
2.09-2.05 (m, 1H, H-12), 1.98-1.92; 1.69-1.62 (m, 2H, H-20); 
13
C NMR (150 MHz, 
CDCl3) 171.3 (Cq), 146.9 (Cq), 141.5(Cq), 136.4 (Cq), 132.1 (2 × CH), 129.7 (Cq), 
128.7 (2 × CH), 128.1 (2 × CH), 128.0 (3 × CH), 127.6 (2 × CH), 127.5 (Cq), 122.0 
(Cq), 113.1 (CH), 56.9 (CH), 52.8 (CH), 49.8 (CH2), 38.2 (CH), 29.8 (CH2), 22.2 
(CH2); HRMS (EI) calcd. for C25H24BrN3O3S [M-H]
-
 524.0722, found 524.0643. 
(7aR,8aS)-6-(4-bromophenyl)-6,6a,7,7a,8a,8b-hexahydro-5H-
oxireno[2',3':3,4]cyclopenta[1,2-c]quinoline-2-sulfonamide (103)  
28b (2.60 mmol, 1.06 g) was dissolved in CH2Cl2 (2 ml) at 0°C. MCPBA (10.4 
mmol, 4 eq, 1.80 g) was added and left to stir overnight. The reaction mixture was 
diluted with EtOAc (5 ml) and washed with saturated solution of NaHCO3 (10 ml) 
followed by brine (10 ml) and water (10 ml). Dried with MgSO4, filtered and 
evaporated. Purification by dry load flash chromatography gradient method in 20-
60% EtOAc: petrol gave a pale brown amorphous solid (541 mg, 49%).  
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103 
m.p. 154-155˚C; Rf = 0.29 (1: 1 EtOAc : petrol); IRυ max 3361 (C-H), 2219 (N-H), 
1488 (aromatic), 1314 (SO2-N), 1147 (O=S=O), 1130 (C-O) cm
-1
; δ 
1
H NMR (600 
MHz, CDCl3) 7.78 (d, 1H, J = 1.8 Hz, H-16), 7.58 (dd, 1H, J = 8.5, 1.8 Hz, H-14), 
7.50 (d, 2H, J = 8.4 Hz, H-1,3), 7.23 (d, 2H, 8.4 Hz, H-4,6), 6.70 (d, 1H, J = 8.5 Hz, 
H-13), 4.84 (s, 2H, NH2), 4.52 (d, 1H, J =4.5 Hz, H-7), 4.33 (br s, 1H, NH), 3,67 (d, 
1H, 7.5 Hz,H-11), 3.66 (d, 1H, 2.4 Hz, H-18), 3.40 (d, 1H, 2.4 Hz, H- 17), 2.43 
(m,1H, H-12), 1.75 (dd, 1H,  J = 14.2, 10.2, H-19), 1.58 (dd, 1H, J = 14.2, 7.5 Hz, 
H-19); 
13
C NMR (150 MHz, CDCl3)  149.1 (Cq), 140.0 (Cq), 132.0 (2 × CH), 131.1 
(Cq), 128.6 (CH), 128.0 (2 × CH), 126.3 (CH), 121.8 (Cq), 119.4 (Cq), 115.6 (CH), 
61.3 (CH), 56.6 (CH), 55.4 (CH), 40.5 (CH), 39.4 (CH), 26.2 (CH2); HRMS (EI) 
cald. for C18H18BrN2O3S [M+H]
+ 
421.3190, found 422.0299. 
4-(4-Bromophenyl)-8-sulfamoyl-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinolin-1-yl acetate (104)  
A solution of 28b (100 mg, 0.25 mmol), Pd(OAc)2 (5.7 mg, 15mol%), benzoquinone 
(10.7 mg, 0.099 mmol), MnO2 (15.6 mg, 0.22 mmol), acetic acid (42 µl, 0.0000734 
mmol), and anhydrous DMSO (1.5 ml) was stirred under argon at 80 °C for 48 hrs. 
To the reaction mixture diethyl ether (5 ml) was added and washed with brine (10 
ml) and water (6 ml). Dried with MgSO4, filtered and concentrated. Purification by 
dry load flash chromatography gradient method 50-40% EtOAc: petrol gave the title 
compound as a light brown viscous oil (18 mg, 10%).  
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104 
Rf = 0.35 (1: 1 EtOAc : petrol); IRυ max 3333 (C-H), 3262 (C-H), 2924 (N-H), 2852 
(N-H), 1714 (C=O), 1498 (aromatic), 1327 (SO2-N), 1250 (C-O), 1301(O=S=O) cm
-
1
; δ 
1
H NMR (600 MHz, CDCl3) 8.14 (d, 1H, J = 1.6 Hz, H-16), 7.57 (dd, 1H,  J = 
7.8, 1.6 Hz, H-14 ), 7.56 (d, 2H, J  = 8.4 Hz, H-1,3), 7.32 (d, 2H, J = 8.4 Hz, H-4,6), 
6.64 (d, 1H, J = 7.8 Hz, H-13), 5.92 (dd, 1H, J = 5.8, 1.4 Hz, H-19), 5.90-5.88 (m, 
1H, H-18), 5.49 (br s, 1H, H-17), 4.90 (s, 2H, NH2), 4.51 (d, 1H, J = 3.2 Hz, H-7), 
4.19 (br s, 1H, NH), 3.70 (d, 1H, J =  6.8 Hz, H-11), 3.57 (br s, 1H, H-12), 2.08 (s, 
3H, H-22); δ 13C NMR (150 MHz, CDCl3) 171.4 (Cq), 149.4 (Cq), 140.0 (Cq), 132.4 
(Cq), 132.2 (2 × CH), 131.9 (CH), 131.0 (CH), 129.7 (CH), 128.4 (2 × CH), 126.1 
(CH), 122.5 (Cq), 121.9 (Cq), 115.6 (CH), 87.6 (CH), 57.3 (CH), 51.2 (CH), 45.8 
(CH), 21.4 (CH3); HRMS (EI) calcd. for C20H19BrO4N2S [M]
+ 
462.0249, found 
462.0246. 
Pyridine-2-sulfonyl chloride (126)
167  
2-mercaptopyridine (5.0 g, 4.5 mol) was dissolved in concentrated sulfuric acid (125 
ml) at -10°C. Sodium hypochlorite solution (chlorine content 5%, 315 ml) was added 
dropwise for 8 hrs. The mixture was stirred for an additional 30 min at the same 
temperature. The reaction mixture was diluted with water (100 ml), and extracted 
with CH2Cl2 (100 ml). The extract was washed with sat. solution of NaHCO3 (500 
ml), saturated brine (500 ml) and water (500 ml), dried over MgSO4 and 
concentrated under reduced pressure to give the title compound as colourless oil (2.5 
g, 77%). 
 
126 
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IRυmax  3113 (C-H), 3087 (C-H), 1578 (aromatic), 1360 (SO2-N), 1180 (S=O), 1149 
(SO2-N), 1086 (S=O) cm
-1
 ; δ 1H NMR (600 MHz, CDCl3) 8.83 (1H, ddd, J = 4.7, 
1.4, 0.8 Hz, H-7), 8.12 (1H, dt, J = 7.7, 0.8 Hz, H-4), 8.06 (td, 1H, J =  7.7, 1.4 Hz, 
H-5), 7.70 (ddd, 1H, J = 7.7, 4.7, 1.1 Hz, H-6); δ 13C NMR (150 MHz, CDCl3) 159.3 
(Cq), 150.8 (CH), 139.2 (CH), 129.2 (CH), 122.1 (CH).  
 
1-(Pyridin-2-ylsulfonyl)-1H-indole (116)
166
 
 
To a flame dried flask under an atmosphere of argon were added indole (840 mg, 7.2 
mmol) and sodium hydride (240 mg, 10.0 mmol) dissolved in dry THF (10 ml) for 
30 min at 0°C. The resulting solution was added dropwise to 2-
pyridylsulfonylchloride (1.9 g, 10.7 mmol) at 0 °C and stirred at r.t. overnight under 
argon. The reaction mixture was quenched with sat aq. NH4Cl solution (5 ml) and 
extracted with EtOAc (2 × 10 ml). The combined organic phases was dried with 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography (0-30% EtOAc: petrol) to afford 1 (1.09 g, 58%) as a 
brown solid. 
 
116 
m.p. 55-57 °C; Rf =  (3 : 2 EtOAc : petrol); IR υmax 3113 (C-H), 3087 (C-H), 1578 
(aromatic), 1368 (SO2-N), 1180 (S=O), 1149 (SO2-N), 1086 (S=O) cm
-1; δ 1 H NMR 
8.59 (ddd, 1H, J = 4.7, 1.7, 1.0 Hz, H-15), 8.12 (dt, 1H, J  = 7.8, 1.0 Hz, H-12), 8.00 
(dd, 1H, J = 7.9, 1.5 Hz, H-3), 7.88 (td, 1H, J = 7.8, 1.7 Hz, H-13), 7.67 (d, 1H, 3.7 
Hz, H-8), 7.54 (ddd, 1H, J = 7.8, 1.3, 0.8 Hz, H-6), 7.44 (ddd, 1H, J = 7.8, 4.7, 1.1 
Hz, H-14), 7.29 (td, 1H, J = 7.9, 1.3 Hz, H-2), 7.23 (td, 1H, J = 7.9, 1.5 Hz, H-1), 
6.68 (dd, 1H,  J = 3.7, 0.8 Hz H-9);  δ 
13
C NMR (150 MHz, CDCl3) 155.5 (Cq), 150.6 
(CH), 138.3 (CH), 135.0 (Cq), 130.9 (Cq), 127.7 (CH), 127.5 (CH), 124.6 (CH), 
123.6 (CH), 122.5 (CH), 121.5 (CH), 113.8 (CH), 109.0 (CH). 
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(E)-3-(1-(Pyridin-2-ylsulfonyl)-1H-indol-2-yl)allyl acetate (123) 
To an oven dried carosuel tube under an atmosphere of argon, N-(2-
pyridyl)sulfonylindole (0.39 mmol, 100 mg), PdCl2(CH3CN)2 (10 mol%, 10 mg) and 
Cu(OAc)2.H2O (0.6 mmol, 120 mg) dissolved in DMA (4 ml) with allyl acetate 
(0.73 mmol, 83 µl, 2 eq.) was stirred at 60°C for 17 hrs. The reaction mixture was 
dissolved with EtOAc (5ml) and washed with water (2 × 10 ml), dried with MgSO4, 
filtered and concentrated to give a brown oil (120 mg). Purification by flash 
chromatography gradient method (20-40% EtOAc: petrol) gave a pale yellow 
viscous oil (72 mg, 53%). 
 
 
 
 
 
                                                      123 
 
Rf  = 0.34 (1 :1 EtOAc : petrol); IR υmax 3020 (aromatic), 2253 (C-H), 1736 (C=O), 
1712 (C=O), 1449 (aromatic), 1378 (SO2-N), 1183 (S=O), 1151 (SO2-N), 1126 
(S=O), 1023 (C-O) cm
-1;  δ 
1
H NMR (600 MHz, CDCl3) 8.54 (ddd, 1H, J = 4.7, 1.7, 
0.9 Hz, H-15), 8.12 (dd, 1H, J = 7.6, 0.9 Hz, H-3), 8.01 (dt, 1H, J = 7.8, 0.9 Hz, H-
12), 7.85 (td, 1H, J = 7.8, 1.7 Hz, H-13), 7.45 (ddd, 1H, J = 7.6, 1.4, 0.7 Hz, H-6), 
7.42 (ddd, 1H, J = 7.8, 4.7, 1.1 Hz, H-14), 7.38 (dtd, 1H, J = 15.8, 1.6, 1.0 Hz, H-
17), 7.27 (td, 1H, J = 7.6, 1.4 Hz, H-2), 7.21 (td, 1H, J = 7.6, 0.9 Hz, H-1), 6.78 (s, 
1H, H-9), 6.24 (dt, 1H, J = 15.8, 6.1 Hz, H-18), 4.77 (dd, 2H, J = 6.1, 1.6 Hz, H-19), 
2.13 (s, 3H, H-23);  
13
C NMR (150 MHz, CDCl3) 170.9 (Cq), 155.8 (Cq), 150.5 
(CH), 138.9 (Cq), 138.1 (CH), 137.4 (Cq), 129.6 (Cq), 127.7 (CH), 127.3 (CH), 124.9 
(CH), 124.1 (CH), 124.0 (CH), 122.3 (CH), 120.8 (CH), 115.0 (CH), 108.8 (CH), 
64.7 (CH2), 21.1 (CH3); HRMS (CI) C18H17N2O4S [M+H]
+
 357.08308 found, 
357.09117. 
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2-Allyl-1-(pyridin-2-ylsulfonyl)-1H-indole (125) 
 
Under dry argon conditions N-(2-pyridyl)sulfonylindole (0.77 mmols, 199.6 mg) 
together with Cu(OAc)2 .H2O (20 mmol, 312 mg) and PdCl2(CH3CN)2 (20 mmol%, 
40.5 mg) were dissolved in anhydrous DMSO (7 ml). Allyl benzoate (2.1 mmol, 
0.22 ml, 2 eq) was then added to the reaction mixture which was stirred at 117 °C for 
17 hrs. The crude mixture was extracted with EtOAc and washed three times with 
water, dried, filtered and concentrated to give a brown oil. Purification by flash 
chromatography using a gradient method (0-20% EtOAc: petrol) gave the title 
compound as a yellow-brown viscous oil (23 mg, 10%) 
 
 
125 
Rf = 0.6 (1: 1 EtOAc : petrol); IR υmax  3398 (C-H), 3079 (C-H), 1579 (aromatic), 
1376 (SO2-N), 1181 (S=O), 1146 (SO2–N), 1053 (S=O) cm
-1;δ 
1
H NMR (600 MHz, 
CDCl3) 8.57 (ddd, 1H, J = 4.7, 1.8, 0.9 Hz, H-15), 8.07 (dq, 1H, J = 7.7, 0.9 Hz, H-
3), 8.04 (dt, 1H, J = 7.8, 0.9 Hz, H-12), 7.84 (td, 1H, J = 7.8, 1.8 Hz, H-13), 7.42 (m, 
1H, H-14), 7.40 (m, 1H, H-6), 7.21 (td, 1H, J = 7.7, 1.3 Hz, H-2), 7.18 (td, 1H, J = 
7.7, 0.9 Hz, H-1), 6.4 (s, 1H, H-9), 6.11 (ddt, 1H, J = 17.0, 10.1, 6.7 Hz, H-22), 5.23 
(dq, 1H, J = 17.0, 1.5 Hz, H-21), 5.20 (dq, 1H, J = 10.1, 1.5 Hz, H-20), 3.97 (dd, 2H, 
J = 6.7, 1.1 Hz, H-17); δ 13C NMR (150 MHz, CDCl3) 156.0 (Cq), 150.5 (CH), 141.8 
(Cq), 138.1 (CH), 137.0 (Cq), 134.5 (CH), 129.9 (Cq), 127.6 (CH), 123.9 (CH), 123.7 
(CH), 122.1 (CH), 120.3 (CH), 117.8 (CH2), 114.6 (CH), 109.1 (CH), 33.5 (CH2);  
HRMS (CI) C16H14N2O2S [M]
+
 298.07705 found, 298.07763. 
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Allyl benzoate (128)
52 
To a solution of benzoyl chloride (3.77 mmol, 0.4 ml) and CH2Cl2 (1 ml) at 0 °C, 
were added allyl alcohol (3.36 mmol, 0.4 ml), pyridine (6.21 mmol, 0.5 ml) and was 
stirred at r.t. overnight.  Added EtOAc (10 ml) and washed with NaHCO3 1M (2 × 5 
ml), HCl 1M (2 × 5 ml), brine (10 ml) and H2O (2 × 50 ml), gave the title compound 
as a colourless oil (0.5 ml, 92%). 
 
128 
 Rf = 0.5 (2: 3 EtOAc : petrol); IRυmax 3072 (aromatic), 1721 (C=O), 1583 
(aromatic), 1451 (aromatic), 1360 (C-O), 1250 (C-O), 1111 (C-O) cm
-1
; δ 
1
H NMR 
(600 MHz, CDCl3) 8.06 (d, 2H, J = 7.5 Hz, H-8, 12), 7.55 (br t, 1H, J = 7.5 Hz, H-
10), 7.43 (br t, 2H, J = 7.5 Hz, H-9, 11), 6.04 (ddt, 1H, J = 17.2, 10.6, 5.6 Hz, H-2), 
5.41 (dd, 1H, J = 17.2, 1.2 Hz, H-1), 5.28 (dd, 1H, J =10.6, 1.2 Hz, H-1), 4.82 (d, 
2H, J = 5.6 Hz, H-3);  
13
C NMR (150 MHz, CDCl3) 166.4 (C=O), 133.1 (CH), 132.4 
(CH), 130.2 (Cq), 129.7 (2 × CH), 128.5 (2 × CH), 118.3 (CH2), 65.7 (CH2). 
 
(E)-3-(1-(Pyridin-2-ylsulfonyl)-1H-indol-2-yl)allyl benzoate (129) 
To an oven dried carosuel tube under an atmosphere of argon N-(2-
pyridyl)sulfonylindole (0.39 mmol, 100 mg),  PdCl2(CH3CN)2 (20 mol%, 21 mg) 
and Cu(OAc)2.H2O (0.78 mmol, 168 mg) was added in dry THF (4 ml) with allyl 
benzoate (1.12 mmol, 0.12 ml, 2 eq.), To the reaction mixture at 60°C for 52 hrs. 
Product was extracted from EtOAc and washed with water twice, dried, filtered and 
concentrated to give a yellow brown oil (154 mg). Crude mixture was purified by 
flash chromatography (0-50% EtOAc: petrol) to give a pale yellow viscous oil (57 
mg, 35%). 
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129 
Rf = 0.34 (1 :1 EtOAc : petrol); IRυ max  3407 (aromatic), 2254 (C-H), 1602 (C=O), 
1450 (aromatic), 1378 (SO2-N), 1181 (S=O), 1151 (SO2–N), 1124 (S=O), 1070 (C-
O) cm
-1 ; δ 
1
H NMR (600 MHz, CDCl3) 8.50 (ddd, 1H, J = 4.6, 1.7, 1.0 Hz, H-15), 
8.15 (dq, 1H, J = 8.2, 1.0, H-3), 8.13 (m, 2H, H-24, 28), 8.00 (dt, 1H, J = 7.8, 1.0 
Hz, H-12), 7.78 (td, 1H, J = 7.8, 1.7 Hz, H-13), 7.59 (tt, 1H, J = 7.4, 1.4 Hz, H-26), 
7.50 (dtd, 1H, J = 15.9, 1.4, 0.8 Hz, H-17), 7.47 (m, 3H, H-6, 25, 27), 7.38 (ddd, 1H, 
J = 7.8, 4.6, 1.1 Hz, H-14), 7.28 (td, 1H, J = 8.2, 1.4 Hz, H-2),  7.22 (ddd, 1H, J = 
8.2, 7.3, 1.0 Hz, H-1), 6.80 (s, 1H, H-9), 6.37 (dt, 1H, J =  15.9, 6.1 Hz, H-18), 5.03 
(dd, 2H, J = 6.1, 1.4 Hz, H-19); δ 13C NMR (150 MHz, CDCl3) 166.4 (Cq), 155.8 
(Cq), 150.5 (CH), 138.8 (Cq), 138.1 (CH), 137.4 (Cq), 133.3 (CH), 130.2 (Cq), 129.8 
(2 × CH), 129.6 (Cq), 128.6 (2 × CH), 127.7 (CH), 127.4 (CH), 125.0 (CH), 124.1 
(d, J = 6.5 Hz, CH), 122.3 (CH), 120.9 (CH), 115.0 (CH), 108.8 (CH), 65.1 (CH2); 
HRMS (CI) C23H19N2O4S [M+H]
+ 
419.09873 found, 419.10532. 
 
Synthesis of substituted 3,3-diallyl-3H-indole  
 
General procedure F: To an oven dried carousel tube under an atmosphere of argon 
were added [Pd(allylCl)2]2 (2.5 mol%) and DPEPhos (5 mol%) in MeCN (0.025M) 
at r.t. After stirring for 15 mintues, allyl acetate (5 eq) was added to the reaction. 
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Potassium carbonate (3 eq), the substituted indole (1 eq) were added 5 minutes later. 
The reaction mixture was degassed and stirred overnight under argon. Then diethyl 
ether was added to the reaction mixture (7 ml) and washed with water (10 ml), dried 
with MgSO4, filtered and concentrated. Purification by dry load flash 
chromatography gave the corresponding substituted 3,3-diallyl-3H-indole 
compound. 
3,3-Diallyl-3H-indole (138a)
182
 
 
138a 
The crude material was purified by gradient method 10% EtOAc: PE to give the title 
compound as a brown oil (70 mg, 82%). Rf = 0.64 (1:1  EtOAc : PE); IRυ max 3074 
(=C-H), 2978 (C-H), 1600 (N=CH), 1559 (aromatic), 1475 (aromatic) cm
-1; δ 1H 
NMR (600 MHz, CDCl3)  8.05 (brs, 1H, H-4), 7.62 (d, 1H, J = 7.1 Hz, H-3), 7.35 
(td, 1H, J = 7.1, 1.1 Hz, H-2), 7.31 (brd, 1H, J = 7.1 Hz, H-6), 7.26 (br t, 1H, J = 7.1 
Hz, H-1), 5.44 (ddt, 2H, J = 17.1, 10.1, 7.3 Hz, H-8), 5.01 (dd, 2H, J = 17.1, 1.1 Hz, 
H-7), 4.95 (dd, 2H, J = 10.1, 1.1 Hz, H-5), 2.57 (dd, 2H, J = 13.9, 7.3 Hz, H-10 and 
9), 2.52 (dd, 2H, J = 13.9, 7.3 Hz, H-10 and 9);  δ 13C NMR (150 MHz, CDCl3) 
177.9 (CH), 155.6 (Cq), 141.4 (Cq), 132.5 (2 × CH), 128.0 (CH), 126.1 (CH), 122.4 
(CH), 121.3 (CH), 118.8 (2 × =CH2), 60.9 (Cq), 38.6 (2 × CH2); HRMS (CI) cald. for
 
C14H15N [M]
+ 
197.12045, found 197.11946. 
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3-Allyl-1H-indole (139) 
207, 208
 
Method F: Using dppf (5 mol%) instead of DPEPhos. Purification by dry load flash 
chromatography method 10% EtOAc: Petrol to give the title compound as a brown 
oil (20 mg, 30%).  
                                                               
                                                                           139 
Rf = 0.74 (3 : 7  EtOAc : Petrol); IRυ max 3056 (=C-H), 2980 (C-H), 2895 (N-H), 
1628 (C=C), 1488 (aromatic), 1345 (CH2), 1253 (N-C), 1052 (N-C) cm
-1; δ 1H NMR 
(600 MHz, CDCl3) 7.61 (d, 1H, J = 7.7 Hz, H-6), 7.36 (d, 1H, J = 7.7 Hz, H-3), 7.20 
(td, 1H, J = 7.7, 0.8 Hz, H-2), 7.12 (td, 1H, J = 7.7, 0.8 Hz, H-1), 6.99 (br s, 1H, H-
8), 5.17 (ddt, 1H, J = 17.1, 10.1, 6.8 Hz, H-11), 5.17 (dq, 1H, J = 17.1, 1.7 Hz, H-
12), 5.08 (dq, 1H, J = 10.1, 1.7 Hz, H-13), 3.53 (dq, 2H, J = 6.8, 1.2 Hz, H-10);  δ 
13
C NMR (150 MHz, CDCl3) 137.5 (CH), 136.5 (Cq), 127.6 (Cq), 121.8 (CH), 119.4 
(CH), 119.2 (CH), 114.7 (Cq), 111.2 (CH), 115.2 (=CH2), 30.0 (CH2). 
 
3,3-Diallyl-5-methoxy-3H-indole (138b)  
 
138b 
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The crude material was purified by gradient method 0-20% EtOAc: PE which gave 
the title compound as a yellow oil (233 mg, 76%). Rf = 0.22 (1 : 4  EtOAc : PE); IRυ 
max 3074 (=C-H), 2921 (C-H), 1591 (N=C), 1500 (aromatic), 1437 (aromatic), 1264 
(C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.91 (s, 1H, H-1), 7.51 (d, 1H, J = 8.3 
Hz, H-3), 6.86 (dd, 1H, J = 8.3, 2.2 Hz, H-2), 6.84 (d, 1H, J = 2.2 Hz, H-6), 5.45 
(ddt, 2H, J = 17.0, 10.1, 7.2 Hz, H-8), 5.02 (dq, 2H, J = 17.0, 1.1 Hz, H-7), 4.96 (dd, 
2H, J = 10.1, 1.1 Hz, H-4), 3.84 (s, 3H, H-10), 2.54 (ddt, 2H, J = 13.9, 7.2, 1.1 Hz, 
H-9 and 5), 2.49 (ddt, 2H, J = 13.9, 7.2, 1.1 Hz, H-9 and 5);  δ 13C NMR (150 MHz, 
CDCl3) 175.8 (CH), 158.6 (Cq), 149.4 (Cq), 143.2 (Cq), 132.5 (2 × CH), 121.6 (CH), 
118.8 (2 × =CH2), 112.4 (CH), 109.2 (CH), 61.0 (Cq), 55.9 (CH3), 38.8 (2 × CH2); 
HRMS (EI)  cald. for C15H17NO [M]
+ 
227.13101, found 227.130326. 
3,3-Diallyl-5-benzyloxy-3H-indole (138c) 
 
138c 
Purification of crude mixture by gradient method 0-30% EtOAc: PE which gave the 
title compound as a purple oil (196 mg, 76%). Rf = 0.29 (1:4  EtOAc : PE); IRυ max  
3076 (=C-H), 2910 (C-H), 1590 (N=C), 1580 (aromatic), 1575 (aromatic), 1181 (C-
O), 1022 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.92 (s, 1H, H-8), 7.52 (d, 1H, J 
= 8.4 Hz, H-3), 7.45 (br d, 2H, J = 7.3 Hz, H-4), 7.40 (t, 2H, J = 7.3 Hz, H-5), 7.34 
(td, 1H, J = 7.3, 1.4 Hz, H-6), 6.95 (dd, 1H, J = 8.4, 2.5 Hz, H-2), 6.92 (d, 1H, J = 
2.5 Hz, H-1), 5.43 (ddt, 2H, J = 17.1, 10.5, 7.4 Hz, H-12), 5.08 (s, 2H, H-7), 5.00 
(dq, 2H, J = 17.1, 1.4 Hz, H-13), 4.96 (br d, 2H, J = 10.5 Hz, H-9), 2.53 (dd, 2H, J = 
14.1, 7.4 Hz, H-10 and 11), 2.48 (dd, 2H, 14.1, 7.4 Hz, H-10 and 11);  δ 13 C NMR 
(150 MHz, CDCl3) 175.9 (CH), 157.7 (Cq), 149.5 (Cq), 143.2 (Cq), 137.0 (Cq), 132.4 
(2 × CH), 128.7 (2 × CH), 128.2 (CH), 127.7 (2 × CH), 121.6 (CH), 118.9 (2 × 
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=CH2), 113.6 (CH), 110.2 (CH), 70.7 (CH2), 61.1 (Cq), 38.8 (2 × CH2); HRMS (EI) 
cald. for C21H21NO [M]
+ 
303.1623 found, 303.1612. 
3,3-Diallyl-5,6-dimethoxy-3H-indole (138d) 
 
138d 
Purification of crude mixture by gradient method 0-20% EtOAc: PE which gave the 
title compound as a yellow oil (169 mg, 88%). Rf = 0.44 (1: 4 EtOAc : PE); IRυ max  
3075 (=C-H), 2938 (C-H), 1600 (N=C), 1465 (aromatic), 1442 (aromatic), 1305 (C-
O), 1214 (C-O) cm
-1;  δ 1H NMR (600 MHz, CDCl3) 7.94 (s, 1H, H-8), 7.20 (s, 1H, 
H-3), 6.81 (s, 1H, H-1), 5.42 (ddt, 2H, J = 17.0, 10.2, 7.3 Hz, H-8), 5.00 (dq, 2H, J 
= 17.0, 1.1 Hz, H-7), 4.95 (dq, 2H, J = 10.2, 1.1 Hz, H-6), 3.92 (s, 3H, H-5), 3.90 (s, 
3H, H-4), 2.53 (ddt, 2H, J = 13.9, 7.3, 1.1 Hz, H-10 and 9), 2.48 (dtd, 2H, J = 13.9, 
7.3, 1.1 Hz, H-10 and 9);  δ 13C NMR (150 MHz, CDCl3) 176.8 (CH), 149. 1 (Cq), 
148.8 (Cq), 148.0 (Cq), 133.3 (Cq), 132.6 (2 × CH), 118.7 (2 × =CH2), 105.6 (CH), 
104.9 (CH), 61.3 (Cq), 56.5 (CH3), 56.2 (CH3), 38.8 (2 × CH2); HRMS (CI) cald. for 
C16H20NO2 [M + H]
+ 
258.1415, found 258.1484. 
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3,3-Diallyl-5-methoxy-2-methyl-3H-indole (138e) 
 
Purification of crude mixture by gradient method 0-10% EtOAc: PE which gave the 
title compound as a yellow oil (173 mg, 80%). Rf = 0.33 (3: 7 EtOAc: PE); IRυ max  
2919 (C-H), 1581 (N=C), 1471 (aromatic), 1266 (C-O) cm
-1; δ 1H NMR (600 MHz, 
CDCl3 )  7.40 (dd, 1H, J = 7.2, 1.8 Hz, H-3), 6.83 (dd, 1H, J = 7.2, 2.5 Hz, H-2), 
6.82 (s, 1H, H-6), 5.12 (ddt, 2H, J = 16.9, 10.1, 7.0 Hz, H-5), 4.96 (dq, 2H, J = 16.9, 
1.4 Hz, H-4), 4.85 (dq, 2H, J = 10.1, 1.2 Hz, H-1), 3.83 (s, 3H, H-10), 2.64 (ddt, 2H, 
J = 13.9, 7.0 Hz, H-8 and 7), 2.44 (ddt, 2H, J = 13.9, 7.0 Hz, H-8 and 7), 2.21 (s, 
3H, H-9);  δ 13C NMR (150 MHz, CDCl3) 183.0 (Cq), 157.9 (Cq), 148.8 (Cq), 143.0 
(Cq), 132.3 (2 × CH), 120.1 (CH), 118.2 (2 × =CH2), 112.2 (CH), 109.2 (CH), 61.9 
(Cq), 55.8 (CH3), 40.5 (2 × CH2), 16.6 (CH3); HRMS (ES) cald. for C16H18NO [M – 
H]
- 
240.1388, found 240.1376. 
3,3-Diallyl-5-bromo-3H-indole (138f) 
 
138f 
Reaction conducted at 50 °C for 8 hrs. The crude mixture was purified by gradient 
method 0-20% EtOAc: PE which gave the title compound as a brown oil (123 mg, 
58%). Rf = 0.36 (3 : 7 EtOAc : PE); IRυ max 3076 (=C-H), 2911 (C-H), 1719 (N=C), 
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1596 (aromatic), 1435 (aromatic) cm
-1; δ 1H NMR  (600 MHz, CDCl3)  8.02 (s, 1H, 
H-1), 7.48 (s, 2H, H-3, 2), 7.44 (s, 1H, H-6), 5.43 (ddt, 2H, J = 17.2, 10.1, 7.3 Hz, 
H-9), 5.03 (dq, 2H, J = 17.2, 1.5 Hz, H-8), 4.99 (dq, 2H, J = 10.1, 1.5 Hz, H-7), 2.55 
(dd, 2H, J = 14.1, 7.3 Hz, H-5 and 4), 2.50 (dd, 2H, J = 14.1, 7.3 Hz, H-5 and 4);  δ 
13
C NMR (150 MHz, CDCl3) 178.4 (CH), 154.7 (Cq), 143.7 (Cq), 131.9 (2 × CH), 
131.2 (CH), 125.8 (CH), 122.7 (CH), 120.2 (Cq), 119.4 (2 × =CH2), 61.5 (Cq), 38.4 
(2 × CH2); HRMS (ES) Cald. for C14H13NBr [M-H]
- 
274.0232, found 274.0231. 
3,3-Diallyl-4-bromo-3H-indole (138g) 
 
138g 
Reaction conducted at 50 °C for 24 hrs. The crude mixture was purified by gradient 
method 0-10% EtOAc: PE which gave the title compound as a light purple oil (159 
mg, 56%) from 4-bromo indole (200 mg). Rf = 0.41 (1:4  EtOAc : PE); IRυ max 3077 
(=C-H), 2979 (C-H), 1641 (N=C), 1574 (aromatic), 719  cm
-1
; δ 1H NMR (600 MHz, 
CDCl3) 8.02 (s, 1H, H-4), 7.53 (d, 1H, J =7.7 Hz, H-3 or 1), 7.36 (d, 1H, J = 7.7 Hz, 
H-3 or 1), 7.21 (t, 1H, J = 7.7 Hz, H-2), 5.24 (ddt, 2H, J = 16.9, 10.2, 7.7 Hz, H-7), 
5.02 (d, 2H, J = 16.9 Hz, H-6), 4.85 (d, 2H, J = 10.2 Hz, H-5), 2.99 (dd, 2H, J = 
13.9, 7.7 Hz, H-9 and 8), 2.78 (dd, 2H, J = 13.9, 7.7 Hz, H-9 and 8);  δ 13C NMR 
(150 MHz, CDCl3) 178.7 (CH), 157.8 (Cq), 138.9 (Cq), 131.8 (2 × CH), 130.2 (CH), 
129.8 (CH), 120.4 (CH), 118.6 (2 × =CH2), 118.0 (Cq), 64.7 (Cq), 36.2 (2 × CH2); 
HRMS (EI) cald. for C14H14NBr [M]
+ 
275.0309, found 275.0302. 
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3,3-Diallyl-5-chloro-3H-indole (138h) 
 
138h 
Purification of crude mixture by gradient method 0-10% EtOAc : PE to give the title 
compound as a pale yellow oil (126 mg, 41%). Rf = 0.21 (1: 4 EtOAc : PE); IRυ max  
3055 (=C-H), 2954 (C-H), 1640 (N=C), 1555 (aromatic), 1447 cm
-1; δ 1H NMR (600 
MHz, CDCl3) 8.03 (s, 1H, H-1), 7.53 (d, 1H, J = 8.3 Hz, H-3), 7.32 (dd, 1H, J = 8.3, 
2.1 Hz, H-2), 7.28 (d, 1H, J = 2.1 Hz, H-6), 5.43 (ddt, 2H, J = 17.0, 10.1, 7.2 Hz, H-
9), 5.03 (dq, 2H, J = 17.0, 1.0 Hz, H-5), 5.00 (br dd, 2H, J = 10.1, 1.0 Hz, H-4), 2.56 
(dd, 2H, J = 13.7, 7.2 Hz, H-12 and 11), 2.51 (dd, 2H, J = 13.7, 7.2 Hz, H-11 and 
12);  δ 13C NMR(150 MHz, CDCl3) 178.2 (CH), 154.2 (Cq), 143.3 (Cq), 132.1 (Cq), 
131.9 (CH), 128.3 (CH), 122.9 (CH), 122.2 (CH), 119.3 (2 × =CH2), 61.5 (Cq), 38.2 
(2 × CH2); HRMS (CI) cald. for C14H15ClN  [M+H]
+ 
232.0815, found 232.0877. 
3,3-Diallyl-5-flouro-3H-indole (138i) 
 
138i 
Purification of crude mixture by gradient method 0-20% EtOAc: PE to give the title 
compound as a red-brown oil (101 mg, 32%). Rf = 0.4 (3 : 7 EtOAc : PE); IRυ max  
3010 (=C-H), 2928 (C-H), 1597 (N=C), 1460 (aromatic), 1165 cm
-1; δ 1H NMR (600 
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MHz, CDCl3)  δ 7.99 (s, 1H, H-1), 7.53 (dd, 1H, J = 8.4, 4.6 Hz, H-3), 7.02 (dd, 1H, 
J = 8.4, 2.8 Hz, H-2), 6.99 (dd, 1H, J = 8.0, 2.8 Hz, H-6), 5.41 (dtd, 2H, J = 17.1, 
10.0, 7.5 Hz, H-9), 5.00 (dd, 2H, J = 17.1, 1.3 Hz, H-4), 4.96 (br d, 2H, J = 10.0 Hz, 
H-5), 2.53 (dd, 2H, J = 14.0, 7.5 Hz, H- 8 and 7), 2.48 (dd, 2H, J = 14.0, 7.5 Hz, H-8 
and 7);  δ 13C NMR (150 MHz, CDCl3) 177.7 (CH), 161.7 (d,  JC-F = 245.8 Hz, Cq), 
151.5 (d,  JC-F  = 2.1 Hz, Cq), 143.6 (d,  JC-F = 8.7 Hz, Cq), 132.0 (2 × CH), 122.0 (d,  
JC-F = 9.1 Hz, CH), 119.2 (2 × =CH2), 114.7 (d,  JC-F = 23.7 Hz, CH), 110.2 (d,  JC-F 
= 24.6 Hz, CH), 61.6 (Cq), 38.5 (2 × CH2); HRMS (CI) cald. for (C14H15NF) [M+H]
+
 
216.1189, found 216.1187. 
3,3-Diallyl-2-methyl-3H-indole (138j)
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138j 
Crude mixture was purified by flash column chromatography 20% EtOAc: PE which 
gave the title compound as a yellow oil (290 mg, 98%). Rf = 0.60 (3: 7 EtOAc: PE); 
IRυ max 3077 (=C-H), 2916 (C-H), 1640 (N=C), 1457 (aromatic) cm
-1; δ 1H NMR 
(600 MHz, CDCl3) 7.51 (d, 1H, J = 7.4 Hz, H-3), 7.31 (t, 1H, J = 7.4 Hz, H-2), 7.26 
(d, 1H, J = 7.4 Hz, H-4), 7.19 (t, 1H, J = 7.4 Hz, H-1), 5.10 (ddt, 2H, J = 16.7, 9.9, 
7.1 Hz, H-7), 4.95 (br d, 2H, J = 16.7 Hz, H-9), 4.84 (br d, 2H, J = 9.9 Hz, H-8), 
2.68 (dd, 2H, J = 14.0, 7.1 Hz, H-10 and 6), 2.45 (dd, 2H, J = 14.0, 7.1 Hz, H-10 
and 6), 2.25 (s, 3H, H-5);  δ 13C NMR (150 MHz, CDCl3) 185.2 (Cq), 155.2(Cq), 
141.2 (Cq), 132.2 (2 × CH), 128.0 (CH), 125.1 (CH), 122.3 (CH), 120.0 (CH), 118.2 
(2 × =CH2), 61.9 (Cq), 40.5 (2 × CH2), 16.7 (CH3); HRMS (ES) cald. for C15H16N 
[M-H]
- 
210.1282, found 210.1273. 
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3,3-Diallyl-2-phenyl-3H-indole (138k) 
 
Crude mixture was purified by gradient method 0-20% EtOAc: PE which gave the 
title compound as a colourless oil (232 mg, 74%). Rf = 0.63 (1 : 4  EtOAc : PE); IRυ 
max 3075 (=C-H), 2924 (C-H), 1640 (N=C), 1522 (aromatic), 1443 (aromatic) cm
-1
; δ 
1
H NMR (600 MHz, CDCl3)  δ 8.11 (m, 2H, H-10), 7.66 (d, 1H, J = 7.5 Hz, H-3), 
7.48 (m, 3H, H-12, 11), 7.37 (td, 1H, J = 7.5, 1.0 Hz, H-2), 7.34 (d, 1H, J = 7.5 Hz, 
H-6), 7.28 (d, 1H, J = 7.5 Hz, H-1), 5.11 (ddt, 2H, 17.2, 9.8, 7.2 Hz, H-7), 4.76 (br d, 
2H, J = 17.2 Hz, H-4), 4.72 (br d, 2H, J = 9.8 Hz, H-5), 2.92 (dd, 2H, J = 14.1, 7.2 
Hz, H-9 and 8), 2.88 (dd, 2H, J = 14.1, 7.2 Hz, H-9 and 8);  δ 13C NMR (150 MHz, 
CDCl3) 180.4 (Cq), 154.6 (Cq), 143.1 (Cq), 134.1 (Cq), 132.0 (2 × =CH2), 130.7 
(CH), 128.7 (2 × CH), 128.2 (2 × CH), 128.1 (CH), 125.8 (CH), 121.8 (CH), 120.9 
(CH), 118.3 (2 × CH), 62.5 (Cq), 42.0 (2 × CH2); HRMS (CI) cald. for C20H20N [M 
+ H]
+  
274.1599, found 274.1571. 
3, 3-Diallyl-5-methyl-3H-indole (138l) 
 
138l 
Purification of crude mixture by gradient method 0-10% EtOAc: PE which gave the 
title compound as a brown oil (212 mg, 66%). Rf = 0.49 (1 : 4 EtOAc : PE); IRυ max 
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3077 (=C-H), 2921 (C-H), 1640 (N=C), 1556 (aromatic), 1465 (aromatic) cm
-1; δ 1H 
NMR (600 MHz, CDCl3)  7.97 (s, 1H, H-5), 7.49 (d, 1H, J = 7.9 Hz, H-3), 7.14 (dd, 
1H, J = 7.9, 1.3 Hz, H-2), 7.11 (d, 1H, J = 1.3 Hz, H-4), 5.44 (ddt, 2H, J = 17.1, 
10.2, 7.3 Hz, H-8), 5.01 (dq, 2H, J = 17.1, 1.4 Hz, H-7), 4.96 (dd, 2H, J = 10.2, 1.4 
Hz, H-6), 2.54 (ddt, 2H, J = 14.0, 7.3, 1.4 Hz, H-10 and 9), 2.49 (ddt, 2H, J = 14.0, 
7.3, 1.4 Hz, H-10 and 9), 2.41 (s, 3H, H-1);  δ 13C NMR (150 MHz, CDCl3) 176.9 
(CH), 153.5 (Cq), 141.7 (Cq), 136.0 (Cq), 132.6 (2 × CH), 128.7 (CH), 123.1 (CH), 
120.8 (CH), 118.7 (2 × =CH2), 60.9 (Cq), 38.8 (2 × CH2), 21.2 (CH3); HRMS (EI) 
C15H17N [M]
+ 
211.1355, found 211.1349. 
3,3-Diallyl-4-methyl-3H-indole (138m) 
 
138m 
Purification of crude mixture by gradient method 30% EtOAc: PE which gave the 
title compound as a purple oil (185 mg, 57%). Rf  = 0.47 (1: 4 EtOAc : PE); IRυ max  
3076 (=C-H), 2921 (C-H), 1640 (N=C), 1558 (aromatic), 1439 (aromatic) cm 
-1; δ 1H 
NMR (600 MHz, CDCl3) 8.04 (s, 1H, H-6), 7.16 (m, 2H, H-4, 3), 7.12 (m, 1H, H-2), 
5.45 (ddt, 2H, J = 17.2, 10.0, 7.3 Hz, H-9), 5.01 (dq, 2H, J = 17.2, 1.4 Hz, H-8), 4.96 
(dq, 2H, J = 10.0, 1.4 Hz, H-7), 2.59 (s, 3H, H-5), 2.55 (ddt, 2H, J = 14.0, 7.3, 1.4 
Hz, H-10 and 11 ), 2.49 (ddt, 2H,  J = 14.0, 7.3, 1.4 Hz, H-10 and 11);  δ 13 C NMR 
(150 MHz, CDCl3) 176.7 (CH), 154.1 (Cq), 141.4 (Cq), 132.7 (2 × CH), 130.9 (Cq), 
129.4 (CH), 126.1 (CH), 119.8 (CH), 118.7 (2 × =CH2), 61.1 (Cq), 38.7 (2 × CH2), 
17.0 (CH3); HRMS (CI) cald. for C15H18N [M + H]
+ 
212.1361, found 212.1446. 
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3,3-diallyl-2-((allyloxy)methyl)-3H-indole (140) 
 
 
 
148 
Purification by dry load flash chromatography gradient method 0-30% EtOAc: 
Petrol gave the title compound as an orange yellow oil (108 mg, 30%) from 2-
methanol indole (200 mg). Rf = 0.23 (3 : 7 EtOAc : Petrol); IRυ max 3070 (C-H), 
2913 (C-H), 1714 (N=C), 1469 (aromatic), 1276 (C-O) cm
-1; δ 1H NMR (600 MHz, 
CDCl3) 7.59 (d, 1H, J = 7.3 Hz, H-3), 7.32 (td, 1H, J = 7.3, 0.9 Hz, H-2), 7.27 (d, 
1H, J = 7.3 Hz, H-4), 7.23 (td, 1H, J = 7.3, 0.9 Hz, H-1), 5.98 (dtd, 1H, J = 16.8, 
10.4, 5.7 Hz, H-7), 5.34 (dq, 1H, J = 16.8, 1.7 Hz, H-8), 5.25 (dq, 1H, J = 10.4, 1.7 
Hz, H-9), 5.17 (dtd, 2H, J = 17.0, 9.9, 7.4 Hz, H-12), 4.94 (dq, 2H, J = 17.0, 1.3 Hz, 
H-14), 4.84 (br d, 2H, J = 9.9 Hz, H-13), 4.51 (s, 2H, H-5), 4.16 (dt, 2H, J = 5.7, 1.5 
Hz, H-6), 2.70 (dd, 2H, J = 14.0, 7.4 Hz, H-11 or 10), 2.64 (dd, 2H, J = 14.0, 7.4 Hz, 
H-11 or 10);  δ 13C NMR (150 MHz, CDCl3) 183.4 (Cq), 154.7 (Cq), 141.9 (Cq), 
134.4 (CH), 132.4 (2 × CH), 128.0 (CH), 125.7 (CH), 122.1 (CH), 120.8 (CH), 
118.3 (2 × =CH2), 117.8 (=CH2), 72.6 (CH2), 68.5 (CH2), 62.0 (Cq), 40.5 (2 × CH2); 
HRMS (CI) cald. for C12H13NO [M + Na]
+ 
198.2420, found 198.1274. 
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2-(((tert-butyldimethylsilyl)oxy)methyl)-1H-indole (127p)
209
  
To an oven dry flask purged with argon, were added indole-2-methanol (250 mg, 1.7 
mmol), NEt3 (0.71 ml, 5.1 mmol, 3 eq) and TBSCl (384 mg, 2.5 mmol, 1.5 eq) in 
CH2Cl2 (2 ml). The reaction mixture was stirred for 4 hrs at r.t.  Organic layer was 
washed with saturated solution of sodium  hydrogen carbonate (2 × 20 ml), water 
(15 ml) and brine (15 ml).   
 
127p 
Flash chromatography gradient method 0-10% EtOAc: PE gave the title compound 
as orange brown oil (254 mg, 57%). Rf = 0.63 (1 : 4 EtOAc: PE); IRυ max 3015 (C-
H), 2928 (C-H), 2857 (N-H), 1457 (aromatic), 1255, 1074 cm
-1; δ 1H NMR (600 
MHz, CDCl3) 8.29 (s, 1H, NH), 7.56 (d, 1H, J = 7.8 Hz, H-3), 7.37 (d, 1H, J = 7.8 
Hz, H-4), 7.16 (td, 1H, J = 7.8, 1.1 Hz, H-1), 7.08 (td, 1H, J = 7.8, 1.1 Hz, H-2), 6.31 
(s, 1H, H-5), 4.87 (s, 2H, H-6), 0.93 (s, 9H, H-8), 0.12 (s, 6H, H-7);  δ 13C NMR 
(150 MHz, CDCl3) 138.3 (Cq), 136.0 (Cq), 128.5 (Cq), 121.7 (CH), 120.5 (CH), 
119.8 (CH), 110.9 (CH), 98.9 (CH), 59.4 (CH2), 26.0 (-C(CH3)3), 18.5 (Cq), -5.17 (-
Si(CH3)2). 
3,3-Diallyl-2-(((tert-butyldimethylsilyl)oxy)methyl)-3H-indole (138n) 
 
138n 
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Purification of crude mixture by gradient method 0-10% EtOAc: PE which gave the 
title compound as an orange yellow oil (172 mg, 66%). Rf = 0.80 (1: 4 EtOAc : PE); 
IRυ max 3015 (=C-H), 2929 (C-H), 1693 (N=C), 1501 (aromatic), 1490 (aromatic), 
1254, 1090  cm
-1; δ 1H (600 MHz, CDCl3) 7.52 (d, 1H, J = 7.5 Hz, H-3), 7.25 (td, 
1H, J = 7.5, 1.3 Hz, H-2), 7.25 (d, 1H, J = 7.5 Hz, H-4), 7.21 (td, 1H, J = 7.5, 1.3 
Hz, H-1), 5.18 (ddt, 2H, J = 17.0, 9.9, 7.2 Hz, H-10), 4.91 (dq, 2H, J = 17.0, 1.9 Hz, 
H-12), 4.80 (dq, 2H, J = 9.9, 1.9 Hz, H-11), 4.77 (s, 2H, H-9), 2.84 (ddt, 2H, J = 
13.5, 7.2, 1.1 Hz, H-8 and 7), 2.71 (ddt, 2H, J = 13.6, 7.2, 1.1 Hz, H-8 and 7), 0.97 
(s, 9H, H-5), 0.17 (s, 6H, H-6);  δ 13C (150 MHz, CDCl3) 185.5 (Cq), 154.5 (Cq), 
142.3 (Cq), 132.9 (2 × CH), 127.9 (CH), 125.6 (CH), 122.1 (CH), 120.5 (CH), 117.9 
(2× =CH2), 64.3 (CH2), 62.7 (Cq), 40.4 (2 × CH2), 26.4 (-C(CH3)3), 18.6 (Cq), -5.6 (-
Si(CH3)2); HRMS (CI) cald. for (C15H16NO) [M-SiC7H16]
-
 226.3070, found 
226.1226. 
3,3-Diallyl-3,6,7,8-tetrahydrocyclopenta-indole (138o) 
 
138o 
Purification of crude mixture by gradient method 0-20% EtOAc: PE which gave a 
yellow oil (152 mg, 50%); Rf = 0.31 (1:4 EtOAc: PE); IRυ max 3078 (C-H), 2951 (C-
H), 1639 (N=C), 1553 (aromatic), 1438 (aromatic) cm
-1; δ 1H NMR (600 MHz, 
CDCl3) 8.03 (br s, 1H, H-6), 7.12 (d, 1H, J = 7.5 Hz, H-4), 7.08 (d, 1H, J = 7.5 Hz, 
H-1), 5.47 (ddt, 2H, J = 17.1, 10.0, 7.2 Hz, H-9), 5.02 (dd, 2H, J = 17.1, 1.2 Hz, H-
10), 4.96 (d, 2H, J = 10.0 Hz, H-11), 3.19 (t, 2H, J = 7.5 Hz, H-3), 2.96 (t, 2H, J = 
7.5 Hz, H-2), 2.70 (dd, 2H, J = 13.4, 7.2 Hz, H-8 and 7), 2.49 (dd, 2H, J = 13.8, 7.2 
Hz, H-8 and 7), 2.16 (quintet, 2H, J = 7.2 Hz, H-5);  δ 13C NMR (150 MHz, CDCl3) 
177.8 (CH), 151.4 (Cq), 145.4 (Cq), 139.4 (Cq), 136.6 (Cq), 132.8 (2 × CH), 122.7 
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(CH), 120.1 (CH), 118.6 (2 × =CH2), 60.6 (Cq), 38.9 (2 × CH2), 33.0 (CH2), 30.0 
(CH2), 25.7 (CH2); HRMS (CI)
 
C17H20N [M+H]
+ 
238.1595, found 238.1590. 
Tert-butyl (2-(1H-indol-3-yl)ethyl)carbamate (149)
190, 210
 
To a solution of tryptamine (200 mg, 1.24 mmol) in CHCl3 (2 ml) and a saturated 
aqueous solution of sodium carbonate (5 ml) in an ice bath, was added acid 
anhydride (0.14 ml, 1.49 mmol, 1.2 eq) dissolved in chloroform (1 ml) and was left 
to stir for 2 hrs. Organic layer was washed with 10% HCl (15 ml), water (15 ml) and 
brine (15 ml) and dried with MgSO4, filtered and evaporated. Purification by dry 
load flash column in a light brown oil (251 mg, 78%). 
                                                              
    149 
Rf = 0.41 (2: 3 EtOAc: Petrol); IRυ max 3405 (C-H), 3336 (C-H), 2977 (N-H), 2934 
(N-H), 1700 (C=O), 1513 (aromatic), 1169 cm
-1; δ 1H NMR (600 MHz, CDCl3) 8.43 
(br s, 1H, NH), 7.62 (d, 1H, J = 7.7 Hz, H-3), 7.36 (d, 1H, J = 7.7 Hz, H-6), 7.21 (td, 
1H, J = 7.7, 1.1 Hz, H-2), 7.14 (td, 1H, J = 7.7 Hz, 0.7, H-1), 6.99 (s, 1H, H-8), 4.72 
(brs, 1H, NHCO2C(CH3)3), 3.49 (q, 2H, J = 7.1 Hz, H-5), 2.97 (t, 2H, J = 7.1 Hz, H-
4), 1.47 (s, 9H, -C(CH3)3); δ 
13
C NMR (150 MHz, CDCl3)  156.3 (Cq), 137.5 (Cq), 
122.4 (Cq), 122.3 (CH), 122.1 (CH), 119.4 (CH), 118.4 (CH), 113.2 (Cq), 111.4 
(CH), 79.4 (Cq), 41.2 (CH2), 28.7 ((CH3)3), 26.0 (CH2); HRMS (EI) calcd. for 
C15H20N2O2 [M]
+ 
260.15248, found 260.15237. 
Tert-butyl3a-allyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-
carboxylate (150)
190
 
Under previous conditions as before for the synthesis of substituted 3, 3-diallyl-3H-
indole. 
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150 
Purification by dry load flash chromatography method 0-20% EtOAc: petrol gave 
the title compound as a pale yellow oil (180 mg, 82%). Rf = 0.66 (2 : 8  EtOAc : 
Petrol); IRυ max 2976 (C-H), 2929 (N-H), 1691 (C=O), 1488 (aromatic), 1393 (C-O), 
1155 (N-C) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.06 (tt, 1H, J = 7.1, 1.2 Hz, H-2), 
7.05 (d, 1H, J = 7.1 Hz, H-6), 6.77-6.72 (m, 1H, H-1), 6.61 (d, 1H, J = 7.1 Hz, H-3), 
5.75 (m, 1H, H-14), 5.12-5.01 (m, 3H, Boc cis/trans isomerization, H-15, 8), 3.69; 
3.53 (m, 1H, H-11), 3.04-2.98 (m, 1H, H-11), 2.46 (dd, 1H, J = 15.0, 6.6 Hz, H-13), 
2.42 (dd, 1H, J = 15.0, 6.6 Hz, H-13), 2.17-2.06 (m, 2H, H-12), 1.52 + 1.44 (2s, Boc 
cis/trans isomerization, 9H, H-10); δ 13C NMR (150 MHz, CDCl3) 154.5 (Cq), 153.3 
(Cq), 149.3 (Cq), 149.0 (Cq), 133.9 (Cq), 131.9 (CH), 131.8 (CH), 128.5 (CH), 128.4 
(CH), 123.40 (CH), 123.36 (CH), 119.2 (CH), 118.7 (CH), 118.4 (=CH2), 118.4 
(=CH2), 109.4 (CH), 109.3 (CH), 80.1 (CH), 79.8 (Cq), 79.6 (Cq), 57.4 (Cq), 56.4 
(Cq), 45.9 (CH2), 45.5 (CH2), 35.1 (CH2), 34.9 (CH2), 28.8 (-C(CH3)3), 28.6 (-
C(CH3)3).  
1-Allyl-2-methyl-5-nitro-1H-indole, nobelium salt (151a) 
Reaction mixture was heated at 50°C overnight under the same conditions as before. 
 
Purification by dry load flash chromatography gradient method 0-20% EtOAc: 
Petrol to give the title compound as a red-yellow oil (234 mg, 86%). Rf = 0.56 (1: 4 
EtOAc : Petrol); IRυ max 2923 (C-H), 1513 (N=C), 1476 (aromatic), 1350 (O=N=O), 
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1071 cm
-1
; δ 1H NMR (600 MHz, CDCl3) 8.48 (d, 1H, J = 1.9 Hz, H-6), 8.04 (dd, 
1H, J = 8.9, 1.9 Hz, H-2), 7.22 (d, 1H, J = 8.9 Hz, H-3), 6.45 (s, 1H, H-1), 5.94 (dtd, 
1H, J = 17.2, 9.7, 5.5 Hz, H-8), 5.16 (d, 1H, J = 9.7 Hz, H-7), 4.77 (d, 2H, J = 17.2 
Hz, H-5), 4.23 (dd, 2H, J = 5.5, 2.8 Hz, H-9), 2.42 (s, 3H, H-4);  δ 13C NMR (150 
MHz, CDCl3) 141.7 (Cq), 140.4 (Cq), 139.9 (Cq), 132.4 (CH), 127.4 (Cq), 116.9 
(=CH2), 108.9 (CH), 102.7 (CH), 45.7 (CH2), 12.8 (CH3); HRMS (ES) cald. for 
C12H12N2O2 [M]
+
 216.24000, found 216.24300. 
1-allyl-5-nitro-1H-indole (151b)
211
 
Reaction mixture was heated at 50°C overnight under the same conditions as before. 
 
151b 
Purification by dry load flash chromatography method 20% EtOAc: Petrol to give 
the title compound as a yellow oil (177 mg, 79%). Rf = 0.88 (3: 7 EtOAc: Petrol); 
IRυmax 2923 (C-H), 2924 (C-H), 1509 (aromatic), 1478 (aromatic), 1340 (O=N=O), 
1069 cm
-1; δ 1H NMR (600 MHz, CDCl3) 8.60 (d, 1H, J = 2.4 Hz, H-1), 8.11 (dd, 
1H, J = 9.2, 2.4 Hz, H-2), 7.34 (d, 1H, J = 9.2 Hz, H-3), 7.25 (d, 1H, J = 3.3 Hz, H-
5), 6.70 (dd, 1H, J = 3.3, 0.7 Hz, H-4), 6.00 (ddt, 1H, J = 17.1, 10.1, 7.8 Hz, H-7), 
5.26 (dq, 1H, J = 10.1, 1.3 Hz, H-8), 5.08 (dq, 1H, J = 17.1, 1.3 Hz, H-9), 4.79 (dt, 
2H, J = 5.3, 1.3 Hz, H-6);  δ 13C NMR (150 MHz, CDCl3) 141.8 (Cq), 139.0 (Cq), 
132.4 (CH), 131.2 (CH), 127.9 (Cq), 118.4 (CH), 118.2 (=CH2), 117.4 (CH), 109.6 
(CH), 104.3 (CH), 49.4 (CH2); HRMS (ES) cald. for C11H11N2O2 [M + H]
+ 
203.2130, found 203.0666. 
(E)-But-2-en-1-yl acetate(152)
212
 
Under dry argon conditions was added acetyl chloride (21.7 ml, 0.31 mmol, 1.1 eq) 
in CH2Cl2 (20 ml) at 0°C. The (E)-but-2-en-1-ol (23 ml, 0.27 mmol) and pyridine 
(39.2 ml, 0.49 mmol, 1.8 eq) was added dropwise with vigorous stirring at 0°C for 2 
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hrs. The reaction was left to stir for a further 10 minutes. To the reaction mixture 
CH2Cl2 (50 ml) was added to the reaction mixture. The organic layer was then 
washed with a solution of HCl (1M) (3 × 100 ml), sodium carbonate (1 M) (3 × 100 
ml), water (3 × 100 ml) and brine (3 × 100 ml), dried with MgSO4, filtered and 
concentrated to give a yellow oil (1.5 g, 43%). 
 
 
152 
IRυ max 2924 (C-H), 1620 (C=O), 1340, 1069 cm
-1; δ 1H NMR (600 MHz, CDCl3) 
5.80 (m, 1H, H-3), 5.77 (m, 1H, H-2), 4.80 (d, 1H, J = 6.2 Hz, H-4), 2.05 (s, 3H, H-
5), 1.73 (m, 3H, H-1);  δ 13C NMR (150 MHz, CDCl3) 172.1 (Cq), 135.0 (CH), 124.4 
(CH), 66.8 (CH2), 20.1 (CH3), 17.2 (CH3). 
3-(but-3-en-2-yl)-1H-indole (153a)
213
 
To a stirred solution of [Pd(allylCl)2]2 (2.5 mol%) and DPEPhos (5 mol%) in MeCN 
(0.025M) was added (E)-but-2-en-2-yl acetate (5 eq) after stirring for 15 mins at rt. 
After stirring for a further 5 mins potassium carbonate (3 eq), the substituted indole 
(1 eq) were added. The reaction mixture was degassed and left to stir overnight 
under argon at 40°C. Then diethyl ether was added to the reaction mixture (7 ml) and 
washed with water (10 ml), dried with MgSO4, filtered and concentrated. 
Purification by dry load flash chromatography gave the corresponding substituted 
3,3-diallyl-3H-indole compound. 
 
145a 
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Reaction mixture was heated at 50°C overnight. Purification by dry load flash 
chromatography method 0-20% EtOAc: petrol to give the title compound as a red 
brown oil (89 mg, 43%); Rf = 0.45 (3 : 7  EtOAc : petrol); IRυmax 3405 (C-H), 2970 
(N-H), 1457 (aromatic), 1295 cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.93 (br s, 1H, 
NH), 7.66 (d, 1H, J = 7.8 Hz, H-6), 7.36 (d, 1H, J = 8.2 Hz, H-3), 7.19 (t, 2H, J = 7.5 
Hz, H-2), 7.11 (t, 1H, J = 7.3 Hz, H-1), 6.98 (d, 2H, J = 1.7 Hz, H-8), 6.08 (ddd, 1H, 
J = 17.0, 10.0, 6.7 Hz, H-11), 5.14 (dt, 1H, J = 17.2, 1.5 Hz, H-15), 5.04 (dt, 1H, J = 
10.2, 1.5 Hz, H-14), 3.77 (m, 1H, H-10), 1.49 (s, 3H, H-13); δ 13C NMR (150 MHz, 
CDCl3) 143.8 (CH), 136.7 (Cq), 126.9 (Cq), 123.2 (CH), 122.1 (CH), 119.7 (CH), 
119.3 (CH), 112.9 (=CH2), 110.5 (Cq), 110.2 (CH), 35.2 (CH), 20.3 (CH3). 
3,3-diallylindoline (154) 
Under dry argon conditions was added 3, 3-diallyl-3H-indole (150 mg, 0.76 mmol) 
in MeOH (2 ml).This was followed by addition of NaBH4 (116 mg, 3 mmol, 4 eq) at 
0°C, and left to stir for 2 hrs at 0°C. Added diethyl ether (5 ml) to the reaction 
mixture and washed with water (10 ml), dried with MgSO4, filtered and 
concentrated. 
 
154 
 Purification by dry load flash chromatography method 0-10% EtOAc : petrol to give 
the title compound as a pale yellow oil (77 mg, 51%); Rf = 0.63 (1 : 4  EtOAc : 
petrol); IRυ max 3072 (C-H), 3074 (C-H), 2919 (N-H), 1487 (aromatic), 1462 
(aromatic) cm
-1; δ 1H NMR (600 MHz, CDCl3) 7.05 (td, 1H, J = 7.5, 1.0 Hz, H-1), 
7.02 (d, 1H, J = 7.5 Hz, H-6), 6.74 (t, 1H, J = 7.5 Hz, H-2), 6.64 (d, 1H, J = 7.5 Hz, 
H-3), 5.72 (ddt, 2H, J = 17.2, 9.7, 7.4 Hz, H-14, 12), 5.07-5.04 (m, 4H, H-15, 16), 
3.37 (s, 2H, H-8), 2.42 (dd, 2H, J = 14.0, 7.4, H-10 or 11), 2.40 (dd, 2H, J = 14.0, 
7.4 Hz, H-10 and 11);  δ 13C NMR (150 MHz, CDCl3) 151.3 (Cq), 134.8 (2 × CH), 
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134.7 (Cq), 127.7 (CH), 123.6 (CH), 118.6 (CH), 117.9 (2 × =CH2), 109.8 (CH), 
56.4 (CH2), 48.5 (Cq), 43.0 (2 × CH2); HRMS (CI) cald. for C14H17N [M + H]
+ 
200.14392, found 200.14292.  
2,3,3-triallylindoline (155)  
Under dry argon conditions at -15°C was added zinc (84 mg, 1.28 mmol, 1.59 eq) 
and allyl bromide (0.11 ml, 1.28 mmol, 1.59 eq) in dry THF (2 ml) for 3 hrs. This 
was followed by dropwise addition of 3,3-diallyl-3H-indole (159 mg, 0.81 mmol) in 
dry THF (2 ml) at -78°C, and was left to stir for 4 hrs under argon. The reaction 
mixture was quenched with saturated aqueous NH4Cl (10 ml). The mixture was 
partitioned with diethyl ether (5 ml). Organic layer was washed with water (10 ml), 
dried with MgSO4, filtered and concentrated. 
 
155 
Purification by dry load flash chromatography method 0-10% EtOAc: petrol to give 
the title compound as a yellow oil (114 mg, 60%). Rf = 0.64 (1 : 1  EtOAc : petrol); 
IRυmax 3350 (C-H), 3075 (C-H), 2922 (N-H), 1607 (aromatic), 1483 (aromatic) cm
-1
; 
δ 1H NMR (600 MHz, CDCl3) 7.03 (td, 1H, J = 7.4, 1.0 Hz, H-2), 7.00 (dd, 1H, J = 
7.4, 1.0 Hz, H-6), 6.72 (td, 1H, J = 7.4, 0.9 Hz, H-1), 6.62 (dd, 1H, J = 7.4, 0.9 Hz, 
H-3), 5.82 (dtd, 1H, J = 16.1, 9.7, 7.2 Hz, H-11), 5.74 (dtd, 2H, J = 16.9, 9.9, 7.6 
Hz, H-15), 5.16 (dq, 1H, J = 17.3, 1.9 Hz, H-5), 5.12 (br d, 1H, J = 9.7 Hz, H-4), 
5.07-4.99 (m, 4H, H-12, 9), 4.00 (br s, 1H, NH), 3.64 (dd, 1H, J = 10.7, 3.0 Hz, H-
8), 2.55 (ddt, 1H, J = 14.4, 6.8, 1.4 Hz, H-14 or 13), 2.47-2.39 (m, 3H, H-14, 13 and 
10), 2.29-2.24 (m, 1H, H-10), 2.18 (ddt, 1H, J = 13.9, 7.7, 1.1, H-14 or 13);  δ 13C 
NMR (150 MHz, CDCl3) 149.7 (Cq), 136.3 (CH), 135.0 (CH), 134.9 (CH), 134.3 
(Cq), 127.6 (CH), 124.3 (CH), 118.4 (CH), 117.9 (=CH2), 117.7 (=CH2), 117.6 
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(=CH2), 109.6 (CH), 66.1 (CH), 49.3 (Cq), 40.7 (CH2), 37.9 (CH2), 34.6 (CH2); 
HRMS (ES) cald. for C17H21N [M]
+ 
239.36200, found 238.1593. 
Reactivity of substituted 3,3-diallyl-3H-indole compounds UGI 
reaction 
 
General procedure G: To a solution of 3,3-diallyl-3H-indole(1eq) in MeOH (0.07 
M) were added the carboxylic acid (1eq) and isocyanide (1eq). Reaction  mixture 
was left to stir overnight at r.t. Added diethyl ether (3 ml) washed with water (5 ml), 
dried with MgSO4, and evaporated solvent.  
3,3-Diallyl-1-benzoyl-N-(tert-butyl)-5,6-dimethoxyindoline-2-
carboxamide (156a) 
                                                                
156a 
Evaporation of solvent gave the title compound as a yellow brown oil (249 mg, 
99%). Rf = 0.15 (1 : 4 EtOAc : Petrol); IRυ max 3342 (N-H), 2966 (C-H), 2936 (C-H), 
1682 (C=C alkene), 1623 (C=O), 1501 (aromatic), 1448 (OC-N), 1214 (C-O) cm
-1; δ 
1
H NMR (400 MHz, CDCl3, 55°C) 7.53 (d, 2H, J = 8.2 Hz, H-5), 7.46 (t, 3H, J  = 
8.2 Hz, H-6, 7), 6.88 (br s, 1H, H-3), 6.76 (s, 1H, H-4), 6.04 (ddt, 1H, J = 17.4, 10.6, 
7.1 Hz, H-14 or 12), 5.61 (ddt, 1H, J = 17.4, 10.6, 7.1 Hz, H-14 or 12), 5.18-5.05 (m, 
4H, H-15, 13), 5.52 (br s, 1H, NH), 4.52 (s, 1H, H-8), 3.84 (s, 3H, H-1), 3.67 (s, 3H, 
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H-2), 2.64 (dd, 1H, J = 14.6, 7.1 Hz, H-11 or 10), 2.59 (dd, 1H, J = 14.6, 7.1 Hz, H-
11 or 10), 2.46 (dd, 1H, J = 13.9, 7.1 Hz, H-11 or 10), 2.40 (dd, 1H, J = 13.7, 7.1 Hz, 
H-11 or 10), 1.30 (s, 9H, H-9);  δ 13C NMR (150 MHz, CDCl3, r.t.) 168.9 (Cq), 167.8 
(Cq), 148.4 (Cq), 145.9 (Cq), 136.2 (Cq), 135.3 (Cq), 134.3 (CH), 133.6 (CH), 130.8 
(CH), 128.8 (2 × CH), 128.4 (Cq), 127.4 (2 × CH), 119.4 (=CH2), 119.1 (=CH2), 
107.4 (CH), 101.0 (Cq), 73.9 (CH), 56.6 (CH3), 55.8 (CH3), 51.8 (Cq), 45.2 (CH2), 
39.1 (CH2), 28.7 (-C(CH3)3); carbon of H-3 and 2 not observed by 
13
C NMR; HRMS 
(EI) cald. for  C28H34N2O4 [M]
+ 
462.2519, found 462.2524. 
3,3-Diallyl-5-(benzyloxy)-N-(tert-butyl)-1-picolinoylindoline-2-
carboxamide (156b) 
 
156b 
Evaporation of solvent gave the title compound as a yellow brown oil (286 mg, 
99%); Rf = 0.15 (1 : 4 EtOAc : petrol); IRυ max 3342 (N-H), 2965 (C-H), 2933 (C-H), 
1683 (C=C alkene), 1630 (C=O), 1501 (aromatic), 1446 (OC-N), 1214 (C-O) cm
-1; δ 
1
H NMR (400 MHz, CDCl3, 55
°
C) 8.56 (d, 1H, J = 4.7 Hz, H-15), 8.12-8.00 (br s, 
1H, H-3), 7.88 (d, 1H, J = 7.6 Hz, H-18), 7.81 (td, 1H, J = 7.6, 1.4 Hz, H-17), 7.44 
(d, 2H, J = 7.4 Hz, H-13), 7.40 (t, 2H, J = 7.4 Hz, H-14), 7.36 (ddd, 1H, J = 7.6, 4.7, 
1.4 Hz, H-16), 7.33 (tt, 1H, J = 7.4, 1.3 Hz, H-20), 6.89 (br s, 1H, H-2), 6.86 (br s, 
1H, H-1), 6.03 (ddt, 1H,  J = 16.8, 10.7, 7.4 Hz, H-8 or 9), 5.51 (ddt, 2H, J = 16.8, 
10.7, 7.4 Hz, H-8 or 9 and NH), 5.10 (dd, 2H,  J = 16.8, 10.7 Hz, H-11 and 10), 5.06 
(s, 2H, H-19), 5.00 (d, 2H, J = 10.7 Hz, H-11 and 10), 4.92 (s, 1H, H-4), 2.58 (m, 
2H, H-6 or 7), 2.34 (br d,  2H, ,J = 7.4 Hz, H-6 or 7), 1.21 (s, 9H, H-12);  δ 13C 
NMR (150 MHz, CDCl3, r.t.) 168.6 (Cq), 166.3 (Cq), 156.3 (Cq), 153.5 (Cq), 147.9 
(CH), 138.9 (Cq), 137.4 (CH), 137.0 (Cq), 136.1 (Cq), 134.4 (CH), 133.5 (CH), 128.7 
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(2 × CH),  128.2 (CH), 127. 2 (2 × CH), 125.2 (CH), 124.4 (CH), 119.1 (=CH2), 
118.8 (=CH2), 118.5 (Cq), 113.7 (CH), 111.6 (CH), 74.1 (CH), 70.7 (CH2), 51.4 (Cq), 
50.9 (Cq), 45.5 (CH2), 39.0 (CH2), 28.6 (CH3); carbon of H-3 not observed by 
13
C 
NMR; HRMS (CI) cald. for C32H36N3O3 [M+H]
+ 
510.2757, found 510.2729. 
Tert-butyl(2-(3,3-diallyl-2-(tert-butylcarbamoyl)-5-chloroindolin-1-
yl)-2-oxoethyl)carbamate (156c) 
 
156c 
After evaporation of volatiles, purification by dry load column chromatography by 
gradient method 0-20% EtOAc: petrol, gave the title compound as a colourless oil 
(106 mg, 91%). Rf = 0.64 (1 : 4 EtOAc : petrol); IRυ max 3455 (C-H), 3348 (C-H), 
2977 (N-H), 2940 (N-H), 1667 (C=O), 1476 (aromatic), 1394 (aromatic), 1366 (OC-
N), 1251 (C-O) cm
-1; δ 1H NMR (400 MHz, CDCl3, 55°C)  7.89 (br s, 1H, H-3), 
7.24 (dd, 1H, J  = 8.5, 1.8 Hz, H-2), 7.19 (d, 1H, J = 1.8 Hz, H-1), 6.00 (ddt, 1H, J = 
16.8, 8.3, 7.3 Hz, H-14 or 12), 5.51 (br s, 1H, NH), 5.50 (ddt, 1H, J = 16.8, 8.3, 7.3 
Hz, H-14 or 12), 5.31 (br s, 1H, NH), 5.23-5.07 (m, 4H, H-15, 13), 4.45 (br s, 1H, H-
9), 4.09 (dd, 1H, J = 16.8, 15.4 Hz, H-4), 3.93 (br d, 1H, J = 15.4 Hz, H-4), 2.67 
(dd, 1H, J = 15.4, 7.3 Hz, H-11 or 10), 4.49 (dd, 1H, J = 15.4, 7.3 Hz, H-11 or 10), 
2.41 (dd, 1H, J = 15.4, 7.3 Hz, H-11 or 10), 2.34 (dd, 1H, J = 15.4, 7.3 Hz, H-11 or 
10), 1.48 (s, 9H, H-7 or 6), 1.33 (s, 9H, H-7 or 6);  δ 13C NMR (150 MHz, CDCl3, 
r.t.) 167.5 (Cq), 167.1 (Cq), 155.8 (Cq), 140.3 (Cq), 138.2 (Cq), 133.3 (CH), 132.5 
(CH), 129.7 (Cq), 128.5 (CH), 124.4 (CH), 120.1 (=CH2), 119.9 (=CH2), 80.2 (Cq), 
71.1 (CH), 52.3 (Cq), 50.8 (Cq), 45.8 (CH2), 44.1 (CH2), 38.2 (CH2), 28.6 (-
C(CH3)3), 28.4 (-C(CH3)3); carbon of H-3 not observed by 
13
C NMR; HRMS (CI) 
cald. for C26H37N3O4Cl [M + H]
+ 
490.2473, found 490.2457. 
225 
 
3,3-Diallyl-1-benzoyl-N-cyclohexylindoline-2-carboxamide (156d) 
 
156d 
After evaporation of the volatiles, purification by dry load flash column 
chromatography 30% EtOAc: petrol gave the title compound as a pale yellow oil 
(174 mg, 87%). Rf = 0.30 (1 : 4 EtOAc : petrol); IRυ max 3314 (C-H), 2930 (C-H), 
2855 (N-H), 1638 (C=O), 1594 (N=CH), 1559 (aromatic), 1470 (OC-N) cm
-1; δ 1H 
NMR (400 MHz, CDCl3, 55°C) 7.54-7.47 (m, 3H, H-7, 4), 7.42 (t, 2H, J  = 7.9 Hz, 
H-5), 7.20 (d, 1H, J = 7.5 Hz, H-6), 7.15 (br s, 1H, H-3), 7.11 (t, 1H, J = 7.8 Hz, H-
2), 7.05 (td, 1H, J = 7.1, 1.4 Hz, H-1), 6.00 (ddt, 1H, J = 17.0, 9.9, 7.5 Hz, H-14 or 
12), 5.62 (ddt, 2H, J = 17.0, 9.9, 7.5 Hz, H-14 or 12, NH), 5.14-5.03 (m, 4H, H-15, 
13), 4.60 (s, 1H, H-8), 3.75 (m, 1H, H-9), 2.63 (dd, 2H, J = 14.3, 7.5 Hz, H-10 or 
11), 2.47 (dt, 2H, J = 14.3, 7.5 Hz, H-11 or 10), 1.95 (dd, 1H, J = 11.7, 2.8 Hz, H-17 
or 16), 1.81-1.73 (m, 1H, H-17 or 16), 1.69-1.64 (m, 1H, H-19, 18), 1.62-1.54 (m, 
2H, H-20 eq, 19 or 18), 1.44-1.28 (m, 2H, H-(19 and 18) or (20 and 18)), 1.23-1.12 
(qd, 2H, J = 12.0, 4.0 Hz, H-20 ax, 17 or 16), 1.07 (qd, 1H, J = 11.3, 3.4 Hz, H-17 or 
16 ax);  δ 13C NMR (150 MHz, CDCl3, r.t.) 169.5 (Cq), 167.6 (Cq), 141.8 (Cq), 137.2 
(Cq), 136.0 (Cq), 133.9 (CH), 133.5 (CH), 131.0 (CH), 128.8 (2 × CH), 128.0 (CH), 
127.4 (2 × CH), 124.3 (2 × CH), 119.5 (=CH2), 119.0 (=CH2), 73.0 (CH), 50.0 (Cq), 
48.2 (CH), 45.1 (CH2), 38.8 (CH2), 32.9 (CH2), 32.8 (CH2), 25.5 (CH2), 24.8 (CH2), 
24.7 (CH2); carbon of H-3 not seen by 
13
C NMR; HRMS (CI) cald. for C28H32N2O2 
[M]
+ 
428.2463, found 428.2460. 
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N-(3,3-Diallyl-1-benzoylindolin-2-yl)pivalamide (156e) 
 
156e 
Evaporation of solvent gave the title compound as a pale yellow solid (81 mg, 79%). 
m.p. 137-138 °C; Rf = 0.37 (1: 4  EtOAc : petrol); IRυ max 3347 (C-H), 2970 (C-H), 
2925 (N-H), 1685 (C=O), 1624 (C=O), 1501 (aromatic), 1393 (OC-N), 1393 (C-O) 
cm
-1; δ 1H NMR (600 MHz, CDCl3, r.t.) 7.53 (d, 2H,  J = 7.4 Hz, H-5), 7.50 (t, 1H, J  
= 7.4 Hz, H-7), 7.43 (t, 2H, J = 7.4 Hz, H-6), 7.17 (d, 1H, J = 7.5 Hz, H-1), 7.06 (br 
s, 1H, H-2), 7.02 (t, 1H, J = 7.5 Hz, H-4), 6.00 (ddt, 1H, J = 16.5, 9.2, 7.2 Hz, H-15 
or 12), 5.58 (ddt, 1H, J = 16.5, 9.2, 7.2 Hz, H-15 or 12), 5.49 (br s, 1H, NH), 5.15-
5.05 (m, 4H, H-14, 13), 4.48 (s, 1H, H-8), 2.62; 2.55 (dd, 1H, J = 14.7, 7.2 Hz, H-11 
or 10) (dd, 1H, J = 14.7, 7.2 Hz, H-11 or 10)), 2.42 (m, 2H, H-11 or 10), 1.30 (s, 9H, 
H-17); missing H-3 peak present at baseline around 7.06 ppm; δ 13C NMR (150 
MHz, CDCl3, r.t) 169.5 (Cq), 167.6 (Cq), 142.0 (Cq), 137.1 (Cq), 136.1 (Cq), 134.0 
(CH), 133.6 (CH), 131.1 (CH), 128.9 (2 × CH), 128.1 (CH), 127.6 (2 × CH), 124.2 
(CH), 124.0 (CH), 119.4 (=CH2), 119.2 (=CH2), 73.1 (CH), 51.9 (Cq), 49.8 (Cq), 
44.7 (CH), 38.9 (CH2), 28.6 (-C(CH3)3); carbon of H-3 not observed by 
13
C NMR); 
HRMS (CI) cald. for C26H31N2O2 [M+H]
+ 
403.2386, found 403.2353. 
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3,3-Diallyl-1-(2-chloroacetyl)-5-methoxy-N-pentylindoline-2-
carboxamide (156f) 
 
156f 
After evaporation of volatiles, purification by dry load column chromatography by 
gradient method 0-20% EtOAc: petrol, gave the title compound as a yellow oil (67 
mg, 61%). Rf = 0.27 (1 : 4 EtOAc : petrol); IRυ max 3010 (C-H), 2930 (N-H), 1648 
(C=O), 1488 (aromatic), 1398 (OC-N), 1246 (C-O-C), 1204 (C-N), 1156 (C-O), 
1033 (C-O-C), 811 (C-Cl) cm
-1; δ 1H NMR (400 MHz, CDCl3, 55°C) 8.00 (br s, 1H, 
H-3), 6.83 (dd, 1H, J  = 8.0, 2.5 Hz, H-2), 6.80 (d, 1H, J = 2.5 Hz, H-1), 5.94 (ddt, 
1H, J = 16.4, 9.5, 7.4 Hz, H-14 or 12), 5.62 (br s, 1H, NH), 5.53 (ddt, 1H,  J = 16.4, 
9.5, 7.4 Hz, H-14 or 12), 5.20-5.05 (m, 4H, H-15, 13), 4.66 (s, 3H, H-9), 4.15 (d, 1H, 
J = 13.0 Hz, H-17), 4.08 (d, 1H, J = 13.0 Hz, H-17), 3.81 (s, 3H, H-18), 3.21 
(sextet, 1H, J = 13.3, 7.1, 6.1  Hz, H-19), 3.10 (sext, 1H, J = 13.3, 7.1, 6.1  Hz, H-
19), 2.64 (d, 2H, J = 7.4 Hz, H-11 or 10), 2.44 (ddt, 1H, J = 13.9, 7.4, 1.0 Hz, H-11 
or 10), 2.39 (ddt, 1H, J = 13.9, 7.4, 1.0 Hz, H-11 or 10), 1.42 (qn, 2H, J = 14.7, 7.1 
Hz, H-16), 1.27 (m, 2H, H-21), 1.18 (m, 2H, H-20), 0.86 (t, 3H, J = 6.7 Hz, H-22);  
δ 13C NMR (150 MHz, CDCl3, r.t.) 168.5 (Cq), 164.1 (Cq), 157.5 (Cq), 137.9 (Cq), 
134.8 (Cq), 133.3 (CH), 132.5 (CH), 120.1 (=CH2), 119.1 (=CH2), 118.2 (CH), 112.9 
(CH), 110.7 (CH), 71.7 (CH), 55.8 (CH3), 51.2 (Cq), 46.6 (CH2), 42.7 (CH2), 39.6 
(CH2), 38.3 (CH2), 29.0 (CH2), 28.9 (CH2), 22.3 (CH2), 14.0 (CH3); HRMS (CI) 
cald. for C23H32ClN2O3 [M + H]
+ 
419.2101, found 419.2074. 
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Grubbs metathesis for ring closing metathesis: 
General procedure H: To a degassed solution of the corresponding UGI substrate 
(1eq) in CH2Cl2 (0.06 M) at 45°C was added Grubbs 1
st
 generation catalyst (15 
mol%). The reaction mixture was refluxed overnight under argon. Workup with 
diethyl ether (5 ml) and washed with water (10 ml), dried with MgSO4, filtered and 
evaporated. 
1'-Benzoyl-N-cyclohexylspiro[cyclopentane-1,3'-indolin]-3-ene-2'-
carboxamide (159a) 
 
159a 
After evaporation of volatiles, purification by dry load column chromatography at 
40% EtOAc: petrol gave the title compound as a grey black oil (60 mg, 98%). Rf = 
0.25 (1 : 4  EtOAc : petrol); IRυ max 3314 (C-H), 2930 (C-H), 2854 (N-H), 1634 
(C=O), 1479 (aromatic), 1374 (OC-N) cm
-1; δ 1H NMR (400 MHz, CDCl3, 55°C) 
7.53 (d, 2H, J = 7.6 Hz, H-4), 7.48 (t, 1H, J  = 6.9 Hz, H-5), 7.44 (t, 2H, J = 7.2 Hz, 
H-7), 7.21 (d, 1H, J = 7.3 Hz, H-6), 7.15 (br s, 1H, H-3), 7.08 (t, 1H, J =  7.1 Hz, H-
2), 7.01 (t, 1H, J = 7.4 Hz, H-1), 5.89 (m, 1H, H-14 or 12), 5.69 (m, 1H, H-14 or 12), 
5.52 (d, 1H, J = 6.5 Hz, NH), 4.64 (s, 1H, H-8), 3.76 (m, 1H, H-19), 2.87 (dd, 1H, J 
= 17.1, 1.5 Hz, H-11 or 10), 2.81 (d, 1H, J = 16.4 Hz, H-11 or 10), 2.68 (d, 1H, J = 
16.9 Hz, H-11 or 10), 2.62 (d, 1H, J = 15.9 Hz, H-11 or 10), 2.81 (d, 1H, J = 16.4 
Hz, H-11 or 10), 2.68 (d, 1H, J = 16.9 Hz, H-11 or 10), 2.62 (d, 1H, J = 15.9 Hz, H-
11 or 10), 1.88 (d, 1H, J = 10.4 Hz, H-15 or 13), 1.77 (m, 1H, H-15 or 13), 1.64 (m, 
1H, H-18 or 16), 1.56 (br d, 1H, J= 12.6 Hz, 18 or 16), 1.39 (m, 3H, H-(18 and 16) 
or (18 and 17)), 1.16 (q, 2H, H-17 ax and 15 or 12), 1.04 (q, 1H, J = 10.9 Hz, H-15 
or 13 ax);  δ 13C NMR (150 MHz, CDCl3, 55
°
C) 169.5 (Cq), 168.1 (Cq), 141.2 (Cq), 
229 
 
140.3 (Cq), 136.0 (Cq), 130.7 (CH), 130.7 (2 × CH), 128.8 (2 × CH), 127.9 (2 × CH), 
127.4 (2 × CH), 124.7 (CH), 122.3 (CH), 75.7 (CH), 53.8  (Cq), 50.2 (CH2), 48.2 
(CH), 40.2 (CH2), 32.9 (CH2), 32.8 (CH2), 25.5 (CH2), 24.7 (CH2), 24.6 (CH2); 
carbon of H-3 was not observed by 
13
C NMR; HRMS (CI) cald. for C26H28N2O2 
[M]
+ 
400.2150, found 400.2146. 
1'-Benzoyl-N-(tert-butyl)-5',6'-dimethoxyspiro[cyclopentane-1,3'-
indolin]-3-ene-2'-carboxamide (159b) 
 
159b 
After evaporation of volatiles, purification by dry load column chromatography by 
gradient method 30-40% EtOAc: petrol gave the title compound as a grey black oil 
(50 mg, 89%). Rf = 0.15 (1 : 4 EtOAc : petrol);  IRυ max 3342 (C-H), 3061 (C-H), 
2965 (N-H), 1686 (C=O), 1634 (C=O), 1500 (aromatic), 1447 (aromatic), 1398 (C-
O), 1215 (C-O) cm
-1; δ 1H NMR (400 MHz, CDCl3, 55°C) 7.77-7.45 (m, 5H, H-14, 
13, 12), 6.76 (s, 1H, H-7), 5.91 (td, 1H, J = 5.7, 2.1 Hz, H-11 or 10), 5.72 (td, 1H, J 
= 5.7, 2.1 Hz, H-11 or 10), 5.36 (br s, 1H, NH), 4.51 (s, 1H, H-4), 3.84 (s, 3H, H-1), 
3.69 (s, 3H, H-2), 2.87 (ddt, 1H, J = 17.1, 5.7, 2.1 Hz, H-9 or 8), 2.76 (ddt, 1H, J = 
16.3, 5.7, 2.1 Hz, H-9 or 8), 2.67 (ddt, 1H, J = 17.1, 5.7, 2.1 Hz, H-9 or 8), 2.60 (ddt, 
1H, J = 16.3, 5.7, 2.1 Hz, H-9 or 8), 1.31 (s, 9H, H-6); δ 13C NMR (150 MHz, 
CDCl3, r.t) 169.3 (Cq), 168.3 (Cq), 148.8 (Cq), 146.3 (Cq), 136.4 (Cq), 134.6 (Cq), 
130.7 (CH), 131.1 (Cq), 130.5 (CH), 128.5 (2 × CH), 128.4 (CH), 127.4 (2 × CH), 
105.6 (CH), 66.0 (CH), 56.4 (CH3), 55.9 (CH3), 54.1 (Cq), 51.8 (Cq), 50.1 (CH2), 
39.8 (CH2), 28.7 (-C(CH3)3); carbon of H-3 not observed in 
13
C NMR; HRMS (CI) 
cald. for C26H30N2O4 [M]
+ 
434.2205, found 434.2202. 
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1'-Benzoyl-N-(tert-butyl)spiro[cyclopentane-1,3'-indolin]-3-ene-2'-
carboxamide (159c) 
                                                                        
159c 
After evaporation of volatiles, purification by dry load column chromatography at 
40% EtOAc: Petrol gave the title compound as a grey black oil (56 mg, 96%). Rf = 
0.44 (1 : 4 EtOAc : Petrol); IRυ max 3339 (C-H), 2967 (C-H), 2925 (N-H), 1679 
(C=O), 1630 (C=O), 1479 (aromatic), 1390 (OC-N) cm
-1; δ 1H NMR (400 MHz, 
CDCl3, 55°C) 7.54 (d, 2H, J = 7.4 Hz, H-4), 7.49 (t, 1H, J  = 7.4 Hz, H-7), 7.44 (t, 
2H, J = 7.4 Hz, H-5), 7.22 (d, 1H, J = 7.6 Hz, H-6), 7.13 (br s, 1H, H-3), 7.08 (t, 1H, 
J = 7.6 Hz, H-2), 7.01 (t, 1H, J = 7.6 Hz, H-1), 5.91 (dt, 1H, J = 5.4, 2.1 Hz, H-14 or 
12), 5.71 (dt, 1H, J = 5.4, 2.1 Hz, H-12 or 14), 5.39 (br s, 1H, NH), 4.50 (s, 1H, H-
8), 2.90 (ddt, 1H, J = 17.0, 5.4, 2.1 Hz, H-11 or 10), 2.79 (ddt, 1H, J = 16.2, 5.4, 2.1 
Hz, H-11 or 10), 2.72 (ddt, 1H, J = 17.0, 5.4, 2.1 Hz, H-11 or 10), 2.62 (ddt, 1H, J = 
16.2, 5.4, 2.1 Hz, H-11 or 10), 1.27 (s, 9H, H-9);  δ 13C NMR (150 MHz, CDCl3, r.t) 
169.3 (Cq), 168.3 (Cq), 141.4 (Cq), 140.1 (Cq), 136.2 (Cq), 130.81 (CH), 130.76 
(CH), 128.9 (2 × CH), 128.1 (CH), 127.8 (CH), 127.5 (2 × CH), 124.5 (CH), 122.3 
(CH), 116.1 (CH), 76.0 (CH), 53.8 (Cq), 51.7 (Cq), 50.4 (CH2), 39.9 (CH2), 28.6 (-
C(CH3)3); HRMS (CI) cald. for C24H27N2O2 [M + 1]
+ 
375.2075, found 375.2057.  
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Tert-Butyl (2-(2'-(tert-butylcarbamoyl)-5'-chlorospiro[cyclopentane-
1,3'-indolin]-3-en-1'-yl)-2-oxoethyl)carbamate (159d) 
                                                               
159d 
After evaporation of volatiles, purification by dry load column chromatography by 
gradient method 0-40% EtOAc: petrol gave the title compound as a pale yellow oil 
(78 mg, 77%). Rf = 0.35 (2 : 3 EtOAc : petrol); IRυ max 3450 (C-H), 3423 (C-H), 
2957 (N-H), 1662 (C=O), 1476 (aromatic), 1366 (OC-N), 1253 (C-O), 821 cm
-1; δ 
1
H NMR (400 MHz, CDCl3, 55°C) 7.94 (brs, 1H, H-3), 7.21 (dd, 1H, J  = 8.8, 2.0 
Hz, H-2), 7.19 (s, 1H, H-1), 5.93 (m, 1H,  H-13 or 12), 5.73 (m, 1H,  H-13 or 12), 
5.54 (br s, 1H, NH), 5.41 (br s, 1H, NH), 4.53 (s, 1H, H-9), 4.20 (dd, 1H, J = 16.7, 
4.9 Hz, H-8), 3.91 (br s, 1H, H-8), 2.89 (d, 1H, J = 16.6 Hz, H-11 or 10), 2.74 (d, 
1H, J = 17.6 Hz, H-11 or 10), 2.69 (d, 1H, J = 17.6 Hz, H-11 or 10), 2.56 (d, 1H, J = 
16.6 Hz, H-11 or 10), 1.48 (s, 9H, H-4), 1.33 (s, 9H, H-5);  δ 13C NMR (150 MHz, 
CDCl3, r.t.) 167.4 (Cq), 155.9 (Cq), 140.5 (Cq), 140.0 (Cq), 138.6 (Cq), 130.7 (CH), 
129.9 (Cq), 128.4 (CH), 128.2 (CH), 122.5 (CH), 117.6 (CH), 80.2 (Cq), 73.8 (CH), 
55.0 (Cq), 52.2 (Cq), 51.0 (CH2), 43.8 (CH2), 40.1 (CH2), 28.6 (-C(CH3)3, 28.4 (-
C(CH3)3); HRMS (CI) C24H33ClN3O4 [M+H]
+ 
462.9870, found 462.2150. 
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Synthesis of substituted methyl-3,3-Diallyl-2-chloroindoline-1-
carboxylate  
 
General procedure I: To a solution of 3,3-diallyl-3H-indole in CHCl3 (0.07 M) 
under argon conditions was added methyl chloroformate (2 eq) and left to stir for 15 
minutes at r.t. before a saturated solution of sodium bicarbonate was added (2 × 10 
ml). After extraction of reaction mixture with chloroform, the combined organic 
layers were washed with water (10 ml) and brine (10 ml), dried over MgSO4 and 
filtered. Evaporation of solvent under vacuum gave the desired compound. 
Methyl 3,3-diallyl-2-chloroindoline-1-carboxylate (160a) 
 
160a 
Brown oil (78 mg, 88%); Rf = 0.47 (1 : 4 EtOAc : Petrol); IRυ max 3055 (C-H), 2938 
(C-H), 1699 (C=O), 1484 (aromatic), 1445,  1385 (OC-N) cm
-1; δ 1H NMR (400 
MHz, CDCl3, 60°C) 7.65 (br s, 1H, H-3), 7.23 (td, 1H, J = 7.4, 1.2 Hz, H-2), 7.12 (d, 
1H, J = 7.4 Hz, H-1), 7.03 (td, 1H J = 7.4, 1.2 Hz, H-4), 5.99 (dtd, 1H, J = 17.8, 
10.7, 7.3 Hz, H-10 or 9), 5.61 (s, 1H, H-6), 5.56 (dtd, 1H, J = 17.8, 10.7, 7.3 Hz, H-
10 or 9), 5.14 (tdd, 2H, J = 17.8, 10.7, 1.6 Hz, H-14 and 13 or 12 and 11), 5.03 (tdd, 
2H, J = 17.8, 10.7, 1.6 Hz, H-14 and 13 or 12), 3.93 (s, 3H,  H-5), 2.65 (d, 2H, J = 
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7.2 Hz, H-8 or 7), 2.39 (dd, 1H, J = 13.9, 7.2 Hz, H-8 or 7), 2.32 (dd, 1H, J = 14.1, 
7.7 Hz, H-8 or 7); δ 13C NMR (100 MHz, CDCl3, 60°C) 139.8 (Cq), 135.1 (CH), 
132.9 (CH), 129.6 (Cq), 128.0 (CH), 123.8 (CH), 122.8 (CH), 118.5 (=CH2), 117.9 
(=CH2), 114.5 (CH), 89.8 (CH), 52.7 (CH3), 50.0 (Cq), 42.8 (CH2), 36.9 (CH2); 
carbamate quaternary carbon  not observed  by 
13
C NMR; HRMS (CI) C16H18NO2 
[M-Cl]
+ 
256.1332, found 256.1333. 
Methyl 3,3-diallyl-2-chloro-5-methoxyindoline-1-carboxylate (160b) 
                                                               
160b 
Red brown oil (91 mg, 91%); Rf = 0.44 (1 : 4 EtOAc : petrol); IRυ max 3075 (C-H), 
2938 (C-H), 1689 (C=O), 1490 (aromatic), 1459 (aromatic), 1320 (OC-N), 1271 (C-
O) cm
-1; δ 1H NMR (600 MHz, CDCl3, 55°C)  7.54 (br s, 1H, H-3), 6.78 (dd, 1H, J = 
9.0, 2.7 Hz, H-2), 6.71 (d, 1H, J = 2.7 Hz, H-1), 6.00 (ddt, 1H, J = 17.0, 10.2, 7.5 
Hz, H-10 or 9), 5.57 (ddt, 2H, J = 17.0, 10.2, 7.5 Hz, H-10 or 9 and 6), 5.17-5.02 (m, 
4H, 14, 13, 12, 11), 3.91 (s, 3H, H-5), 3.79 (s, 3H, H-4), 2.65 (dd, 1H, J = 14.3, 7.5 
Hz, H-8 and 7), 2.60 (dd, 1H, J  = 14.3, 7.5 Hz, H-8 and 7), 2.38 (dd, 1H, J = 14.0, 
7.5 Hz, H-8 and 7), 2.31 (dd, 1H, J = 13.7, 7.5 Hz, H-8 and 7);  δ 13C NMR (150 
MHz, CDCl3, r.t) 156.0 (Cq), 137.1 (Cq), 136.5 (Cq), 135.5 (CH), 133.9 (Cq), 132.9 
(CH), 119.0 (=CH2), 118.5 (=CH2), 115.8 (CH), 112.5 (CH), 110.8 (CH), 90.4 (CH), 
55.7 (CH3), 54.6 (Cq), 52.5 (CH3), 47.6 (CH2), 37.3 (CH2); HRMS (CI) C17H20NO3 
[M-Cl]
+ 
286.1437, found 286.1439. 
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To a solution of substituted 3,3-diallyl-3H-indole in CHCl3 (0.13 M) under argon 
conditions was added methyl chloroformate (2 eq) and left to stir for 15 minutes at 
r.t. before a saturated solution of sodium bicarbonate was added (2 × 10 ml). After 
extraction of reaction mixture with chloroform, the combined organic layers were 
washed with water (10 ml) and brine (10 ml), dried over MgSO4 and filtered. 
Evaporation of solvent under vacuum gave the desired compound as an oil. 
Methyl 3,3-diallyl-2-methyleneindoline-1-carboxylate (164) 
                                                                      
164 
Gave the title compound as a dark purple oil (280 mg, 86%). Rf = 0.58 (1 : 4 EtOAc 
: petrol); IRυ max 3020 (C-H), 2938 (C-H), 1714 (C=O), 1481 (aromatic), 1354 (C-
O), 1237 (C-N), 1094 (C-O) cm
-1; δ 1H NMR (600 MHz, CDCl3, r.t) 7.76 (d, 1H, J = 
7.6 Hz, H-4), 7.20 (td, 1H, J = 7.6, 1.5 Hz, H-3), 7.13 (dd, 1H, J = 7.6, 0.9 Hz, H-1), 
7.07 (td, 1H, J = 7.6, 0.9 Hz, H-2), 5.82 (s, 1H, H-7 or 6), 5.43 (ddt, 2H, J = 17.2, 
10.2, 7.2 Hz, H-10), 4.93-4.87 (m, 4H, H-12, 11), 4.62 (d, 1H, J = 1.5 Hz, H-7 or 6), 
3.95 (s, 3H, H-5), 2.56 (dd, 2H, J = 13.8, 7.2 Hz, H-9 and 8), 2.43 (dd, 2H, J = 13.8, 
7.2 Hz, H-9 and 8); δ 13C NMR (100 MHz, CDCl3, 55°C) 153.5 (Cq), 150.2 (Cq), 
141.7 (Cq), 133.8 (Cq), 133.2 (2 × CH), 127.9 (CH), 123.5 (CH), 123.2 (CH), 118.4 
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(2 × =CH2), 94.3 (=CH2), 53.0 (CH3), 52.2 (Cq), 46.6 (2 × CH2); HRMS (CI) 
C17H20NO2 [M + H]
+ 
270.1942 found, 270.14815. 
Synthesis of spiro-indolin carboxylates by ring closing metathesis 
 
General procedure J: To a refluxed solution of Grubbs 1
st
 generation catalyst (15 
mol%) in CH2Cl2 (0.04 M) was added the corresponding substituted methyl-3,3-
Diallyl-2-chloroindoline-1-carboxylate compound under argon. The reaction was 
refluxed for 24 hrs under argon. After extraction with diethyl ether (3 ml), the 
combined organic layers were washed with water (10 ml), dried over MgSO4, filtered 
and evaporated under vacuo. The crude material was purified by dry load flash 
chromatography which gave the desired product.  
Methyl 2'-chlorospiro[cyclopentane-1,3'-indolin]-3-ene-1'-
carboxylate (164a) 
 
     163a 
Purification by dry load flash chromatography gradient method 0-20% EtOAc: petrol 
which gave the title compound as a dark green oil (59 mg, 78%). Rf = 0.20 (1 : 4 
EtOAc : petrol); IRυ max 3020 (C-H), 2938 (C-H), 1687 (C=O), 1481 (aromatic), 
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1381 (C-O), 1135 (C-N), 690 cm
-1; δ 1H NMR (400 MHz, CDCl3, 55°C)  7.64 (br s, 
1H, H-3), 7.28-7.20 (m, 2H, H-4, 1), 7.02 (t, 1H, J = 7.1 Hz, H-2), 5.90 (s, 1H, H-10, 
9), 5.71 (s, 1H, H-10, 9), 5.59 (s, 1H, H-6), 3.94 (s, 3H, H-5), 3.26 (dd, 1H, J = 16.9 
Hz, H-8 or 7), 2.66 (t, 2H, J = 16.9 Hz, H-8 or 7), 2.41 (d, 1H, J = 16.9 Hz, H-8 or 
7);  δ 13C NMR (100 MHz, CDCl3, 60°C) 139.9 (Cq), 138.1 (Cq), 130.5 (CH), 127.8 
(CH), 127.5 (CH), 123.4 (CH), 122.2 (CH), 114.5 (CH), 91.3 (CH), 55.0 (Cq), 52.7 
(CH3), 47.7 (CH2), 37.3 (CH2); carbamate carbon not observed by 
13
C NMR at 60°C; 
HRMS (CI) cald. for C14H14NO2 [M-Cl-H]
+ 
228.1019, found 228.1018. 
Methyl 2'-chloro-5'-methoxyspiro[cyclopentane-1,3'-indolin]-3-ene-
1'-carboxylate (163b) 
                                                               
                                                                                163b 
Purification by dry load flash chromatography gradient method 0-30% EtOAc: petrol 
which gave the title compound as a dark green oil (59 mg, 70%). Rf = 0.29 (3 : 7 
EtOAc : petrol); IRυ max 3075 (C-H), 2890 (C-H), 1692 (C=O), 1490 (aromatic), 
1272 (C-O), 1135 (C-N), 1032, 694 cm
-1; δ 1H NMR (400 MHz, CDCl3, 60°C) 7.53 
(br s, 1H, H-3), 6.81 (d, 1H, J = 2.6 Hz, H-1), 6.75 (dd, 1H, J = 8.5, 2.6 Hz, H-2), 
5.90 (dtd, 1H, J = 6.4, 4.5, 2.3 Hz, H-10 or 9), 5.70 (dtd, 1H, J = 6.4, 4.5, 2.3 Hz, H-
10 or 9), 5.57 (br s, 1H, H-6), 3.91 (s, 3H, H-5), 3.79 (s, 3H, H-4), 3.24 (d, 1H, J = 
17.3 Hz, H-8 or 7), 2.67 (d, 1H, J = 16.5 Hz, H-8 or 7), 2.61 (d, 1H, J = 17.3 Hz, H-8 
or 7), 2.40 (d, 1H, J = 16.5 Hz, H-8 or 7);  δ 13C NMR (150 MHz, CDCl3, 60°C) 
156.6 (Cq), 140.0 (Cq), 132.7 (Cq), 130.4 (CH), 127.5 (CH), 125.8 (Cq), 115.1 (CH), 
112.7 (CH), 108.9 (CH), 91.5 (CH), 55.7 (CH3), 54.6 (Cq), 52.6 (CH3), 47.5 (CH2), 
37.3 (CH2); HRMS (CI) cald. for C15H16NO3 [M-Cl-H]
+ 
258.1125, found 258.1127. 
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(L)-Proline catalysed asymmetric Mannich reaction 
 
General Procedure for asymmetric Mannich reaction: 
 Method K: To the substituted 3,3-diallyl-3H-indole (1 eq) were added (1 : 4.5) 
CHCl3: acetone (0.022 M) and 30 mol% of L-proline at 0°C and left to stir for 2 days 
allowing the reaction temperature to rise to r.t. Evaporation of solvent and 
purification of dry load flash column chromatography gave the desired product. 
Method L: To the substituted 3,3-diallyl-3H-indole (1 eq) were added (1 : 4.0) 
DMSO: acetone (0.016 M) and 30 mol% of L-proline at 0°C and left to stir for 2 
days allowing the reaction temperature to rise to r.t. The reaction mixture was diluted 
with diethyl ether (5ml) and washed with saturated solution of sodium bicarbonate (5 
ml), water (10 ml), and brine (5 ml), dried with MgSO4, filtered and concentrated to 
give the crude oil. Purification by dry load flash column chromatography gave the 
desired product. 
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1-(3,3-Diallyl-5-methoxyindolin-2-yl)propan-2-one (168a) 
                                                         
168a 
Using method A: Purification by dry load flash chromatography gradient method 0-
5% Et2O: CH2Cl2  which gave the title compound as a yellow oil (60 mg, 96%); Rf = 
0.50 (9.5 : 0.5 CH2Cl2 : Et2O); IRυ max 3367 (C-H), 2977 (N-H), 1713 (C=O), 1500 
(aromatic), 1434, 1220 (C-O), 1168 (C-N) cm
-1; δ 1H NMR (600 MHz, CDCl3) 6.61 
(dd, 1H,  J = 8.3, 2.4 Hz, H-2), 6.59 (d, 1H, J  = 2.4 Hz, H-6), 6.56 (d, 1H, J = 8.3 
Hz, H-3), 5.74 (dtd, 1H, J = 16.3, 9.2, 7.3 Hz, H-14 or 12), 5.67(dtd, 1H, J = 16.3, 
9.2, 7.3 Hz, H-14 or 12), 5.06-5.00 (m, 4H, H-13, 9), 3.99 (dd, 1H, J = 10.5, 2.4 Hz, 
H-8), 3.74 (s, 3H, H-1), 2.81 (m, 2H, H-5), 2.51; 2.39 ((dd, 1H, J = 14.3, 7.3 Hz, H-
11 or 10) (dd, 1H,  J = 14.3, 7.3 Hz, H-11 or 10)), 2.36; 2.12 ((dd, 1H, J = 14.3, 7.3 
Hz, H-11 or 10) (dd, 1H,  J = 14.3, 7.3 Hz, H-11 or 10), 2.20 (s, 3H, H-4);  δ 13C 
NMR (150 MHz, CDCl3) 208.9 (Cq), 154.3 (Cq), 143.8 (Cq), 135.5 (Cq), 134.7 (CH), 
134.3 (CH), 118.3 (=CH2), 118.1 (=CH2), 112.4 (CH), 111.4 (CH), 110.1 (CH), 62.6 
(CH), 56.1 (CH3), 49.3 (Cq), 44.3 (CH2), 40.9 (CH2), 38.4 (CH2), 30.8 (CH3); HRMS 
(CI) cald. for C18H24NO2 [M+H]
+ 
286.18070, found 286.17948. Enantiomeric ratio 
98.8: 1.2 (major: minor) by chiral HPLC (Chiralpak Diacel AD, 75:25 hexane: 
iPrOH, 0.5 mL/min, 15.12 min (minor), 16.70 min (major). [α]D
20
 = + 0.100 (c = 
1.01 mg/mL, CHCl3). 
 
 
 
 
239 
 
1-(3,3-Diallyl-5-chloroindolin-2-yl)propan-2-one (168b) 
                                                            
                                                                                168b 
Using method B: Purification by dry load flash chromatography gradient method 0-
20% EtOAc: Petrol which gave the title compound as a yellow oil (28 mg, 64%). Rf 
= 0.50 (9.5 : 0.5 CH2Cl2 : Et2O); IRυ max 3010 (=C-H), 2918 (N-H), 1713 (C=O), 
1479 (aromatic), 1427, 1169 (C-N)  cm
-1
; δ 1H (600 MHz, CDCl3) 6.98 (dd, 1H,  J = 
8.3, 2.3 Hz, H-2), 6.90 (d, 1H, J  = 2.3 Hz, H-1), 6.53 (d, 1H, J = 8.3 Hz, H-3), 5.71 
(dtd, 1H, J = 17.0, 9.8, 7.0 Hz, H-11or 10), 5.65 (dtd, 1H, J = 17.0, 9.8, 7.0 Hz, H-
11 or 10), 5.09-5.00 (m, 4H, H-13, 12), 4.55 (br s, 1H, NH), 4.01 (dd, 1H, J = 8.4, 
4.8 Hz, H-7), 2.79 (m, 2H, H-6), 2.48; 2.39 ((dd, 1H, J = 13.8, 7.0 Hz, H-9 or 8) (dd, 
1H,  J = 13.8, 7.0 Hz, H-9 or 8), 2.35; 2.12 (dd, 1H, J = 13.8, 7.0 Hz, H-9 or 8) (dd, 
1H,  J = 13.8, 7.0 Hz, H-9 or 8)), 2.20 (s, 3H, H-5); δ 13C (150 MHz, CDCl3) 208.3 
(Cq), 148.4 (Cq), 135.9 (Cq), 134.1 (CH), 134.0 (CH), 127.7 (CH), 124.3 (CH), 123.2 
(Cq), 118.6 (=CH2), 118.5 (=CH2), 110.8 (CH), 63.1 (CH), 49.2 (Cq), 43.8 (CH2), 
40.7 (CH2), 38.2 (CH2), 30.7 (CH3); HRMS (CI) cald. for C17H21NO [M+H]
+
  290. 
8030, found 290.1311. Enantiomeric ratio 99.0: 1.0 (major: minor) by chiral HPLC 
(Chiralpak Diacel AD, 75:25 hexane : iPrOH, 0.5 mL/min, 11.56 min minor, 13.14 
min major). [α]D
20
 = + 0.360 (c = 1.36 mg/mL, CHCl3). 
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1-(3,3-Diallylindolin-2-yl)propan-2-one (168c) 
                                                              
168c 
Using method A: (61 mg, 81% pale yellow oil); Rf = 0.50 (9.5 : 0.5 CH2Cl2 : Et2O); 
IRυ max 3010 (=C-H), 2929 (N-H), 1693 (C=O), 1505 (aromatic), 1253 cm
-1; δ 1H 
(600 MHz, CDCl3) 7.04 (td, 1H,  J = 7.4, 1.0 Hz, H- 2), 6.97 (d, 1H, J  = 7.4 Hz, H-
1), 6.73 (td, 1H, J = 7.4, 1.0 Hz, H-14), 6.63 (d, 1H, J = 7.4 Hz, H-3), 5.75 (dtd, 1H, 
J = 17.1, 9.7, 7.3 Hz, H-11 or 10), 5.68 (dtd, 1H, J = 17.1, 9.7, 7.3 Hz, H-11 or 10), 
5.07-5.00 (m, 4H, H-13, 12), 4.53 (br s, 1H, NH), 4.00 (dd, 1H,  J = 8.5, 4.6 Hz, H-
7), 2.80 (m, 2H, H-6), 2.52; 2.38 ((dd, 1H, J = 14.1, 7.3 Hz, H-9 or 8) (dd, 1H,  J = 
14.1, 7.3 Hz, H-9 or 8)), 2.43; 2.10 ((dd, 1H, J = 14.1, 7.3 Hz, H-9 or 8) (dd, 1H,  J = 
14.1, 7.3 Hz, H-9 or 8), 2.20 (s, 3H, H-5);  δ 13C (150 MHz, CDCl3) 208.6 (Cq), 
150.0 (Cq), 143.8 (CH), 134.4 (CH), 133.8 (Cq), 127.8 (CH), 124.1 (CH), 118.6 
(CH), 118.2 (=CH2), 118.0 (=CH2), 109.9 (CH), 62.1 (CH), 49.0 (Cq), 44.0 (CH2), 
41.0 (CH2), 38.5 (CH2), 30.7 (CH3); HRMS (CI) cald. for C17H22NO [M+H]
+ 
256.17012, found 256.16980. Enantiomeric ratio 99.3: 0.7 (major: minor) by chiral 
HPLC (Chiralpak Diacel AD, 95:5 hexane : iPrOH, 0.5 mL/min, 16.71 min minor, 
21.45 min major). [α]D
20
 = + 0.111 (c = 1.01 mg/mL, CHCl3). 
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Experimental for Molecular Modelling: 
 
Molecular modelling was carried out using PCModel software and MMX force 
field.
214
  Vicinal 
3
JHH couplings were calculated using empirically parameterized 
Karplus equations of Haasnoot et al.
215
 These equations contain terms accounting for 
the differences in electronegativities of α- and β-substituents, and hence are better 
suited for the analysis of the 
3
JHH couplings than the original Karplus equation.
216, 217
 
The precision of equations proposed by Haasnoot et al. is estimated to be <0.6 Hz 
(expressed as the rms deviation) using a set of 100 experimental 
3
JHH couplings.
217
  
 
Experimental data of TQS compounds showing tables of measured coupling constant 
values determined by 
1
H NMR and calculated coupling constants determined by PC 
Model V8 software for: 
 
Methylated TQS compounds isolated as cis: cis isomers 
 
Entry J value (Hz) 
for A-C 
determined 
by 
1
H NMR 
J value (Hz) 
for A-B 
determined 
by 
1
H NMR 
Entry Energy 
minimized 
J value 
(Hz) for 
A- C 
determined 
by PC 
Model 
Energy 
minimized 
J value 
(Hz) for  
A-B 
determined 
by PC 
Model 
47b 8.7 2.8 47b 6.8 3.3 
48b 8.7 2.9 48b 7.0 3.1 
49b 8.3 3.2 49b 6.8 3.3 
50b 8.8 3.3 50b 8.8 2.5 
52b 9.0 2.6 52b 9.0 2.8 
53b 8.6 3.0 53b 8.6 3.1 
54b 8.6 3.2 54b 8.6 2.1 
56b 6.3 3.0 56b 6.3 3.2 
59b 9.4 2.8 59b 9.4 2.7 
60b 8.5 2.8 60b 8.5 2.7 
62b 8.6 2.9 62b 8.6 3.1 
63b 8.7 2.8 63b 8.7 2.7 
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Methylated TQS compounds isolated as trans: cis isomers 
 
Entry J value (Hz) 
for A-C 
determined 
by 
1
 H NMR 
J value (Hz) 
for A-B 
determined 
by 
1
H NMR 
Entry Energy 
minimized J 
value (Hz) 
for A-C 
determined 
by PC 
Model 
Energy 
minimized 
J value 
(Hz) for 
A-B 
determined 
by PC 
Model 
      50a 6.8 10.9 50a 6.8 11.1 
55a 5.4 10.8 55a 5.4 11.2 
57a 6.9 10.7 57a 6.9 11.2 
58a 6.8 11.0 58a 6.8 11.2 
61a 8.8 9.8 61a 8.8 11.2 
64a 7.9 10.0 64b 6.9 11.2 
 
Additional para- substituted TQS compounds isolated as cis: cis isomers 
 
Entry J value (Hz) 
for A-C 
determined 
by 
1
H NMR 
J value 
(Hz) for A-
B 
determined 
by 
1
H NMR 
Entry Energy 
minimized 
J value (Hz) 
for A-C 
determined 
by PC 
Model 
Energy 
minimized J 
value (Hz) 
for 
A-B 
determined 
by PC 
Model 
65b 8.7 3.3 65b 7.0 3.1 
66b 8.5 2.6 66b 7.0 3.1 
67b 8.5 3.6 67b 7.0 3.1 
68b 8.6 2.8 68b 7.0 3.1 
69b 9.8 2.9 69b 7.0 3.1 
70b 7.0 2.5 70b 7.0 3.1 
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71b 8.5 2.9 71b 7.0 3.1 
72b 8.5 2.7 72b 7.0 3.1 
73b 8.8 2.7 73b 7.1 2.9 
 
 
Heteroaromatic TQS compounds 
Entry J value (Hz) 
for A-C 
determined 
by 
1
H NMR 
J value (Hz) 
for A-B 
determined 
by 
1
H NMR 
Entry Energy 
minimized J 
value (Hz) 
for A-C 
determined 
by PC 
Model 
Energy 
minimized 
J value 
(Hz) for 
A-B 
determined 
by PC 
Model 
74b 8.9 2.8 74b 7.1 3.0 
75b 8.9 3.0 75b 7.1 3.1 
76b 8.4 2.8 76b 7.0 2.7 
77b 8.6 7.0 77b 2.8 3.1 
 
 
Substituted Sulfanilamide TQS compounds 
Entry J value (Hz) 
for A-C 
determined 
by 
1
H NMR 
J value (Hz) 
for A-B 
determined 
by 
1
H NMR 
Entry Energy 
minimized 
J value 
(Hz) for A-
C 
determined 
by PC 
Model 
Energy 
minimized 
J value 
(Hz) for 
A-B 
determine
d by PC 
Model 
94b 8.6 2.9 94b 7.0 3.1 
92b 8.5 2.9 92b 7.0 3.1 
93b 8.1 3.0 93b 7.0 3.1 
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